1471-2431-7-27.txt	Pacifier use reduced FLACC score (not statistically significant), crying times (statistically significant) but not heart rate.	FLACC score	21	32	not statistically significant	34	63	1
cc11249.txt	Mean ICU length of stay after extubation was significantly lower in the study group when compared with controls (3.1 ± 2.5 versus 9.8 ± 6.7 days; P < 0.05).	Mean ICU length of stay after extubation	0	40	significantly	45	58	1
1471-2458-12-602.txt	There was also a significant improvement in mental HRQL, with a mean increase of 1.9 in the intervention arm, while the usual care arm decreased by 0.8 (p = 0.007).	mental HRQL	44	55	significant	17	28	1
1471-2431-9-21.txt	Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).	overall functioning	95	114	significantly	25	38	1
cc11215.txt	Conclusions ARDS patients surviving after treatment with low-dose iNO had significantly better values for select pulmonary function tests at six months post-treatment than placebo-treated patients.	values for select pulmonary function tests	95	137	significantly	74	87	1
1472-6920-6-38.txt	Changes in all outcomes were similar in the "Training + Feedback" group compared to the "Feedback Only" group (PRPCC: 3.7 vs1.8; trust: -0.7 vs -0.2 ; satisfaction: 1.9 vs 2.5; weight: -2.5 lbs vs -0.7 lbs; systolic blood pressure: 1.7 mm Hg vs 0.1 mm Hg; glycosylated hemoglobin 0.02% vs 0.07%; p = NS for all).	satisfaction	151	163	p = NS	296	302	1
1471-2474-11-64.txt	A significant difference in weeks missed due to non-contact knee injury was noted (1 v 24, χ2:6.70, p = 0.01).	weeks missed due to non-contact knee injury	28	71	p = 0.01	100	108	1
1471-244X-5-5.txt	Results There was significant improvement from baseline to endpoint on the Yale-Brown Obsessive-Compulsive Scale in both the quetiapine and placebo groups (quetiapine, n = 20, p < 0.0001; placebo, n = 21, p = 0.001) with 40% (n = 8) of quetiapine and 47.6% (n = 10) of placebo treated subjects being classified as responders.	the Yale-Brown Obsessive-Compulsive Scale	71	112	p < 0.0001	176	186	1
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	eye contact	227	238	p = 0.0102	240	250	1
1477-7827-2-70.txt	Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs 12%, p > 0.05).	Caesarean section (CS) rate	48	75	p > 0.05	122	130	1
1471-244X-7-13.txt	Additionally, patients of the treatment condition showed significantly greater reduction of co-morbid depression and anxiety as compared to the waiting list condition.	anxiety	117	124	significantly	57	70	1
1472-6831-12-13.txt	The change in mean tooth shade scores was statistically significantly greater in the gum-group than in the tablet group at 2 (p = 0.015), 6 (p = 0.011) and 12 weeks (p = 0.003) with greater lightening in the gum-group at each examination period.	mean tooth shade scores	14	37	significantly	56	69	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	significant	63	74	1
1471-2474-11-229.txt	A mean reduction in bone gap area also favored LIPUS treatment (p = 0.014).	bone gap area	20	33	p = 0.014	64	73	1
1741-7015-4-14.txt	Significantly more patients in the WS ® 5570 treatment groups than in the placebo group showed treatment response and remission.	treatment response	95	113	Significantly	0	13	1
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	components of metabolic syndrome	126	158	p < 0.027	160	169	1
1472-6882-7-34.txt	Rescue medication use was significantly lower in the reparagen group (p < 0.01) at each assessment period.	Rescue medication use	0	21	p < 0.01	70	78	1
1741-7015-10-71.txt	Conclusions CPs can significantly improve the outcomes of patients with ischemic patients with stroke, indicating better application of evidence-based key interventions and of diagnostic and therapeutic procedures.	the outcomes	42	54	significantly	20	33	1
1475-2875-6-138.txt	Results Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups.	Time to regain consciousness	8	36	p = 0.11	38	46	1
1471-2458-12-602.txt	There was also a significant improvement in mental HRQL, with a mean increase of 1.9 in the intervention arm, while the usual care arm decreased by 0.8 (p = 0.007).	mental HRQL	44	55	p = 0.007	153	162	1
1471-230X-12-58.txt	Overall discomfort score was less in WC than in SC patients (26 ± 4 mm vs 39 ± 4 mm VAS, respectively, p = 0.012) but there were no significant group differences in throat, chest, or overall discomfort during placement.	Overall discomfort score	0	24	p = 0.012	103	112	1
1475-2875-6-138.txt	There was no significant difference in the mortality between the placebo (13/80 or 16.3%) and mannitol (10/76 or 13.2%) groups: RR = 1.2 (CI 0.5–2.7).	the mortality	39	52	no significant	10	24	1
1471-2369-13-49.txt	In group-1 the iFGF23 level was higher after treatment with alphacalcidol compared with sevelamer carbonate (mean 105.8 ± 41.6 vs 79.1 ± 36.5 pg/ml, p = 0.047 (CI: 0.4-52.9), and the iPTH level was lower (median: 26.5, range: 14.6-55.2 vs median 36.1, range 13.4-106.9 pg/ml, p = 0.011).	the iFGF23 level	11	27	p = 0.047	149	158	1
1471-244X-12-44.txt	In contrast to controls, significant treatment effects were found at outcome on self-reported measures of violent attitudes, rational problem-solving and anger cognitions.	self-reported measures of violent attitudes	80	123	significant	25	36	1
1471-2474-8-36.txt	Conclusion When used for the short-term treatment of plantar heel pain, a two-week stretching program provides no statistically significant benefit in 'first-step' pain, foot pain, foot function or general foot health compared to not stretching.	general foot health	198	217	no statistically significant	111	139	1
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	HRQoL assessed with the Maugeri Respiratory Failure questionnaire	252	317	p = 0.005	342	351	1
1479-5868-8-41.txt	Significant waist circumference reductions were achieved in all 4 groups at month 9 (Standard Care, 3.49 cm, P = 0.0004; GWL, 2.42 cm, P = 0.008; SWA-alone, 3.59 cm, P < 0.0001; GWL+SWA, 6.77 cm, P < 0.0001), but no intervention group had significantly reduced waist circumference compared to the Standard Care group.	waist circumference reductions	12	42	P < 0.0001	166	176	1
1471-244X-2-2.txt	The differences in the outcomes between the two different doses of RUL ECT treatment were not statistically significant.	the outcomes	19	31	not statistically significant	90	119	1
1471-2466-10-11.txt	Standardised AUC measurements for FEV 1 (between 5 min and 4 h, 5 min and 1 h, and 1 and 4 h post-dose) at Week 12 were all significantly greater with indacaterol than placebo (p < 0.001), with LSM (± SEM) differences of 170 ± 24, 180 ± 24, and 170 ± 24 mL, respectively.	Standardised AUC measurements for FEV 1	0	39	significantly	124	137	1
cc1476.txt	Both TEF10 and the ratio of the tidal expiratory flow at 25% of the remaining tidal volume to PTEF (25/PT) decreased significantly ( P < 0.05) after administration of albuterol.	TEF10	5	10	P < 0.05	133	141	1
cc10453.txt	The specific data were as follows (median (IQR)): 9.7% (2.6 to 19.8) for TP, 8.9% (0.0 to 17.8) for AVP, and 6.9% (3.5 to 10.1) for placebo ( P < 0.05 vs baseline for each comparison), as well as perfused vessel density 18.6% (8.6 to 36.9) for TP, 20.2% (-3.0 to 37.2) for AVP, and 11.4% (-3.0 to 19.4) for placebo ( P < 0.05 vs baseline for each comparison).	perfused vessel density	196	219	P < 0.05	317	325	1
1471-2474-13-141.txt	Evaluation of the intensity of pain with a visual analogue scale (VAS) showed a statistically significant difference (p = 0,035) at day 16.	Evaluation of the intensity of pain with a visual analogue scale (VAS)	0	70	significant	94	105	1
1741-7015-9-10.txt	Furthermore, the probability of DFS at three years was 0.78 and 0.76 for patients in Arm A and Arm B, respectively ( P = 0.334).	the probability of DFS at three years	13	50	P = 0.334	117	126	1
1471-230X-9-22.txt	The proportion of patients who remained relapse-free at Week 26 did not differ significantly between the placebo group (5/16, 31%) and the IFN beta-1a 44 mcg biw (6/17, 35%; p = 0.497), 44 mcg tiw (7/16, 44%; p = 0.280) or 66 mcg tiw (2/18, 11%; p = 0.333) groups.	The proportion of patients who remained relapse-free at Week 26	0	63	p = 0.280	209	218	1
1741-7015-10-54.txt	With regard to secondary outcomes, blood glucose, HbA1c, low-density lipoprotein/high-density lipoprotein ratio, and HR were significantly decreased by phlebotomy.	blood glucose	35	48	significantly	125	138	1
1471-2474-9-118.txt	At Week 6 there was a significantly lower msSBP and msDBP in the lumiracoxib group compared to the rofecoxib group ( p < 0.05).	msSBP	42	47	significantly	22	35	1
1471-2350-12-137.txt	Results Significant differences in response to induced ketosis were found among non-carriers of putative gain-of-function polymorphisms in rs1143627 and rs16944 in the IL1B gene and among variants of the polymorphism rs2251101 in the IDE gene.	response to induced ketosis	35	62	Significant	8	19	1
1471-2466-12-14.txt	The improvement in FEV 1 was 5.8% in the SINA group compared to 3.4% in the GINA group ( p = 0.46).	FEV 1	19	24	p = 0.46	89	97	1
1465-9921-7-110.txt	Results In study A, a single inhalation of SFC and FBC produced a sustained bronchodilation at 16 hours with an adjusted mean increase in FEV 1 from pre-dose of 0.22 L (95% CI 0.19, 0.35 L) for SFC and 0.25 L (95% CI 0.21, 0.37 L) for FBC, which was significantly greater than placebo for both treatments (-0.05 L; p < 0.001).	FEV 1	138	143	p < 0.001	315	324	1
ar4072.txt	In the double-blind part, more patients on adalimumab achieved an ASAS40 at week 4 (41%), week 8 (53%) and week 12 (53%) than on placebo (20%, 33%, 33%), while differences at week 8 only reached borderline significance ( P = 0.05).	an ASAS40	63	72	P = 0.05	221	229	1
1471-2393-11-85.txt	MLU women were significantly less likely to have continuous electronic fetal monitoring (397 [36.1%] vs 313 [56.7%]; RR 0.64 [0.57 to 0.71]), or augmentation of labour (436 [39.6%] vs 314 [56.9%]; RR 0.50 [0.40 to 0.61]).	likely to have continuous electronic fetal monitoring	34	87	significantly	15	28	1
1471-2474-8-36.txt	Conclusion When used for the short-term treatment of plantar heel pain, a two-week stretching program provides no statistically significant benefit in 'first-step' pain, foot pain, foot function or general foot health compared to not stretching.	foot function	181	194	no statistically significant	111	139	1
1477-7827-2-70.txt	Results The induction-delivery interval was significantly lower in the misoprostol group than in the dinoprostone group (11.9 h vs 15.5 h, p < 0.001).	The induction-delivery interval	8	39	significantly	44	57	1
1745-6215-12-146.txt	Results The results showed that the NRS score for pain decreased (-16.0 [95% CI: -24.4 to -7.7] in the wet-cupping group and -9.1 [-18.1 to -0.1] in the waiting-list group), but there was no statistical difference between the groups (p = 0.52).	the NRS score for pain	32	54	p = 0.52	234	242	1
cc11300.txt	The corrected colonisation index was similar in the two groups at T0 ( P = 0.36), while a significant statistical difference was observed between the treatment and control groups at T6 (median 0.14 and 0.33, respectively; P = 0.0016), at T9 (median 0.00 and 0.28, respectively; P = 0.0001), at T12 (median 0.00 and 0.41, respectively; P = 0.0008), and at T15 (median 0.00 and 0.42, respectively; P < 0.0003).	The corrected colonisation index	0	32	P = 0.0008	335	345	1
1471-2407-9-66.txt	Median overall survival was 5.2 months (95% confidence interval = 3.3 to 9 months), with no significant difference between the intravenous and intra-arterial arms (log rank test p = 0.79).	Median overall survival	0	23	no significant	89	103	1
1471-2288-12-147.txt	Results Overall, 33% (762/2340) of invitees took part in the Link-Up Study; 41% (410/1002) among regional and 26% (352/1338) among urban-area residents (p < 0.0001).	took part in the Link-Up Study	44	74	p < 0.0001	153	163	1
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	satisfaction	404	416	no statistically significant	231	259	1
1471-2415-7-3.txt	There was a statistically significant improvement in VA from baseline with P = .045.	VA	53	55	significant	26	37	1
1465-9921-13-86.txt	After 26 weeks there were clinically significant differences between the groups for 6 minute-walk-distance (+59 m, 95% CI 28–89 m), maximum work load (+7.4 Watt, 95% CI 0.5-13.4 Watt) and St. George’s Respiratory Questionnaire score (−5 points, 95% CI −10 to −1 points).	St. George’s Respiratory Questionnaire score	188	232	significant	37	48	1
cc10143.txt	In the TA group, bleeding duration was shorter and progression to severe PPH and PRBC transfusion was less frequent than in controls ( P < 0.03).	bleeding duration	17	34	P < 0.03	135	143	1
1471-2458-12-944.txt	Results Average population CVD risk decreased from 32.9% to 29.4% (p <0.001) in the NHS Health Check only group and from 31.9% to 29.2% (p <0.001) in the NHS Health Check plus additional lifestyle support group.	Average population CVD risk	8	35	p <0.001	137	145	1
1471-2377-12-36.txt	This positive, albeit non-statistically significant response was observed as early as month-3 and sustained through to month-18, with similar trends seen in the PPMS and rfSPMS subpopulations.	response	52	60	non-statistically significant	22	51	1
1471-2458-11-475.txt	Heightened decisional conflict was evident for parents making the MMR decision for their first child (effect estimate = -0.25, p = 0.003), who were concerned (effect estimate = 0.07, p < 0.001), had less positive attitudes (effect estimate = -0.20, p < 0.001) yet stronger intentions (effect estimate = 0.09, p = 0.006).	decisional conflict	11	30	p < 0.001	183	192	1
1471-2407-9-66.txt	Median overall survival was 5.2 months (95% confidence interval = 3.3 to 9 months), with no significant difference between the intravenous and intra-arterial arms (log rank test p = 0.79).	Median overall survival	0	23	p = 0.79	178	186	1
1741-7015-10-54.txt	Results SBP decreased from 148.5 ± 12.3 mmHg to 130.5 ± 11.8 mmHg in the phlebotomy group, and from 144.7 ± 14.4 mmHg to 143.8 ± 11.9 mmHg in the control group (difference -16.6 mmHg; 95% CI -20.7 to -12.5; P < 0.001).	SBP	8	11	P < 0.001	207	216	1
1471-2466-10-11.txt	Indacaterol significantly reduced the percentage of days of poor control versus placebo by 22.5% (p < 0.001) and was also associated with significantly reduced use of rescue medication (p < 0.001).	use of rescue medication	160	184	significantly	138	151	1
1471-2474-8-23.txt	Sensitivity analyses confirmed an advantage for hydrotherapy if we assumed non-completers would all not have responded (response rates 70% versus 38%; p < 0.001) or if we assumed that non-completers would have had the same response as completers (response rates 82% versus 55% p = 0.002).	response rates	120	134	p < 0.001	151	160	1
1471-244X-3-7.txt	The difference between the two groups in the frequency of side effects was not significant Conclusions The efficacy of ritanserin to obtain a better improvement in patients with mania seems to support the 5-HT hypothesis of bipolar disorder.	the frequency of side effects	41	70	not significant	75	90	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.011	538	547	1
1475-2875-5-113.txt	The 28-day PCR-corrected cure rate was 90.1% [95% CI 80.7–95.9] for AS+SP, 98.5% [95% CI 92.0–100] for AS+AQ and 100% [95.8–100] for AL, thereby revealing a weaker response to AS+SP than to AL (p = 0.003) and to AS+AQ (p = 0.06).	response	164	172	p = 0.003	194	203	1
cc2896.txt	Overall, mean neurological assessment times were significantly shorter when using remifentanil (remifentanil 0.41 hour versus fentanyl 0.71 hour [ P = 0.001] versus morphine 0.82 hour [ P < 0.001]).	mean neurological assessment times	9	43	P < 0.001	186	195	1
1471-230X-11-81.txt	At the third interim analysis, the sample path crossed the upper boundary and the trial was stopped, the cure-markedly effective rates were 45% for IFCS group and 67% for IFCA group, respectively, the one-sided p -value was 0.0036, the median unbiased estimate of the odds ratio (OR) for the benefit of IFCA relative to IFCS was 2.91 with 95%CI: 1.40 to 6.06.	the cure-markedly effective rates	101	134	p -value was 0.0036	211	230	1
1741-7015-9-10.txt	Results The probability of overall survival (OS) at three years was 0.88 for patients in Arm A and 0.86 for those in Arm B, while the five-year OS probability was 0.78 and 0.76 for patients in Arm A and Arm B, respectively (P = 0.436).	the five-year OS probability	130	158	P = 0.436	224	233	1
1471-2474-11-244.txt	Results We found differences between the intervention group and the control group, comparing the results at baseline and after 6 months in EuroQol-5D (p < 0.001) and in standing one leg eyes closed (p = 0.02) in favour of the intervention group.	EuroQol-5D	139	149	p < 0.001	151	160	1
cc10367.txt	Results There was no difference between succinylcholine and rocuronium regarding oxygen desaturations (succinylcholine 73/196; rocuronium 66/195; P = 0.67); severe oxygen desaturations (succinylcholine 20/196; rocuronium 20/195; P = 1.0); and extent of oxygen desaturations (succinylcholine -14 ± 12%; rocuronium -16 ± 13%; P = 0.77).	severe oxygen desaturations	157	184	P = 1.0	229	236	1
1471-2334-12-111.txt	Stool concentration of LL-37 remained significantly higher in the Intervention group on days 4 and 7.	Stool concentration of LL-37	0	28	significantly	38	51	1
1471-2458-12-706.txt	Controls had significantly poorer appetites (P = 0.01) (OR 2.9, [1.24-6.82]) compared to treated children.	appetites	34	43	significantly	13	26	1
1471-2458-12-944.txt	Conclusions The NHS Health Check service in Stoke on Trent resulted in significant reduction in estimated population CVD risk.	estimated population CVD risk	96	125	significant	71	82	1
1475-2891-10-72.txt	Results No significant between-group differences in endothelial function with daily treatment for 8 weeks were seen.	endothelial function	52	72	No significant	8	22	1
1471-2431-9-21.txt	On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.	stereotypy	104	114	p < 0.03	143	151	1
1477-5751-8-3.txt	The primary efficacy criterion 'TQ total score' failed to demonstrate significant improvement compared to placebo.	The primary efficacy criterion 'TQ total score'	0	47	failed to demonstrate significant	48	81	1
1472-6882-12-7.txt	Changes in sway parameters were significantly improved by TC vs UC (average sway velocity, P = 0.027; anterior-posterior sway range, P = 0.014).	sway parameters	11	26	significantly	32	45	1
1757-7241-20-16.txt	Significant differences were not found in secondary outcome and in other performance variables between the groups and over time Conclusions Quality of CPR was maintained during 2 minutes of continuous compressions regardless of feedback in a group of trained rescuers.	other performance variables	67	94	Significant differences were not found	0	38	1
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	The overall mortality rate	0	26	p = 0.36	38	46	1
1471-5945-5-13.txt	Improvements from baseline on the SF-36, PSA, PGPA, and itching VAS at Week 12 were also significantly greater in efalizumab-treated patients than for placebo.	itching VAS	56	67	significantly	89	102	1
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the local recurrence rate	99	124	p = .16	135	142	1
1475-2891-11-57.txt	There were no significant differences among the three groups in any variable related to body composition, dietary composition, or MetS components.	body composition	88	104	no significant	11	25	1
1471-2407-9-21.txt	In children over 6-year of age (n = 72), the rate of success was significantly higher in the pillow group (58.5% vs 41.5%, p = 0.031), with a tendency to feel less pain (median VAS 25 vs 15 mm, p = 0.39) and being more satisfied (84.4% vs 75.0%, p = 0.34).	VAS	177	180	p = 0.39	194	202	1
cc10143.txt	Mild, transient adverse manifestations occurred more often in the TA group than in the control group ( P = 0.03).	Mild, transient adverse manifestations	0	38	P = 0.03	103	111	1
1472-6963-5-28.txt	However, when analyzed by exposure to EWRs, nurses in the control group who did not participate in EWRs (n = 198) had lower safety climate scores than nurses in the intervention group who did participate in an EWR session (n = 85) (74.88 versus 81.01, P = 0.02; 52.5% positive versus 72.9% positive).	safety climate scores	124	145	P = 0.02	252	260	1
1465-9921-13-86.txt	After 26 weeks there were clinically significant differences between the groups for 6 minute-walk-distance (+59 m, 95% CI 28–89 m), maximum work load (+7.4 Watt, 95% CI 0.5-13.4 Watt) and St. George’s Respiratory Questionnaire score (−5 points, 95% CI −10 to −1 points).	maximum work load	132	149	significant	37	48	1
1471-2474-12-132.txt	Age, race/ethnicity, education, military status, smoking history, BMI, and whether a Soldier received the physical/USI examination remained statistically significant (p < .05) when considered in a full multivariate model.	 whether a Soldier received the physical/USI examination	74	130	significant	154	165	1
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	total cholesterol	107	124	P < 0.001	144	153	1
1465-9921-13-54.txt	No significant differences between the groups were detected in any other parameter, including exacerbation frequency and adverse events.	adverse events	121	135	No significant	0	14	1
1471-2474-11-26.txt	There were also significant differences in improvement in bodily pain and social function (subscales of SF-36 health status) favoring the Index Group.	bodily pain	58	69	significant	16	27	1
1471-2431-8-23.txt	Amoxicillin significantly reduced the proportion of children with i) perforation at the end of therapy (27% to 12% RD = -16% [-31,-1]), ii) recurrent perforation during therapy (18% to 4% RD = -14% [-25,-2]), and iii) reduced the proportion of examinations with a diagnosis of perforation during therapy (20% to 8% adjusted risk ratio 0.36 [0.15,0.83] p = 0.017).	the proportion of children with i) perforation at the end of therapy (27% to 12% RD = -16% [-31,-1]), ii) recurrent perforation during therapy (18% to 4% RD = -14% [-25,-2])	34	207	significantly	12	25	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	significant	63	74	1
1471-2318-12-22.txt	Moreover, the test absorbent pad group healed significantly faster than the usual absorbent pad group (p = 0.009).	healed	39	45	significantly	46	59	1
1471-2318-3-3.txt	For the resistance exercise group, participation was 71% (p = 0.004) and adherence was 63% (p = 0.020).	participation	35	48	p = 0.004	58	67	1
cc11180.txt	Systemic ionized calcium concentrations were significantly reduced during citrate anticoagulation ( P < 0.001) but remained within a safe range.	Systemic ionized calcium concentrations	0	39	P < 0.001	100	109	1
1471-2458-10-123.txt	Total nutrition knowledge score at follow-up, adjusted for baseline score, deprivation, and school size, was higher in intervention than in control schools (mean difference = 1.1; 95% CI: 0.05 to 2.16; p = 0.042).	Total nutrition knowledge score	0	31	p = 0.042	202	211	1
1471-2431-8-13.txt	Results PIPP scores at 90 seconds post lance were significantly lower in the KMC condition (8.871 (95% CI 7.852–9.889) versus 10.677 (95% CI 9.563–11.792) p < .001) and non-significant mean differences ranging from 1.2 to1.8.	PIPP scores	8	19	p < .001	155	163	1
1475-2891-10-120.txt	However, significant differences in weight gain were observed among children aged six weeks to six months in subgroup analyses (n = 22; 1.08 kg, compared to 0.46 kg in the placebo group; 95% CI = 0.12, 1.10; p = 0.01).	weight gain	36	47	significant	9	20	1
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	components of metabolic syndrome	126	158	significant	64	75	1
1475-2875-11-355.txt	The PCR-corrected adequate clinical and parasitological response (APCR) rates in the three groups were 94%, 100%, and 100% (p=0.04).	The PCR-corrected adequate clinical and parasitological response (APCR) rates	0	77	p=0.04	124	130	1
1471-2474-12-153.txt	Compared to placebo, this dosage of canakinumab was also associated with significantly more favorable responses at week 12 with respect to secondary endpoints including the Disease Activity Score 28, scores on the Health Assessment Questionnaire and Functional Assessment of Chronic Illness Therapy-Fatigue, swollen 28-joint count, and patient's and physician's global assessments of disease activity.	Functional Assessment of Chronic Illness Therapy-Fatigue	250	306	significantly	73	86	1
1471-2474-10-118.txt	When analysing the results in a mixed model analysis on repeated measures including interaction between age-group and treatment effect the training group demonstrated significantly improved results compared to the control group in subjects younger than 40 years of age regarding OMAS (p = 0.028), muscle strength in the plantar flexors (p = 0.029) and dorsiflexors (p = 0.030).	OMAS	279	283	significantly	167	180	1
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	FEV 1 /FVC	258	268	significantly	16	29	1
cc2896.txt	Results Overall, between-patient variability around the time of neurological assessment was statistically significantly smaller when using remifentanil (remifentanil 0.44 versus fentanyl 0.86 [ P = 0.024] versus morphine 0.98 [ P = 0.006].	between-patient variability around the time of neurological assessment	17	87	P = 0.006	228	237	1
1477-7525-1-10.txt	There was a mean reduction of 0.3 suspension days due to behavior-related problems in the meditation group compared to an increase of 1.2 in the control group (p < .04).	suspension days due to behavior-related problems	34	82	p < .04	160	167	1
1471-2474-10-118.txt	When analysing the results in a mixed model analysis on repeated measures including interaction between age-group and treatment effect the training group demonstrated significantly improved results compared to the control group in subjects younger than 40 years of age regarding OMAS (p = 0.028), muscle strength in the plantar flexors (p = 0.029) and dorsiflexors (p = 0.030).	dorsiflexors	352	364	significantly	167	180	1
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	main effect of time	22	41	p < 0.001	44	53	1
cc7890.txt	Dexmedetomidine significantly decreased ICU length of stay, from 6.5 (IQR 4 to 9) to 1.5 (IQR 1 to 3) days ( P = 0.004) after study drug commencement.	ICU length of stay	40	58	significantly	16	29	1
1532-429X-14-61.txt	CMR performed better than SPECT in MVD (p = 0.003 vs all SPECT, p = 0.04 vs gated-SPECT), in men (p = 0.004, n = 313) and in women (p = 0.03, n = 112) as well as in the non-infarct patients (p = 0.005, n = 186 in 1–3 vessel disease and p = 0.015, n = 140 in MVD).	MVD	35	38	p = 0.005	191	200	1
1465-9921-10-69.txt	Improvement of lung function, dyspnea and quality of life as multiple criteria were statistically significant relative to placebo.	lung function	15	28	significant	98	109	1
1471-230X-12-37.txt	No significant differences in blood ΔpH were found between the two groups.	blood ΔpH	30	39	No significant	0	14	1
cc1476.txt	Both TEF10 and the ratio of the tidal expiratory flow at 25% of the remaining tidal volume to PTEF (25/PT) decreased significantly ( P < 0.05) after administration of albuterol.	TEF10	5	10	significantly	117	130	1
1475-2875-10-185.txt	More than 96% of patients who received DPT were apyrexial 48 hours after treatment compared to 83.5% in the AL group (p < 0.001).	apyrexial	48	57	p < 0.001	118	127	1
1471-5945-5-13.txt	Corresponding improvements in DLQI in the High-Need cohort were 5.4 points for efalizumab compared to 2.3 for placebo ( P < .001).	DLQI	30	34	P < .001	120	128	1
1471-2474-11-26.txt	The differences between the groups in pain and disability considered over one year were statistically significant favoring naprapathy (p ≤ 0.005).	disability	47	57	significant	102	113	1
1471-2458-11-475.txt	Heightened decisional conflict was evident for parents making the MMR decision for their first child (effect estimate = -0.25, p = 0.003), who were concerned (effect estimate = 0.07, p < 0.001), had less positive attitudes (effect estimate = -0.20, p < 0.001) yet stronger intentions (effect estimate = 0.09, p = 0.006).	decisional conflict	11	30	p = 0.003	127	136	1
1471-2458-6-134.txt	However there were also changes in the ethnic control group scores; respectively +5.0%, +16.3% (significant P < 0.001), +1.5%, +1.7%.	the ethnic control group scores	35	66	P < 0.001	108	117	1
1471-2393-11-85.txt	Results No statistically significant difference was found between MLU and CLU in the seven key outcomes: caesarean birth (163 [14.8%] vs 84 [15.2%]; relative risk (RR) 0.97 [95% CI 0.76 to 1.24]), induction (248 [22.5%] vs 138 [25.0%]; RR 0.90 [0.75 to 1.08]), episiotomy (126 [11.4%] vs 68 [12.3%]; RR 0.93 [0.70 to 1.23]), instrumental birth (139 [12.6%] vs 79 [14.3%]; RR 0.88 [0.68 to 1.14]), Apgar scores < 8 (10 [0.9%] vs 9 [1.6%]; RR 0.56 [0.23 to 1.36]), postpartum haemorrhage (144 [13.1%] vs 75 [13.6%]; RR 0.96 [0.74 to 1.25]); breastfeeding initiation (616 [55.9%] vs 317 [57.4%]; RR 0.97 [0.89 to 1.06]).	caesarean birth	105	120	No statistically significant	8	36	1
1477-7525-5-57.txt	Results and discussion Significant Questionnaire effects and a Questionnaire × Ceiling interaction (p < 0.001) in both trial datasets showed that the DTSQc detected more improvement in Treatment Satisfaction than the DTSQs, especially when patients had DTSQs scores at/near ceiling at baseline.	a Questionnaire × Ceiling interaction	61	98	p < 0.001	100	109	1
1471-2369-10-7.txt	In hypertensive patients there was a substantial reduction in BP (-7.8 mmHg, p < 0.01).	BP	62	64	p < 0.01	77	85	1
1471-2458-6-299.txt	There were no significant differences between intervention and comparison arms in the proportion of women having a preterm birth, an infant with low birthweight, or an infant with a birth weight <10 th percentile.	the proportion of women having a preterm birth	82	128	no significant	11	25	1
1475-2875-10-2.txt	The incidence rate of malaria in children who received IPTc was 0.44 clinical attacks per 1,000 child months at risk while that for control children was 1.32 per 1,000 child months at risk, a protective efficacy of 66% (95% CI -23% to 96%; p = 0.35).	a protective efficacy	190	211	p = 0.35	240	248	1
1471-2377-11-96.txt	Results Significant intervention effects were observed in the intervention group for learning mean score (SE), [93.89 (4.00) vs 106.38 (4.32), P = 0.04] but for working memory the intervention group performed poorly [27.42 (0.66) vs 25.34 (0.73), P = 0.04].	learning mean score	85	104	Significant	8	19	1
1471-2458-12-706.txt	However, treated children had significantly less pain experience (P = 0.006) (OR 0.09, [0.01-0.51]) and higher satisfaction with teeth (P = 0.001) (OR 9.91, [2.68-36.51]) compared to controls.	pain experience	49	64	significantly	30	43	1
1532-429X-14-61.txt	CMR performed better than SPECT in MVD (p = 0.003 vs all SPECT, p = 0.04 vs gated-SPECT), in men (p = 0.004, n = 313) and in women (p = 0.03, n = 112) as well as in the non-infarct patients (p = 0.005, n = 186 in 1–3 vessel disease and p = 0.015, n = 140 in MVD).	MVD	35	38	p = 0.04	64	72	1
1465-9921-11-112.txt	Results After three month training period, in the Nordic Walking group time spent walking and standing as well as intensity of walking increased (Δ walking time: +14.9 ± 1.9 min/day; Δ standing time: +129 ± 26 min/day; Δ movement intensity: +0.40 ± 0.14 m/s 2 ) while time spent sitting decreased (Δ sitting time: -128 ± 15 min/day) compared to baseline (all: p < 0.01) as well as compared to controls (all: p < 0.01).	time spent sitting	268	286	p < 0.01	360	368	1
1475-2875-10-185.txt	More than 95% of the people in the DPT group had a parasite clearance time of 48 hours or less compared to approximately 90% in the AL group (p = 0.023).	a parasite clearance time	49	74	p = 0.023	142	151	1
1472-6947-8-4.txt	Comparing participants that viewed the 5-option version with participants who viewed the 2-option version, there were no differences in screening interest after viewing (1.8 vs 1.9, t-test p = 0.76).	screening interest	136	154	p = 0.76	189	197	1
1471-2431-11-82.txt	[Na] increased significantly in the 0.9% group (+0.20 mmol/L/h [IQR +0.03, +0.4]; P = 0.02) and increased, but not significantly, in the 0.45% group (+0.08 mmol/L/h [IQR -0.15, +0.16]; P = 0.07).	[Na]	0	4	P = 0.07	185	193	1
1471-5945-5-13.txt	Among all efalizumab-treated patients, the DLQI improved by 5.7 points from baseline to Week 12, relative to an improvement of 2.3 points for placebo patients ( P < .001).	the DLQI	39	47	P < .001	161	169	1
1477-7525-5-57.txt	Additionally, significant Treatment effects favouring insulin glargine (p < 0.001) and a Treatment × Questionnaire interaction (p < 0.019), with the DTSQc showing more benefits, were found in the type 1 trial.	Treatment effects	26	43	significant	14	25	1
1479-5868-8-59.txt	Significant decreases in the primary blood pressure outcomes demonstrate early effectiveness.	the primary blood pressure outcomes	25	60	Significant	0	11	1
1465-9921-7-110.txt	Results In study A, a single inhalation of SFC and FBC produced a sustained bronchodilation at 16 hours with an adjusted mean increase in FEV 1 from pre-dose of 0.22 L (95% CI 0.19, 0.35 L) for SFC and 0.25 L (95% CI 0.21, 0.37 L) for FBC, which was significantly greater than placebo for both treatments (-0.05 L; p < 0.001).	FEV 1	138	143	significantly	250	263	1
ar4072.txt	At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% ( P <0.001), the back pain score decreased by 50% ( P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% ( P <0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% ( P <0.005).	the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score	244	322	P <0.005	341	349	1
1475-2891-10-120.txt	Results There was no significant effect of multivitamin supplementation on the primary endpoint of the trial: weight gain after eight weeks.	the primary endpoint of the trial: weight gain after eight weeks	75	139	no significant	18	32	1
1745-6215-10-103.txt	No significant differences between the groups concerning effectiveness at one year follow-up were found.	effectiveness at one year follow-up	57	92	No significant	0	14	1
1472-6882-12-19.txt	In the primary outcome model, there was no significant difference in weight regain between the two arms (1.72 kg (se 0.85) weight regain for TAT and 2.96 kg (se 0.96) weight regain for SS, p < 0.097) Tests of between- arm differences for secondary outcomes were also not significant.	secondary outcomes	238	256	not significant	267	282	1
1471-2407-12-495.txt	ANOVA with the Bonferroni correction did not show any significant differences between groups in HRQOL scores.	HRQOL scores	96	108	not show any significant	41	65	1
1756-9966-28-131.txt	Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01).	appetite loss evolution	203	226	significant	58	69	1
1471-2474-8-23.txt	Sensitivity analyses confirmed an advantage for hydrotherapy if we assumed non-completers would all not have responded (response rates 70% versus 38%; p < 0.001) or if we assumed that non-completers would have had the same response as completers (response rates 82% versus 55% p = 0.002).	response rates	247	261	p = 0.002	277	286	1
1472-6882-12-7.txt	Results For BMD, no intent-to-treat analyses were statistically significant; however, per protocol analyses (ie, only including TC participants who completed ≥ 75% training requirements) of femoral neck BMD changes were significantly different between TC and UC (+0.04 vs -0.98%; P = 0.05).	BMD	12	15	significant	64	75	1
1471-244X-12-66.txt	Immediate and 4-month follow-up results revealed a significant time effect on all measured dimensions (social anxiety scales, general anxiety and depression levels, quality of life).	general anxiety and depression levels	126	163	significant	51	62	1
1471-2431-6-29.txt	Children who learned guided imagery with progressive muscle relaxation had significantly greater decrease in the number of days with pain than those learning breathing exercises alone after one (67% vs 21%, P = 0.05), and two (82% vs 45%, P < 0.01) months and significantly greater decrease in days with missed activities at one (85% vs 15%, P = 0.02) and two (95% vs 77%.	the number of days with pain	109	137	P = 0.05	207	215	1
1471-5945-4-18.txt	This "per patient" analysis showed that complete ulcer healing in the HD group was better than in the PC [20/28(71.4%) vs 11/28 (39.3%); difference: 32.1%, 95% CI = 7.4–56.7, (P < 0.01)] or SD [20/28(71.4%) vs 8/27 (29.6%); difference: 41.8%, 95% CI = 17.7–65.8, (P < 0.005)] groups.	complete ulcer healing	40	62	P < 0.01	176	184	1
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	the Chronic Respiratory Questionnaire	69	106	not significantly	43	60	1
1465-9921-8-67.txt	Results Both treatments had no significant effect on induced sputum inflammatory cells, although there was a trend for a reduction in sputum eosinophils.	induced sputum inflammatory cells	53	86	no significant	28	42	1
1471-244X-3-16.txt	Additionally, the drug side effects of the two groups were not significantly different.	the drug side effects	14	35	not significantly	59	76	1
1745-6215-12-239.txt	The corresponding actual treatment figures were zero and 0.32 (0.09, 1.19), which were ns with p = 0.12 and 0.06.	The corresponding actual treatment figures	0	42	p = 0.12 and 0.06	95	112	1
1475-2891-10-85.txt	Results The results indicated a small decrease in the number of migraine like headaches over 12 weeks, although this difference was not statistically significant (IRR 1.15 95% CI 0.94 to 1.41, p = 0.18).	the number of migraine like headaches	50	87	not statistically significant	132	161	1
1479-5868-9-108.txt	The Prudence Score (10 items) in the intervention group at baseline was 5.88, improving to 6.25 at 3 months (improvement = 0.37), compared with 5.84 to 5.96 (improvement = 0.12) in the control group (F = 13.3, p = 0.01).	The Prudence Score (10 items)	0	29	p = 0.01	210	218	1
1471-2458-11-267.txt	Results Glycated hemoglobin A1c and systolic blood pressure (SBP) levels decreased significantly in the PRECEDE group (multivariate analysis of covariance, with baseline glycated hemoglobin A1c, SBP, and variables showing statistically significant differences between groups at baseline visits).	Glycated hemoglobin A1c	8	31	significantly	83	96	1
cc6887.txt	The mean intracranial pressure values 72 hours and 7 days after injury were lower in the progesterone group than in the placebo group, but there was no statistical significance between the two groups ( P > 0.05).	The mean intracranial pressure values	0	37	no statistical significance	149	176	1
1824-7288-38-36.txt	The respiratory rate, chest indrawing, cyanosis, stridor, nasal flaring, wheeze and fever in both groups recorded at enrollment and parameters did not differ significantly between the two groups.	nasal flaring	58	71	not differ significantly	147	171	1
1471-2296-12-2.txt	A significant change was observed for the B12 serum level, but not for the homocysteine level, hematocrit, or mean corpuscular volume.	the B12 serum level	38	57	significant	2	13	1
1475-2891-10-134.txt	MMS resulted in more stunting than standard Fe60F (p = 0.02).	stunting	21	29	p = 0.02	51	59	1
1477-7525-5-57.txt	Results and discussion Significant Questionnaire effects and a Questionnaire × Ceiling interaction (p < 0.001) in both trial datasets showed that the DTSQc detected more improvement in Treatment Satisfaction than the DTSQs, especially when patients had DTSQs scores at/near ceiling at baseline.	Questionnaire effects	35	56	p < 0.001	100	109	1
1472-6882-12-7.txt	Clinical measures of balance and function showed non-significant trends in favor of TC.	function	33	41	non-significant	49	64	1
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	335	347	p < 0.05	383	391	1
1471-5945-4-18.txt	Complete healing of stage II ulcer in the HD group [12/18 (67%)] was better than in the SD group [3/19(16%); difference: 51%, 95% CI = 23.73–78.26, (P < 0.005)], but not significantly different from the PC group [10/21 (48%); difference: 19%, 95% CI = -11.47–49.47, (P > 0.05)].	Complete healing of stage II ulcer	0	34	P < 0.005	149	158	1
1471-2296-4-7.txt	A trend towards a superior improvement in glycemic control was found in the paroxetine group (p = 0.08).	glycemic control	42	58	p = 0.08	94	102	1
cc10289.txt	Of 6 BP measures (taken every 5 minutes) during the study period, nicardipine patients had higher rates of five and six instances within TR than labetalol (47.3% vs 32.8%, P = 0.026).	rates of five and six instances within TR	98	139	P = 0.026	172	181	1
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the distant metastasis rate	145	172	not statistically significant	229	258	1
1471-2474-8-23.txt	Significantly more patients treated with hydrotherapy (40/46, 87%) were much better or very much better than the patients treated with land exercise (19/40, 47.5%), p < 0.001 Fisher's exact test.	were much better or very much better	67	103	Significantly	0	13	1
1741-7015-9-10.txt	With the exception of leucopenia and neutropenia, which were higher in patients in Arm A, there were no significant differences in Grades 3 and 4 toxicities between the two regimens.	Grades 3 and 4 toxicities	131	156	no significant	101	115	1
1471-2377-8-33.txt	For all four nerves, 95% CIs for median differences in amplitude and velocity from baseline to endpoint and baseline to follow-up included 0 (ie, no significant difference vs placebo).	velocity	69	77	no significant	146	160	1
1471-2474-12-132.txt	Responders were more likely to be older, Caucasian, have higher levels of education and income, reservist military status, non smoker, lower BMI, and have received individualized attention via the physical/USI examination (p < .05).	reservist military status	96	121	p < .05	223	230	1
1465-9921-7-141.txt	At 1 minute after inhalation, statistically significant decreases in Borg score were observed for budesonide/formoterol and salbutamol (p = 0.0233 and p < 0.0001, respectively, versus placebo), with similar rapid increases in FEV 1 (both active treatments p < 0.0001 versus placebo).	Borg score	69	79	p < 0.0001	151	161	1
1471-244X-7-13.txt	Additionally, patients of the treatment condition showed significantly greater reduction of co-morbid depression and anxiety as compared to the waiting list condition.	co-morbid depression	92	112	significantly	57	70	1
1471-2466-10-11.txt	Trough FEV 1 after one dose was significantly higher with indacaterol than placebo (p < 0.001).	Trough FEV 1 after one dose	0	27	significantly	32	45	1
cc10367.txt	Intubation conditions (succinylcholine 8.3 ± 0.8; rocuronium 8.2 ± 0.9; P = 0.7) and failed first intubation attempts (succinylcholine 32/200; rocuronium 36/201; P = 1.0) did not differ between the groups.	failed first intubation attempts	85	117	P = 1.0	162	169	1
cc11676.txt	Concentration of troponin T as the most sensitive marker for myocardial injury at POD1 was significantly lower in the sevoflurane group compared with the propofol group (unadjusted difference, -0.4; 95% CI, -0.7 to -0.1; P < 0.01; adjusted difference, -0.2; 95% CI, -0.4 to -0.02; P = 0.03, respectively).	Concentration of troponin T as the most sensitive marker for myocardial injury at POD1	0	86	P = 0.03	281	289	1
1471-2474-8-119.txt	Similar improvements were observed in FIQ score (p < 0.05) and EQ-VAS scale (p < 0.001).	EQ-VAS scale	63	75	p < 0.001	77	86	1
1471-230X-9-85.txt	Results Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061).	GSRS abdominal pain subscore	107	135	significant	79	90	1
1472-6920-12-85.txt	The benefit of the ASK module was limited to the shoulder area (p < 0.001).	the shoulder area	45	62	p < 0.001	64	73	1
1749-8090-4-60.txt	The mean time to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034).	mean blood loss during the operation	139	175	p < 0.001	280	289	1
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	rated as "very much improved" or "much improved"	301	349	p = 0.0471	385	395	1
1471-2377-8-33.txt	More pregabalin-treated patients (49%) than controls (23%) were responders (p <.001).	responders	64	74	p <.001	76	83	1
1471-2474-11-26.txt	The differences between the groups in pain and disability considered over one year were statistically significant favoring naprapathy (p ≤ 0.005).	pain	38	42	p ≤ 0.005	135	144	1
1471-2458-6-299.txt	There were no significant differences between intervention and comparison arms in the proportion of women having a preterm birth, an infant with low birthweight, or an infant with a birth weight <10 th percentile.	an infant with low birthweight	130	160	no significant	11	25	1
cc11300.txt	The corrected colonisation index was similar in the two groups at T0 ( P = 0.36), while a significant statistical difference was observed between the treatment and control groups at T6 (median 0.14 and 0.33, respectively; P = 0.0016), at T9 (median 0.00 and 0.28, respectively; P = 0.0001), at T12 (median 0.00 and 0.41, respectively; P = 0.0008), and at T15 (median 0.00 and 0.42, respectively; P < 0.0003).	The corrected colonisation index	0	32	P < 0.0003	396	406	1
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	TLC	321	324	P < 0.001	358	367	1
1471-2431-9-21.txt	On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.	speech	135	141	significant	12	23	1
ar4072.txt	ANCOVA analysis demonstrated superiority of adalimumab over placebo for the physician global assessment of disease activity, parents' global assessment of subject's overall well-being, active joint count (all P <0.05) and erythrocyte sedimentation rate (ESR) ( P <0.01).	parents' global assessment of subject's overall well-being	125	183	P <0.05	209	216	1
1471-2334-5-2.txt	No significant changes in glucose, insulin, insulin resistance, C-peptide, or waist-to-hip ratios were observed in either treatment arm, nor were differences in these parameters noted between treatments.	insulin resistance	44	62	No significant	0	14	1
1471-2458-6-134.txt	The intervention group showed significant improvements in scores for Knowledge (+12.5%); Attitudes toward seriousness (+13.5%), complications (+8.1%), Practice (+20.0%).	Attitudes toward seriousness	89	117	significant	30	41	1
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for acute nausea and vomiting	29	76	p > 0.05	110	118	1
cc11445.txt	Hemodynamic stability did not differ between SLED-BD and CVVH, whereas patients in the SLED-BD group had significantly fewer days of mechanical ventilation (17.7 ± 19.4 vs 20.9 ± 19.8, P = 0.047) and fewer days in the ICU (19.6 ± 20.1 vs 23.7 ± 21.9, P = 0.04).	days of mechanical ventilation	125	155	P = 0.047	185	194	1
1471-2458-11-711.txt	The difference in obesity rates at the end of the study was even greater among the subgroup of students who were overweight or obese at baseline; 44.6% for the "public commitment" group, versus 53.2% for the control group (p = 0.01).	obesity rates	18	31	p = 0.01	223	231	1
1471-2474-13-81.txt	Conclusion Treatment of acute ankle sprain with semi-rigid brace leads to significantly higher patient comfort and satisfaction, both with similar good outcome.	patient comfort	95	110	significantly	74	87	1
1471-2474-11-64.txt	Conclusions This study demonstrated a trend towards lower limb injury prevention with a significant reduction in primary lower limb muscle strains and weeks missed due to non-contact knee injuries through the addition of a sports chiropractic intervention to the current best practice management.	primary lower limb muscle strains	113	146	significant	88	99	1
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	able to assess the severity of asthma attack	125	169	p = 0.01	221	229	1
1472-6882-12-7.txt	Changes in bone formation markers and physical domains of quality of life were also more favorable in per protocol TC vs UC (P = 0.05).	bone formation markers	11	33	P = 0.05	125	133	1
1742-4690-3-63.txt	No significant changes in pain, bladder function, disability score, gait, proviral load or markers of T-cell activation or proliferation were seen between the two arms.	markers of T-cell activation or proliferation	91	136	No significant	0	14	1
1745-6215-10-103.txt	Conclusion Although our trial failed to find significant differences in VAS, QALYs and ICERs based on VAS and QALYs at one-year follow-up, CEACs suggest that postural exercise therapy according to Mensendieck/Cesar has a higher probability of being cost-effective compared to regular physiotherapy; however further research is required.	ICERs	87	92	failed to find significant	30	56	1
1472-6920-12-85.txt	The final examination (OSCE) showed no significant differences between any of the groups with good overall performances.	The final examination (OSCE)	0	28	no significant	36	50	1
1471-2474-9-143.txt	Muscle force improved in both treatment groups and the AM revealed small, non-significant improvements in time spent standing, walking, and the number of short walking periods.	time spent standing, walking	106	134	non-significant	74	89	1
1471-2318-12-22.txt	Moreover, the test absorbent pad group healed significantly faster than the usual absorbent pad group (p = 0.009).	healed	39	45	p = 0.009	103	112	1
1471-2458-11-475.txt	Significantly more parents in the intervention arm reported vaccinating their child (93% versus 73%, p = 0.04).	reported vaccinating their child	51	83	p = 0.04	101	109	1
cc7695.txt	PSV levels were significantly higher in MRV compared with that of the PSV manual reduction (p < 0.05).	PSV levels	0	10	p < 0.05	92	100	1
1479-5868-8-41.txt	Significant waist circumference reductions were achieved in all 4 groups at month 9 (Standard Care, 3.49 cm, P = 0.0004; GWL, 2.42 cm, P = 0.008; SWA-alone, 3.59 cm, P < 0.0001; GWL+SWA, 6.77 cm, P < 0.0001), but no intervention group had significantly reduced waist circumference compared to the Standard Care group.	waist circumference reductions	12	42	P = 0.0004	109	119	1
cc10143.txt	Invasive procedures were performed in four women in the TA group and in seven controls ( P = NS).	Invasive procedures	0	19	P = NS	89	95	1
ar3703.txt	For the period between baseline and month 6, WOMAC Pain, Physical Function and Total dimensions significantly improved in the OAK group compared to the control group, as did the SF-36 Physical Function, Role Physical, Body Pain, Vitality and Social Functioning domains, as well as hamstring strength in both legs.	hamstring strength in both legs	281	312	significantly	96	109	1
1475-2875-11-217.txt	The median parasite clearance time was significantly slower in the ARPQ group compared with the ASAQ group (48 h vs 36 h, P <0.001) and fever clearance times were shorter in the ASAQ group (12 h vs 24 h, P  = 0.07).	The median parasite clearance time	0	34	significantly	39	52	1
1465-9921-10-69.txt	Improvement of lung function, dyspnea and quality of life as multiple criteria were statistically significant relative to placebo.	quality of life	42	57	significant	98	109	1
1477-5751-8-3.txt	Subjective reports of TQ subscales and general quality of life areas (SF-36), objective audiometric examinations as well as investigated biomarkers for oxidative stress did not reveal any significant treatment effects.	investigated biomarkers for oxidative stress	124	168	not reveal any significant	173	199	1
1471-2474-8-112.txt	Results Multilevel analysis failed to show a significant effect of the EAP on either functional limitations or patient-perceived recovery.	patient-perceived recovery	111	137	failed to show a significant	28	56	1
1472-6963-5-28.txt	After EWRs the mean safety climate scores were not significantly different for all providers nor for nurses in the control units and EWR units (77.93 and 78.33, P = 0.854) and (56.5% positive and 62.7% positive).	the mean safety climate scores	11	41	not significantly	47	64	1
1472-6920-6-38.txt	Changes in all outcomes were similar in the "Training + Feedback" group compared to the "Feedback Only" group (PRPCC: 3.7 vs1.8; trust: -0.7 vs -0.2 ; satisfaction: 1.9 vs 2.5; weight: -2.5 lbs vs -0.7 lbs; systolic blood pressure: 1.7 mm Hg vs 0.1 mm Hg; glycosylated hemoglobin 0.02% vs 0.07%; p = NS for all).	systolic blood pressure	207	230	p = NS	296	302	1
1471-2296-13-98.txt	Costs were not statistically significantly different between the two groups (95% CI -4698;359).	Costs	0	5	not statistically significantly	11	42	1
1472-6882-12-7.txt	Changes in sway parameters were significantly improved by TC vs UC (average sway velocity, P = 0.027; anterior-posterior sway range, P = 0.014).	sway velocity	76	89	P = 0.027	91	100	1
1471-2458-6-134.txt	The intervention group showed significant improvements in scores for Knowledge (+12.5%); Attitudes toward seriousness (+13.5%), complications (+8.1%), Practice (+20.0%).	complications	128	141	significant	30	41	1
1471-244X-3-16.txt	Non-significant, but generally favorable responses were seen in the baclofen group with other outcome measures including intensity of opioid craving and self-reported opioid and alcohol use.	self-reported opioid and alcohol use	153	189	Non-significant	0	15	1
1471-2415-9-7.txt	Mean patient cooperation was also marginally better in the TV group (8.3 ± 0.3) compared to LG group (8.4 ± 0.6) (P = 0.25).	Mean patient cooperation	0	24	P = 0.25	114	122	1
1472-6963-6-145.txt	Results Significant short-term improvements were seen for one recommendation: mupirocin.	one recommendation: mupirocin	58	87	Significant	8	19	1
1824-7288-38-36.txt	The respiratory rate, chest indrawing, cyanosis, stridor, nasal flaring, wheeze and fever in both groups recorded at enrollment and parameters did not differ significantly between the two groups.	cyanosis	39	47	not differ significantly	147	171	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	significant	63	74	1
ar2702.txt	Results Subjects with lower HAQ-DI or SF-36 scores generally had statistically greater RA-associated losses in productivity within and outside the home compared with subjects with higher scores (25 of 32 evaluations were statistically significant).	RA-associated losses in productivity within and outside the home	87	151	significant	235	246	1
1471-2466-11-31.txt	Study sensitivity was confirmed with moxifloxacin demonstrating a significant maximal time-matched QTcF prolongation of 13.90 (10.58, 17.22) ms compared to placebo.	maximal time-matched QTcF prolongation	78	116	significant	66	77	1
1477-7827-2-70.txt	Results The induction-delivery interval was significantly lower in the misoprostol group than in the dinoprostone group (11.9 h vs 15.5 h, p < 0.001).	The induction-delivery interval	8	39	p < 0.001	139	148	1
cc11249.txt	Study group patients had a significant lower reintubation rate than did controls; six patients (17%) versus 19 patients (48%), P < 0.05; respectively, and a significantly lower time under MV; 17.8 ± 6.4 versus 11.7 ± 3.5 days; P < 0.05; respectively.	time under MV	177	190	P < 0.05	227	235	1
1475-2891-6-8.txt	Only stool consistency was significantly different between the two formulas (17% had soft stools on NF and hard stools on SF; no infants had soft stools on SF and hard stools on NF, McNemar test p = 0.046).	stool consistency	5	22	significantly	27	40	1
1471-230X-12-58.txt	Overall discomfort score was less in WC than in SC patients (26 ± 4 mm vs 39 ± 4 mm VAS, respectively, p = 0.012) but there were no significant group differences in throat, chest, or overall discomfort during placement.	throat, chest, or overall discomfort during placement	165	218	no significant	129	143	1
1749-799X-6-45.txt	The subjects receiving InterX fared significantly better clinically.	fared	30	35	significantly	36	49	1
1477-7525-9-110.txt	Hyperglycaemic and hypoglycaemic distress decreased significantly after individual counselling than after group-based rehabilitation (difference -0.3 points, p = 0.04).	Hyperglycaemic and hypoglycaemic distress	0	41	p = 0.04	158	166	1
1479-5868-8-41.txt	Only the GWL+SWA group achieved significant weight loss at month 9 compared to the Standard Care group (P = 0.04).	weight loss	44	55	significant	32	43	1
cc11159.txt	Results There was a significant ( P = 0.02) difference in favor of AP treatment relative to controls for the primary outcome variable.	the primary outcome variable	105	133	significant	20	31	1
1471-2458-9-200.txt	Both types of physical training and usual care improved in pain and functional status over time, but there was only a statistically significant difference in favor of PT on pain improvement at 6 months.	pain improvement at 6 months	173	201	significant	132	143	1
1745-6215-13-59.txt	At randomization, the R and E groups were similar ( P  ≥ 0.11) with respect to mean age (50.7 years), body mass index (28.2 kg/m 2 ), blood pressure (153.9/91.5 mmHg) and the proportions of women (53.6%) and treatment naïve patients (72.7%).	mean age	79	87	P  ≥ 0.11	52	61	1
1471-244X-5-5.txt	Results There was significant improvement from baseline to endpoint on the Yale-Brown Obsessive-Compulsive Scale in both the quetiapine and placebo groups (quetiapine, n = 20, p < 0.0001; placebo, n = 21, p = 0.001) with 40% (n = 8) of quetiapine and 47.6% (n = 10) of placebo treated subjects being classified as responders.	the Yale-Brown Obsessive-Compulsive Scale	71	112	p = 0.001	205	214	1
cc10343.txt	Conclusions CoQ10 levels are significantly lower in septic shock patients than in healthy controls.	CoQ10 levels	12	24	significantly	29	42	1
1472-6904-8-10.txt	With fenofibrate, LDLP size increased from 20.4 nm to 20.8 nm (p = .037).	LDLP size	18	27	p = .037	63	71	1
1471-2474-11-99.txt	With regard to symptoms and sick leave, only small and non-significant effects were found.	sick leave	28	38	non-significant	55	70	1
1471-2369-13-15.txt	U-AQP2 CR increased significantly more after saline in patients than controls, whereas u-ENaC β-CR increased similarly.	U-AQP2 CR	0	9	significantly	20	33	1
1471-2431-9-21.txt	On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.	total score	77	88	significant	12	23	1
1745-6215-12-146.txt	The ODQ score did not show significant differences between the two groups (-5.60 [-8.90 to -2.30] in the wet-cupping group and -1.8 [-5.8 to 2.2] in the waiting-list group, p = 0.14).	The ODQ score	0	13	p = 0.14	173	181	1
1471-230X-12-18.txt	There was no significant difference in the reduction in pain intensity between groups by D7 ( p = 0.11) or D14 ( p = 0.08).	pain intensity	56	70	p = 0.08	113	121	1
1471-2431-11-82.txt	[Na] increased significantly in the 0.9% group (+0.20 mmol/L/h [IQR +0.03, +0.4]; P = 0.02) and increased, but not significantly, in the 0.45% group (+0.08 mmol/L/h [IQR -0.15, +0.16]; P = 0.07).	[Na]	0	4	significantly	15	28	1
1748-5908-6-129.txt	The BP message produced a statistically significant reduction in diastolic BP (-0.62 mmHg; 95% confidence interval -0.82 to -0.42 mmHg) but not systolic BP (-0.06 mmHg, -0.42 to 0.30 mmHg) and increased the odds of achieving target BP control (odds ratio 1.05; 1.00, 1.10).	diastolic BP	65	77	significant	40	51	1
ar3703.txt	Results In the OAK group, VAS pain improved from baseline to week 8 from mean (SEM) 5.21 (0.30) to 3.65 (0.29) ( P ≤ 0.001).	VAS pain	26	34	P ≤ 0.001	113	122	1
1477-7525-1-53.txt	The four measures also demonstrated significant responsiveness to change in underlying clinical status of the patients over the course of the trial, as measured by the independently assessed clinical outcomes.	responsiveness to change in underlying clinical status of the patients	48	118	significant	36	47	1
1746-160X-8-9.txt	The minor irritation of the teeth, experienced prior to treatment, was similar in both groups; however, 4 h after treatment this value was significantly higher in the Provicol group than in the Ledermix group (p < 0.005, t-test).	The minor irritation of the teeth	0	33	significantly	139	152	1
1471-2474-12-132.txt	Responders were more likely to be older, Caucasian, have higher levels of education and income, reservist military status, non smoker, lower BMI, and have received individualized attention via the physical/USI examination (p < .05).	have received individualized attention via the physical/USI examination	150	221	p < .05	223	230	1
cc2896.txt	Results Overall, between-patient variability around the time of neurological assessment was statistically significantly smaller when using remifentanil (remifentanil 0.44 versus fentanyl 0.86 [ P = 0.024] versus morphine 0.98 [ P = 0.006].	between-patient variability around the time of neurological assessment	17	87	P = 0.024	194	203	1
cc10592.txt	Conclusions Pre-operative intravenous fluid loading leads to a non-significant reduction in hospital length of stay after high-risk major surgery and is likely to be cost-effective.	hospital length of stay after high-risk major surgery	92	145	non-significant	63	78	1
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	overall functioning	123	142	p = 0.0008	144	154	1
1465-9921-8-52.txt	Results A comparison of the geometric mean sRaw at 12 hrs post dose in the SFC group to the FP group gave a ratio of 0.76 (0.66 – 0.89, p < 0.001) at week 2 and 0.81 (0.71 – 0.94, p = 0.006) at week 4.	the geometric mean sRaw at 12 hrs post dose	24	67	p = 0.006	180	189	1
1471-2431-8-23.txt	Amoxicillin significantly reduced the proportion of children with i) perforation at the end of therapy (27% to 12% RD = -16% [-31,-1]), ii) recurrent perforation during therapy (18% to 4% RD = -14% [-25,-2]), and iii) reduced the proportion of examinations with a diagnosis of perforation during therapy (20% to 8% adjusted risk ratio 0.36 [0.15,0.83] p = 0.017).	the proportion of examinations with a diagnosis of perforation during therapy	226	303	p = 0.017	352	361	1
1475-2891-10-120.txt	However, significant differences in weight gain were observed among children aged six weeks to six months in subgroup analyses (n = 22; 1.08 kg, compared to 0.46 kg in the placebo group; 95% CI = 0.12, 1.10; p = 0.01).	weight gain	36	47	p = 0.01	208	216	1
1471-2415-8-11.txt	The mean age of bimatoprost was 43.0 ± 3.4 days and the mean age of latanoprost was 43.9 ± 2.8 days (P = .072).	the mean age of latanoprost	52	79	P = .072	101	109	1
1471-2334-3-10.txt	In the APV600/RTV arm, significantly more patients achieved HIV-1 RNA <50 copies/mL (48% [57/118] vs 29% [11/38] with APV1200, P = 0.04), and greater mean reduction from baseline in HIV-1 RNA was observed (-2.21 vs -1.59 log 10 copies/mL, P = 0.028).	HIV-1 RNA	60	69	significantly	23	36	1
1745-6215-13-11.txt	All groups showed significant improvement in time to complete the MT (p < 0.001) and degree of help needed to perform the task: minimal assistance to supervision (CG) and independent performance (EG1+2).	independent performance (EG1+2)	171	202	significant	18	29	1
cc7695.txt	Nineteen patients presented complications during the trial (4 in the PSV manual group and 15 in the MRV automatic group, p < 0.05).	presented complications during the trial	18	58	p < 0.05	121	129	1
1477-7525-9-110.txt	In fact, the individual group experienced a significant relief in hyper- and hypoglycaemic distress compared with the rehabilitation group.	relief in hyper- and hypoglycaemic distress	56	99	significant	44	55	1
1471-2296-8-34.txt	After three months of treatment we found a statistically significant difference between the two treatment groups in GHbA 1c (mean difference = 0.59%-units, p = 0.018) and in SF-36 score (mean difference = 11.0 points, p = 0.039).	SF-36 score	174	185	p = 0.039	218	227	1
1465-9921-11-112.txt	Results After three month training period, in the Nordic Walking group time spent walking and standing as well as intensity of walking increased (Δ walking time: +14.9 ± 1.9 min/day; Δ standing time: +129 ± 26 min/day; Δ movement intensity: +0.40 ± 0.14 m/s 2 ) while time spent sitting decreased (Δ sitting time: -128 ± 15 min/day) compared to baseline (all: p < 0.01) as well as compared to controls (all: p < 0.01).	sitting time	300	312	p < 0.01	408	416	1
cc11215.txt	Results At 6 months post-treatment, results indicated significantly better absolute values for iNO versus placebo for mean ± SD total lung capacity (TLC, 5.54 ± 1.42 vs 4.81 ± 1.00; P = 0.026).	mean ± SD total lung capacity	118	147	P = 0.026	182	191	1
1477-7525-9-110.txt	In the rehabilitation group cardiovascular distress decreased 0.25 points ( p = 0.01).	cardiovascular distress	28	51	p = 0.01	76	84	1
1471-2466-11-16.txt	Results At 4 weeks, there was no improvement in the atorvastatin group compared to the placebo group in morning peak expiratory flow [-10.67 L/min, 95% CI -38.70 to 17.37, p = 0.449], but there was an improvement with atorvastatin in asthma quality of life score [0.52, 95% CI 0.17 to 0.87 p = 0.005].	asthma quality of life score	234	262	p = 0.005	290	299	1
1471-2407-9-21.txt	In children over 6-year of age (n = 72), the rate of success was significantly higher in the pillow group (58.5% vs 41.5%, p = 0.031), with a tendency to feel less pain (median VAS 25 vs 15 mm, p = 0.39) and being more satisfied (84.4% vs 75.0%, p = 0.34).	the rate of success	41	60	significantly	65	78	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.001	570	579	1
1756-9966-28-131.txt	Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01).	insomnia	190	198	p < 0.01	256	264	1
1471-2415-6-23.txt	Lutein had a statistically significant effect on visual field (p-value: 0.038) and this effect increased in the model assuming a 6-week delay in effect of lutein.	visual field	49	61	significant	27	38	1
1471-2318-11-27.txt	Results Intervention attendance rates were higher in the CT and PACT groups: CT: 96%, PA: 76%, PACT: 90% (p=0.004), the interventions produced marked changes in cognitive and physical performance measures (p≤0.05), and retention rates exceeded 90%.	Intervention attendance rates	8	37	p=0.004	106	113	1
1741-7015-10-71.txt	Results Compared with the patients in the UC arm, the patients in the CP arm had a significantly lower risk of mortality at 7 days (OR = 0.10; 95% CI 0.01 to 0.95) and significantly lower rates of adverse functional outcomes, expressed as the odds of not returning to pre-stroke functioning in their daily life (OR = 0.42; 95 CI 0.18 to 0.98).	risk of mortality	103	120	significantly	83	96	1
1471-2458-12-944.txt	Prevalence of high blood pressure, high cholesterol and smoking were reduced significantly (p <0.01) in both groups.	high cholesterol	35	51	significantly	77	90	1
1475-2891-11-57.txt	Conclusion Different dietary approaches based on portion control, low energy density, or low glycemic index produced similar, significant short-term improvements in body composition, diet compositin, and MetS components in overweight and obese adults undergoing weekly weight loss meetings.	body composition	165	181	significant	126	137	1
1741-7015-4-14.txt	Significantly more patients in the WS ® 5570 treatment groups than in the placebo group showed treatment response and remission.	remission	118	127	Significantly	0	13	1
cc2896.txt	Conclusions Analgesia-based sedation with remifentanil permitted significantly faster and more predictable awakening for neurological assessment.	awakening for neurological assessment	107	144	significantly	65	78	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.000	586	595	1
1465-9921-11-112.txt	Results After three month training period, in the Nordic Walking group time spent walking and standing as well as intensity of walking increased (Δ walking time: +14.9 ± 1.9 min/day; Δ standing time: +129 ± 26 min/day; Δ movement intensity: +0.40 ± 0.14 m/s 2 ) while time spent sitting decreased (Δ sitting time: -128 ± 15 min/day) compared to baseline (all: p < 0.01) as well as compared to controls (all: p < 0.01).	movement intensity	221	239	p < 0.01	408	416	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	significant	63	74	1
1471-227X-9-18.txt	Following training, time to correct placement decreased significantly with 22.9 ± 13.5 s for the LMA-Classic and 22.9 ± 19.0 s for the LMA-Fastrach, respectively (p < 0.05).	time to correct placement	20	45	significantly	56	69	1
1471-2474-11-64.txt	The difference for primary lower-limb muscle strains was significant (OR:0.097, 95%CI:0.011-0.839, p = 0.025).	primary lower-limb muscle strains	19	52	p = 0.025	99	108	1
1472-6831-12-13.txt	The change in mean tooth shade scores was statistically significantly greater in the gum-group than in the tablet group at 2 (p = 0.015), 6 (p = 0.011) and 12 weeks (p = 0.003) with greater lightening in the gum-group at each examination period.	mean tooth shade scores	14	37	p = 0.011	141	150	1
1475-2891-11-57.txt	There were no significant differences among the three groups in any variable related to body composition, dietary composition, or MetS components.	dietary composition	106	125	no significant	11	25	1
1471-2377-10-92.txt	Post hoc analyses of patients with PHN for at least 6 months showed significantly greater reductions in "average pain for the past 24 hours" NPRS scores from baseline to weeks 2-8 in NGX-4010 patients compared to controls (37.6% versus 23.4%; p = 0.0291).	"average pain for the past 24 hours" NPRS scores	104	152	significantly	68	81	1
1471-2377-10-92.txt	PGIC analysis in this subgroup demonstrated that significantly more NGX-4010 recipients considered themselves much or very much improved compared with control at week 12 (40% versus 20%; p = 0.0403;).	considered themselves much or very much improved	88	136	p = 0.0403	187	197	1
1471-2466-10-11.txt	Trough FEV 1 after one dose was significantly higher with indacaterol than placebo (p < 0.001).	Trough FEV 1 after one dose	0	27	p < 0.001	84	93	1
cc6104.txt	Results Temperature decline was significantly higher with the water-circulating blankets (1.33 ± 0.63°C/h), gel-pads (1.04 ± 0.14°C/h) and intravascular cooling (1.46 ± 0.42°C/h) compared to conventional cooling (0.31 ± 0.23°C/h) and the air-circulating blankets (0.18 ± 0.2°C/h) (p < 0.01).	Temperature decline	8	27	p < 0.01	281	289	1
1471-2458-12-602.txt	Over the six-month period from baseline, participants receiving the Australian TLC (Telephone-Linked Care) Diabetes program showed a 0.8% decrease in geometric mean HbA 1c from 8.7% to 7.9%, compared with a 0.2% HbA 1c reduction (8.9% to 8.7%) in the usual care arm (p = 0.002).	geometric mean HbA 1c	150	171	p = 0.002	267	276	1
1471-2369-12-9.txt	The albumin-adjusted serum calcium concentration was significantly higher (9.5 ± 0.8 vs 8.8 ± 0.8; p < 0.001) and iPTH was significantly lower in the calcium acetate group compared to placebo (150 ± 157 vs 351 ± 292 pg/mL respectively; p < 0.001).	The albumin-adjusted serum calcium concentration	0	48	significantly	53	66	1
1471-2474-13-141.txt	Results A statistically significant difference (p = 0,009) regarding the mobility as measured with the four-item Barthel index was found at the 5th postoperative day, favouring the DAA.	the mobility as measured with the four-item Barthel index	69	126	p = 0	48	53	1
1471-2407-12-423.txt	Although the median PFS time for maintenance phase for both arms was 3.2 months, the one-sided p-value for the PFS HR comparison was less than the prespecified limit of 0.2 (HR = 0.76, two-sided 95% confidence interval [CI]: 0.42 to 1.37; one-sided p-value = 0.1815), indicating that PFS was sufficiently long in the pemetrexed/BSC arm to warrant further investigation.	the PFS HR	107	117	p-value = 0.1815	249	265	1
1465-9921-7-141.txt	At 1 minute after inhalation, statistically significant decreases in Borg score were observed for budesonide/formoterol and salbutamol (p = 0.0233 and p < 0.0001, respectively, versus placebo), with similar rapid increases in FEV 1 (both active treatments p < 0.0001 versus placebo).	FEV 1	226	231	p < 0.0001	256	266	1
1477-7525-1-10.txt	The meditation group exhibited a mean decrease of 0.1 infractions over the four months compared to an increase of 0.3 in the control group (p < .03).	infractions	54	65	p < .03	140	147	1
1471-2474-11-229.txt	Results Based on log-transformed data, mean improvement in BMD was 1.34 (90% confidence interval (CI) 1.14 to 1.57) times greater for LIPUS-treated subjects compared to sham (p = 0.002).	BMD	59	62	p = 0.002	175	184	1
cc6999.txt	Uncontrollable intracranial pressure occurred in 11 patients (50%) in the thiopental treatment group and in 18 patients (82%) in the pentobarbital group ( P = 0.03).	Uncontrollable intracranial pressure	0	36	P = 0.03	155	163	1
1471-5945-4-18.txt	This "per patient" analysis showed that complete ulcer healing in the HD group was better than in the PC [20/28(71.4%) vs 11/28 (39.3%); difference: 32.1%, 95% CI = 7.4–56.7, (P < 0.01)] or SD [20/28(71.4%) vs 8/27 (29.6%); difference: 41.8%, 95% CI = 17.7–65.8, (P < 0.005)] groups.	complete ulcer healing	40	62	P < 0.005	264	273	1
1477-7525-9-110.txt	However, vitality-score increased 5.2 points ( p = 0.12) within the rehabilitation group and 5.6 points ( p = 0.03) points among individual counselling participants.	vitality-score	9	23	p = 0.12	47	55	1
1742-4690-3-63.txt	No significant changes in pain, bladder function, disability score, gait, proviral load or markers of T-cell activation or proliferation were seen between the two arms.	pain	26	30	No significant	0	14	1
1471-2458-10-81.txt	In troop meetings, intervention troop leaders promoted PA (x 2 = 23.46, p < .001) and healthful eating (x 2 = 18.14, p < .001) more frequently, and discouraged healthful eating and PA less frequently (x 2 = 9.63, p = .002) compared to control troop leaders.	discouraged healthful eating and PA	148	183	p = .002	213	221	1
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	412	424	p < 0.05	460	468	1
cc6999.txt	Under logistic regression analysis – undertaken in an effort to adjust for the cranial tomography characteristics, which were unfavourable for pentobarbital – thiopental was more effective than pentobarbital in terms of controlling intracranial pressure (odds ratio = 5.1, 95% confidence interval 1.2 to 21.9; P = 0.027).	controlling intracranial pressure	220	253	P = 0.027	310	319	1
1465-9921-11-135.txt	At 5 min post-dose on Day 1, the mean FEV 1 for both indacaterol doses was significantly higher than placebo (by 120 and 130 mL for indacaterol 150 and 300 μg, respectively; p < 0.001) and tiotropium (by 80 mL for both doses; p < 0.001).	the mean FEV 1	29	43	p < 0.001	226	235	1
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	HDL	190	193	p < 0.001	205	214	1
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	delivered within 12 hours	29	54	p < 0.01	72	80	1
ar4072.txt	At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% ( P <0.001), the back pain score decreased by 50% ( P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% ( P <0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% ( P <0.005).	the back pain score	116	135	P <0.005	155	163	1
1471-2415-6-23.txt	The changes in normal (100%), low (4%), and very low (0.1%) illumination log CS were not statistically significant (p-values: 0.34, 0.23, and 0.32, respectively).	normal (100%), low (4%), and very low (0.1%) illumination log CS	15	79	not statistically significant	85	114	1
1471-2415-9-7.txt	Results The mean age in TetraVisc (TV) group was 70.4 years and in the lidocaine gel group (LG) it was 70.6 years (p = 0.89).	The mean age	8	20	p = 0.89	115	123	1
cc6173.txt	These patients showed significantly lower D-dimer, plasminogen activator inhibitor 1, and creatine-kinase levels and a trend toward lower levels of soluble tumor necrosis factor receptor and interleukin-6 within the first 24 hours after CPB.	plasminogen activator inhibitor 1	51	84	significantly	22	35	1
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	HDL-cholesterol	304	319	P = 0.583	341	350	1
1756-9966-28-131.txt	Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01).	global health status	95	115	p < 0.01	256	264	1
1756-9966-28-131.txt	Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01).	fatigue	160	167	significant	58	69	1
1471-2407-7-166.txt	After three and six months the treatment group showed a significant improvement in shoulder mobility and had significantly less pain than the control group.	pain	128	132	significantly	109	122	1
1471-2288-12-147.txt	The response rate was 22% among individuals randomised to attend the Parramatta pathology centre without a reminder and 23% among those sent a reminder letter (RR = 1.01, 0.93-1.09, p = 0.74).	The response rate	0	17	p = 0.74	182	190	1
1472-6882-11-49.txt	Outcomes associated with cognitive dysfunction were not statistically significant.	Outcomes associated with cognitive dysfunction	0	46	not statistically significant	52	81	1
1472-6882-12-19.txt	Conclusions The primary analysis showed no significant difference in weight regain between TAT and SS, while secondary and post hoc analyses indicate direction for future research.	weight regain	69	82	no significant	40	54	1
1471-2474-8-36.txt	Conclusion When used for the short-term treatment of plantar heel pain, a two-week stretching program provides no statistically significant benefit in 'first-step' pain, foot pain, foot function or general foot health compared to not stretching.	foot pain	170	179	no statistically significant	111	139	1
1475-2891-3-20.txt	There was also a significant between-group difference between the fish oil group and the no-treatment controls in the rate of stress reduction ( p < 0.05).	the rate of stress reduction	114	142	significant	17	28	1
1471-230X-11-110.txt	The ICBT group demonstrated significantly ( p < .001) larger improvements on the IBS-related outcome scales than the waiting list group.	the IBS-related outcome scales	77	107	significantly	28	41	1
1471-2318-11-27.txt	Results Intervention attendance rates were higher in the CT and PACT groups: CT: 96%, PA: 76%, PACT: 90% (p=0.004), the interventions produced marked changes in cognitive and physical performance measures (p≤0.05), and retention rates exceeded 90%.	cognitive and physical performance measures	161	204	p≤0.05	206	212	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.042	381	390	1
1475-2875-10-358.txt	Conclusion Combining IPTc and HMM can provide significant additional benefit in preventing clinical episodes of malaria as well as anaemia among children in Senegal.	anaemia	131	138	significant	46	57	1
1745-6215-12-239.txt	For the non-HPD stratum, the intent-to-treat relative risks of spontaneous premature birth at < 34 and < 37 weeks' gestation were 0.33 (0.03, 3.16) and 0.49 (0.17, 1.44), respectively, and they were non-significant (ns) with p = 0.31 and 0.14.	spontaneous premature birth at < 34	63	98	p = 0.31	225	233	1
1477-7827-1-63.txt	There were no differences in the nature or number of adverse events between the treatment groups although Bravelle(R) injections were reported to be significantly less painful.	painful	168	175	significantly	149	162	1
1824-7288-38-36.txt	The respiratory rate, chest indrawing, cyanosis, stridor, nasal flaring, wheeze and fever in both groups recorded at enrollment and parameters did not differ significantly between the two groups.	The respiratory rate	0	20	not differ significantly	147	171	1
1471-2466-10-11.txt	Indacaterol demonstrated significantly higher peak FEV 1 than placebo, both on Day 1 and at Week 12, with indacaterol-placebo differences (LSM ± SEM) of 190 ± 28 (p < 0.001) and 160 ± 28 mL (p < 0.001), respectively.	peak FEV 1	46	56	p < 0.001	163	172	1
bcr1757.txt	In the active-treatment groups, the baseline-adjusted AUC at weeks 0–12 and 0–24 for PINP was significantly greater for exemestane than the other aromatase inhibitors.	PINP	85	89	significantly	94	107	1
1477-7819-10-94.txt	The overall rate of surgical-site infection was lower in the experimental group (11.1% center 1, 17.5% center 2; overall 15.5%) than in controls (14.3% center 1, 24.2% center 2, overall 20.4%), but the observed difference was not statistically significant ( P  = 0.451), even with respect to surgical-site infection grade 1 (superficial) versus grades 2 and 3, or grade 1 and 2 versus grade 3.	The overall rate of surgical-site infection	0	43	not statistically significant	226	255	1
1471-2369-12-9.txt	The albumin-adjusted serum calcium concentration was significantly higher (9.5 ± 0.8 vs 8.8 ± 0.8; p < 0.001) and iPTH was significantly lower in the calcium acetate group compared to placebo (150 ± 157 vs 351 ± 292 pg/mL respectively; p < 0.001).	iPTH	114	118	significantly	123	136	1
1479-5868-8-29.txt	Results and discussion Multilevel modelling found no significant effect of the intervention on MET minutes of activity (from the IPAQ) at any of the follow-up time points controlling for baseline activity.	MET minutes of activity (from the IPAQ)	95	134	no significant	50	64	1
1471-2407-11-131.txt	However, non-PDP patients with RTDI-cut-off levels <85% showed a shorter OS than patients with higher RTDI levels (p = 0.0086).	OS	73	75	p = 0.0086	115	125	1
1471-2288-7-30.txt	There was no significant difference on carer quality of life.	carer quality of life	39	60	no significant	10	24	1
1471-2474-12-132.txt	Age, race/ethnicity, education, military status, smoking history, BMI, and whether a Soldier received the physical/USI examination remained statistically significant (p < .05) when considered in a full multivariate model.	race/ethnicity	5	19	significant	154	165	1
cc11215.txt	Nonsignificant differences were found in absolute FEV1, FEV1/FVC, FVC, forced expiratory flow from 25% to 75% of FVC, functional residual capacity, and CO diffusion.	FEV1/FVC	56	64	Nonsignificant	0	14	1
1471-2474-12-153.txt	Compared to placebo, this dosage of canakinumab was also associated with significantly more favorable responses at week 12 with respect to secondary endpoints including the Disease Activity Score 28, scores on the Health Assessment Questionnaire and Functional Assessment of Chronic Illness Therapy-Fatigue, swollen 28-joint count, and patient's and physician's global assessments of disease activity.	swollen 28-joint count	308	330	significantly	73	86	1
1745-6215-12-13.txt	In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg ( P = 0.03) for systolic office BP; 0.70 mm Hg ( P = 0.08) for diastolic office BP; 0.36 mm Hg ( P = 0.49) for 24-h systolic BP; and 0.05 mm Hg ( P = 0.88) for 24-h diastolic BP.	systolic office BP	89	107	P = 0.03	75	83	1
1471-2458-11-475.txt	Heightened decisional conflict was evident for parents making the MMR decision for their first child (effect estimate = -0.25, p = 0.003), who were concerned (effect estimate = 0.07, p < 0.001), had less positive attitudes (effect estimate = -0.20, p < 0.001) yet stronger intentions (effect estimate = 0.09, p = 0.006).	decisional conflict	11	30	p = 0.006	309	318	1
1471-2393-10-15.txt	The decision aid group were significantly more likely to consider their care providers opinion (RR 1.28 95%CI 0.64, 0.95).	likely to consider their care providers opinion	47	94	significantly	28	41	1
1472-6920-11-57.txt	Results Additional mannequin training was not associated with improved performance (37% of intervention participants received an overall placement rating of > 3/5 on their first patient compared to 48% of the control group, X 2 = 0.81, p = 0.37).	improved performance	62	82	p = 0.37	236	244	1
1471-2431-9-21.txt	Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).	overall functioning	95	114	p = 0.0336	116	126	1
1471-2431-6-29.txt	Children who learned guided imagery with progressive muscle relaxation had significantly greater decrease in the number of days with pain than those learning breathing exercises alone after one (67% vs 21%, P = 0.05), and two (82% vs 45%, P < 0.01) months and significantly greater decrease in days with missed activities at one (85% vs 15%, P = 0.02) and two (95% vs 77%.	days with missed activities	294	321	P = 0.02	342	350	1
1756-0500-5-273.txt	Knee-specific scores continued to improve for both groups over the 10-years, despite diminishing overall health with no significant group differences seen.	overall health	97	111	no significant	117	131	1
1471-230X-12-37.txt	The end-tidal CO 2 level was significantly lower in the duodenal balloon group than in the regular group ( P  = 0.0001).	The end-tidal CO 2 level	0	24	significantly	29	42	1
1475-2891-11-47.txt	Net changes in GPx, SOD and catalase activities, and DNA tail length and tail moment were significantly different between the high-dose group and the placebo group.	DNA tail length	53	68	significantly	90	103	1
cc11159.txt	The results in renal parameters were supported by significantly more pronounced reductions in the systemic markers C-reactive protein, Interleukin-6, LPS-binding protein and in the urinary excretion of Kidney Injury Molecule-1 and Interleukin-18 in AP-treated patients relative to placebo.	LPS-binding protein	150	169	significantly	50	63	1
1471-2431-7-27.txt	Pacifier use reduced FLACC score (not statistically significant), crying times (statistically significant) but not heart rate.	crying times	66	78	significant	94	105	1
1471-2466-11-61.txt	However, non-study COPD medication costs were higher for the LABA or LAMA therapy group ($911 SE = 91) compared to the LABA and LAMA therapy group ($668 SE = 58; p = 0.0238) and non-study respiratory medications were approximately $100 greater for the LABA or LAMA therapy group relative to both LABA and LAMA (p = .0018) and LABA, LAMA, and ICS (p = .0071) therapy groups.	non-study respiratory medications	178	211	p = .0071	347	356	1
1471-2458-12-706.txt	Controls had significantly poorer appetites (P = 0.01) (OR 2.9, [1.24-6.82]) compared to treated children.	appetites	34	43	P = 0.01	45	53	1
1471-2474-11-26.txt	The differences between the groups in pain and disability considered over one year were statistically significant favoring naprapathy (p ≤ 0.005).	pain	38	42	significant	102	113	1
1475-2891-7-7.txt	Time to first malaria episode was longer in the supplemented group (p = 0.015).	Time to first malaria episode	0	29	p = 0.015	68	77	1
1472-6882-7-34.txt	Compared to baseline both treatments showed significant benefits in WOMAC and VAS outcomes within one week (P < 0.05), with a similar, progressive improvement over the course of the 8 week treatment protocol (45–62% reduction in WOMAC or VAS scores).	VAS outcomes	78	90	P < 0.05	108	116	1
1471-2318-6-18.txt	There were no significant group differences on the GDS at follow-up.	the GDS	47	54	no significant	11	25	1
1471-2474-13-118.txt	Results There were similar, significant improvements in functional capacity for the RT and NMES groups at week 8 compared to week 1 (p≤0.001) and compared to the control group (p < 0.005), and the improvements were maintained at week 14 (p≤0.001).	functional capacity	56	75	p≤0.001	238	245	1
1745-6215-12-146.txt	The ODQ score did not show significant differences between the two groups (-5.60 [-8.90 to -2.30] in the wet-cupping group and -1.8 [-5.8 to 2.2] in the waiting-list group, p = 0.14).	The ODQ score	0	13	significant	27	38	1
1471-244X-3-16.txt	Baclofen also showed a significant superiority over placebo in terms of opiate withdrawal syndrome and depressive symptoms.	opiate withdrawal syndrome	72	98	significant	23	34	1
1471-2474-8-23.txt	Similarly there were no significant differences between groups in terms of changes to HAQ, EQ-5D utility score, EQ VAS and pain VAS.	EQ VAS	112	118	no significant	21	35	1
1475-2891-10-85.txt	Conclusions Use of the ELISA test with subsequent diet elimination advice did not reduce the disability or impact on daily life of migraine like headaches or the number of migraine like headaches at 12 weeks but it did significantly reduce the number of migraine like headaches at 4 weeks.	the number of migraine like headaches at 4 weeks	240	288	significantly	219	232	1
1475-2875-9-378.txt	The re-infection rate was 1.7% in the AS + AQ arm and 5.7% in the AS + SMP arm (p = 0.021).	The re-infection rate	0	21	p = 0.021	80	89	1
1471-244X-7-13.txt	Significant improvement of the online working alliance in the course of treatment and a substantial correlation between the quality of the online relationship at the end of treatment and treatment outcome emerged.	the online working alliance	27	54	Significant	0	11	1
cc3737.txt	There were no statistically significant differences in survival without supplemental oxygen or on ventilator, mortality, therapy failure, or crossover.	crossover	141	150	no statistically significant	11	39	1
ar4034.txt	A significant treatment effect for DAS28(CRP) was only observed at Day 15 in the prednisone 15 mg group (effect size = 0.95, P = 0.032).	DAS28(CRP)	35	45	significant	2	13	1
1471-5945-4-18.txt	Complete healing of stage II ulcer in the HD group [12/18 (67%)] was better than in the SD group [3/19(16%); difference: 51%, 95% CI = 23.73–78.26, (P < 0.005)], but not significantly different from the PC group [10/21 (48%); difference: 19%, 95% CI = -11.47–49.47, (P > 0.05)].	Complete healing of stage II ulcer	0	34	not significantly	166	183	1
1472-6882-11-93.txt	The groups differed regarding large bowel movements which decreased linearly in the control group (p = 0,011) but not in the acupuncture group (p = 0,787).	large bowel movements	30	51	p = 0,787	144	153	1
1477-7525-9-110.txt	However, fatigue distress decreased 0.40 points within the rehabilitation group ( p = 0.01) and 0.34 points within the individual counselling group ( p < 0.01).	fatigue distress	9	25	p = 0.01	82	90	1
1472-6904-8-10.txt	Fenofibrate resulted in 17% rise in large LDLP (p = .06 vs pre) and 32% drop in small LDLP (p = .007 vs pre).	small LDLP	80	90	p = .007	92	100	1
1471-230X-12-37.txt	The VAS score for the occurrence of nausea due to abdominal distension after ESD indicated a significant difference ( P  = 0.031).	The VAS score for the occurrence of nausea due to abdominal distension	0	70	significant	93	104	1
1471-2474-12-132.txt	Age, race/ethnicity, education, military status, smoking history, BMI, and whether a Soldier received the physical/USI examination remained statistically significant (p < .05) when considered in a full multivariate model.	 whether a Soldier received the physical/USI examination	74	130	p < .05	167	174	1
1475-2875-5-113.txt	There was no significant difference between groups in fever and parasite clearance time, improvement of anaemia and gametocyte carriage at day 28.	gametocyte carriage	116	135	no significant	10	24	1
1471-2415-6-23.txt	Results For visual acuity (VA) at normal illumination level, treatment with lutein reduced logMAR, ie improved VA, but this effect was not statistically significant.	VA	111	113	not statistically significant	135	164	1
1471-2334-5-2.txt	No significant changes in glucose, insulin, insulin resistance, C-peptide, or waist-to-hip ratios were observed in either treatment arm, nor were differences in these parameters noted between treatments.	waist-to-hip ratios	78	97	No significant	0	14	1
1756-9966-28-131.txt	Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01).	nausea	169	175	p < 0.01	256	264	1
1471-2474-13-15.txt	Significantly more African American subjects with mild or moderate renal impairment achieved sUA < 6.0 mg/dL in the febuxostat 80 group than in either the febuxostat 40 mg or allopurinol group ( p < 0.05).	sUA	93	96	Significantly	0	13	1
1471-2377-10-91.txt	Results The ABC-C Irritability Subscale scores showed significant improvement (p < 0.001), as did the VAS (p = 0.003) and the CGI (p < 0.001).	the CGI	122	129	p < 0.001	131	140	1
1471-2466-10-11.txt	provided clinically significant and sustained bronchodilation, reduced rescue medication use, and had a safety and tolerability profile similar to placebo.	bronchodilation	46	61	significant	20	31	1
1746-6148-8-157.txt	When comparing variables within the fish oil group as change from baseline to trial end, there were significant positive changes in PVF, HCPI, NSAID use, Quality of life VAS, as well as in all three scores in the comparative questionnaire (locomotion, every-day situations, and skin & coat).	PVF	132	135	significant	100	111	1
1471-2458-11-573.txt	Conclusion This study shows that high coverage of the IPTi can be obtained when the strategy is implemented using routine health services and implementation results in a significant increase in coverage of EPI vaccines in the district of Kolokani, Mali.	coverage of EPI vaccines	194	218	significant	170	181	1
1824-7288-37-48.txt	Paracetamol was significantly more effective than placebo in the SPID of children and parents ( P < 0.05) but not in the SPID reported by investigators, 1 hour after drug administration.	the SPID of children and parents	61	93	P < 0.05	96	104	1
1471-2334-8-17.txt	Significant increments in serum TGF-beta and advanced oxidation protein products were observed in the placebo group but not among IFN receiving patients.	serum TGF-beta	26	40	Significant	0	11	1
1471-2474-7-5.txt	After treatment, significant reductions were observed in functional limitations, patient's main complaints and pain intensity for all three active treatments compared to the WL.	patient's main complaints	81	106	significant	17	28	1
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	529	590	p < 0.05	691	699	1
1745-6215-13-59.txt	At randomization, the R and E groups were similar ( P  ≥ 0.11) with respect to mean age (50.7 years), body mass index (28.2 kg/m 2 ), blood pressure (153.9/91.5 mmHg) and the proportions of women (53.6%) and treatment naïve patients (72.7%).	the proportions of women (53.6%) and treatment naïve patients	171	232	P  ≥ 0.11	52	61	1
1472-6831-11-35.txt	There were no statistically significant differences between groups with respect to follow-up prevalence of plaque and calculus.	follow-up prevalence of plaque and calculus	83	126	no statistically significant	11	39	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.002	413	422	1
1471-2474-12-132.txt	Age, race/ethnicity, education, military status, smoking history, BMI, and whether a Soldier received the physical/USI examination remained statistically significant (p < .05) when considered in a full multivariate model.	military status	32	47	p < .05	167	174	1
1741-7015-10-54.txt	With regard to secondary outcomes, blood glucose, HbA1c, low-density lipoprotein/high-density lipoprotein ratio, and HR were significantly decreased by phlebotomy.	low-density lipoprotein/high-density lipoprotein ratio	57	111	significantly	125	138	1
cc6173.txt	In the TA group, we observed a significant reduction in the incidence of VS ( P = 0.003), the use of norepinephrine ( P = 0.029), and time on mechanical ventilation ( P = 0.018).	time on mechanical ventilation	134	164	significant	31	42	1
1472-6920-6-38.txt	Changes in all outcomes were similar in the "Training + Feedback" group compared to the "Feedback Only" group (PRPCC: 3.7 vs1.8; trust: -0.7 vs -0.2 ; satisfaction: 1.9 vs 2.5; weight: -2.5 lbs vs -0.7 lbs; systolic blood pressure: 1.7 mm Hg vs 0.1 mm Hg; glycosylated hemoglobin 0.02% vs 0.07%; p = NS for all).	PRPCC	111	116	p = NS	296	302	1
ar4034.txt	The comparison between daily 15 mg prednisone and placebo at Day 15 yielded a statistically significant treatment effect (effect size = 1.17, P = 0.013) in change from baseline in the primary endpoint, but borderline for prednisone 7.5 mg daily versus placebo (effect size = 0.61, P = 0.071).	the primary endpoint	180	200	significant	92	103	1
1471-2466-10-11.txt	Indacaterol demonstrated significantly higher peak FEV 1 than placebo, both on Day 1 and at Week 12, with indacaterol-placebo differences (LSM ± SEM) of 190 ± 28 (p < 0.001) and 160 ± 28 mL (p < 0.001), respectively.	peak FEV 1	46	56	significantly	25	38	1
1471-2466-10-11.txt	Indacaterol significantly reduced the percentage of days of poor control versus placebo by 22.5% (p < 0.001) and was also associated with significantly reduced use of rescue medication (p < 0.001).	use of rescue medication	160	184	p < 0.001	186	195	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	significant	63	74	1
1471-2334-8-17.txt	Significant increments in serum TGF-beta and advanced oxidation protein products were observed in the placebo group but not among IFN receiving patients.	advanced oxidation protein products	45	80	Significant	0	11	1
1471-230X-10-72.txt	In multivariate analysis, HIV infection (OR 4.1; 95%CI 2.2-7.8; P < 0.001) was associated with hypochlorhydria, but taking anti-retroviral treatment (OR 0.16; 0.04-0.67; P = 0.01) and allocation to micronutrient supplementation (OR 0.53; 0.28-0.99; P < 0.05) were protective.	allocation to micronutrient supplementation	184	227	P < 0.05	249	257	1
1471-2466-7-4.txt	Trends to clinical improvements favouring active treatment were however consistently seen in the patient-centered outcomes: Asthma Control Questionnaire mean difference (active – placebo) [95% CI] = -0.35 [-0.78 to 0.07], p = 0.10, Asthma Quality of Life Questionnaire mean difference 0.42 [-0.08 to 0.93], p = 0.09, Leicester Cough Questionnaire mean difference 0.49, [-0.18 to 1.16], p = 0.15.	Asthma Quality of Life Questionnaire mean difference	232	284	p = 0.09	307	315	1
1465-9921-8-52.txt	FEV 1 was also significantly superior at week 2 in the SFC group (mean difference 0.16L, 95% CI; 0.03 – 0.28, p = 0.015), but not at week 4 (mean difference 0.17L, 95% CI -0.01 – 0.34, p = 0.060).	FEV 1	0	5	significantly	15	28	1
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	steps/day	122	131	p < 0.001	327	336	1
1824-7288-37-48.txt	Global evaluation of efficacy showed a statistically significant advantage of paracetamol over placebo after 1 hour either for children, parents or investigators.	Global evaluation of efficacy	0	29	significant	53	64	1
1471-230X-11-100.txt	Meta-analysis of studies (regardless of indication) did not find any significant differences in the mean number of polyps (5 RCT, 2479 participants; WMD -0.07 95% CI -0.21 to 0.07; I2 68%), the mean number of adenomas (8 RCT, 3517 participants; WMD -0.08 95% CI -0.17; 0.01 to I2 62%) and the rate of patients with at least one adenoma (8 RCT, 3512 participants, RR 0.96 95% CI 0.88 to 1,04;I2 0%).	the mean number of polyps	96	121	not find any significant	56	81	1
1471-2474-9-143.txt	Muscle force improved in both treatment groups and the AM revealed small, non-significant improvements in time spent standing, walking, and the number of short walking periods.	the number of short walking periods	140	175	non-significant	74	89	1
1741-7015-10-54.txt	With regard to secondary outcomes, blood glucose, HbA1c, low-density lipoprotein/high-density lipoprotein ratio, and HR were significantly decreased by phlebotomy.	HR	117	119	significantly	125	138	1
1471-2296-8-34.txt	After three months of treatment we found a statistically significant difference between the two treatment groups in GHbA 1c (mean difference = 0.59%-units, p = 0.018) and in SF-36 score (mean difference = 11.0 points, p = 0.039).	GHbA 1c	116	123	significant	57	68	1
1471-2474-13-15.txt	The proportions of African American subjects with a baseline history of diabetes, renal impairment, or cardiovascular disease were significantly higher compared to Caucasians ( p < 0.001).	The proportions of African American subjects with a baseline history of diabetes, renal impairment, or cardiovascular disease	0	125	significantly	131	144	1
1756-9966-28-131.txt	Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01).	vomiting	180	188	significant	58	69	1
1471-2377-4-13.txt	Therapy effect in the second period was less; finally resulting in no significant effect combining results of both periods.	effect	82	88	no significant	67	81	1
1471-2334-5-88.txt	Nausea (31.0% tigecycline, 24.8% IMI/CIS [ P = 0.052]), vomiting (25.7% tigecycline, 19.4% IMI/CIS [ P = 0.037]), and diarrhea (21.3% tigecycline, 18.9% IMI/CIS [ P = 0.435]) were the most frequently reported adverse events.	diarrhea	118	126	P = 0.435	163	172	1
1479-5868-8-41.txt	Only the GWL+SWA group achieved significant weight loss at month 9 compared to the Standard Care group (P = 0.04).	weight loss	44	55	P = 0.04	104	112	1
1475-2875-9-378.txt	Serious Adverse Events were not reported in any of the patients and in all children, laboratory values (packed cell volume, liver enzymes, bilirubin) remained within normal levels during the follow-up period but the packed cell volume was significantly lower in the AS + SMP group.	the packed cell volume	212	234	significantly	239	252	1
1471-244X-3-7.txt	The means Extrapyramidal Symptoms Rating Scale scores for the placebo group were higher than the ritanserin group and the difference was significant in day 42.	The means Extrapyramidal Symptoms Rating Scale scores	0	53	significant	137	148	1
1465-9921-11-135.txt	Trough FEV 1 after 14 days with indacaterol 150 μg and 300 μg was statistically and clinically superior to placebo, with differences (95% CI) of 170 (120-220) and 150 (100-200) mL respectively (both p < 0.001).	Trough FEV 1 after 14 days	0	26	p < 0.001	199	208	1
1471-2474-11-229.txt	Conclusions These findings demonstrate significantly greater progress toward bone healing after LIPUS treatment compared to no LIPUS treatment in subjects with established delayed unions of the tibia.	progress toward bone healing	61	89	significantly	39	52	1
1471-2334-8-17.txt	A more rapid complete response was obtained in the IFN group (5 months before), with a significantly earlier improvement in respiratory symptoms and pulmonary lesions reduction.	respiratory symptoms	124	144	significantly	87	100	1
1472-6963-12-250.txt	In RCT B there was no evidence that a full questionnaire reminder statistically significantly improved response rates compared to a postcard reminder (10.4% versus 7.3%, RD 3 (95%CI −0.1, 6.8).	response rates	103	117	no evidence that a full questionnaire reminder statistically significantly	19	93	1
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the cancer-related death rate	49	78	p = .2	90	96	1
1471-2458-12-944.txt	Results Average population CVD risk decreased from 32.9% to 29.4% (p <0.001) in the NHS Health Check only group and from 31.9% to 29.2% (p <0.001) in the NHS Health Check plus additional lifestyle support group.	Average population CVD risk	8	35	p <0.001	67	75	1
1471-2474-13-141.txt	Results A statistically significant difference (p = 0,009) regarding the mobility as measured with the four-item Barthel index was found at the 5th postoperative day, favouring the DAA.	the mobility as measured with the four-item Barthel index	69	126	p = 0,009	48	57	1
ar3703.txt	For the period between baseline and month 6, WOMAC Pain, Physical Function and Total dimensions significantly improved in the OAK group compared to the control group, as did the SF-36 Physical Function, Role Physical, Body Pain, Vitality and Social Functioning domains, as well as hamstring strength in both legs.	Body Pain	218	227	significantly	96	109	1
1471-2377-8-33.txt	Significant pain improvement among pregabalin-treated patients was evident at week 1 and sustained at every weekly timepoint.	pain	12	16	Significant	0	11	1
1471-2474-10-118.txt	When analysing the results in a mixed model analysis on repeated measures including interaction between age-group and treatment effect the training group demonstrated significantly improved results compared to the control group in subjects younger than 40 years of age regarding OMAS (p = 0.028), muscle strength in the plantar flexors (p = 0.029) and dorsiflexors (p = 0.030).	OMAS	279	283	p = 0.028	285	294	1
cc6173.txt	In the TA group, we observed a significant reduction in the incidence of VS ( P = 0.003), the use of norepinephrine ( P = 0.029), and time on mechanical ventilation ( P = 0.018).	the use of norepinephrine	90	115	significant	31	42	1
cc7725.txt	The duration of use of paralysing or sedative agents, mechanical ventilation, stay in the intensive care unit and mortality at 28 days did not differ significantly between the decremental PEEP titration and control groups.	mortality at 28 days	114	134	not differ significantly	139	163	1
1479-5868-9-108.txt	However, these differences were significant only for fish intake (OR 1.37, 95% CI 1.11-1.68) , salt intake (OR 1.19, 95% CI 1.05-1.38) , and type of spread used (OR 1.28, 95% CI 1.06-1.51).	salt intake	95	106	significant	32	43	1
cc6887.txt	The mean intracranial pressure values 72 hours and 7 days after injury were lower in the progesterone group than in the placebo group, but there was no statistical significance between the two groups ( P > 0.05).	The mean intracranial pressure values	0	37	P > 0.05	202	210	1
1465-9921-11-74.txt	Daily inhaled corticosteroid dose significantly increased in the Internet group compared to usual care in the first 3 months in patients with uncontrolled asthma (+278 μg, p = 0.001), but not in patients with well or partly controlled asthma.	Daily inhaled corticosteroid dose	0	33	significantly	34	47	1
1471-2466-7-4.txt	Trends to clinical improvements favouring active treatment were however consistently seen in the patient-centered outcomes: Asthma Control Questionnaire mean difference (active – placebo) [95% CI] = -0.35 [-0.78 to 0.07], p = 0.10, Asthma Quality of Life Questionnaire mean difference 0.42 [-0.08 to 0.93], p = 0.09, Leicester Cough Questionnaire mean difference 0.49, [-0.18 to 1.16], p = 0.15.	Leicester Cough Questionnaire mean difference	317	362	p = 0.15	386	394	1
1749-8090-4-60.txt	The mean time to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034).	mean blood loss after cross-clamp removal	292	333	p < 0.001	422	431	1
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	The overall mortality rate	0	26	not statistically significant	229	258	1
cc2896.txt	Results Overall, between-patient variability around the time of neurological assessment was statistically significantly smaller when using remifentanil (remifentanil 0.44 versus fentanyl 0.86 [ P = 0.024] versus morphine 0.98 [ P = 0.006].	between-patient variability around the time of neurological assessment	17	87	significantly	106	119	1
1746-6148-8-157.txt	Results When comparing the two test groups at the end of the trial (16 weeks) there was no significant difference in any of the main outcome variables but owners of dogs that had taken fish oil were significantly happier with the treatment at the end visit and did significantly better at guessing what group their dogs had been in, compared to the placebo group.	any of the main outcome variables	117	150	no significant	88	102	1
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	forced expiratory volume in 1 second	775	811	p = 0.019	832	841	1
1824-7288-38-36.txt	The respiratory rate, chest indrawing, cyanosis, stridor, nasal flaring, wheeze and fever in both groups recorded at enrollment and parameters did not differ significantly between the two groups.	stridor	49	56	not differ significantly	147	171	1
cc7695.txt	PSV levels were significantly higher in MRV compared with that of the PSV manual reduction (p < 0.05).	PSV levels	0	10	significantly	16	29	1
1471-2458-12-602.txt	No significant improvements in physical HRQL were observed.	physical HRQL	31	44	No significant	0	14	1
1746-6148-8-157.txt	There were similar positive trends in force platform impulse and in the veterinary assessment variables, although they did not reach significance.	the veterinary assessment variables	68	103	not reach significance	123	145	1
1471-227X-9-18.txt	Following training, time to correct placement decreased significantly with 22.9 ± 13.5 s for the LMA-Classic and 22.9 ± 19.0 s for the LMA-Fastrach, respectively (p < 0.05).	time to correct placement	20	45	p < 0.05	163	171	1
1479-5868-9-108.txt	However, these differences were significant only for fish intake (OR 1.37, 95% CI 1.11-1.68) , salt intake (OR 1.19, 95% CI 1.05-1.38) , and type of spread used (OR 1.28, 95% CI 1.06-1.51).	fish intake	53	64	significant	32	43	1
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	LDL-cholesterol	156	171	P = 0.016	190	199	1
1745-6215-12-13.txt	In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg ( P = 0.03) for systolic office BP; 0.70 mm Hg ( P = 0.08) for diastolic office BP; 0.36 mm Hg ( P = 0.49) for 24-h systolic BP; and 0.05 mm Hg ( P = 0.88) for 24-h diastolic BP.	24-h diastolic BP	233	250	P = 0.88	219	227	1
1471-2431-7-7.txt	Sucrose had a significant effect on the PIPP score, as assessed by an ANOVA model (p = 0.0026).	the PIPP score	36	50	p = 0.0026	83	93	1
1479-5868-8-29.txt	However, the intervention did significantly reduce systolic blood pressure (B = -1.79 mm/Hg) and resting heart rate (B = -2.08 beats) and significantly increased body mass index (B = .18 units) compared to control.	resting heart rate	97	115	significantly	30	43	1
1472-6882-7-34.txt	Compared to baseline both treatments showed significant benefits in WOMAC and VAS outcomes within one week (P < 0.05), with a similar, progressive improvement over the course of the 8 week treatment protocol (45–62% reduction in WOMAC or VAS scores).	VAS outcomes	78	90	significant	44	55	1
1471-2431-9-21.txt	In the treatment group compared to the control group, mean changes on the ABC total score and subscales were similar except a greater number of children improved in irritability (p = 0.0311).	irritability	165	177	p = 0.0311	179	189	1
1471-2288-7-30.txt	In the ANCOVA model with baseline score as a co-variate, follow-up group had a significant effect on outcome at six months on the ADAS-Cog score (n = 140; mean difference = -2.018; 95%CI -3.914, -0.121; p = 0.037 favouring the intensive follow-up group), and on participant-rated quality of life score (n = 142; mean difference = -1.382; 95%CI -2.642, -0.122; p = 0.032 favouring minimal follow-up group).	participant-rated quality of life score	262	301	significant	79	90	1
1471-2458-11-267.txt	Results Glycated hemoglobin A1c and systolic blood pressure (SBP) levels decreased significantly in the PRECEDE group (multivariate analysis of covariance, with baseline glycated hemoglobin A1c, SBP, and variables showing statistically significant differences between groups at baseline visits).	systolic blood pressure (SBP) levels	36	72	significantly	83	96	1
1471-2415-12-9.txt	There were no statistically significant differences in IOP reductions from baseline to week 4 at either time point between those treated with higher concentrations of latanoprost versus those receiving 50 μg/mL.	IOP	55	58	no statistically significant	11	39	1
1472-6920-4-17.txt	Physicians with higher baseline screening rates were significantly more likely to log on to the course.	likely to log on to the course	72	102	significantly	53	66	1
1471-244X-3-16.txt	Results Treatment retention was significantly higher in the baclofen group.	Treatment retention	8	27	significantly	32	45	1
1475-2891-11-47.txt	Net changes in GPx, SOD and catalase activities, and DNA tail length and tail moment were significantly different between the high-dose group and the placebo group.	tail moment	73	84	significantly	90	103	1
1465-9921-8-67.txt	FP/M led to significantly greater reductions in sputum cysteinyl leukotrienes than SFC (treatment ratio 1.80; 95% CI 1.09, 2.94).	sputum cysteinyl leukotrienes	48	77	significantly	12	25	1
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	additional doses were required	296	326	p < 0.05	341	349	1
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	satisfaction	157	169	p = 0.819	215	224	1
1471-230X-9-22.txt	The proportion of patients who remained relapse-free at Week 26 did not differ significantly between the placebo group (5/16, 31%) and the IFN beta-1a 44 mcg biw (6/17, 35%; p = 0.497), 44 mcg tiw (7/16, 44%; p = 0.280) or 66 mcg tiw (2/18, 11%; p = 0.333) groups.	The proportion of patients who remained relapse-free at Week 26	0	63	p = 0.497	174	183	1
1471-2474-13-229.txt	At the follow-up evaluations, both groups presented a clinical improvement but the comparison between the two groups showed a not statistically significant difference in all scores evaluated.	all scores evaluated	170	190	not statistically significant	126	155	1
cc7112.txt	There were no unexpected deaths and no significant differences in secondary measures.	secondary measures	66	84	no significant	36	50	1
1471-2458-10-81.txt	In troop meetings, intervention troop leaders promoted PA (x 2 = 23.46, p < .001) and healthful eating (x 2 = 18.14, p < .001) more frequently, and discouraged healthful eating and PA less frequently (x 2 = 9.63, p = .002) compared to control troop leaders.	promoted PA	46	57	p < .001	72	80	1
1465-9921-10-75.txt	Assessment of the progression of emphysema in the apical, middle and basal regions of the lung by measurement with PD15 showed that this treatment effect was more evident when the basal third was sampled (1.722 g/L, p = 0.040).	this treatment effect was more evident when the basal third was sampled	132	203	p = 0.040	216	225	1
1471-2407-11-75.txt	Global quality of life was better in the 3-weekly arm (p = 0.03); patients treated with weekly schedules presented a significantly worsening in role functioning and financial scores (p = 0.02 and p < 0.001).	financial scores	165	181	significantly	117	130	1
1756-9966-28-131.txt	Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01).	fatigue	160	167	p < 0.01	256	264	1
1471-5945-5-13.txt	Improvements from baseline on the SF-36, PSA, PGPA, and itching VAS at Week 12 were also significantly greater in efalizumab-treated patients than for placebo.	PSA	41	44	significantly	89	102	1
1475-2891-10-85.txt	At the 4 week assessment, use of the ELISA test with subsequent diet elimination advice significantly reduced the number of migraine like headaches (IRR 1.23 95%CI 1.01 to 1.50, p = 0.04).	the number of migraine like headaches	110	147	p = 0.04	178	186	1
1471-2474-13-229.txt	Results Only minor adverse events were detected in some patients, such as mild pain and effusion after the injections, in particular in the PRP group, where a significantly higher post-injective pain reaction was observed (p=0.039).	post-injective pain reaction	180	208	p=0.039	223	230	1
cc11676.txt	Concentration of troponin T as the most sensitive marker for myocardial injury at POD1 was significantly lower in the sevoflurane group compared with the propofol group (unadjusted difference, -0.4; 95% CI, -0.7 to -0.1; P < 0.01; adjusted difference, -0.2; 95% CI, -0.4 to -0.02; P = 0.03, respectively).	Concentration of troponin T as the most sensitive marker for myocardial injury at POD1	0	86	P < 0.01	221	229	1
1471-230X-12-18.txt	The mean number of heartburn-free days by D7 was significantly greater in the omeprazole group: 3.7 ± 2.3 days vs 3.1 ± 2.1 ( p = 0.02).	The mean number of heartburn-free days by D7	0	44	significantly	49	62	1
cc11657.txt	Glucose complexity was significantly lower (higher DFA) in ICU non-survivors (n = 36) compared to survivors (n = 138) (DFA: 1.61 (1.46 to 1.68) versus 1.52 (1.44 to 1.58); P = 0.003).	Glucose complexity	0	18	significantly	23	36	1
ar3703.txt	For the period between baseline and month 6, WOMAC Pain, Physical Function and Total dimensions significantly improved in the OAK group compared to the control group, as did the SF-36 Physical Function, Role Physical, Body Pain, Vitality and Social Functioning domains, as well as hamstring strength in both legs.	Vitality	229	237	significantly	96	109	1
1471-230X-11-100.txt	The overall rate of polyp detection was significantly higher in the conventional group compared to the NBI group (RR 0.75, 95%CI 0.60 to 0.96).	The overall rate of polyp detection	0	35	significantly	40	53	1
1472-6904-8-10.txt	Simvastatin led to decrease in both LDLP fractions (19% large LDLP; p = .001 vs fenofibrate end; 34% small LDLP, p = .019 vs pre).	large LDLP	56	66	p = .001	68	76	1
1471-2288-11-126.txt	The difference in response rate between the sequential and simultaneous modes was not statistically significant.	response rate	18	31	not statistically significant	82	111	1
1532-429X-14-61.txt	Results The diagnostic performance (= area under ROC = AUC) of CMR was superior to SPECT (p = 0.0004, n = 425) and to gated-SPECT (p = 0.018, n = 253).	The diagnostic performance (= area under ROC = AUC)	8	59	p = 0.018	131	140	1
1475-2891-6-8.txt	A significant increase in defecation frequency (NF: 3.5 pre versus 5.6/week post treatment; SF 3.6 pre versus 4.9/week post treatment) was found in both groups, but was not significantly different between the two formulas (p = 0.36).	defecation frequency	26	46	significant	2	13	1
1745-6215-12-239.txt	For the non-HPD stratum, the intent-to-treat relative risks of spontaneous premature birth at < 34 and < 37 weeks' gestation were 0.33 (0.03, 3.16) and 0.49 (0.17, 1.44), respectively, and they were non-significant (ns) with p = 0.31 and 0.14.	spontaneous premature birth at < 34 and < 37 weeks' gestation	63	124	non-significant	199	214	1
1472-6963-9-33.txt	There was a small fall in HbA1c in the yoga group which was not statistically significant and which was not sustained six months later, and no significant change in other outcome measures.	other outcome measures	165	187	no significant	140	154	1
cc10289.txt	Rescue medication need did not differ between nicardipine and labetalol (15.5 vs 22.4%, P = 0.183).	Rescue medication need	0	22	P = 0.183	88	97	1
1824-7288-38-36.txt	The respiratory rate, chest indrawing, cyanosis, stridor, nasal flaring, wheeze and fever in both groups recorded at enrollment and parameters did not differ significantly between the two groups.	chest indrawing	22	37	not differ significantly	147	171	1
1471-2474-13-118.txt	Results There were similar, significant improvements in functional capacity for the RT and NMES groups at week 8 compared to week 1 (p≤0.001) and compared to the control group (p < 0.005), and the improvements were maintained at week 14 (p≤0.001).	functional capacity	56	75	p≤0.001	133	140	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	significant	63	74	1
1471-2458-11-573.txt	After one year of implementation of IPTi-SP using routine health services, the proportion of children completely vaccinated rose to 53.8% in the non intervention zone and 69.5% in the IPTi intervention zone (P <0.001).	the proportion of children completely vaccinated	75	123	P <0.001	208	216	1
1471-2431-9-21.txt	Conclusion Children with autism who received hyperbaric treatment at 1.3 atm and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.	sensory/cognitive awareness	225	252	significant	119	130	1
cc10367.txt	Results There was no difference between succinylcholine and rocuronium regarding oxygen desaturations (succinylcholine 73/196; rocuronium 66/195; P = 0.67); severe oxygen desaturations (succinylcholine 20/196; rocuronium 20/195; P = 1.0); and extent of oxygen desaturations (succinylcholine -14 ± 12%; rocuronium -16 ± 13%; P = 0.77).	extent of oxygen desaturations	243	273	P = 0.77	324	332	1
1471-2474-13-229.txt	Conclusions Results suggest that PRP injections offer a significant clinical improvement up to one year of follow-up.	clinical improvement	68	88	significant	56	67	1
1471-2431-9-21.txt	On the ATEC, sensory/cognitive awareness significantly improved (p = 0.0367) in the treatment group compared to the control group.	sensory/cognitive awareness	13	40	significantly	41	54	1
cc11215.txt	Nonsignificant differences were found in absolute FEV1, FEV1/FVC, FVC, forced expiratory flow from 25% to 75% of FVC, functional residual capacity, and CO diffusion.	forced expiratory flow from 25% to 75% of FVC	71	116	Nonsignificant	0	14	1
1475-2875-7-199.txt	Antimalarial prescriptions were significantly reduced in Arm-I (61.3%) compared to Arms-II (95.3%) and III (99.5%) (both P < 0.001), whereas antibiotic prescriptions did not vary significantly between the arms (49.9%, 54.8% and 34.2%, respectively).	Antimalarial prescriptions	0	26	P < 0.001	121	130	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.009	642	651	1
cc10343.txt	Statin therapy had no effect on plasma CoQ10 levels over time ( P = 0.13).	plasma CoQ10 levels	32	51	P = 0.13	64	72	1
cc11300.txt	The corrected colonisation index was similar in the two groups at T0 ( P = 0.36), while a significant statistical difference was observed between the treatment and control groups at T6 (median 0.14 and 0.33, respectively; P = 0.0016), at T9 (median 0.00 and 0.28, respectively; P = 0.0001), at T12 (median 0.00 and 0.41, respectively; P = 0.0008), and at T15 (median 0.00 and 0.42, respectively; P < 0.0003).	The corrected colonisation index	0	32	significant	90	101	1
1477-7827-1-63.txt	Although patients receiving Bravelle(R) consistently reported a greater number of chemical, clinical and continuing pregnancies, as well as an increased rate of live birth, the data did not attain statistical significance (P > 0.05).	chemical, clinical and continuing pregnancies	82	127	not attain statistical significance	186	221	1
1471-2474-11-64.txt	Results After 24 matches there was no statistical significant difference between the groups for the incidence of hamstring injury (OR:0.116, 95% CI:0.013-1.019, p = 0.051) and primary non-contact knee injury (OR:0.116, 95% CI:0.013-1.019, p = 0.051).	primary non-contact knee injury	176	207	p = 0.051	239	248	1
1471-2369-10-7.txt	Results Patients receiving the citrate dialysate had significantly lower systolic blood pressure (BP) (-4.3 mmHg, p < 0.01) and peripheral resistances (PR) (-51 dyne.sec.cm -5 , p < 0.001) while stroke volume was not increased.	systolic blood pressure (BP)	73	101	significantly	53	66	1
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the cancer-related death rate	49	78	not statistically significant	229	258	1
1471-2431-12-21.txt	There was significant improvement in FEV1 (% predicted) from baseline in both the groups as early as 1 min after drug administration.	FEV1 (% predicted)	37	55	significant	10	21	1
1471-2431-8-13.txt	Time to recovery was significantly shorter, by a minute(123 seconds (95% CI 103–142) versus 193 seconds (95% CI 158–227).	Time to recovery	0	16	significantly	21	34	1
1471-2393-11-85.txt	Results No statistically significant difference was found between MLU and CLU in the seven key outcomes: caesarean birth (163 [14.8%] vs 84 [15.2%]; relative risk (RR) 0.97 [95% CI 0.76 to 1.24]), induction (248 [22.5%] vs 138 [25.0%]; RR 0.90 [0.75 to 1.08]), episiotomy (126 [11.4%] vs 68 [12.3%]; RR 0.93 [0.70 to 1.23]), instrumental birth (139 [12.6%] vs 79 [14.3%]; RR 0.88 [0.68 to 1.14]), Apgar scores < 8 (10 [0.9%] vs 9 [1.6%]; RR 0.56 [0.23 to 1.36]), postpartum haemorrhage (144 [13.1%] vs 75 [13.6%]; RR 0.96 [0.74 to 1.25]); breastfeeding initiation (616 [55.9%] vs 317 [57.4%]; RR 0.97 [0.89 to 1.06]).	episiotomy	261	271	No statistically significant	8	36	1
cc11300.txt	The corrected colonisation index was similar in the two groups at T0 ( P = 0.36), while a significant statistical difference was observed between the treatment and control groups at T6 (median 0.14 and 0.33, respectively; P = 0.0016), at T9 (median 0.00 and 0.28, respectively; P = 0.0001), at T12 (median 0.00 and 0.41, respectively; P = 0.0008), and at T15 (median 0.00 and 0.42, respectively; P < 0.0003).	The corrected colonisation index	0	32	P = 0.0001	278	288	1
1475-2891-10-120.txt	HIV-infected children between six months and three years of age had a significantly higher gain in height if they received multivitamins (n = 48; 2 cm, compared to 1 cm in the placebo group; 95% CI = 0.20, 1.70; p = 0.01; p for interaction by age group = 0.01).	gain in height	91	105	p = 0.01	212	220	1
1471-2474-8-36.txt	Results Both treatment groups improved over the two week period of follow-up but there were no statistically significant differences in improvement between groups for any of the measured outcomes.	any of the measured outcomes	167	195	no statistically significant	92	120	1
1742-4690-3-63.txt	No significant changes in pain, bladder function, disability score, gait, proviral load or markers of T-cell activation or proliferation were seen between the two arms.	proviral load	74	87	No significant	0	14	1
1471-2288-12-147.txt	In total, the response rate was 38% (514/1336) at the dedicated clinics and 25% (248/1004) at the pathology centres (RR = 0.67, 0.56-0.78, p < 0.01); measures of height, weight and systolic and diastolic blood pressure did not vary materially between these groups, nor did the median number of aliquots of plasma, buffy coat and red cells collected.	the response rate	10	27	p < 0.01	139	147	1
cc10120.txt	From day 0 to day 7, total serum calcium levels increased by 0.10 (PBO) and 0.15 mmol/L (VITD; P < 0.05 for both), while ionized calcium levels increased by 0.11 (PBO) and 0.05 mmol/L (VITD; P < 0.05 for both).	ionized calcium levels	121	143	P < 0.05	191	199	1
1471-2474-3-7.txt	At 6 and 12 weeks, bone marker concentrations were not different from baseline, and no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.	bone marker concentrations	114	140	no significant	84	98	1
1471-2288-5-34.txt	Results The response rates were not significantly different Odds Ratio 0.88 (95% confidence intervals 0.48 to 1.63) p = 0.69.	The response rates	8	26	p = 0.69	116	124	1
1742-4690-3-63.txt	No significant changes in pain, bladder function, disability score, gait, proviral load or markers of T-cell activation or proliferation were seen between the two arms.	disability score	50	66	No significant	0	14	1
1471-244X-12-44.txt	In contrast to controls, significant treatment effects were found at outcome on self-reported measures of violent attitudes, rational problem-solving and anger cognitions.	anger cognitions	154	170	significant	25	36	1
cc1476.txt	Both TEF10 and the ratio of the tidal expiratory flow at 25% of the remaining tidal volume to PTEF (25/PT) decreased significantly ( P < 0.05) after administration of albuterol.	the ratio of the tidal expiratory flow at 25% of the remaining tidal volume to PTEF (25/PT)	15	106	significantly	117	130	1
1471-2296-13-30.txt	There was no significant adverse impact on functional status or treatment satisfaction.	treatment satisfaction	64	86	no significant	10	24	1
ar3703.txt	For the period between baseline and month 6, WOMAC Pain, Physical Function and Total dimensions significantly improved in the OAK group compared to the control group, as did the SF-36 Physical Function, Role Physical, Body Pain, Vitality and Social Functioning domains, as well as hamstring strength in both legs.	the SF-36 Physical Function	174	201	significantly	96	109	1
1471-2288-5-34.txt	Results The response rates were not significantly different Odds Ratio 0.88 (95% confidence intervals 0.48 to 1.63) p = 0.69.	The response rates	8	26	not significantly	32	49	1
1471-5945-4-18.txt	Complete healing of stage II ulcer in the HD group [12/18 (67%)] was better than in the SD group [3/19(16%); difference: 51%, 95% CI = 23.73–78.26, (P < 0.005)], but not significantly different from the PC group [10/21 (48%); difference: 19%, 95% CI = -11.47–49.47, (P > 0.05)].	Complete healing of stage II ulcer	0	34	P > 0.05	267	275	1
1471-2377-10-91.txt	Results The ABC-C Irritability Subscale scores showed significant improvement (p < 0.001), as did the VAS (p = 0.003) and the CGI (p < 0.001).	the VAS	98	105	p = 0.003	107	116	1
1477-7525-5-57.txt	Results and discussion Significant Questionnaire effects and a Questionnaire × Ceiling interaction (p < 0.001) in both trial datasets showed that the DTSQc detected more improvement in Treatment Satisfaction than the DTSQs, especially when patients had DTSQs scores at/near ceiling at baseline.	a Questionnaire × Ceiling interaction	61	98	Significant	23	34	1
1471-2369-13-99.txt	However, patients that experienced a cystatin C increase of ≥10% showed significantly higher MBL levels than patients with a rise of <10% (median 2885 (IQR 1193–4471) vs 1997 (IQR 439–3504)ng/mL, p = 0.01).	MBL levels	93	103	significantly	72	85	1
1465-9921-13-54.txt	No significant differences between the groups were detected in any other parameter, including exacerbation frequency and adverse events.	exacerbation frequency	94	116	No significant	0	14	1
1471-2458-11-893.txt	There were no significant differences in changes in lifestyle behaviours between the two groups.	lifestyle behaviours	52	72	no significant	11	25	1
cc6887.txt	The mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up ( P < 0.05).	The mortality rate	0	18	significantly	49	62	1
1465-9921-11-112.txt	Results After three month training period, in the Nordic Walking group time spent walking and standing as well as intensity of walking increased (Δ walking time: +14.9 ± 1.9 min/day; Δ standing time: +129 ± 26 min/day; Δ movement intensity: +0.40 ± 0.14 m/s 2 ) while time spent sitting decreased (Δ sitting time: -128 ± 15 min/day) compared to baseline (all: p < 0.01) as well as compared to controls (all: p < 0.01).	intensity of walking	114	134	p < 0.01	408	416	1
1471-2288-12-147.txt	At the dedicated clinics, response rates were 38% (257/668) not fasting and 38% fasting (257/668) (participation rate ratio (RR) = 1.00, 95%CI 0.91-1.08, p = 0.98).	response rates	26	40	p = 0.98	154	162	1
1471-2431-6-29.txt	Children who learned guided imagery with progressive muscle relaxation had significantly greater decrease in the number of days with pain than those learning breathing exercises alone after one (67% vs 21%, P = 0.05), and two (82% vs 45%, P < 0.01) months and significantly greater decrease in days with missed activities at one (85% vs 15%, P = 0.02) and two (95% vs 77%.	the number of days with pain	109	137	significantly	75	88	1
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	179	191	p < 0.05	227	235	1
cc7890.txt	Dexmedetomidine significantly decreased ICU length of stay, from 6.5 (IQR 4 to 9) to 1.5 (IQR 1 to 3) days ( P = 0.004) after study drug commencement.	ICU length of stay	40	58	P = 0.004	109	118	1
1471-2393-11-85.txt	Results No statistically significant difference was found between MLU and CLU in the seven key outcomes: caesarean birth (163 [14.8%] vs 84 [15.2%]; relative risk (RR) 0.97 [95% CI 0.76 to 1.24]), induction (248 [22.5%] vs 138 [25.0%]; RR 0.90 [0.75 to 1.08]), episiotomy (126 [11.4%] vs 68 [12.3%]; RR 0.93 [0.70 to 1.23]), instrumental birth (139 [12.6%] vs 79 [14.3%]; RR 0.88 [0.68 to 1.14]), Apgar scores < 8 (10 [0.9%] vs 9 [1.6%]; RR 0.56 [0.23 to 1.36]), postpartum haemorrhage (144 [13.1%] vs 75 [13.6%]; RR 0.96 [0.74 to 1.25]); breastfeeding initiation (616 [55.9%] vs 317 [57.4%]; RR 0.97 [0.89 to 1.06]).	postpartum haemorrhage	463	485	No statistically significant	8	36	1
ar3703.txt	Conclusions We recorded statistically significant improvements compared with a control group with regard to pain, quality of life and function for participants in the OAK program on the basis of WOMAC and SF-36 measures taken 8 weeks and 6 months from baseline.	quality of life	114	129	significant	38	49	1
1471-2474-13-81.txt	The rate of skin complication in this group was significantly lower compared to the tape group (14.6% versus 59.1%, P < 0.0001).	The rate of skin complication	0	29	P < 0.0001	116	126	1
1465-9921-8-67.txt	Both treatments significantly improved airway responsiveness, whereas SFC generally led to greater improvements in symptom control and lung function than FP/M.	airway responsiveness	39	60	significantly	16	29	1
1471-2334-5-88.txt	Nausea (31.0% tigecycline, 24.8% IMI/CIS [ P = 0.052]), vomiting (25.7% tigecycline, 19.4% IMI/CIS [ P = 0.037]), and diarrhea (21.3% tigecycline, 18.9% IMI/CIS [ P = 0.435]) were the most frequently reported adverse events.	Nausea	0	6	P = 0.052	43	52	1
1475-2875-7-199.txt	Antimalarial prescriptions were significantly reduced in Arm-I (61.3%) compared to Arms-II (95.3%) and III (99.5%) (both P < 0.001), whereas antibiotic prescriptions did not vary significantly between the arms (49.9%, 54.8% and 34.2%, respectively).	Antimalarial prescriptions	0	26	significantly	32	45	1
1471-2458-12-944.txt	Prevalence of high blood pressure, high cholesterol and smoking were reduced significantly (p <0.01) in both groups.	Prevalence of high blood pressure	0	33	p <0.01	92	99	1
1471-2466-7-4.txt	No significant improvements in lung function, symptoms, or quality of life were seen, although consistent trends were seen to improvements in patient-centered outcomes.	lung function	31	44	No significant	0	14	1
1471-2458-12-944.txt	Prevalence of central obesity was reduced significantly (p <0.01) in the group receiving additional lifestyle support but not in the NHS Health Check only group.	Prevalence of central obesity	0	29	p <0.01	57	64	1
1475-2875-5-113.txt	There was no significant difference between groups in fever and parasite clearance time, improvement of anaemia and gametocyte carriage at day 28.	improvement of anaemia	89	111	no significant	10	24	1
1471-2458-10-123.txt	At follow-up, more children in the intervention schools said they 'are currently eating a healthy diet' (39.6%) or 'would try to eat a healthy diet' (35.7%) than in control schools (34.4% and 31.7% respectively; chi-square test p < 0.001).	said they 'are currently eating a healthy diet' (39.6%) or 'would try to eat a healthy diet'	56	148	p < 0.001	228	237	1
1471-2466-11-61.txt	While there was no observed difference in outpatient costs, there was a slightly higher number of outpatient visits per patient in the LABA and LAMA (25.5 SE = 0.9, p = 0.0070) relative to the LABA or LAMA therapy group (22.3 SE = 0.8) and higher utilization (89.7% of patients) with COPD visits in the LABA and LAMA therapy group relative to both the LABA or LAMA (73.8%; p < .0001) and LABA, LAMA and ICS therapy groups (85.3; p = 0.0305).	number of outpatient visits per patient	88	127	p = 0.0070	165	175	1
1471-2407-11-75.txt	Global quality of life was better in the 3-weekly arm (p = 0.03); patients treated with weekly schedules presented a significantly worsening in role functioning and financial scores (p = 0.02 and p < 0.001).	role functioning	144	160	p = 0.02	183	191	1
1479-5868-8-41.txt	There was significant weight loss in all 3 intervention groups (GWL, 1.86 kg, P = 0.05; SWA-alone, 3.55 kg, P = 0.0002; GWL+SWA, 6.59 kg, P < 0.0001) but not in the Standard Care group (0.89 kg, P = 0.39) at month 9.	weight loss	22	33	P = 0.05	78	86	1
1477-5751-8-3.txt	Subjective reports of TQ subscales and general quality of life areas (SF-36), objective audiometric examinations as well as investigated biomarkers for oxidative stress did not reveal any significant treatment effects.	general quality of life areas (SF-36)	39	76	not reveal any significant	173	199	1
1471-2458-11-475.txt	Heightened decisional conflict was evident for parents making the MMR decision for their first child (effect estimate = -0.25, p = 0.003), who were concerned (effect estimate = 0.07, p < 0.001), had less positive attitudes (effect estimate = -0.20, p < 0.001) yet stronger intentions (effect estimate = 0.09, p = 0.006).	decisional conflict	11	30	p < 0.001	249	258	1
bcr2320.txt	Results TC and LDL levels increased significantly across time for both arms; TC increase was more pronounced for the observation arm, and that was sustained up to 24 months.	LDL levels	15	25	significantly	36	49	1
1471-2474-11-99.txt	However, some significant positive effects were found as to an increase in receiving education and a decrease in exposure to adverse postures and movements.	exposure to adverse postures and movements	113	155	significant	14	25	1
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	LDL-cholesterol	156	171	significantly	40	53	1
1471-2474-9-118.txt	At Week 6 there was a significantly lower msSBP and msDBP in the lumiracoxib group compared to the rofecoxib group ( p < 0.05).	msDBP	52	57	p < 0.05	117	125	1
1471-2466-11-61.txt	However, non-study COPD medication costs were higher for the LABA or LAMA therapy group ($911 SE = 91) compared to the LABA and LAMA therapy group ($668 SE = 58; p = 0.0238) and non-study respiratory medications were approximately $100 greater for the LABA or LAMA therapy group relative to both LABA and LAMA (p = .0018) and LABA, LAMA, and ICS (p = .0071) therapy groups.	non-study COPD medication costs	9	40	p = 0.0238	162	172	1
1471-2474-11-99.txt	However, some significant positive effects were found as to an increase in receiving education and a decrease in exposure to adverse postures and movements.	receiving education	75	94	significant	14	25	1
1475-2891-10-85.txt	The disability and impact on daily life of migraines were not significantly different between the true and sham diet groups.	impact on daily life of migraines	19	52	not significantly	58	75	1
1472-6904-8-10.txt	Pre- and post-therapy LDLP/HDLP ratio was similar with fenofibrate but was reduced by simvastatin (p = .045).	Pre- and post-therapy LDLP/HDLP ratio	0	37	p = .045	99	107	1
1741-7015-10-71.txt	There was no significant effect on 30-day mortality.	30-day mortality	35	51	no significant	10	24	1
cc11159.txt	The results in renal parameters were supported by significantly more pronounced reductions in the systemic markers C-reactive protein, Interleukin-6, LPS-binding protein and in the urinary excretion of Kidney Injury Molecule-1 and Interleukin-18 in AP-treated patients relative to placebo.	the systemic markers C-reactive protein	94	133	significantly	50	63	1
1465-9921-7-13.txt	No statistically significant difference between the treatment groups was apparent for the primary outcome variable, or for any of the other efficacy endpoints.	any of the other efficacy endpoints	123	158	No statistically significant	0	28	1
1471-2458-9-200.txt	Results After 12 months of follow-up there was no difference in claim duration between PT and usual care (Hazard Ratio 0.7; 95%CI, 0.4–1.1; p = 0.12) or PTCBWE and usual care (Hazard Ratio 0.9; 95%CI, 0.6–1.4; p = 0.72).	claim duration	64	78	p = 0.12	140	148	1
1471-244X-7-13.txt	Results From baseline to post-treatment assessment, PTSD severity and other psychopathological symptoms were significantly improved for the treatment group (intent-to-treat group × time interaction effect size d = 1.40).	PTSD severity	52	65	significantly	109	122	1
1471-2415-7-3.txt	There was a statistically significant improvement in VA from baseline with P = .045.	VA	53	55	P = .045	75	83	1
1742-4690-3-63.txt	No significant changes in pain, bladder function, disability score, gait, proviral load or markers of T-cell activation or proliferation were seen between the two arms.	bladder function	32	48	No significant	0	14	1
1475-2891-11-47.txt	Furthermore, the DNA tail length and tail moment were significantly reduced after the supplementation (low-dose and high-dose), and plasma oxidized low-density lipoprotein (LDL) levels were reduced in low-dose and high-dose groups, but increased in the placebo group.	the DNA tail length	13	32	significantly	54	67	1
1747-597X-3-1.txt	After controlling for age, body weight, baseline alcohol intake, subsequent change in alcohol intake and baseline S-AST, the after-treatment S-AST levels were found to be lower among the Mg-treated group than in the placebo group (t-test 2.061, df = 49, p = 0.045).	the after-treatment S-AST levels	121	153	p = 0.045	254	263	1
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	529	590	p < 0.05	732	740	1
1471-244X-9-54.txt	Patients undergoing medication switches also used acute-care services significantly sooner (p = .004) and accrued an additional $3,000 (a 25% increase) in annual total health care costs per patient, most of which was due to acute-care expenditures.	used acute-care services	45	69	p = .004	92	100	1
cc7017.txt	There was no statistically significant reduction in the rate of ICU-acquired infections: 33.2% in the standard insulin therapy group compared with 27.17% in the intensive insulin therapy group (RR: 0.82; 95%CI: 0.63 to 1.07).	the rate of ICU-acquired infections	52	87	no statistically significant	10	38	1
cc10143.txt	In the TA group, bleeding duration was shorter and progression to severe PPH and PRBC transfusion was less frequent than in controls ( P < 0.03).	progression to severe PPH	51	76	P < 0.03	135	143	1
1477-7827-2-70.txt	Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs 12%, p > 0.05).	abnormal fetal heart rate (FHR) tracings	168	208	p > 0.05	224	232	1
cc6173.txt	These patients showed significantly lower D-dimer, plasminogen activator inhibitor 1, and creatine-kinase levels and a trend toward lower levels of soluble tumor necrosis factor receptor and interleukin-6 within the first 24 hours after CPB.	creatine-kinase levels	90	112	significantly	22	35	1
1472-6963-12-147.txt	However, the target levels of systolic blood pressure and waist circumference were reached non-significantly more frequently in the intervention arm.	systolic blood pressure	30	53	non-significantly	91	108	1
1479-5868-8-41.txt	Significant waist circumference reductions were achieved in all 4 groups at month 9 (Standard Care, 3.49 cm, P = 0.0004; GWL, 2.42 cm, P = 0.008; SWA-alone, 3.59 cm, P < 0.0001; GWL+SWA, 6.77 cm, P < 0.0001), but no intervention group had significantly reduced waist circumference compared to the Standard Care group.	waist circumference reductions	12	42	Significant	0	11	1
1471-2377-7-20.txt	Parkinson motor scores did not change significantly (active group 0.1, CI -3.4 to 3.7) versus controls (4.5, CI 1.6 to 7.1), p = 0.06.	Parkinson motor scores	0	22	not change significantly	27	51	1
1475-2875-6-138.txt	Conclusion Mannitol had no significant impact on clinical outcome of cerebral malaria.	clinical outcome of cerebral malaria	49	85	no significant	24	38	1
1475-2875-6-170.txt	Results Treatment failure (PCR corrected) was significantly lower in the artesunate + sulphadoxine-pyrimethamine group (4/77, 5.3%) than in chloroquine group(51/71, 71.8%) or the sulphadoxine-pyrimethamine alone group (30/70, 44.1%) (p < 0.001).	Treatment failure (PCR corrected)	8	41	significantly	46	59	1
cc10367.txt	Intubation conditions (succinylcholine 8.3 ± 0.8; rocuronium 8.2 ± 0.9; P = 0.7) and failed first intubation attempts (succinylcholine 32/200; rocuronium 36/201; P = 1.0) did not differ between the groups.	Intubation conditions	0	21	P = 0.7	72	79	1
1745-6215-13-11.txt	All groups showed significant improvement in time to complete the MT (p < 0.001) and degree of help needed to perform the task: minimal assistance to supervision (CG) and independent performance (EG1+2).	minimal assistance to supervision (CG)	128	166	significant	18	29	1
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	able to assess the severity of asthma attack	125	169	p = 0.05	189	197	1
1471-2318-11-27.txt	There were no statistically significant differences in 4-month changes in composite scores of cognitive, executive, and episodic memory function among arms.	composite scores of cognitive, executive, and episodic memory function	74	144	no statistically significant	11	39	1
1745-6215-13-11.txt	All groups showed significant improvement in time to complete the MT (p < 0.001) and degree of help needed to perform the task: minimal assistance to supervision (CG) and independent performance (EG1+2).	time to complete the MT	45	68	significant	18	29	1
1471-230X-11-100.txt	However, no significant differences were found in the mean number of polyps (MD -0.1; 95%CI -0.25 to 0.05), and the mean number of adenomas (MD 0.04 95%CI -0.09 to 0.17).	the mean number of polyps	50	75	no significant	9	23	1
1475-2891-6-8.txt	Improvement of hard stool consistency to soft stool consistency was found more often with NF than SF, but did not reach statistical significance (90% versus 50%; RR, 1.8; 95% CI, 0.9–3.5; p = 0.14).	Improvement of hard stool consistency to soft stool consistency	0	63	not reach statistical significance	110	144	1
1471-244X-5-5.txt	Results There was significant improvement from baseline to endpoint on the Yale-Brown Obsessive-Compulsive Scale in both the quetiapine and placebo groups (quetiapine, n = 20, p < 0.0001; placebo, n = 21, p = 0.001) with 40% (n = 8) of quetiapine and 47.6% (n = 10) of placebo treated subjects being classified as responders.	the Yale-Brown Obsessive-Compulsive Scale	71	112	significant	18	29	1
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	score higher on the asthma knowledge questionnaire	339	389	p = 0.2	442	449	1
ar4034.txt	The comparison between daily 15 mg prednisone and placebo at Day 15 yielded a statistically significant treatment effect (effect size = 1.17, P = 0.013) in change from baseline in the primary endpoint, but borderline for prednisone 7.5 mg daily versus placebo (effect size = 0.61, P = 0.071).	the primary endpoint	180	200	P = 0.071	281	290	1
1477-7525-5-57.txt	Tests of effect sizes showed these differences in response to change to be significantly in favour of the DTSQc.	response to change	50	68	significantly	75	88	1
1475-2891-10-120.txt	Supplementation resulted in significant improvement in hemoglobin levels at the end of follow-up in children of all age groups; the median increase in children receiving multivitamins was 1.0 g/dL, compared to 0.4 g/dL in children receiving placebo (p < 0.01).	hemoglobin levels	55	72	significant	28	39	1
1471-227X-9-3.txt	Results Compared to preformed teams, ad-hoc forming teams had less hands-on time during the first 180 seconds of the arrest (93 ± 37 vs 124 ± 33 sec, P < 0.0001), delayed their first defibrillation (67 ± 42 vs 107 ± 46 sec, P < 0.0001), and made less leadership statements (15 ± 5 vs 21 ± 6, P < 0.0001).	delayed their first defibrillation	163	197	P < 0.0001	224	234	1
1471-2431-9-21.txt	Conclusion Children with autism who received hyperbaric treatment at 1.3 atm and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.	receptive language	168	186	significant	119	130	1
1471-2458-12-706.txt	However, treated children had significantly less pain experience (P = 0.006) (OR 0.09, [0.01-0.51]) and higher satisfaction with teeth (P = 0.001) (OR 9.91, [2.68-36.51]) compared to controls.	pain experience	49	64	P = 0.006	66	75	1
1472-6920-12-85.txt	In the evaluation, the students certified the arthroscopic tutorial a greater advantage concerning anatomical skills with higher spatial imagination in comparison to the ultrasound tutorial (p = 0.002; p < 0.001).	spatial imagination	129	148	p < 0.001	202	211	1
1471-2296-8-23.txt	There was no significant improvement in our primary outcome measure (the proportion with peak flow compared to best/predicted) at either the 6 or 12 month time points after adjustment for baseline and practice effects.	our primary outcome measure (the proportion with peak flow compared to best/predicted)	40	126	no significant	10	24	1
cc6999.txt	There were no significant differences between the two groups with respect to the incidence of arterial hypotension or infection.	the incidence of arterial hypotension	77	114	no significant	11	25		1
1471-2474-13-81.txt	Conclusion Treatment of acute ankle sprain with semi-rigid brace leads to significantly higher patient comfort and satisfaction, both with similar good outcome.	satisfaction	115	127	significantly	74	87	1
1471-2393-11-85.txt	Results No statistically significant difference was found between MLU and CLU in the seven key outcomes: caesarean birth (163 [14.8%] vs 84 [15.2%]; relative risk (RR) 0.97 [95% CI 0.76 to 1.24]), induction (248 [22.5%] vs 138 [25.0%]; RR 0.90 [0.75 to 1.08]), episiotomy (126 [11.4%] vs 68 [12.3%]; RR 0.93 [0.70 to 1.23]), instrumental birth (139 [12.6%] vs 79 [14.3%]; RR 0.88 [0.68 to 1.14]), Apgar scores < 8 (10 [0.9%] vs 9 [1.6%]; RR 0.56 [0.23 to 1.36]), postpartum haemorrhage (144 [13.1%] vs 75 [13.6%]; RR 0.96 [0.74 to 1.25]); breastfeeding initiation (616 [55.9%] vs 317 [57.4%]; RR 0.97 [0.89 to 1.06]).	Apgar scores	397	409	No statistically significant	8	36	1
1465-9921-11-74.txt	Improvements in ACQ score after 12 months were -0.14 (p = 0.23), -0.52 (p < 0.001) and -0.82 (p < 0.001) in the Internet group compared to usual care for patients with well, partly and uncontrolled asthma at baseline, respectively.	ACQ score	16	25	p < 0.001	72	81	1
cc10143.txt	Blood loss between enrolment and 6 hours later was significantly lower in the TA group than in the control group (median, 173 mL; first to third quartiles, 59 to 377) than in controls (221 mL; first to third quartiles 105 to 564) ( P = 0.041).	Blood loss between enrolment and 6 hours later	0	46	significantly	51	64	1
1471-2288-7-50.txt	Results Computer-aided telephone interviews (CATI) resulted in significantly fewer missing data (0.5%) than did mailed questionnaires (2.8%; p < 0.001).	missing data	83	95	p < 0.001	141	150	1
1472-6882-12-7.txt	Changes in bone formation markers and physical domains of quality of life were also more favorable in per protocol TC vs UC (P = 0.05).	physical domains of quality of life	38	73	P = 0.05	125	133	1
1465-9921-8-52.txt	Similarly, significant results in favour of SFC for oscillometry measurements of resistance and reactance were observed.	oscillometry measurements of resistance and reactance	52	105	significant	11	22	1
cc6887.txt	The modified Functional Independence Measure scores in the progesterone group were higher than those in the placebo group at both 3-month and 6-month follow-up ( P < 0.05 and P < 0.01).	The modified Functional Independence Measure scores	0	51	P < 0.01	175	183	1
1746-6148-8-157.txt	There were similar positive trends in force platform impulse and in the veterinary assessment variables, although they did not reach significance.	force platform impulse	38	60	not reach significance	123	145	1
1471-2431-8-23.txt	During therapy, the proportion of examinations with penicillin non-susceptible (MIC > 0.1 microg/ml) pneumococci was not significantly different between the amoxicillin group (34%) and the placebo group (40%).	the proportion of examinations with penicillin non-susceptible (MIC > 0.1 microg/ml) pneumococci	16	112	not significantly	117	134	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.000	467	476	1
1465-9921-10-69.txt	During the treatment period of 6 months the multiple criteria frequency, severity and duration of exacerbations were significantly lower in the group treated with cineole in comparison to placebo.	frequency	62	71	significantly	117	130	1
1471-230X-12-18.txt	On D7, overall quality of pain relief was slightly in favour of omeprazole ( p = 0.049).	overall quality of pain relief	7	37	p = 0.049	77	86	1
cc10120.txt	From day 0 to day 7, total serum calcium levels increased by 0.10 (PBO) and 0.15 mmol/L (VITD; P < 0.05 for both), while ionized calcium levels increased by 0.11 (PBO) and 0.05 mmol/L (VITD; P < 0.05 for both).	total serum calcium levels	21	47	P < 0.05	95	103	1
1475-2840-10-78.txt	Results Cinnamon did not change gastric emptying parameters, postprandial triacylglycerol or glucose concentrations, oxidative stress, arterial function or appetite (p < 0.05).	appetite	156	164	p < 0.05	166	174	1
1471-2474-8-112.txt	Conclusion The EAP has no significant effect on the outcome of SCs after 6 and 26 weeks.	the outcome of SCs	48	66	no significant	23	37	1
1471-2334-5-2.txt	At week 28, an intent-to treat: missing = failure analysis showed that the abacavir-switch and PI-continuation arms did not differ significantly with respect to proportion of patients maintaining HIV-1 RNA <400 or <50 copies/mL or adjusted mean change from baseline in CD4+ cell count.	proportion of patients maintaining HIV-1 RNA <400 or <50 copies/mL	161	227	not differ significantly	120	144	1
1472-6904-8-10.txt	There was 18% increase in HDL particle number (HDLP) with fenofibrate (p = .05).	HDL particle number (HDLP)	26	52	p = .05	71	78	1
ar3703.txt	Conclusions We recorded statistically significant improvements compared with a control group with regard to pain, quality of life and function for participants in the OAK program on the basis of WOMAC and SF-36 measures taken 8 weeks and 6 months from baseline.	pain	108	112	significant	38	49	1
1471-2369-10-7.txt	With the C+ dialysate the BP gap was less pronounced but the reduction in PR was even greater (-226 dyne.sec.cm -5 , p < 0.001).	PR	74	76	p < 0.001	117	126	1
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	steps/day	122	131	p < 0.001	423	432	1
1741-7015-4-12.txt	The directions of the results for the differences in EC50 (low – medium) were consistent for collagen, ADP and epinephrine at -0.07 (-0.53 to 0.40), -0.08 (-0.28 to 0.11) and -4.41 (-10.56 to 1.72) respectively, but none were statistically significant.	EC50	53	57	significant	240	251	1
cc6999.txt	There were no significant differences between the two groups with respect to the incidence of arterial hypotension or infection.	infection	118	127	no significant	11	25	1
1756-9966-28-131.txt	Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01).	emotional functioning	117	138	p < 0.01	256	264	1
1477-7827-1-63.txt	Although patients receiving Bravelle(R) consistently reported a greater number of chemical, clinical and continuing pregnancies, as well as an increased rate of live birth, the data did not attain statistical significance (P > 0.05).	live birth	161	171	P > 0.05	223	231	1
1471-2377-8-33.txt	For all four nerves, 95% CIs for median differences in amplitude and velocity from baseline to endpoint and baseline to follow-up included 0 (ie, no significant difference vs placebo).	amplitude	55	64	no significant	146	160	1
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	323	372	p < 0.05	518	526	1
1475-2891-10-85.txt	At the 4 week assessment, use of the ELISA test with subsequent diet elimination advice significantly reduced the number of migraine like headaches (IRR 1.23 95%CI 1.01 to 1.50, p = 0.04).	the number of migraine like headaches	110	147	significantly	88	101	1
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	receptive language	157	175	p < 0.0001	177	187	1
1465-9921-8-52.txt	Results A comparison of the geometric mean sRaw at 12 hrs post dose in the SFC group to the FP group gave a ratio of 0.76 (0.66 – 0.89, p < 0.001) at week 2 and 0.81 (0.71 – 0.94, p = 0.006) at week 4.	the geometric mean sRaw at 12 hrs post dose	24	67	p < 0.001	136	145	1
cc1476.txt	PTEF increased significantly both after albuterol and saline treatments but the difference between the two treatments was not significant ( P = 0.6).	PTEF	0	4	P = 0.6	140	147	1
1746-6148-8-162.txt	Changes in the PVF BW (P adj  = 0.0004), the CSOM (P adj  = 0.006) and the MA intensity (P adj  = 0.02) from D0 to D90 suggested an effect of diet(s).	the PVF BW	11	21	P adj  = 0.0004	23	38	1
1471-2296-8-3.txt	Risk of non-completion of detoxification was reduced if allocated buprenorphine (68% vs 88%, RR 0.58 CI 0.35–0.96, p = 0.065).	Risk of non-completion of detoxification	0	40	p = 0.065	115	124	1
1471-2474-9-143.txt	Results At the end of the study period, the temperature asymmetry was not significantly reduced in the tadalafil group compared with the placebo group, but there was a significant and clinically relevant reduction of pain in the tadalafil group.	pain	217	221	significant	168	179	1
1471-2334-8-17.txt	Although differences in bacteriology were not significant during the treatment period, some patients in the placebo group converted again to positive during follow-up.	bacteriology	24	36	not significant	42	57	1
1477-7525-5-57.txt	Additionally, significant Treatment effects favouring insulin glargine (p < 0.001) and a Treatment × Questionnaire interaction (p < 0.019), with the DTSQc showing more benefits, were found in the type 1 trial.	a Treatment × Questionnaire interaction	87	126	p < 0.019	128	137	1
1741-7015-2-6.txt	Fascial interposition decreased time to azoospermia (hazard ratio [HR], 1.35; P < 0.0001) and time to severe oligozoospermia (HR, 1.32; P < 0.0001) and reduced failures based on semen analysis by about half, from 12.7% (95% confidence interval [CI], 9.7 to 16.3) to 5.9% (95% CI, 3.8 to 8.6) (P < 0.0001).	failures based on semen analysis	160	192	P < 0.0001	293	303	1
1465-9921-11-112.txt	Results After three month training period, in the Nordic Walking group time spent walking and standing as well as intensity of walking increased (Δ walking time: +14.9 ± 1.9 min/day; Δ standing time: +129 ± 26 min/day; Δ movement intensity: +0.40 ± 0.14 m/s 2 ) while time spent sitting decreased (Δ sitting time: -128 ± 15 min/day) compared to baseline (all: p < 0.01) as well as compared to controls (all: p < 0.01).	standing time	185	198	p < 0.01	408	416	1
1471-2288-7-30.txt	In the ANCOVA model with baseline score as a co-variate, follow-up group had a significant effect on outcome at six months on the ADAS-Cog score (n = 140; mean difference = -2.018; 95%CI -3.914, -0.121; p = 0.037 favouring the intensive follow-up group), and on participant-rated quality of life score (n = 142; mean difference = -1.382; 95%CI -2.642, -0.122; p = 0.032 favouring minimal follow-up group).	the ADAS-Cog score	126	144	significant	79	90	1
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	alliance	89	97	p = 0.760	143	152	1
1471-2369-13-99.txt	However, patients that experienced a cystatin C increase of ≥10% showed significantly higher MBL levels than patients with a rise of <10% (median 2885 (IQR 1193–4471) vs 1997 (IQR 439–3504)ng/mL, p = 0.01).	MBL levels	93	103	p = 0.01	196	204	1
1471-2474-13-15.txt	The proportions of African American subjects with a baseline history of diabetes, renal impairment, or cardiovascular disease were significantly higher compared to Caucasians ( p < 0.001).	The proportions of African American subjects with a baseline history of diabetes, renal impairment, or cardiovascular disease	0	125	p < 0.001	177	186	1
1471-2474-12-132.txt	Age, race/ethnicity, education, military status, smoking history, BMI, and whether a Soldier received the physical/USI examination remained statistically significant (p < .05) when considered in a full multivariate model.	BMI	66	69	significant	154	165	1
1475-2891-6-8.txt	Improvement of hard stool consistency to soft stool consistency was found more often with NF than SF, but did not reach statistical significance (90% versus 50%; RR, 1.8; 95% CI, 0.9–3.5; p = 0.14).	Improvement of hard stool consistency to soft stool consistency	0	63	p = 0.14	188	196	1
1471-5945-4-18.txt	Results Complete healing of ulcers, regardless of location and stage, was better in the HD group than the PC [23/31(74.19%) vs 12/30(40%); difference: 34.19%, 95% CI = 10.85–57.52, (P < 0.01)] or the SD [23/31(74.19%) vs 8/30(26.66%); difference: 47.53%, 95% CI = 25.45–69.61, (P < 0.005)] groups.	Complete healing of ulcers, regardless of location and stage,	8	69	P < 0.005	278	287	1
1471-2474-11-64.txt	There was no significant difference for weeks missed due to hamstring injury (4 v14, χ2:1.12, p = 0.29) and lower-limb muscle strains (4 v 21, χ2:2.66, p = 0.10).	lower-limb muscle strains	108	133	no significant	10	24	1
1477-7819-7-32.txt	Results Cytokine values were significantly lower after TRD lavage for IL-1beta, IL-6, and IL-10.	Cytokine values	8	23	significantly	29	42	1
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	FEV 1 /FVC	258	268	P = 0.033	302	311	1
cc7890.txt	Results Dexmedetomidine significantly shortened median time to extubation from 42.5 (IQR 23.2 to 117.8) to 19.9 (IQR 7.3 to 24) hours ( P = 0.016).	median time to extubation	48	73	significantly	24	37	1
1471-244X-9-54.txt	Compared with their counterparts who remained on their initial therapies, individuals who switched antipsychotics experienced a significantly higher risk of acute-care services, including hospitalization (p = .013) and crisis services (p = .011).	risk of acute-care services	149	176	significantly	128	141	1
1471-230X-11-100.txt	Meta-analysis of studies (regardless of indication) did not find any significant differences in the mean number of polyps (5 RCT, 2479 participants; WMD -0.07 95% CI -0.21 to 0.07; I2 68%), the mean number of adenomas (8 RCT, 3517 participants; WMD -0.08 95% CI -0.17; 0.01 to I2 62%) and the rate of patients with at least one adenoma (8 RCT, 3512 participants, RR 0.96 95% CI 0.88 to 1,04;I2 0%).	the mean number of adenomas	190	217	not find any significant	56	81	1
1471-2334-3-10.txt	In the APV600/RTV arm, significantly more patients achieved HIV-1 RNA <50 copies/mL (48% [57/118] vs 29% [11/38] with APV1200, P = 0.04), and greater mean reduction from baseline in HIV-1 RNA was observed (-2.21 vs -1.59 log 10 copies/mL, P = 0.028).	HIV-1 RNA	60	69	P = 0.04	127	135	1
1477-7525-1-53.txt	The patient reported outcome measures were all shown to have significant construct validity with respect to each other and with respect to the clinical assessments.	construct validity	73	91	significant	61	72	1
cc10592.txt	There was a reduction in adverse events in the fluid intervention group ( P = 0.048) and no increase in fluid based complications.	adverse events	25	39	P = 0.048	74	83	1
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	moderate	181	189	significantly	162	175	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.001	326	335	1
1471-2415-8-11.txt	The mean percentage of labeled concentration was 103.7% in the bimatoprost bottles and 88.1% in the latanoprost bottles (P < 001).	The mean percentage of labeled concentration	0	44	P < 001	121	128	1
1757-7241-20-16.txt	Significant differences were not found in secondary outcome and in other performance variables between the groups and over time Conclusions Quality of CPR was maintained during 2 minutes of continuous compressions regardless of feedback in a group of trained rescuers.	secondary outcome	42	59	Significant differences were not found	0	38	1
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	sedentary	129	138	p = .011	151	159	1
1475-2875-10-237.txt	A better improvement of haemoglobin at day 28 was noted in the ASAQ versus the AL group (12.2 versus 11.8 g/dL; p = 0.03).	haemoglobin	24	35	p = 0.03	112	120	1
1475-2891-3-20.txt	The significant stress reductions in both the fish oil and the placebo group are considered in view of statistical regression, an effect likely to have been exaggerated by the time course of the study, a large placebo effect and the possibility of an active effect from the placebo.	stress reductions	16	33	significant	4	15	1
1471-2458-11-475.txt	Significantly more parents in the intervention arm reported vaccinating their child (93% versus 73%, p = 0.04).	reported vaccinating their child	51	83	Significantly	0	13	1
1471-2369-12-9.txt	The albumin-adjusted serum calcium concentration was significantly higher (9.5 ± 0.8 vs 8.8 ± 0.8; p < 0.001) and iPTH was significantly lower in the calcium acetate group compared to placebo (150 ± 157 vs 351 ± 292 pg/mL respectively; p < 0.001).	iPTH	114	118	p < 0.001	236	245	1
1472-6904-8-10.txt	Simvastatin led to decrease in both LDLP fractions (19% large LDLP; p = .001 vs fenofibrate end; 34% small LDLP, p = .019 vs pre).	small LDLP	101	111	p = .019	113	121	1
1746-6148-8-162.txt	Changes in the PVF BW (P adj  = 0.0004), the CSOM (P adj  = 0.006) and the MA intensity (P adj  = 0.02) from D0 to D90 suggested an effect of diet(s).	the CSOM	41	49	P adj  = 0.006	51	65	1
cc6173.txt	These patients showed significantly lower D-dimer, plasminogen activator inhibitor 1, and creatine-kinase levels and a trend toward lower levels of soluble tumor necrosis factor receptor and interleukin-6 within the first 24 hours after CPB.	D-dimer	42	49	significantly	22	35	1
bcr3051.txt	Results Progesterone receptor-negativity (HR = 0.66; 95% CI 0.47 to 0.92, P = 0.013), and Ki67-positivity (HR = 1.53; 95% CI 1.12 to 2.08, P = 0.007) were independent adverse prognostic factors.	Ki67-positivity	90	105	P = 0.007	139	148	1
1471-230X-9-85.txt	Results Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061).	the GSRS abdominal distension subscore	225	263	p = 0.061	265	274	1
1471-2458-11-475.txt	Results Decisional conflict decreased for both arms to a level where an 'effective' MMR decision could be made one-week (effect estimate = -0.54, p < 0.001) and three-months (effect estimate = -0.60, p < 0.001) post-intervention.	Decisional conflict	8	27	p < 0.001	200	209	1
1471-2474-11-64.txt	There was no significant difference for weeks missed due to hamstring injury (4 v14, χ2:1.12, p = 0.29) and lower-limb muscle strains (4 v 21, χ2:2.66, p = 0.10).	weeks missed due to hamstring injury	40	76	no significant	10	24	1
1472-6963-11-58.txt	Results Overall at long-term follow-up (average 6 years) significantly more individuals in the CNP group (72%) had improved (i.e had fewer symptoms) compared to those in the SC group (67%) (difference of 5% 95% (CI = 0.6 to 9;p = 0.02)).	improved	115	123	p = 0.02	226	234	1
1745-6215-13-11.txt	All groups showed significant improvement in time to complete the MT (p < 0.001) and degree of help needed to perform the task: minimal assistance to supervision (CG) and independent performance (EG1+2).	time to complete the MT	45	68	p < 0.001	70	79	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.004	429	438	1
1471-244X-12-151.txt	After adjusting for confounders, participants without health insurance were found to experience a higher risk of developing severe depressive symptoms than participants with health insurance (7 months: OR, 1.40; 95% CI, 1.09-1.82; p = 0.01; 20 months: OR, 1.89; 95% CI, 1.37-2.61; p < 0.001).	risk of developing severe depressive symptoms	105	150	p < 0.001	281	290	1
1471-2431-9-21.txt	On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.	hyperactivity	116	129	p < 0.03	143	151	1
1475-2875-10-358.txt	Conclusion Combining IPTc and HMM can provide significant additional benefit in preventing clinical episodes of malaria as well as anaemia among children in Senegal.	preventing clinical episodes of malaria	80	119	significant	46	57	1
cc11445.txt	Hemodynamic stability did not differ between SLED-BD and CVVH, whereas patients in the SLED-BD group had significantly fewer days of mechanical ventilation (17.7 ± 19.4 vs 20.9 ± 19.8, P = 0.047) and fewer days in the ICU (19.6 ± 20.1 vs 23.7 ± 21.9, P = 0.04).	days in the ICU	206	221	P = 0.04	251	259	1
ar2702.txt	At week 24, ACR20 and HAQ-DI responders reported large improvements in productivity within and outside the home; non-responders reported mainly a worsening in productivity ( P ≤ 0.05).	productivity	159	171	P ≤ 0.05	174	182	1
1471-2474-9-143.txt	Results At the end of the study period, the temperature asymmetry was not significantly reduced in the tadalafil group compared with the placebo group, but there was a significant and clinically relevant reduction of pain in the tadalafil group.	the temperature asymmetry	40	65	not significantly	70	87	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	significant	63	74	1
1472-6882-7-34.txt	Rescue medication use was significantly lower in the reparagen group (p < 0.01) at each assessment period.	Rescue medication use	0	21	significantly	26	39	1
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the local recurrence rate	99	124	not statistically significant	229	258	1
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	satisfaction	404	416	p = 0.248	462	471	1
1472-6882-12-19.txt	In the primary outcome model, there was no significant difference in weight regain between the two arms (1.72 kg (se 0.85) weight regain for TAT and 2.96 kg (se 0.96) weight regain for SS, p < 0.097) Tests of between- arm differences for secondary outcomes were also not significant.	weight regain	69	82	p < 0.097	189	198	1
1472-6947-12-71.txt	Seventy-two percent of participants in CaPRA group had intention to visit a psychosocial counselor, compared to 46 % in usual care group [ X 2 (1)=3.47, p  = 0.06].	intention to visit a psychosocial counselor	55	98	p  = 0.06	153	162	1
1479-5868-9-108.txt	However, these differences were significant only for fish intake (OR 1.37, 95% CI 1.11-1.68) , salt intake (OR 1.19, 95% CI 1.05-1.38) , and type of spread used (OR 1.28, 95% CI 1.06-1.51).	type of spread used	141	160	significant	32	43	1
ar4072.txt	ANCOVA analysis demonstrated superiority of adalimumab over placebo for the physician global assessment of disease activity, parents' global assessment of subject's overall well-being, active joint count (all P <0.05) and erythrocyte sedimentation rate (ESR) ( P <0.01).	erythrocyte sedimentation rate (ESR)	222	258	P <0.01	261	268	1
1471-2431-9-21.txt	Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).	receptive language	129	147	p = 0.0168	149	159	1
1475-2891-11-57.txt	Conclusion Different dietary approaches based on portion control, low energy density, or low glycemic index produced similar, significant short-term improvements in body composition, diet compositin, and MetS components in overweight and obese adults undergoing weekly weight loss meetings.	MetS components	204	219	significant	126	137	1
1471-2466-11-16.txt	Results At 4 weeks, there was no improvement in the atorvastatin group compared to the placebo group in morning peak expiratory flow [-10.67 L/min, 95% CI -38.70 to 17.37, p = 0.449], but there was an improvement with atorvastatin in asthma quality of life score [0.52, 95% CI 0.17 to 0.87 p = 0.005].	morning peak expiratory flow	104	132	p = 0.449	172	181	1
cc6887.txt	The modified Functional Independence Measure scores in the progesterone group were higher than those in the placebo group at both 3-month and 6-month follow-up ( P < 0.05 and P < 0.01).	The modified Functional Independence Measure scores	0	51	P < 0.05	162	170	1
1471-2466-10-11.txt	Indacaterol significantly reduced the percentage of days of poor control versus placebo by 22.5% (p < 0.001) and was also associated with significantly reduced use of rescue medication (p < 0.001).	the percentage of days of poor control	34	72	significantly	12	25	1
1465-9921-11-135.txt	At 5 min post-dose on Day 1, the mean FEV 1 for both indacaterol doses was significantly higher than placebo (by 120 and 130 mL for indacaterol 150 and 300 μg, respectively; p < 0.001) and tiotropium (by 80 mL for both doses; p < 0.001).	the mean FEV 1	29	43	significantly	75	88	1
cc11180.txt	This translates into higher bilirubin reduction ratios when citrate was applied (reduction ratio 0.25 vs 0.15, P 0.02).	bilirubin	28	37	P 0.02	111	117	1
1471-2377-10-92.txt	Post hoc analyses of patients with PHN for at least 6 months showed significantly greater reductions in "average pain for the past 24 hours" NPRS scores from baseline to weeks 2-8 in NGX-4010 patients compared to controls (37.6% versus 23.4%; p = 0.0291).	"average pain for the past 24 hours" NPRS scores	104	152	p = 0.0291	243	253	1
1471-2474-12-132.txt	Age, race/ethnicity, education, military status, smoking history, BMI, and whether a Soldier received the physical/USI examination remained statistically significant (p < .05) when considered in a full multivariate model.	Age	0	3	significant	154	165	1
1471-2393-11-85.txt	MLU women were significantly less likely to have continuous electronic fetal monitoring (397 [36.1%] vs 313 [56.7%]; RR 0.64 [0.57 to 0.71]), or augmentation of labour (436 [39.6%] vs 314 [56.9%]; RR 0.50 [0.40 to 0.61]).	augmentation of labour	145	167	significantly	15	28	1
cc6104.txt	After the target temperature was reached, the intravascular cooling device was 11.2 ± 18.7% of the time out of range, which was significantly less compared to all other methods.	out of range	104	116	significantly	128	141	1
1475-2891-10-120.txt	HIV-infected children between six months and three years of age had a significantly higher gain in height if they received multivitamins (n = 48; 2 cm, compared to 1 cm in the placebo group; 95% CI = 0.20, 1.70; p = 0.01; p for interaction by age group = 0.01).	gain in height	91	105	p for interaction by age group = 0.01	222	259	1
1743-0003-8-50.txt	Conclusion Our findings indicated that robotic arm therapy alone, without additional physical therapy interventions tailored to the paretic arm, was as effective as standard physiotherapy treatment for all responses and more effective than conventional treatment for the CMSA Arm (p = 0.04) and Hand (p = 0.04).	Hand	295	299	p = 0.04	301	309	1
1471-2474-8-36.txt	Conclusion When used for the short-term treatment of plantar heel pain, a two-week stretching program provides no statistically significant benefit in 'first-step' pain, foot pain, foot function or general foot health compared to not stretching.	'first-step' pain	151	168	no statistically significant	111	139	1
1745-6215-12-146.txt	In addition, less acetaminophen was used in the wet-cupping group during 4 weeks (p = 0.09).	acetaminophen	18	31	p = 0.09	82	90	1
1471-2415-6-23.txt	Comparing the development of vision measures against the natural loss expected to occur over the course of 48 weeks, most measures showed reduced decline, and these reductions were significant for normal illumination VA and CS.	CS	224	226	significant	181	192	1
cc7695.txt	Results In the intention to treat analysis there were no statistically significant differences between the 53 patients selected for each group regarding gender (p = 0.541), age (p = 0.585) and type of surgery (p = 0.172).	type of surgery	193	208	no statistically significant	54	82	1
1471-227X-9-3.txt	Results Compared to preformed teams, ad-hoc forming teams had less hands-on time during the first 180 seconds of the arrest (93 ± 37 vs 124 ± 33 sec, P < 0.0001), delayed their first defibrillation (67 ± 42 vs 107 ± 46 sec, P < 0.0001), and made less leadership statements (15 ± 5 vs 21 ± 6, P < 0.0001).	hands-on time during the first 180 seconds of the arrest	67	123	P < 0.0001	150	160	1
1471-2407-12-495.txt	At 3 months post-radiotherapy, TT patients had a clinically significant increase in role- and social-functioning scores and a clinically significant decrease in fatigue.	role- and social-functioning scores	84	119	significant	60	71	1
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	forced vital capacity (FVC	183	209	P = 0.019	243	252	1
1471-2474-11-155.txt	During treatment, low back pain decreased from 6.2 (SD 2.2) to 1.6 (2.3, p < 0.001) and disc height increased from 7.5 (1.7) mm to 8.8 (1.7) mm (p < 0.001).	disc height	88	99	p < 0.001	145	154	1
1471-244X-4-22.txt	Overall, light had a significant effect on the number of responders, as assessed with the HDRS (X 2 = .02).	the number of responders, as assessed with the HDRS (X 2 = .02)	43	106	significant	21	32	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.001	342	351	1
1477-7827-2-70.txt	From the misoprostol group more neonates were admitted to the intensive neonatal unit, than from the dinoprostone group (13.5% vs 4.8%, p > 0.05).	neonates were admitted to the intensive neonatal unit	32	85	p > 0.05	136	144	1
1471-2474-12-136.txt	0.66, 95%CI - 2.79 to 4.11, p = 0.703), total extension deficit of operated digits (degrees: adjusted mean diff 5.11, 95%CI -2.33 to 12.55, p = 0.172) or patient satisfaction (0-10 numerical rating scale: adjusted mean diff -0.35, 95%CI -1.04 to 0.34, p = 0.315) at 1 year post surgery.	total extension deficit of operated digits	40	82	p = 0.172	140	149	1
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	forced vital capacity (FVC	183	209	significantly	16	29	1
1471-2377-11-96.txt	Results Significant intervention effects were observed in the intervention group for learning mean score (SE), [93.89 (4.00) vs 106.38 (4.32), P = 0.04] but for working memory the intervention group performed poorly [27.42 (0.66) vs 25.34 (0.73), P = 0.04].	learning mean score	85	104	P = 0.04	143	151	1
1471-2407-11-131.txt	Overall higher RTDI was correlated with a shorter TTDP (log-rank p = 0.0525 for 85% RTDI cut-off).	Overall higher RTDI was correlated with a shorter TTDP	0	54	p = 0.0525	65	75	1
1472-6963-9-14.txt	thrombolysis, 15/175 (8.6%) in the intervention arm and 2/115 (1.7%) in the control arm received thrombolysis (p = 0.02) in the ITT analysis, and respectively 15/99 (15.1%) and 2/107 (1.9%)(p = 0.001) in the PP analysis.	thrombolysis	97	109	p = 0.001	190	199	1
1471-230X-11-100.txt	Meta-analysis of studies (regardless of indication) did not find any significant differences in the mean number of polyps (5 RCT, 2479 participants; WMD -0.07 95% CI -0.21 to 0.07; I2 68%), the mean number of adenomas (8 RCT, 3517 participants; WMD -0.08 95% CI -0.17; 0.01 to I2 62%) and the rate of patients with at least one adenoma (8 RCT, 3512 participants, RR 0.96 95% CI 0.88 to 1,04;I2 0%).	the rate of patients with at least one adenoma	289	335	not find any significant	56	81	1
cc3737.txt	There were no statistically significant differences in survival without supplemental oxygen or on ventilator, mortality, therapy failure, or crossover.	mortality	110	119	no statistically significant	11	39	1
1745-6215-10-103.txt	Conclusion Although our trial failed to find significant differences in VAS, QALYs and ICERs based on VAS and QALYs at one-year follow-up, CEACs suggest that postural exercise therapy according to Mensendieck/Cesar has a higher probability of being cost-effective compared to regular physiotherapy; however further research is required.	QALYs	77	82	failed to find significant	30	56	1
cc10289.txt	Within 30 minutes, nicardipine patients more often reached TR than labetalol (91.7 vs 82.5%, P = 0.039).	often reached TR	45	61	P = 0.039	93	102	1
1471-2369-13-67.txt	However, women and patients age < 60 who were randomized to frequent nocturnal hemodialysis were less bothered by the impact of kidney disease on their sex life at 6 months, compared with patients allocated to conventional hemodialysis (p = 0.005 and p = 0.024 respectively).	bothered by the impact of kidney disease on their sex life	102	160	p = 0.005	237	246	1
1465-9921-11-112.txt	Furthermore, 6MWD significantly increased compared to baseline (Δ 6MWD: +79 ± 28 meters) as well as compared to controls (both: p < 0.01).	6MWD	13	17	p < 0.01	128	136	1
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	alliance	336	344	no statistically significant	231	259	1
1475-2891-11-57.txt	Conclusion Different dietary approaches based on portion control, low energy density, or low glycemic index produced similar, significant short-term improvements in body composition, diet compositin, and MetS components in overweight and obese adults undergoing weekly weight loss meetings.	diet compositin	183	198	significant	126	137	1
1465-9921-12-93.txt	Further, the baseline characteristics of patients worsened at month 3 had generally severe impairment, and their clinical outcomes including mortality were also significantly worsened after 1 year.	their clinical outcomes including mortality	107	150	significantly	161	174	1
1756-9966-28-131.txt	Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01).	appetite loss evolution	203	226	p < 0.01	256	264	1
1475-2875-10-358.txt	The incidence of malaria episodes was 7.1/100 child months at risk [95% CI (3.7-13.7)] in communities with IPTc + HMM compared to 35.6/100 child months at risk [95% CI (26.7-47.4)] in communities with only HMM (aOR = 0.20; 95% CI 0.09-0.41; p = 0.04).	The incidence of malaria episodes	0	33	p = 0.04	241	249	1
1471-2393-11-85.txt	Results No statistically significant difference was found between MLU and CLU in the seven key outcomes: caesarean birth (163 [14.8%] vs 84 [15.2%]; relative risk (RR) 0.97 [95% CI 0.76 to 1.24]), induction (248 [22.5%] vs 138 [25.0%]; RR 0.90 [0.75 to 1.08]), episiotomy (126 [11.4%] vs 68 [12.3%]; RR 0.93 [0.70 to 1.23]), instrumental birth (139 [12.6%] vs 79 [14.3%]; RR 0.88 [0.68 to 1.14]), Apgar scores < 8 (10 [0.9%] vs 9 [1.6%]; RR 0.56 [0.23 to 1.36]), postpartum haemorrhage (144 [13.1%] vs 75 [13.6%]; RR 0.96 [0.74 to 1.25]); breastfeeding initiation (616 [55.9%] vs 317 [57.4%]; RR 0.97 [0.89 to 1.06]).	induction	197	206	No statistically significant	8	36	1
1471-2415-6-23.txt	Comparing the development of vision measures against the natural loss expected to occur over the course of 48 weeks, most measures showed reduced decline, and these reductions were significant for normal illumination VA and CS.	normal illumination VA	197	219	significant	181	192	1
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	Groningen Activity and Restriction scale	690	730	p = 0.03	759	767	1
1471-2318-3-3.txt	For the resistance exercise group, participation was 71% (p = 0.004) and adherence was 63% (p = 0.020).	adherence	73	82	p = 0.020	92	101	1
cc11180.txt	Systemic ionized calcium concentrations were significantly reduced during citrate anticoagulation ( P < 0.001) but remained within a safe range.	Systemic ionized calcium concentrations	0	39	significantly	45	58	1
1471-2458-10-81.txt	Most effects of the intervention on individual-level variables of girls and parents were not significantly different from the control condition, including the primary outcome of child BMI z-score (F 1, 5 = 0.42, p = .544), parent BMI (F 1, 5 = 1.58, p = .264), and related behavioral variables.	parent BMI	223	233	p = .264	250	258	1
1472-6882-12-19.txt	In the primary outcome model, there was no significant difference in weight regain between the two arms (1.72 kg (se 0.85) weight regain for TAT and 2.96 kg (se 0.96) weight regain for SS, p < 0.097) Tests of between- arm differences for secondary outcomes were also not significant.	weight regain	69	82	no significant	40	54	1
ar4072.txt	In the double-blind part, more patients on adalimumab achieved an ASAS40 at week 4 (41%), week 8 (53%) and week 12 (53%) than on placebo (20%, 33%, 33%), while differences at week 8 only reached borderline significance ( P = 0.05).	an ASAS40	63	72	significance	206	218	1
1477-7827-1-63.txt	Although patients receiving Bravelle(R) consistently reported a greater number of chemical, clinical and continuing pregnancies, as well as an increased rate of live birth, the data did not attain statistical significance (P > 0.05).	chemical, clinical and continuing pregnancies	82	127	P > 0.05	223	231	1
1475-2875-11-217.txt	The median parasite clearance time was significantly slower in the ARPQ group compared with the ASAQ group (48 h vs 36 h, P <0.001) and fever clearance times were shorter in the ASAQ group (12 h vs 24 h, P  = 0.07).	The median parasite clearance time	0	34	P <0.001	122	130	1
cc3737.txt	In the HFOV group the OI response was significantly higher than in the CV group between the first and the second day.	the OI response	18	33	significantly	38	51	1
1748-717X-7-82.txt	At 4.7 years median follow-up, three US-IMRT and no S-IMRT patients experienced PSA failure (p = 0.06; HR 8.8, 95% CI 0.9–86).	PSA failure	80	91	p = 0.06	93	101	1
cc11215.txt	Nonsignificant differences were found in absolute FEV1, FEV1/FVC, FVC, forced expiratory flow from 25% to 75% of FVC, functional residual capacity, and CO diffusion.	absolute FEV1	41	54	Nonsignificant	0	14	1
1471-2288-7-30.txt	In the ANCOVA model with baseline score as a co-variate, follow-up group had a significant effect on outcome at six months on the ADAS-Cog score (n = 140; mean difference = -2.018; 95%CI -3.914, -0.121; p = 0.037 favouring the intensive follow-up group), and on participant-rated quality of life score (n = 142; mean difference = -1.382; 95%CI -2.642, -0.122; p = 0.032 favouring minimal follow-up group).	the ADAS-Cog score	126	144	p = 0.037	203	212	1
1471-2377-10-91.txt	Results The ABC-C Irritability Subscale scores showed significant improvement (p < 0.001), as did the VAS (p = 0.003) and the CGI (p < 0.001).	The ABC-C Irritability Subscale scores	8	46	p < 0.001	79	88	1
1471-2466-11-16.txt	There was no significant improvement with atorvastatin and inhaled beclometasone compared to inhaled beclometasone alone in outcome measures at 8 weeks.	outcome measures at 8 weeks	124	151	no significant	10	24	1
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	improved	433	441	p = 0.0024	479	489	1
1471-2474-8-119.txt	Results At the end of the study, the GH group showed a 60% reduction in the mean number of tender points (pairs) compared to the control group (p < 0.05; 3.25 ± 0.8 vs 8.25 ± 0.9).	the mean number of tender points (pairs)	72	112	p < 0.05	144	152	1
1471-2466-11-61.txt	COPD-related costs differed among groups (LABA or LAMA $2,051 SE = 91; LABA and LAMA $2,823 SE = 62; LABA, LAMA and ICS $3,546 SE = 89; all p < .0001) with the differences driven by study medication costs.	COPD-related costs	0	18	p < .0001	140	149	1
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	steps/day	122	131	p < 0.001	235	244	1
cc7695.txt	Results In the intention to treat analysis there were no statistically significant differences between the 53 patients selected for each group regarding gender (p = 0.541), age (p = 0.585) and type of surgery (p = 0.172).	age	173	176	no statistically significant	54	82	1
1745-6215-12-13.txt	In the 2 treatment groups combined, systolic (-1.36 mm Hg) and diastolic (-0.97 mm Hg) office BPs decreased from week 5 to 10 ( P for period effect ≤0.028), but carry-over effects were not significant ( P ≥ 0.11).	carry-over effects	161	179	not significant	185	200	1
1471-2474-13-118.txt	Cross sectional area of the QFM increased in both training groups (NMES: +5.4%; RT: +4.3%; p = 0.404).	Cross sectional area of the QFM	0	31	p = 0.404	91	100	1
1471-2474-12-132.txt	Responders were more likely to be older, Caucasian, have higher levels of education and income, reservist military status, non smoker, lower BMI, and have received individualized attention via the physical/USI examination (p < .05).	have higher levels of education and income	52	94	p < .05	223	230	1
ar4034.txt	However, significant treatment effects at all time points for a variety of ultrasound (US) endpoints were detected with both prednisone doses; the largest observed effect size = 2.33.	a variety of ultrasound (US) endpoints	62	100	significant	9	20	1
1471-2474-13-141.txt	Results A statistically significant difference (p = 0,009) regarding the mobility as measured with the four-item Barthel index was found at the 5th postoperative day, favouring the DAA.	the mobility as measured with the four-item Barthel index	69	126	significant	24	35	1
1471-2474-13-118.txt	Results There were similar, significant improvements in functional capacity for the RT and NMES groups at week 8 compared to week 1 (p≤0.001) and compared to the control group (p < 0.005), and the improvements were maintained at week 14 (p≤0.001).	functional capacity	56	75	significant	28	39	1
bcr1732.txt	No significant differences were seen between letrozole and anastrozole in terms of molecular effects.	molecular effects	83	100	No significant	0	14	1
1471-2431-7-27.txt	For subgroup age > 3 months pacifier did not have any significant effect on crying time.	crying time	76	87	not have any significant	41	65	1
1471-2458-12-944.txt	Prevalence of high blood pressure, high cholesterol and smoking were reduced significantly (p <0.01) in both groups.	smoking	56	63	p <0.01	92	99	1
1471-2296-13-30.txt	Mean (sd) percentage of adherent days was 77.4% (26.3) in the intervention group and 69.0% (30.8) in standard care (mean difference between groups 8.4%, 95% confidence interval 0.2% to 16.7%, p  = 0.044).	adherent days	24	37	p  = 0.044	192	202	1
1756-9966-28-131.txt	Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01).	emotional functioning	117	138	significant	58	69	1
1471-2431-9-21.txt	On the ATEC, sensory/cognitive awareness significantly improved (p = 0.0367) in the treatment group compared to the control group.	sensory/cognitive awareness	13	40	p = 0.0367	65	75	1
1471-2474-11-64.txt	Results After 24 matches there was no statistical significant difference between the groups for the incidence of hamstring injury (OR:0.116, 95% CI:0.013-1.019, p = 0.051) and primary non-contact knee injury (OR:0.116, 95% CI:0.013-1.019, p = 0.051).	primary non-contact knee injury	176	207	no statistical significant	35	61	1
1471-2431-9-21.txt	On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.	hyperactivity	116	129	significant	12	23	1
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	body composition	92	108	significant	64	75	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.045	365	374	1
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	score higher on the asthma knowledge questionnaire	339	389	p = 0.06	410	418	1
cc11445.txt	Patients treated with SLED needed fewer blood transfusions (1,375 ± 2,573 ml vs 1,976 ± 3,316 ml, P = 0.02) and had a substantial reduction in nursing time spent for renal replacement therapy ( P < 0.001) resulting in lower costs.	blood transfusions	40	58	P = 0.02	98	106	1
1471-2474-11-99.txt	There were no significant differences in changes in the prevalence of arm, shoulder and neck symptoms or sick leave between the intervention and usual care group.	the prevalence of arm, shoulder and neck symptoms	52	101	no significant	11	25	1
1471-244X-9-54.txt	Compared with their counterparts who remained on their initial therapies, individuals who switched antipsychotics experienced a significantly higher risk of acute-care services, including hospitalization (p = .013) and crisis services (p = .011).	hospitalization	188	203	p = .013	205	213	1
cc6173.txt	In the TA group, we observed a significant reduction in the incidence of VS ( P = 0.003), the use of norepinephrine ( P = 0.029), and time on mechanical ventilation ( P = 0.018).	the incidence of VS	56	75	significant	31	42	1
1745-6215-12-146.txt	However, the PPI scores showed significant differences between the two groups (-1.2 [-1.6 to -0.8] for the wet-cupping group and -0.2 [-0.8 to 0.4] for the waiting-list group, p < 0.01).	the PPI scores	9	23	significant	31	42	1
1471-2474-13-118.txt	Results There were similar, significant improvements in functional capacity for the RT and NMES groups at week 8 compared to week 1 (p≤0.001) and compared to the control group (p < 0.005), and the improvements were maintained at week 14 (p≤0.001).	functional capacity	56	75	p < 0.005	177	186	1
1471-2377-10-91.txt	Results The ABC-C Irritability Subscale scores showed significant improvement (p < 0.001), as did the VAS (p = 0.003) and the CGI (p < 0.001).	The ABC-C Irritability Subscale scores	8	46	significant	54	65	1
1471-2296-4-7.txt	Results At the end of the study no significant difference between groups in improvement of quality of life was found.	quality of life	91	106	no significant	32	46	1
1475-2891-10-72.txt	No other significant treatment effects were discerned in glucose, insulin, lipids, and weight.	glucose	57	64	No other significant	0	20	1
1743-0003-8-50.txt	Conclusion Our findings indicated that robotic arm therapy alone, without additional physical therapy interventions tailored to the paretic arm, was as effective as standard physiotherapy treatment for all responses and more effective than conventional treatment for the CMSA Arm (p = 0.04) and Hand (p = 0.04).	the CMSA Arm	267	279	p = 0.04	281	289	1
1472-6831-11-35.txt	Statistically significant differences detected in the amount (millimetres) of calculus were too small to be clinically significant.	the amount (millimetres) of calculus	50	86	significant	14	25	1
1741-7015-2-7.txt	Results At one year, there was no difference in the rate of renal involvement (3/21 prednisone group vs 2/19 placebo group, P = 1.0).	the rate of renal involvement	48	77	P = 1.0	124	131	1
1472-6963-1-10.txt	Intensity of prescribing of blood pressure lowering drugs was not significantly different between the two groups at six months follow up.	Intensity of prescribing of blood pressure lowering drugs	0	57	not significantly	62	79	1
1471-2407-12-495.txt	At 3 months post-radiotherapy, TT patients had a clinically significant increase in role- and social-functioning scores and a clinically significant decrease in fatigue.	fatigue	161	168	significant	137	148	1
1471-2407-9-21.txt	The LP pillow tended to increase the success rate of LPs (67% vs 57%, p = 0.23), and decreased the post-LP syndromes (15% vs 24%, p = 0.17) but the differences were not statistically significant.	the success rate of LPs	33	56	p = 0.23	70	78	1
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	able to identify patients at high risk of severe attack	239	294	p = 0.06	314	322	1
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	eye contact	227	238	significantly	53	66	1
1745-6215-13-1.txt	Results The primary combined endpoint of death, recurrent MI and unstable angina was 7.5% (8/106) in the invasive group and 17.3% (19/110) in the conservative group (Hazard ratio 0.42; 95% confidence interval [CI] 0.18-0.96; p = 0.032).	The primary combined endpoint of death, recurrent MI and unstable angina	8	80	p = 0.032	225	234	1
1471-2466-10-11.txt	Serum potassium and blood glucose levels did not differ significantly between the two groups, and no patient had QTc >500 ms.	blood glucose levels	20	40	not differ significantly	45	69	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.000	483	492	1
1532-429X-14-61.txt	CMR performed better than SPECT in MVD (p = 0.003 vs all SPECT, p = 0.04 vs gated-SPECT), in men (p = 0.004, n = 313) and in women (p = 0.03, n = 112) as well as in the non-infarct patients (p = 0.005, n = 186 in 1–3 vessel disease and p = 0.015, n = 140 in MVD).	MVD	35	38	p = 0.03	132	140	1
1748-717X-7-82.txt	Median PSA nadir was higher in the US-IMRT arm (1.46 vs 0.78, p = 0.05).	PSA nadir	7	16	p = 0.05	62	70	1
cc3737.txt	There were no statistically significant differences in survival without supplemental oxygen or on ventilator, mortality, therapy failure, or crossover.	therapy failure	121	136	no statistically significant	11	39	1
1745-6215-13-1.txt	During follow up revascularization-procedures were performed in 6.6% (7/106) in the invasive group and 31.8% (35/110) in the conservative group (Hazard ratio 0.18; 95% CI 0.13-0.43; p < 0.0001).	revascularization-procedures	17	45	p < 0.0001	182	192	1
1475-2875-11-355.txt	The median parasite-reduction ratio at 24 hours was 48 in the AS 2mg/kg group compared with 212 and 113 in the other two groups, respectively (p=0.02).	The median parasite-reduction ratio	0	35	p=0.02	143	149	1
1471-244X-12-44.txt	In contrast to controls, significant treatment effects were found at outcome on self-reported measures of violent attitudes, rational problem-solving and anger cognitions.	rational problem-solving	125	149	significant	25	36	1
1471-2458-6-37.txt	Women's physical health scores were not significantly different in intervention and comparison arms (PCS mean scores 52.86 and 52.88).	Women's physical health scores	0	30	not significantly	36	53	1
1471-2393-8-19.txt	Results Intention-to-treat outcomes showed a statistical significant better estimated regression coefficient RDQ -1.6 [-2.9;-0.5] associated with treatment, as well as better IPA subscale autonomy in self-care -1.0 [-1.9;-0.03] and TSK -2.4 [-3.8;-1.1] but were not clinical relevant over time.	RDQ	109	112	significant	57	68	1
cc11300.txt	The corrected colonisation index was similar in the two groups at T0 ( P = 0.36), while a significant statistical difference was observed between the treatment and control groups at T6 (median 0.14 and 0.33, respectively; P = 0.0016), at T9 (median 0.00 and 0.28, respectively; P = 0.0001), at T12 (median 0.00 and 0.41, respectively; P = 0.0008), and at T15 (median 0.00 and 0.42, respectively; P < 0.0003).	The corrected colonisation index	0	32	P = 0.36	71	79	1
1471-2431-9-21.txt	Conclusion Children with autism who received hyperbaric treatment at 1.3 atm and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.	eye contact	208	219	significant	119	130	1
1471-2474-11-64.txt	There was no significant difference for weeks missed due to hamstring injury (4 v14, χ2:1.12, p = 0.29) and lower-limb muscle strains (4 v 21, χ2:2.66, p = 0.10).	weeks missed due to hamstring injury	40	76	p = 0.29	94	102	1
1741-7015-7-22.txt	Results The mean duration of diarrhea from enrolment and the mean stool weight during hospital stay were 63.7 hours and 940 grams, respectively, and there were no significant differences in the adjusted means across treatment groups.	the mean stool weight during hospital stay	57	99	no significant	160	174	1
cc6173.txt	Incidence of IR was 17% in the TA group versus 42% in the placebo group ( P = 0.047).	Incidence of IR	0	15	P = 0.047	74	83	1
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	121	170	p < 0.05	271	279	1
ar4072.txt	In the adalimumab group a significant decrease of all disease activity parameters was noted at week 12 and was even more pronounced at week 24.	all disease activity parameters	50	81	significant	26	37	1
1471-244X-12-66.txt	Immediate and 4-month follow-up results revealed a significant time effect on all measured dimensions (social anxiety scales, general anxiety and depression levels, quality of life).	social anxiety scales	103	124	significant	51	62	1
1471-2474-12-136.txt	0.66, 95%CI - 2.79 to 4.11, p = 0.703), total extension deficit of operated digits (degrees: adjusted mean diff 5.11, 95%CI -2.33 to 12.55, p = 0.172) or patient satisfaction (0-10 numerical rating scale: adjusted mean diff -0.35, 95%CI -1.04 to 0.34, p = 0.315) at 1 year post surgery.	patient satisfaction	154	174	p = 0.315	252	261	1
1757-7241-20-16.txt	Although median values for proportion of delivered compressions within target depth were higher in the feedback group (0-30 s: 54.0%; 30-60 s: 88.0%; 60-90 s: 72.6%; 90-120 s: 87.0%), no significant difference was found when compared to without feedback (0-30 s: 19.6%; 30-60 s: 33.1%; 60-90 s: 44.5%; 90-120 s: 32.7%) and no significant deteriorations over time were found within the groups.	median values for proportion of delivered compressions within target depth	9	83	no significant	184	198	1
1471-244X-7-13.txt	Results From baseline to post-treatment assessment, PTSD severity and other psychopathological symptoms were significantly improved for the treatment group (intent-to-treat group × time interaction effect size d = 1.40).	other psychopathological symptoms	70	103	significantly	109	122	1
1471-227X-9-18.txt	After six months, the results are comparable prior (55.6 ± 29.9 vs 43.1 ± 34.7 s) and after a further training period (23.5 ± 13.2 vs 26.6 ± 21.6, p < 0.05).	the results	18	29	p < 0.05	147	155	1
1471-227X-9-3.txt	Results Compared to preformed teams, ad-hoc forming teams had less hands-on time during the first 180 seconds of the arrest (93 ± 37 vs 124 ± 33 sec, P < 0.0001), delayed their first defibrillation (67 ± 42 vs 107 ± 46 sec, P < 0.0001), and made less leadership statements (15 ± 5 vs 21 ± 6, P < 0.0001).	leadership statements	251	272	P < 0.0001	292	302	1
cc11300.txt	The corrected colonisation index was similar in the two groups at T0 ( P = 0.36), while a significant statistical difference was observed between the treatment and control groups at T6 (median 0.14 and 0.33, respectively; P = 0.0016), at T9 (median 0.00 and 0.28, respectively; P = 0.0001), at T12 (median 0.00 and 0.41, respectively; P = 0.0008), and at T15 (median 0.00 and 0.42, respectively; P < 0.0003).	The corrected colonisation index	0	32	P = 0.0016	222	232	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.001	260	269	1
1471-2431-11-82.txt	[Na] increased significantly in the 0.9% group (+0.20 mmol/L/h [IQR +0.03, +0.4]; P = 0.02) and increased, but not significantly, in the 0.45% group (+0.08 mmol/L/h [IQR -0.15, +0.16]; P = 0.07).	[Na]	0	4	P = 0.02	82	90	1
1471-2466-12-14.txt	The improvement in ACT score after treatment initiation was significantly higher when the SINA approach was used (2.9 in the SINA group compared to 1.7 in the GINA group ( p = 0.04)).	ACT score	19	28	p = 0.04	172	180	1
1475-2875-11-217.txt	The median parasite clearance time was significantly slower in the ARPQ group compared with the ASAQ group (48 h vs 36 h, P <0.001) and fever clearance times were shorter in the ASAQ group (12 h vs 24 h, P  = 0.07).	fever clearance times	136	157	P  = 0.07	204	213	1
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	main effect of time	22	41	significant	10	21	1
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	daytime arterial blood gases	516	544	p = 0.03	615	623	1
1465-9921-13-86.txt	After 26 weeks there were clinically significant differences between the groups for 6 minute-walk-distance (+59 m, 95% CI 28–89 m), maximum work load (+7.4 Watt, 95% CI 0.5-13.4 Watt) and St. George’s Respiratory Questionnaire score (−5 points, 95% CI −10 to −1 points).	6 minute-walk-distance	84	106	significant	37	48	1
1471-2261-3-2.txt	Acetaminophen had no significant effect on body temperature during the subsequent four days compared to placebo, and ibuprofen had no statistically significant effect on body temperature during the entire study period.	body temperature	170	186	no statistically significant	131	159	1
1471-2458-12-344.txt	At 12 months, there was no significant difference in physical activity levels between the intervention group (n = 264) and the control group (n = 257).	physical activity levels	53	77	no significant	24	38	1
cc10453.txt	The proportions of perfused vessels increased in relation to baseline within all study groups, and there were no significant differences between groups.	The proportions of perfused vessels	0	35	no significant	110	124	1
1471-244X-10-54.txt	Patients in both treatment conditions showed significant improvement on the main outcome measure, the Panic Disorder Severity Scale (PDSS) after treatment.	the main outcome measure, the Panic Disorder Severity Scale (PDSS) after treatment	72	154	significant	45	56	1
1756-9966-28-131.txt	Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01).	social functioning	140	158	significant	58	69	1
cc11249.txt	Considering only the subgroup of patients that used NIV, the reintubation rates related to NIV failure were significantly lower in the study group when compared with controls; two patients (6%) versus 13 (33%); P < 0.05, respectively.	the reintubation rates related to NIV failure	57	102	P < 0.05	211	219	1
1471-2458-6-37.txt	Women's mental health scores were not significantly different in the intervention arm and the comparison arm (MCS mean score 45.98 and 46.30, mean EPDS score 6.91 and 6.82, EPDS ≥ 13 ('probable depression') 15.7% vs 14.9%, Odds ratio adj 1.06 (95%CI 0.91–1.24).	Women's mental health scores	0	28	not significantly	34	51	1
1471-2458-6-37.txt	Women's mental health scores were not significantly different in the intervention arm and the comparison arm (MCS mean score 45.98 and 46.30, mean EPDS score 6.91 and 6.82, EPDS ≥ 13 ('probable depression') 15.7% vs 14.9%, Odds ratio adj 1.06 (95%CI 0.91–1.24).	MCS	110	113	not significantly	34	51	1
1471-2458-6-37.txt	Women's mental health scores were not significantly different in the intervention arm and the comparison arm (MCS mean score 45.98 and 46.30, mean EPDS score 6.91 and 6.82, EPDS ≥ 13 ('probable depression') 15.7% vs 14.9%, Odds ratio adj 1.06 (95%CI 0.91–1.24).	EPDS score	147	157	not significantly	34	51	1
1471-2458-6-37.txt	Women's mental health scores were not significantly different in the intervention arm and the comparison arm (MCS mean score 45.98 and 46.30, mean EPDS score 6.91 and 6.82, EPDS ≥ 13 ('probable depression') 15.7% vs 14.9%, Odds ratio adj 1.06 (95%CI 0.91–1.24).	EPDS ≥ 13 ('probable depression')	173	206	not significantly	34	51	1
1472-6882-11-93.txt	More parents in the acupuncture group than in the control group (28% and 15% respectively, p = 0.006) experienced the infant's sleep to be "better" or "much better."	the infant's sleep	114	132	p = 0.006	91	100	1
1471-2474-11-99.txt	At 12-month follow-up, the intervention group showed a significant positive change (OR = 0.48) in receiving information on healthy computer use, as well as a significant positive change regarding risk indicators for work posture and movement, compared to the usual care group.	risk indicators for work posture and movement	196	241	significant	158	169	1
cc11159.txt	Individual renal parameters showed that endogenous creatinine clearance (baseline to Day 28) was significantly higher in the treated group relative to placebo (from 50 ± 27 to 108 ± 73 mL/minute (mean ± SEM) for the AP group; and from 40 ± 37 to 65 ± 30 mL/minute for placebo; P = 0.01).	endogenous creatinine clearance (baseline to Day 28)	40	92	P = 0.01	277	285	1
1471-2474-11-99.txt	With regard to symptoms and sick leave, only small and non-significant effects were found.	symptoms	15	23	non-significant	55	70	1
1741-7015-2-6.txt	Fascial interposition decreased time to azoospermia (hazard ratio [HR], 1.35; P < 0.0001) and time to severe oligozoospermia (HR, 1.32; P < 0.0001) and reduced failures based on semen analysis by about half, from 12.7% (95% confidence interval [CI], 9.7 to 16.3) to 5.9% (95% CI, 3.8 to 8.6) (P < 0.0001).	time to azoospermia	32	51	P < 0.0001	78	88	1
1471-2474-10-118.txt	When analysing the results in a mixed model analysis on repeated measures including interaction between age-group and treatment effect the training group demonstrated significantly improved results compared to the control group in subjects younger than 40 years of age regarding OMAS (p = 0.028), muscle strength in the plantar flexors (p = 0.029) and dorsiflexors (p = 0.030).	dorsiflexors	352	364	p = 0.029	337	346	1
1471-2474-13-15.txt	Conclusions In African American subjects with significant comorbidities, febuxostat 80 mg is significantly more efficacious than either febuxostat 40 mg or allopurinol 200/300 mg. Febuxostat was well tolerated in this African American population.	efficacious	112	123	significantly	93	106	1
1471-2474-11-99.txt	At 12-month follow-up, the intervention group showed a significant positive change (OR = 0.48) in receiving information on healthy computer use, as well as a significant positive change regarding risk indicators for work posture and movement, compared to the usual care group.	receiving information on healthy computer use	98	143	significant	55	66	1
1749-799X-6-45.txt	The NIN pre-treatment score at Final was used for the primary ANCOVA comparison, demonstrating a significantly greater cumulative treatment effect of a mean 2.2 (SE 0.49) points pain reduction (p = 0.002).	cumulative treatment effect	119	146	significantly	97	110	1
1471-2334-3-10.txt	In the APV600/RTV arm, significantly more patients achieved HIV-1 RNA <50 copies/mL (48% [57/118] vs 29% [11/38] with APV1200, P = 0.04), and greater mean reduction from baseline in HIV-1 RNA was observed (-2.21 vs -1.59 log 10 copies/mL, P = 0.028).	HIV-1 RNA	182	191	P = 0.028	239	248	1
1472-6882-7-8.txt	Participants who dropped out reported significantly fewer previous quit attempts, but no other significant differences.	previous quit attempts	58	80	significantly	38	51	1
1471-2474-12-132.txt	Responders were more likely to be older, Caucasian, have higher levels of education and income, reservist military status, non smoker, lower BMI, and have received individualized attention via the physical/USI examination (p < .05).	likely to be older	21	39	p < .05	223	230	1
1465-9921-11-112.txt	Results After three month training period, in the Nordic Walking group time spent walking and standing as well as intensity of walking increased (Δ walking time: +14.9 ± 1.9 min/day; Δ standing time: +129 ± 26 min/day; Δ movement intensity: +0.40 ± 0.14 m/s 2 ) while time spent sitting decreased (Δ sitting time: -128 ± 15 min/day) compared to baseline (all: p < 0.01) as well as compared to controls (all: p < 0.01).	time spent walking and standing	71	102	p < 0.01	360	368	1
1471-2466-12-14.txt	The improvement in ACT score after treatment initiation was significantly higher when the SINA approach was used (2.9 in the SINA group compared to 1.7 in the GINA group ( p = 0.04)).	ACT score	19	28	significantly	60	73	1
1471-2458-12-602.txt	Conclusions These analyses indicate the efficacy of the Australian TLC Diabetes program with clinically significant post-intervention improvements in both glycaemic control and mental HRQL.	glycaemic control	155	172	significant	104	115	1
1471-2431-6-29.txt	Children who learned guided imagery with progressive muscle relaxation had significantly greater decrease in the number of days with pain than those learning breathing exercises alone after one (67% vs 21%, P = 0.05), and two (82% vs 45%, P < 0.01) months and significantly greater decrease in days with missed activities at one (85% vs 15%, P = 0.02) and two (95% vs 77%.	the number of days with pain	109	137	P < 0.01	239	247	1
1472-6831-11-35.txt	Results Prevalence of gingival bleeding at follow-up was 78.5% (6-month), 78% (12-month) and 82% (24-month) (p = 0.746).	Prevalence of gingival bleeding at follow-up	8	52	p = 0.746	109	118	1
1471-2393-11-85.txt	Results No statistically significant difference was found between MLU and CLU in the seven key outcomes: caesarean birth (163 [14.8%] vs 84 [15.2%]; relative risk (RR) 0.97 [95% CI 0.76 to 1.24]), induction (248 [22.5%] vs 138 [25.0%]; RR 0.90 [0.75 to 1.08]), episiotomy (126 [11.4%] vs 68 [12.3%]; RR 0.93 [0.70 to 1.23]), instrumental birth (139 [12.6%] vs 79 [14.3%]; RR 0.88 [0.68 to 1.14]), Apgar scores < 8 (10 [0.9%] vs 9 [1.6%]; RR 0.56 [0.23 to 1.36]), postpartum haemorrhage (144 [13.1%] vs 75 [13.6%]; RR 0.96 [0.74 to 1.25]); breastfeeding initiation (616 [55.9%] vs 317 [57.4%]; RR 0.97 [0.89 to 1.06]).	instrumental birth	325	343	No statistically significant	8	36	1
1471-2458-12-944.txt	Prevalence of high blood pressure, high cholesterol and smoking were reduced significantly (p <0.01) in both groups.	high cholesterol	35	51	p <0.01	92	99	1
1748-717X-7-82.txt	Mean change in EPIC urinary HRQOL at 3 months was −0.5 ± 11.2 in the US-IMRT arm and +3.9 ± 15.3 in the S-IMRT arm (p = 0.52).	EPIC urinary HRQOL at 3 months	15	45	p = 0.52	116	124	1
1471-230X-12-18.txt	The mean time to onset of the first 24-h heartburn-free period after initial dosing was 2.0 (± 2.2) days for Gaviscon ® and 2.0 (± 2.3) days for omeprazole ( p = 0.93); mean intergroup difference was 0.01 ± 1.55 days (95% CI = -0.41 to 0.43): ie, less than the lower limit of the 95% CI of -0.5 days predetermined to demonstrate non-inferiority.	The mean time to onset of the first 24-h heartburn-free period	0	62	p = 0.93	158	166	1
1471-2431-9-21.txt	Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).	Mean parental CGI scores	0	24	significantly	25	38	1
1471-2407-11-75.txt	Global quality of life was better in the 3-weekly arm (p = 0.03); patients treated with weekly schedules presented a significantly worsening in role functioning and financial scores (p = 0.02 and p < 0.001).	Global quality of life	0	22	p = 0.03	55	63	1
cc7695.txt	Non-invasive ventilation was necessary for two patients, in the manual group after cardiac surgery (p = 0.51).	Non-invasive ventilation was necessary	0	38	p = 0.51	100	108	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	significant	63	74	1
1756-9966-28-131.txt	Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01).	vomiting	180	188	p < 0.01	256	264	1
1756-9966-28-131.txt	Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01).	insomnia	190	198	significant	58	69	1
1532-429X-14-61.txt	CMR performed better than SPECT in MVD (p = 0.003 vs all SPECT, p = 0.04 vs gated-SPECT), in men (p = 0.004, n = 313) and in women (p = 0.03, n = 112) as well as in the non-infarct patients (p = 0.005, n = 186 in 1–3 vessel disease and p = 0.015, n = 140 in MVD).	MVD	35	38	p = 0.003	40	49	1
1471-2458-6-299.txt	There were no significant differences between intervention and comparison arms in the proportion of women having a preterm birth, an infant with low birthweight, or an infant with a birth weight <10 th percentile.	an infant with a birth weight <10 th percentile	165	212	no significant	11	25	1
1475-2891-10-85.txt	Results The results indicated a small decrease in the number of migraine like headaches over 12 weeks, although this difference was not statistically significant (IRR 1.15 95% CI 0.94 to 1.41, p = 0.18).	the number of migraine like headaches	50	87	p = 0.18	193	201	1
1471-2466-10-11.txt	Indacaterol demonstrated significantly higher peak FEV 1 than placebo, both on Day 1 and at Week 12, with indacaterol-placebo differences (LSM ± SEM) of 190 ± 28 (p < 0.001) and 160 ± 28 mL (p < 0.001), respectively.	peak FEV 1	46	56	p < 0.001	191	200	1
1465-9921-11-112.txt	Results After three month training period, in the Nordic Walking group time spent walking and standing as well as intensity of walking increased (Δ walking time: +14.9 ± 1.9 min/day; Δ standing time: +129 ± 26 min/day; Δ movement intensity: +0.40 ± 0.14 m/s 2 ) while time spent sitting decreased (Δ sitting time: -128 ± 15 min/day) compared to baseline (all: p < 0.01) as well as compared to controls (all: p < 0.01).	sitting time	300	312	p < 0.01	360	368	1
1472-6882-11-93.txt	Furthermore there were no significant differences between the groups regarding the frequency of stooling, neither at baseline, at which point the infants of both groups had bowel movements 4.2 times/day, nor during the intervention weeks.	the frequency of stooling	79	104	no significant	23	37	1
1471-244X-12-151.txt	After adjusting for confounders, participants without health insurance were found to experience a higher risk of developing severe depressive symptoms than participants with health insurance (7 months: OR, 1.40; 95% CI, 1.09-1.82; p = 0.01; 20 months: OR, 1.89; 95% CI, 1.37-2.61; p < 0.001).	risk of developing severe depressive symptoms	105	150	p = 0.01	231	239	1
1475-2891-11-47.txt	Net changes in GPx, SOD and catalase activities, and DNA tail length and tail moment were significantly different between the high-dose group and the placebo group.	SOD	20	23	significantly	90	103	1
1471-2431-7-7.txt	Sucrose had a significant effect on the PIPP score, as assessed by an ANOVA model (p = 0.0026).	the PIPP score	36	50	significant	14	25	1
1472-6963-12-348.txt	Among the other outcomes, the PCOMS group had better motivation for treatment (estimated mean difference ITT: 0.29, 95% CI 0.00 to 0.57, p = 0.05, PP: 0.28, 95% CI 0.04, 0.52, p = 0.024).	motivation for treatment	53	77	p = 0.024	176	185	1
1746-6148-8-157.txt	When comparing variables within the fish oil group as change from baseline to trial end, there were significant positive changes in PVF, HCPI, NSAID use, Quality of life VAS, as well as in all three scores in the comparative questionnaire (locomotion, every-day situations, and skin & coat).	HCPI	137	141	significant	100	111	1
1756-9966-28-131.txt	Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01).	social functioning	140	158	p < 0.01	256	264	1
1475-2875-10-358.txt	Adjusted for age groups, sex, Plasmodium falciparum carriage and prevalence of malnutrition, IPTc + HMM showed a significant protective effect against anaemia (aOR = 0.59; 95% CI 0.42-0.82; p = 0.02).	protective effect against anaemia	125	158	significant	113	124	1
cc10592.txt	The median pre-operative fluid loading volume was 1,875 ml (IQR 1,375 to 2,025) in the fluid group compared to 0 (IQR 0 to 0) in controls with days in hospital after surgery 12.2 (SD 11.5) days compared to 17.4 (SD 20.0) and an adjusted mean difference of 5.5 days (median 2.2 days; 95% CI -0.44 to 11.44; P = 0.07).	days in hospital after surgery	143	173	P = 0.07	306	314	1
1465-9921-11-74.txt	Improvements in ACQ score after 12 months were -0.14 (p = 0.23), -0.52 (p < 0.001) and -0.82 (p < 0.001) in the Internet group compared to usual care for patients with well, partly and uncontrolled asthma at baseline, respectively.	ACQ score	16	25	p < 0.001	94	103	1
cc3737.txt	There were no statistically significant differences in survival without supplemental oxygen or on ventilator, mortality, therapy failure, or crossover.	survival without supplemental oxygen or on ventilator	55	108	no statistically significant	11	39	1
cc7695.txt	The mean ± sd (standard deviation) duration of the weaning process was 221 ± 192 for the manual group, and 271 ± 369 minutes for the automatic group (p = 0.375).	The mean ± sd (standard deviation) duration of the weaning process	0	66	p = 0.375	150	159	1
1741-7015-7-54.txt	Mud plastering did not reduce sand fly density (Bangladesh study); lime plastering in India and one Nepali site, resulted in a significant reduction of sand fly density but not in the second Nepali site.	sand fly density	152	168	significant	127	138	1
1471-230X-12-18.txt	There was no significant difference in the reduction in pain intensity between groups by D7 ( p = 0.11) or D14 ( p = 0.08).	pain intensity	56	70	no significant	10	24	1
1471-2458-6-134.txt	However there were also changes in the ethnic control group scores; respectively +5.0%, +16.3% (significant P < 0.001), +1.5%, +1.7%.	the ethnic control group scores	35	66	significant	96	107	1
bcr2320.txt	Conclusions Exemestane lacks the beneficial effect of tamoxifen on lipids; however, sequential adjuvant treatment with exemestane in postmenopausal breast cancer patients after cessation of 5 to 7 years of tamoxifen does not appear to alter the lipid profile significantly compared with that of an observational arm.	the lipid profile	241	258	does not appear to alter the lipid profile significantly	216	272	1
1471-230X-12-18.txt	There was no significant difference in the reduction in pain intensity between groups by D7 ( p = 0.11) or D14 ( p = 0.08).	pain intensity	56	70	p = 0.11	94	102	1
1475-2891-7-7.txt	Malaria episodes were lower in the supplemented group (p = 0.029), with a 30.2% reduction of malaria cases (p = 0.025).	malaria cases	93	106	p = 0.025	108	117	1
1471-2334-5-2.txt	No significant changes in glucose, insulin, insulin resistance, C-peptide, or waist-to-hip ratios were observed in either treatment arm, nor were differences in these parameters noted between treatments.	C-peptide	64	73	No significant	0	14	1
1465-9921-11-135.txt	Conclusions Once-daily indacaterol provided clinically and statistically significant 24-h bronchodilation.	24-h bronchodilation	85	105	significant	73	84	1
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	need for oxytocin augmentation	228	258	p < 0.05	276	284	1
1471-2369-13-146.txt	Flow issues requiring catheter removal occurred at a rate of 1.6 vs 1.4 per 1000 catheter days in the heparin and ethanol groups respectively (IRR 0.85; 95% CI 0.20-3.5 p =0.82 (for ethanol vs heparin).	Flow issues requiring catheter removal	0	38	p =0.82	169	176	1
1471-2431-9-21.txt	Conclusion Children with autism who received hyperbaric treatment at 1.3 atm and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.	overall functioning	147	166	significant	119	130	1
1471-2458-11-267.txt	Results Glycated hemoglobin A1c and systolic blood pressure (SBP) levels decreased significantly in the PRECEDE group (multivariate analysis of covariance, with baseline glycated hemoglobin A1c, SBP, and variables showing statistically significant differences between groups at baseline visits).	baseline glycated hemoglobin A1c	161	193	significant	236	247	1
1477-7525-5-57.txt	Results and discussion Significant Questionnaire effects and a Questionnaire × Ceiling interaction (p < 0.001) in both trial datasets showed that the DTSQc detected more improvement in Treatment Satisfaction than the DTSQs, especially when patients had DTSQs scores at/near ceiling at baseline.	Questionnaire effects	35	56	Significant	23	34	1
1471-2431-8-13.txt	Facial actions were highly significantly lower across all points in time reaching a two-fold difference by 120 seconds post-lance and heart rate was significantly lower across the first 90 seconds in the KMC condition.	heart rate	134	144	significantly	149	162	1
1471-2431-7-27.txt	Age adjusted regression analysis revealed that both sucrose and pacifier had significant effects on crying time.	crying time	100	111	significant	77	88	1
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	121	170	p < 0.05	312	320	1
1471-2377-8-33.txt	Pregabalin-treated patients had lower MPS than controls (mean difference, -1.28; p <.001).	MPS	38	41	p <.001	81	88	1
1745-6215-13-59.txt	At randomization, the R and E groups were similar ( P  ≥ 0.11) with respect to mean age (50.7 years), body mass index (28.2 kg/m 2 ), blood pressure (153.9/91.5 mmHg) and the proportions of women (53.6%) and treatment naïve patients (72.7%).	blood pressure	134	148	P  ≥ 0.11	52	61	1
1471-2474-8-112.txt	Results Multilevel analysis failed to show a significant effect of the EAP on either functional limitations or patient-perceived recovery.	functional limitations	85	107	failed to show a significant	28	56	1
1471-2474-12-153.txt	Results Among 274 patients with evaluable efficacy data, the percentage of responders according to American College of Rheumatology 50 criteria (the primary endpoint, based on a 28-joint count) was significantly higher with canakinumab 150 mg SC q4wk than with placebo (26.5% vs 11.4%, respectively; p = 0.028).	the percentage of responders according to American College of Rheumatology 50 criteria (the primary endpoint, based on a 28-joint count)	57	193	p = 0.028	300	309	1
1745-6215-12-23.txt	There was no significant difference between the screening and the usual care group for the main outcome (hazard ratio = 1.00 95%CI 0.59 to 1.71).	the main outcome	87	103	no significant	10	24	1
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	spontaneous rupture of the membranes occurred	123	168	p < 0.05	202	210	1
1471-2466-11-61.txt	While there was no observed difference in outpatient costs, there was a slightly higher number of outpatient visits per patient in the LABA and LAMA (25.5 SE = 0.9, p = 0.0070) relative to the LABA or LAMA therapy group (22.3 SE = 0.8) and higher utilization (89.7% of patients) with COPD visits in the LABA and LAMA therapy group relative to both the LABA or LAMA (73.8%; p < .0001) and LABA, LAMA and ICS therapy groups (85.3; p = 0.0305).	utilization (89.7% of patients) with COPD visits	247	295	p = 0.0305	429	439	1
1477-7525-5-57.txt	Additionally, significant Treatment effects favouring insulin glargine (p < 0.001) and a Treatment × Questionnaire interaction (p < 0.019), with the DTSQc showing more benefits, were found in the type 1 trial.	Treatment effects	26	43	p < 0.001	72	81	1
1471-2296-13-98.txt	Results There were no statistically significant differences in clinical outcomes at 9 months.	clinical outcomes	63	80	no statistically significant	19	47	1
1756-9966-28-131.txt	Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01).	global health status	95	115	significant	58	69	1
1471-2458-12-206.txt	Significant effects were found for several variables of self-reported physical activity, mood and quality of life and are discussed.	quality of life	98	113	Significant	0	11	1
1749-8090-4-60.txt	The mean time to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034).	mean drain volume	437	454	p = 0.034	558	567	1
cc10143.txt	PPH stopped after only uterotonics and PRBC transfusion in 93% of women in the TA group versus 79% of controls ( P = 0.016).	PPH stopped after only uterotonics and PRBC transfusion	0	55	P = 0.016	113	122	1
1471-2474-7-92.txt	Results After 8 months, BMD at the femoral neck in the WBV group was increased by 4.3% ( P = 0.011) compared to the Walking group.	BMD at the femoral neck	24	47	P = 0.011	89	98	1
1741-7015-10-71.txt	Results Compared with the patients in the UC arm, the patients in the CP arm had a significantly lower risk of mortality at 7 days (OR = 0.10; 95% CI 0.01 to 0.95) and significantly lower rates of adverse functional outcomes, expressed as the odds of not returning to pre-stroke functioning in their daily life (OR = 0.42; 95 CI 0.18 to 0.98).	rates of adverse functional outcomes, expressed as the odds of not returning to pre-stroke functioning in their daily life	188	310	significantly	168	181	1
1472-6882-7-34.txt	Compared to baseline both treatments showed significant benefits in WOMAC and VAS outcomes within one week (P < 0.05), with a similar, progressive improvement over the course of the 8 week treatment protocol (45–62% reduction in WOMAC or VAS scores).	WOMAC	68	73	P < 0.05	108	116	1
1471-244X-9-54.txt	Patients undergoing medication switches also used acute-care services significantly sooner (p = .004) and accrued an additional $3,000 (a 25% increase) in annual total health care costs per patient, most of which was due to acute-care expenditures.	used acute-care services	45	69	significantly	70	83	1
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	dyspnea	443	450	p = 0.05	504	512	1
1471-2407-9-21.txt	In children over 6-year of age (n = 72), the rate of success was significantly higher in the pillow group (58.5% vs 41.5%, p = 0.031), with a tendency to feel less pain (median VAS 25 vs 15 mm, p = 0.39) and being more satisfied (84.4% vs 75.0%, p = 0.34).	satisfied	219	228	p = 0.34	246	254	1
1471-2474-11-64.txt	Results After 24 matches there was no statistical significant difference between the groups for the incidence of hamstring injury (OR:0.116, 95% CI:0.013-1.019, p = 0.051) and primary non-contact knee injury (OR:0.116, 95% CI:0.013-1.019, p = 0.051).	the incidence of hamstring injury	96	129	no statistical significant	35	61	1
1475-2891-10-134.txt	Early invitation to food supplementation (in comparison with usual invitation) reduced the proportion of stunting from early infancy up to 54 months for boys (p = 0.01), but not for girls (p = 0.31).	the proportion of stunting	87	113	p = 0.01	159	167	1
1471-2474-8-23.txt	Eleven patients allocated land exercise failed to complete treatment compared with 4 patients allocated hydrotherapy (p = 0.09).	failed to complete treatment	40	68	p = 0.09	118	126	1
1746-160X-8-9.txt	The minor irritation of the teeth, experienced prior to treatment, was similar in both groups; however, 4 h after treatment this value was significantly higher in the Provicol group than in the Ledermix group (p < 0.005, t-test).	The minor irritation of the teeth	0	33	p < 0.005	210	219	1
1465-9921-11-66.txt	In addition all three active treatments significantly increased FEV 1 within 3 minutes of administration, at a time when inhaled AMP had induced the 30% fall in FEV 1 .	FEV 1	64	69	significantly	40	53	1
1475-2891-11-47.txt	Net changes in GPx, SOD and catalase activities, and DNA tail length and tail moment were significantly different between the high-dose group and the placebo group.	catalase activities	28	47	significantly	90	103	1
1471-2466-11-61.txt	Conclusions Significant cost differences driven mainly by pharmaceuticals were observed among LABA or LAMA, LABA and LAMA and LABA, LAMA and ICS therapies.	cost	24	28	Significant	12	23	1
1746-6148-8-157.txt	Within the placebo group there were significant positive changes only in the HCPI and a significant deterioration according to veterinary assessment.	the HCPI	73	81	significant	36	47	1
1471-2474-10-118.txt	When analysing the results in a mixed model analysis on repeated measures including interaction between age-group and treatment effect the training group demonstrated significantly improved results compared to the control group in subjects younger than 40 years of age regarding OMAS (p = 0.028), muscle strength in the plantar flexors (p = 0.029) and dorsiflexors (p = 0.030).	muscle strength in the plantar flexors	297	335	p = 0.029	337	346	1
1472-6920-6-38.txt	Changes in all outcomes were similar in the "Training + Feedback" group compared to the "Feedback Only" group (PRPCC: 3.7 vs1.8; trust: -0.7 vs -0.2 ; satisfaction: 1.9 vs 2.5; weight: -2.5 lbs vs -0.7 lbs; systolic blood pressure: 1.7 mm Hg vs 0.1 mm Hg; glycosylated hemoglobin 0.02% vs 0.07%; p = NS for all).	weight	177	183	p = NS	296	302	1
1471-2377-10-92.txt	Results The mean percent reduction in "average pain for the past 24 hours" NPRS scores from baseline to weeks 2-8 was greater in the NGX-4010 group (36.5%) compared with control (29.9%) although the difference was not significant (p = 0.296).	"average pain for the past 24 hours" NPRS scores	38	86	p = 0.296	231	240	1
1472-6831-12-13.txt	The change in mean tooth shade scores was statistically significantly greater in the gum-group than in the tablet group at 2 (p = 0.015), 6 (p = 0.011) and 12 weeks (p = 0.003) with greater lightening in the gum-group at each examination period.	mean tooth shade scores	14	37	p = 0.003	166	175	1
1471-2288-7-30.txt	In the ANCOVA model with baseline score as a co-variate, follow-up group had a significant effect on outcome at six months on the ADAS-Cog score (n = 140; mean difference = -2.018; 95%CI -3.914, -0.121; p = 0.037 favouring the intensive follow-up group), and on participant-rated quality of life score (n = 142; mean difference = -1.382; 95%CI -2.642, -0.122; p = 0.032 favouring minimal follow-up group).	participant-rated quality of life score	262	301	p = 0.032	360	369	1
1477-7827-5-45.txt	Results No statistically significant difference in the mean number of collected oocytes (primary endpoint) was observed between the two study subgroups (7.46, SD 4.24 vs 7.86, SD 4.28 in the s.c. and i.m.	the mean number of collected oocytes (primary endpoint)	51	106	No statistically significant	8	36	1
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	323	372	p < 0.05	477	485	1
1741-7015-7-54.txt	Results IRS, and to a lesser extent EVM and LLINs, significantly reduced sand fly densities for at least 5 months in the study households irrespective of type of walls or whether or not people shared their house with cattle.	sand fly densities	73	91	significantly	51	64	1
1471-2474-10-118.txt	When analysing the results in a mixed model analysis on repeated measures including interaction between age-group and treatment effect the training group demonstrated significantly improved results compared to the control group in subjects younger than 40 years of age regarding OMAS (p = 0.028), muscle strength in the plantar flexors (p = 0.029) and dorsiflexors (p = 0.030).	muscle strength in the plantar flexors	297	335	significantly	167	180	1
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	body composition	92	108	p < 0.001	110	119	1
1756-0500-5-273.txt	Knee-specific scores continued to improve for both groups over the 10-years, despite diminishing overall health with no significant group differences seen.	Knee-specific scores	0	20	no significant	117	131	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.008	522	531	1
1472-6963-12-250.txt	Results There was no evidence that an incentive (52% versus 43%, Risk Difference (RD) -8.8 (95%CI −22.5, 4.8); or abridged questionnaire (46% versus 43%, RD −2.9 (95%CI −16.5, 10.7); statistically significantly improved dentist response rates compared to a full length questionnaire in RCT A.	dentist response rates	220	242	significantly	197	210	1
1471-2431-7-27.txt	Subgroup analysis revealed a mean crying time difference of 76.52 seconds (p < 0.0171) (0–1 month) and 123.9 seconds (p < 0.0029) (1–3 month).	crying time	34	45	p < 0.0029	118	128	1
1757-7241-20-16.txt	In the feedback group a significant improvement was found in the proportion of delivered compressions below target depth when the subsequent intervals were compared to the first 30 seconds (0-30 s: 3.9%; 30-60 s: 0.0%; 60-90 s: 0.0%; 90-120 s: 0.0%).	the proportion of delivered compressions below target depth	61	120	significant	24	35	1
1471-2474-8-23.txt	Significantly more patients treated with hydrotherapy (40/46, 87%) were much better or very much better than the patients treated with land exercise (19/40, 47.5%), p < 0.001 Fisher's exact test.	were much better or very much better	67	103	p < 0.001	165	174	1
1472-6963-11-58.txt	Results Overall at long-term follow-up (average 6 years) significantly more individuals in the CNP group (72%) had improved (i.e had fewer symptoms) compared to those in the SC group (67%) (difference of 5% 95% (CI = 0.6 to 9;p = 0.02)).	improved	115	123	significantly	57	70	1
1471-2296-4-7.txt	A superior increase in sex-hormone-binding-globuline (SHBG) levels was evidenced in the paroxetine group (p = 0.01) as a sign of improved insulin sensitivity.	sex-hormone-binding-globuline (SHBG) levels	23	66	p = 0.01	106	114	1
1471-2377-10-91.txt	Conclusions Results from this study demonstrate that minocycline provides significant functional benefits to FXS patients and that it is well-tolerated.	functional benefits	86	105	significant	74	85	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.015	626	635	1
1465-9921-8-52.txt	FEV 1 was also significantly superior at week 2 in the SFC group (mean difference 0.16L, 95% CI; 0.03 – 0.28, p = 0.015), but not at week 4 (mean difference 0.17L, 95% CI -0.01 – 0.34, p = 0.060).	FEV 1	0	5	p = 0.060	185	194	1
1472-6882-7-34.txt	Response rates were high and the safety profile was excellent, with significantly less rescue medication use with reparagen.	rescue medication use	87	108	significantly	68	81	1
1532-429X-13-65.txt	Interestingly, LV mass-I significantly decreased in the placebo group (48.9 ± 5.3 g/m 2 vs 44.3 ± 5.6 g/m 2 , p < 0.001) indicating reverse remodeling, whereas LV mass-I remained unchanged in the rosiglitazone group (54.7 ± 9.9 g/m 2 vs 53.7 ± 9.2 g/m 2 , p = 0.3).	LV mass-I	160	169	p = 0.3	256	263	1
1746-6148-8-157.txt	Results When comparing the two test groups at the end of the trial (16 weeks) there was no significant difference in any of the main outcome variables but owners of dogs that had taken fish oil were significantly happier with the treatment at the end visit and did significantly better at guessing what group their dogs had been in, compared to the placebo group.	guessing what group their dogs had been in	289	331	significantly	265	278	1
1475-2891-10-72.txt	No other significant treatment effects were discerned in glucose, insulin, lipids, and weight.	weight	87	93	No other significant	0	20	1
1471-2458-12-1073.txt	However, there were few statistically significant differences observed for quality of life and clinical outcomes at long-term measurements at 12-months end of intervention and at 6- months post intervention (18-month follow-up).	clinical outcomes	95	112	significant	38	49	1
1475-2875-6-170.txt	Results Treatment failure (PCR corrected) was significantly lower in the artesunate + sulphadoxine-pyrimethamine group (4/77, 5.3%) than in chloroquine group(51/71, 71.8%) or the sulphadoxine-pyrimethamine alone group (30/70, 44.1%) (p < 0.001).	Treatment failure (PCR corrected)	8	41	p < 0.001	234	243	1
1471-230X-9-85.txt	Results Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061).	the GSRS total score	152	172	significant	79	90	1
1475-2891-6-8.txt	A significant increase in defecation frequency (NF: 3.5 pre versus 5.6/week post treatment; SF 3.6 pre versus 4.9/week post treatment) was found in both groups, but was not significantly different between the two formulas (p = 0.36).	defecation frequency	26	46	p = 0.36	223	231	1
1471-230X-10-72.txt	Anti-LPS IgM was reduced in the micronutrient recipients ( P < 0.05).	Anti-LPS IgM	0	12	P < 0.05	59	67	1
1471-2466-7-4.txt	No significant improvements in lung function, symptoms, or quality of life were seen, although consistent trends were seen to improvements in patient-centered outcomes.	symptoms	46	54	No significant	0	14	1
1471-2474-10-115.txt	Results Significant improvements on primary and secondary outcome measures were recorded in both treatment groups.	primary and secondary outcome measures	36	74	Significant	8	19	1
1471-2431-8-23.txt	There was no statistically significant increase in resistant pneumococci or NCHi in amoxicillin children compared to placebo children who received regular paediatric care and antibiotic treatment for symptomatic illnesses.	NCHi	76	80	no statistically significant	10	38	1
1475-2875-10-237.txt	Treatment-related adverse events were reported in 11.7% of the patients, without significant differences between the two groups.	Treatment-related adverse events	0	32	without significant	73	92	1
ar4072.txt	ANCOVA analysis demonstrated superiority of adalimumab over placebo for the physician global assessment of disease activity, parents' global assessment of subject's overall well-being, active joint count (all P <0.05) and erythrocyte sedimentation rate (ESR) ( P <0.01).	the physician global assessment of disease activity	72	123	P <0.05	209	216	1
1471-2474-11-218.txt	Low education and poor self-reported health status predicted a work status of "not working": Odds Ratio, OR = 4.3(95% CI (1.3 to 14.9)), p = 0.02 for education, and OR = 1.06 (95% CI (1.0 to 1.1)), p = 0.001 for self-reported health status, respectively.	self-reported health status	212	239	p = 0.001	198	207	1
cc6173.txt	In the TA group, we observed a significant reduction in the incidence of VS ( P = 0.003), the use of norepinephrine ( P = 0.029), and time on mechanical ventilation ( P = 0.018).	the use of norepinephrine	90	115	P = 0.029	118	127	1
1477-7827-1-63.txt	Although patients receiving Bravelle(R) consistently reported a greater number of chemical, clinical and continuing pregnancies, as well as an increased rate of live birth, the data did not attain statistical significance (P > 0.05).	live birth	161	171	not attain statistical significance	186	221	1
1471-2474-12-132.txt	Age, race/ethnicity, education, military status, smoking history, BMI, and whether a Soldier received the physical/USI examination remained statistically significant (p < .05) when considered in a full multivariate model.	education	21	30	p < .05	167	174	1
1477-5751-8-3.txt	Subjective reports of TQ subscales and general quality of life areas (SF-36), objective audiometric examinations as well as investigated biomarkers for oxidative stress did not reveal any significant treatment effects.	objective audiometric examinations	78	112	not reveal any significant	173	199	1
1465-9921-7-13.txt	There were no statistically significant between-group differences for treatment success, treatment failure or patient assessment of medication effectiveness.	treatment success	70	87	no statistically significant	11	39	1
1471-2474-11-155.txt	During treatment, low back pain decreased from 6.2 (SD 2.2) to 1.6 (2.3, p < 0.001) and disc height increased from 7.5 (1.7) mm to 8.8 (1.7) mm (p < 0.001).	low back pain	18	31	p < 0.001	73	82	1
1471-2474-13-81.txt	The rate of skin complication in this group was significantly lower compared to the tape group (14.6% versus 59.1%, P < 0.0001).	The rate of skin complication	0	29	significantly	48	61	1
1471-230X-12-37.txt	The end-tidal CO 2 level was significantly lower in the duodenal balloon group than in the regular group ( P  = 0.0001).	The end-tidal CO 2 level	0	24	P  = 0.0001	107	118	1
1471-2377-10-92.txt	Results The mean percent reduction in "average pain for the past 24 hours" NPRS scores from baseline to weeks 2-8 was greater in the NGX-4010 group (36.5%) compared with control (29.9%) although the difference was not significant (p = 0.296).	"average pain for the past 24 hours" NPRS scores	38	86	not significant	214	229	1
1741-7015-10-54.txt	With regard to secondary outcomes, blood glucose, HbA1c, low-density lipoprotein/high-density lipoprotein ratio, and HR were significantly decreased by phlebotomy.	HbA1c	50	55	significantly	125	138	1
1471-2466-7-4.txt	No significant improvements in lung function, symptoms, or quality of life were seen, although consistent trends were seen to improvements in patient-centered outcomes.	quality of life	59	74	No significant	0	14	1
cc10143.txt	Blood loss between enrolment and 6 hours later was significantly lower in the TA group than in the control group (median, 173 mL; first to third quartiles, 59 to 377) than in controls (221 mL; first to third quartiles 105 to 564) ( P = 0.041).	Blood loss between enrolment and 6 hours later	0	46	P = 0.041	232	241	1
1477-7525-9-110.txt	However, vitality-score increased 5.2 points ( p = 0.12) within the rehabilitation group and 5.6 points ( p = 0.03) points among individual counselling participants.	vitality-score	9	23	p = 0.03	106	114	1
cc11657.txt	Glucose complexity was significantly lower (higher DFA) in ICU non-survivors (n = 36) compared to survivors (n = 138) (DFA: 1.61 (1.46 to 1.68) versus 1.52 (1.44 to 1.58); P = 0.003).	Glucose complexity	0	18	P = 0.003	172	181	1
1471-5945-5-13.txt	Improvements from baseline on the SF-36, PSA, PGPA, and itching VAS at Week 12 were also significantly greater in efalizumab-treated patients than for placebo.	PGPA	46	50	significantly	89	102	1
1471-2393-10-84.txt	Results For all three screenings, the identification rate in the interview group was significantly lower than that for the self-administered questionnaire group (relative risk 0.66, 95% CI 0.46 to 0.97), even after controlling for smoking (adjusted odds ratio 0.59, 95% CI 0.35 to 0.98).	the identification rate	34	57	significantly	85	98	1
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	social interaction	190	208	p = 0.0473	210	220	1
1465-9921-11-74.txt	Daily inhaled corticosteroid dose significantly increased in the Internet group compared to usual care in the first 3 months in patients with uncontrolled asthma (+278 μg, p = 0.001), but not in patients with well or partly controlled asthma.	Daily inhaled corticosteroid dose	0	33	p = 0.001	172	181	1
1472-6963-12-147.txt	However, the target levels of systolic blood pressure and waist circumference were reached non-significantly more frequently in the intervention arm.	waist circumference	58	77	non-significantly	91	108	1
1471-2369-13-146.txt	CRBSI occurred at a rate of 0.85 vs 0.28 per 1000 catheter days in the heparin vs ethanol group by intention to treat analysis (incident rate ratio (IRR) for ethanol vs heparin 0.17; 95%CI 0.02-1.63; p=0.12).	CRBSI	0	5	p=0.12	200	206	1
1471-2407-7-166.txt	After three and six months the treatment group showed a significant improvement in shoulder mobility and had significantly less pain than the control group.	shoulder mobility	83	100	significant	56	67	1
1471-2288-7-50.txt	Results Computer-aided telephone interviews (CATI) resulted in significantly fewer missing data (0.5%) than did mailed questionnaires (2.8%; p < 0.001).	missing data	83	95	significantly	63	76	1
1471-2334-5-2.txt	No significant changes in glucose, insulin, insulin resistance, C-peptide, or waist-to-hip ratios were observed in either treatment arm, nor were differences in these parameters noted between treatments.	glucose	26	33	No significant	0	14	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	significant	63	74	1
cc11159.txt	The results in renal parameters were supported by significantly more pronounced reductions in the systemic markers C-reactive protein, Interleukin-6, LPS-binding protein and in the urinary excretion of Kidney Injury Molecule-1 and Interleukin-18 in AP-treated patients relative to placebo.	Interleukin-6	135	148	significantly	50	63	1
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	743	804	p < 0.05	950	958	1
cc11249.txt	Study group patients had a significant lower reintubation rate than did controls; six patients (17%) versus 19 patients (48%), P < 0.05; respectively, and a significantly lower time under MV; 17.8 ± 6.4 versus 11.7 ± 3.5 days; P < 0.05; respectively.	reintubation rate	45	62	P < 0.05	127	135	1
1471-2474-12-153.txt	Compared to placebo, this dosage of canakinumab was also associated with significantly more favorable responses at week 12 with respect to secondary endpoints including the Disease Activity Score 28, scores on the Health Assessment Questionnaire and Functional Assessment of Chronic Illness Therapy-Fatigue, swollen 28-joint count, and patient's and physician's global assessments of disease activity.	patient's and physician's global assessments of disease activity	336	400	significantly	73	86	1
1471-2318-6-18.txt	At six months there was a trend for the PRT intervention group to have lower GDS scores than the comparison group, but this finding did not reach significance (p = 0.08).	GDS scores	77	87	not reach significance	136	158	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.000	195	204	1
ar3703.txt	Conclusions We recorded statistically significant improvements compared with a control group with regard to pain, quality of life and function for participants in the OAK program on the basis of WOMAC and SF-36 measures taken 8 weeks and 6 months from baseline.	function	134	142	significant	38	49	1
1747-597X-3-1.txt	In intention-to-treat-analyses and in most analyses of study completers, there were no significant differences between the Mg-treated and placebo groups in the outcome variables.	the outcome variables	156	177	no significant	84	98	1
cc6104.txt	Results Temperature decline was significantly higher with the water-circulating blankets (1.33 ± 0.63°C/h), gel-pads (1.04 ± 0.14°C/h) and intravascular cooling (1.46 ± 0.42°C/h) compared to conventional cooling (0.31 ± 0.23°C/h) and the air-circulating blankets (0.18 ± 0.2°C/h) (p < 0.01).	Temperature decline	8	27	significantly	32	45	1
1472-6947-8-4.txt	Those viewing the 2-option version were somewhat more likely to choose colonoscopy than those viewing the 5-option version when no out of pocket costs were assumed (68% vs 46%, p = 0.11), but not when such costs were imposed (41% vs 42%, p = 1.00).	likely to choose colonoscopy	54	82	p = 1.00	238	246	1
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	overall functioning	123	142	significantly	53	66	1
1471-2334-5-2.txt	At week 28, an intent-to treat: missing = failure analysis showed that the abacavir-switch and PI-continuation arms did not differ significantly with respect to proportion of patients maintaining HIV-1 RNA <400 or <50 copies/mL or adjusted mean change from baseline in CD4+ cell count.	adjusted mean change from baseline in CD4+ cell count	231	284	not differ significantly	120	144	1
1471-2296-12-2.txt	After three months without active treatment (at four months), significant differences in MMA levels were no longer detected.	MMA levels	89	99	significant differences in MMA levels were no longer detected	62	123	1
1471-2296-13-30.txt	There was no significant adverse impact on functional status or treatment satisfaction.	functional status	43	60	no significant	10	24	1
1465-9921-10-69.txt	During the treatment period of 6 months the multiple criteria frequency, severity and duration of exacerbations were significantly lower in the group treated with cineole in comparison to placebo.	duration of exacerbations	86	111	significantly	117	130	1
1477-7525-9-110.txt	However, fatigue distress decreased 0.40 points within the rehabilitation group ( p = 0.01) and 0.34 points within the individual counselling group ( p < 0.01).	fatigue distress	9	25	p < 0.01	150	158	1
1745-6215-12-13.txt	In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg ( P = 0.03) for systolic office BP; 0.70 mm Hg ( P = 0.08) for diastolic office BP; 0.36 mm Hg ( P = 0.49) for 24-h systolic BP; and 0.05 mm Hg ( P = 0.88) for 24-h diastolic BP.	diastolic office BP	136	155	P = 0.08	122	130	1
1471-2296-8-34.txt	After three months of treatment we found a statistically significant difference between the two treatment groups in GHbA 1c (mean difference = 0.59%-units, p = 0.018) and in SF-36 score (mean difference = 11.0 points, p = 0.039).	SF-36 score	174	185	significant	57	68	1
1532-429X-14-61.txt	CMR performed better than SPECT in MVD (p = 0.003 vs all SPECT, p = 0.04 vs gated-SPECT), in men (p = 0.004, n = 313) and in women (p = 0.03, n = 112) as well as in the non-infarct patients (p = 0.005, n = 186 in 1–3 vessel disease and p = 0.015, n = 140 in MVD).	MVD	35	38	p = 0.015	236	245	1
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	488	500	p < 0.05	536	544	1
1471-2474-13-141.txt	Evaluation of the intensity of pain with a visual analogue scale (VAS) showed a statistically significant difference (p = 0,035) at day 16.	Evaluation of the intensity of pain with a visual analogue scale (VAS)	0	70	p = 0,035	118	127	1
1477-7827-2-70.txt	Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs 12%, p > 0.05).	Caesarean section (CS) rate	48	75	not statistically significant	9	38	1
1471-2458-12-206.txt	Significant effects were found for several variables of self-reported physical activity, mood and quality of life and are discussed.	several variables of self-reported physical activity	35	87	Significant	0	11	1
1471-2466-11-61.txt	While there was no observed difference in outpatient costs, there was a slightly higher number of outpatient visits per patient in the LABA and LAMA (25.5 SE = 0.9, p = 0.0070) relative to the LABA or LAMA therapy group (22.3 SE = 0.8) and higher utilization (89.7% of patients) with COPD visits in the LABA and LAMA therapy group relative to both the LABA or LAMA (73.8%; p < .0001) and LABA, LAMA and ICS therapy groups (85.3; p = 0.0305).	utilization (89.7% of patients) with COPD visits	247	295	p < .0001	373	382	1
1747-597X-3-1.txt	When baseline serum Mg level, coffee intake, and the number of unused Mg tablets were controlled for in a multivariate regression model, after-treatment serum Mg levels were found to be higher among the Mg-treated group than in the placebo group (t-test 3.334, df = 53, p = 0.002).	after-treatment serum Mg levels	137	168	p = 0.002	270	279	1
1471-2474-12-136.txt	No statistically significant differences were observed on the DASH questionnaire (0-100 scale: adjusted mean diff.	the DASH questionnaire	58	80	No statistically significant	0	28	1
ar3703.txt	For the period between baseline and month 6, WOMAC Pain, Physical Function and Total dimensions significantly improved in the OAK group compared to the control group, as did the SF-36 Physical Function, Role Physical, Body Pain, Vitality and Social Functioning domains, as well as hamstring strength in both legs.	Role Physical	203	216	significantly	96	109	1
1471-2431-8-23.txt	There was no statistically significant increase in resistant pneumococci or NCHi in amoxicillin children compared to placebo children who received regular paediatric care and antibiotic treatment for symptomatic illnesses.	resistant pneumococci	51	72	no statistically significant	10	38	1
1741-7015-2-7.txt	There was also no statistically significant difference in the rate of acute gastrointestinal complications (2/21 prednisone group vs 3/19 placebo group, P = 0.7).	the rate of acute gastrointestinal complications	58	106	P = 0.7	153	160	1
ar3703.txt	For the period between baseline and month 6, WOMAC Pain, Physical Function and Total dimensions significantly improved in the OAK group compared to the control group, as did the SF-36 Physical Function, Role Physical, Body Pain, Vitality and Social Functioning domains, as well as hamstring strength in both legs.	WOMAC Pain	45	55	significantly	96	109	1
1472-6904-8-10.txt	Reduction in LDLP was greater with simvastatin (32%, p < .001) compared to fenofibrate (17%; p = .036 vs pre; p = .027 vs simvastatin end).	LDLP	13	17	p = .036	93	101	1
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	sedentary	129	138	significantly	110	123	1
1471-244X-3-16.txt	Baclofen also showed a significant superiority over placebo in terms of opiate withdrawal syndrome and depressive symptoms.	depressive symptoms	103	122	significant	23	34	1
cc10367.txt	The duration of the intubation sequence was shorter after succinycholine than after rocuronium (81 ± 38 sec versus 95 ± 48 sec; P = 0.002).	The duration of the intubation sequence	0	39	P = 0.002	128	137	1
1475-2875-11-355.txt	The median parasite clearance half-lives were 3.54 (AS 2mg/kg), 2.72 (AS 4mg/kg), and 2.98 hours (DHA-PPQ) (p=0.19).	The median parasite clearance half-lives	0	40	p=0.19	108	114	1
cc7695.txt	Results In the intention to treat analysis there were no statistically significant differences between the 53 patients selected for each group regarding gender (p = 0.541), age (p = 0.585) and type of surgery (p = 0.172).	age	173	176	p = 0.585	178	187	1
1472-6947-8-4.txt	Those viewing the 2-option version were somewhat more likely to choose colonoscopy than those viewing the 5-option version when no out of pocket costs were assumed (68% vs 46%, p = 0.11), but not when such costs were imposed (41% vs 42%, p = 1.00).	likely to choose colonoscopy	54	82	p = 0.11	177	185	1
1471-2474-10-118.txt	When analysing the results in a mixed model analysis on repeated measures including interaction between age-group and treatment effect the training group demonstrated significantly improved results compared to the control group in subjects younger than 40 years of age regarding OMAS (p = 0.028), muscle strength in the plantar flexors (p = 0.029) and dorsiflexors (p = 0.030).	muscle strength in the plantar flexors (p = 0.029) and dorsiflexors	297	364	significantly	167	180	1
bcr2320.txt	Results TC and LDL levels increased significantly across time for both arms; TC increase was more pronounced for the observation arm, and that was sustained up to 24 months.	TC	8	10	significantly	36	49	1
ar4034.txt	A significant treatment effect for DAS28(CRP) was only observed at Day 15 in the prednisone 15 mg group (effect size = 0.95, P = 0.032).	DAS28(CRP)	35	45	P = 0.032	125	134	1
cc7725.txt	The duration of use of paralysing or sedative agents, mechanical ventilation, stay in the intensive care unit and mortality at 28 days did not differ significantly between the decremental PEEP titration and control groups.	stay in the intensive care unit	78	109	not differ significantly	139	163	1
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	mood state	355	365	p = 0.05	431	439	1
1471-2296-8-3.txt	A higher proportion of people allocated to buprenorphine provided a clean urine sample compared with those who received dihydrocodeine (21% vs 3%, RR 2.06 CI 1.33–3.21, p = 0.028).	provided a clean urine sample	57	86	p = 0.028	169	178	1
cc1476.txt	PTEF increased significantly both after albuterol and saline treatments but the difference between the two treatments was not significant ( P = 0.6).	PTEF	0	4	significantly	15	28	1
1471-2474-11-26.txt	The differences between the groups in pain and disability considered over one year were statistically significant favoring naprapathy (p ≤ 0.005).	disability	47	57	p ≤ 0.005	135	144	1
1472-6831-12-13.txt	Results At week 6, the gum-group experienced a reduction in mean stain scores whilst the tablet-group experienced an increase with mean changes of -0.14 and +0.12 respectively, (p = 0.005, ANCOVA).	mean stain scores	60	77	p = 0.005	178	187	1
1479-5868-8-41.txt	There was significant weight loss in all 3 intervention groups (GWL, 1.86 kg, P = 0.05; SWA-alone, 3.55 kg, P = 0.0002; GWL+SWA, 6.59 kg, P < 0.0001) but not in the Standard Care group (0.89 kg, P = 0.39) at month 9.	weight loss	22	33	significant	10	21	1
cc7890.txt	Results Dexmedetomidine significantly shortened median time to extubation from 42.5 (IQR 23.2 to 117.8) to 19.9 (IQR 7.3 to 24) hours ( P = 0.016).	median time to extubation	48	73	P = 0.016	136	145	1
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	mean physician CGI scores	27	52	significantly	53	66	1
1471-2431-6-29.txt	Results At baseline the children who received guided imagery had more days of pain during the preceding month (23 vs 14 days, P = 0.04).	days of pain	70	82	P = 0.04	126	134	1
1471-2431-12-21.txt	Results We did not observe any significant differences in the % predicted FEV1 and MPIS between formoterol and salbutamol at various time points from 1 min to 60 min post drug administration.	the % predicted FEV1	58	78	not observe any significant	15	42	1
1471-2431-12-21.txt	Results We did not observe any significant differences in the % predicted FEV1 and MPIS between formoterol and salbutamol at various time points from 1 min to 60 min post drug administration.	MPIS	83	87	not observe any significant	15	42	1
1471-2474-7-5.txt	After treatment, significant reductions were observed in functional limitations, patient's main complaints and pain intensity for all three active treatments compared to the WL.	pain intensity	111	125	significant	17	28	1
1477-7819-10-94.txt	Conclusions This randomized trial did not confirm a statistically significant superiority of Aquacel® Ag Hydrofiber dressing in reducing surgical-site infection after elective colorectal cancer surgery.	surgical-site infection	137	160	not confirm a statistically significant	38	77	1
1475-2891-11-47.txt	Furthermore, the DNA tail length and tail moment were significantly reduced after the supplementation (low-dose and high-dose), and plasma oxidized low-density lipoprotein (LDL) levels were reduced in low-dose and high-dose groups, but increased in the placebo group.	tail moment	37	48	significantly	54	67	1
1475-2891-11-47.txt	Net changes in GPx, SOD and catalase activities, and DNA tail length and tail moment were significantly different between the high-dose group and the placebo group.	GPx	15	18	significantly	90	103	1
1471-2296-4-7.txt	This notion was supported by a trend for superior decrease of serum cortisol levels in the paroxetine group (p = 0.06).	serum cortisol levels	62	83	p = 0.06	109	117	1
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	total cholesterol	107	124	significantly	40	53	1
1471-230X-4-5.txt	The median time to relapse was 16 ± 4 weeks in the L. GG group and 12 ± 4.3 weeks in the placebo group (p = 0.5).	The median time to relapse	0	26	p = 0.5	104	111	1
1471-2466-7-4.txt	Trends to clinical improvements favouring active treatment were however consistently seen in the patient-centered outcomes: Asthma Control Questionnaire mean difference (active – placebo) [95% CI] = -0.35 [-0.78 to 0.07], p = 0.10, Asthma Quality of Life Questionnaire mean difference 0.42 [-0.08 to 0.93], p = 0.09, Leicester Cough Questionnaire mean difference 0.49, [-0.18 to 1.16], p = 0.15.	Asthma Control Questionnaire mean difference	124	168	p = 0.10	222	230	1
1465-9921-11-112.txt	Results After three month training period, in the Nordic Walking group time spent walking and standing as well as intensity of walking increased (Δ walking time: +14.9 ± 1.9 min/day; Δ standing time: +129 ± 26 min/day; Δ movement intensity: +0.40 ± 0.14 m/s 2 ) while time spent sitting decreased (Δ sitting time: -128 ± 15 min/day) compared to baseline (all: p < 0.01) as well as compared to controls (all: p < 0.01).	standing time	185	198	p < 0.01	360	368	1
1824-7288-37-48.txt	Paracetamol was significantly more effective than placebo in the SPID of children and parents ( P < 0.05) but not in the SPID reported by investigators, 1 hour after drug administration.	the SPID of children and parents	61	93	significantly	16	29	1
1471-2474-10-118.txt	When analysing the results in a mixed model analysis on repeated measures including interaction between age-group and treatment effect the training group demonstrated significantly improved results compared to the control group in subjects younger than 40 years of age regarding OMAS (p = 0.028), muscle strength in the plantar flexors (p = 0.029) and dorsiflexors (p = 0.030).	dorsiflexors	352	364	p = 0.030	366	375	1
cc6887.txt	The mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up ( P < 0.05).	The mortality rate	0	18	P < 0.05	123	131	1
cc11159.txt	Results There was a significant ( P = 0.02) difference in favor of AP treatment relative to controls for the primary outcome variable.	the primary outcome variable	105	133	P = 0.02	34	42	1
1472-6920-12-107.txt	The knowledge level was higher after the intervention in the M5 EBM group compared to the M5 non-EBM group (p<0.001, Cohen's d =0.88 with Taylor's instrument and 3.54 with the 100-item MCQ test).	The knowledge level	0	19	p<0.001	108	115	1
cc10343.txt	CoQ10 levels were low, with a median of 0.49 (interquartile range 0.26 to 0.62) compared to levels in healthy control patients (CoQ10 = 0.95 μmol/L ± 0.29; P < 0.0001).	CoQ10 levels	0	12	P < 0.0001	156	166	1
1472-6831-12-13.txt	The change in mean tooth shade scores was statistically significantly greater in the gum-group than in the tablet group at 2 (p = 0.015), 6 (p = 0.011) and 12 weeks (p = 0.003) with greater lightening in the gum-group at each examination period.	mean tooth shade scores	14	37	p = 0.015	126	135	1
1471-2474-12-136.txt	Similarly, in a secondary per protocol analysis no statistically significant differences were observed between the groups in any of the outcomes.	any of the outcomes	125	144	no statistically significant	48	76	1
1472-6963-8-243.txt	No differences in 3-month healing rates: clinic 58.3% compared to home care at 56.7% (p = 0.5) or in secondary outcomes.	3-month healing rates	18	39	p = 0.5	86	93	1
cc2896.txt	Overall, mean neurological assessment times were significantly shorter when using remifentanil (remifentanil 0.41 hour versus fentanyl 0.71 hour [ P = 0.001] versus morphine 0.82 hour [ P < 0.001]).	mean neurological assessment times	9	43	significantly	49	62	1
1471-2474-13-15.txt	Significantly more African American subjects with mild or moderate renal impairment achieved sUA < 6.0 mg/dL in the febuxostat 80 group than in either the febuxostat 40 mg or allopurinol group ( p < 0.05).	sUA	93	96	p < 0.05	195	203	1
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	VI-950	255	261	p = 0.452	271	280	1
1465-9921-11-135.txt	At 5 min post-dose on Day 1, the mean FEV 1 for both indacaterol doses was significantly higher than placebo (by 120 and 130 mL for indacaterol 150 and 300 μg, respectively; p < 0.001) and tiotropium (by 80 mL for both doses; p < 0.001).	the mean FEV 1	29	43	p < 0.001	174	183	1
1745-6215-12-239.txt	The intent-to-treat relative risk of spontaneous premature birth at < 37 weeks of gestation for the trial as a whole, including HPD and non-HPD participants, was 0.69 (0.26, 1.78), p = 0.30 (ns).	spontaneous premature birth at < 37 weeks of gestation	37	91	p = 0.30	181	189	1
1471-2369-13-67.txt	However, women and patients age < 60 who were randomized to frequent nocturnal hemodialysis were less bothered by the impact of kidney disease on their sex life at 6 months, compared with patients allocated to conventional hemodialysis (p = 0.005 and p = 0.024 respectively).	bothered by the impact of kidney disease on their sex life	102	160	p = 0.024	251	260	1
1472-6882-11-93.txt	The groups differed regarding large bowel movements which decreased linearly in the control group (p = 0,011) but not in the acupuncture group (p = 0,787).	large bowel movements	30	51	p = 0,011	99	108	1
1465-9921-11-112.txt	Results After three month training period, in the Nordic Walking group time spent walking and standing as well as intensity of walking increased (Δ walking time: +14.9 ± 1.9 min/day; Δ standing time: +129 ± 26 min/day; Δ movement intensity: +0.40 ± 0.14 m/s 2 ) while time spent sitting decreased (Δ sitting time: -128 ± 15 min/day) compared to baseline (all: p < 0.01) as well as compared to controls (all: p < 0.01).	intensity of walking	114	134	p < 0.01	360	368	1
cc11445.txt	Patients treated with SLED needed fewer blood transfusions (1,375 ± 2,573 ml vs 1,976 ± 3,316 ml, P = 0.02) and had a substantial reduction in nursing time spent for renal replacement therapy ( P < 0.001) resulting in lower costs.	nursing time spent for renal replacement therapy	143	191	P < 0.001	194	203	1
1741-7015-9-93.txt	However, there was a gradual but significant decline in perinatal mortality during the year following ENC training (RR 0.73; 95% CI: 0.56-0.96), which was independently associated with time following training.	perinatal mortality	56	75	significant	33	44	1
1471-2369-12-9.txt	Results At 12 weeks, serum phosphorus concentration was significantly lower in the calcium acetate group compared to the placebo group (4.4 ± 1.2 mg/dL vs 5.1 ± 1.4 mg/dL; p = 0.04).	serum phosphorus concentration	21	51	p = 0.04	172	180	1
1741-7015-2-7.txt	Two children in the placebo group did experience intussusceptions compared with none in the prednisone group ( P = 0.2).	intussusceptions	49	65	P = 0.2	111	118	1
1472-6882-12-7.txt	Clinical measures of balance and function showed non-significant trends in favor of TC.	Clinical measures of balance	0	28	non-significant	49	64	1
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	alliance	336	344	p = 0.137	390	399	1
1465-9921-11-112.txt	Results After three month training period, in the Nordic Walking group time spent walking and standing as well as intensity of walking increased (Δ walking time: +14.9 ± 1.9 min/day; Δ standing time: +129 ± 26 min/day; Δ movement intensity: +0.40 ± 0.14 m/s 2 ) while time spent sitting decreased (Δ sitting time: -128 ± 15 min/day) compared to baseline (all: p < 0.01) as well as compared to controls (all: p < 0.01).	walking time	148	160	p < 0.01	360	368	1
1471-2474-9-118.txt	Results Lumiracoxib and rofecoxib displayed similar GI safety profiles with no statistically significant difference in predefined GI AEs between the two groups (43.5% vs 37.4%, respectively).	predefined GI AEs	119	136	no statistically significant	76	104	1
1472-6963-5-28.txt	After EWRs the mean safety climate scores were not significantly different for all providers nor for nurses in the control units and EWR units (77.93 and 78.33, P = 0.854) and (56.5% positive and 62.7% positive).	the mean safety climate scores	11	41	P = 0.854	161	170	1
1465-9921-11-112.txt	Results After three month training period, in the Nordic Walking group time spent walking and standing as well as intensity of walking increased (Δ walking time: +14.9 ± 1.9 min/day; Δ standing time: +129 ± 26 min/day; Δ movement intensity: +0.40 ± 0.14 m/s 2 ) while time spent sitting decreased (Δ sitting time: -128 ± 15 min/day) compared to baseline (all: p < 0.01) as well as compared to controls (all: p < 0.01).	time spent walking and standing	71	102	p < 0.01	408	416	1
1471-5945-4-18.txt	Complete healing of stage I ulcers in the HD group [11/13(85%)] was better than in the SD [5/11(45%); difference: 40%, 95% CI = 4.7–75.22, (P < 0.05)] or PC [2/9 (22%); difference: 63%, 95% CI = 29.69–96.3, (P < 0.005)] groups.	Complete healing of stage I ulcers	0	34	P < 0.005	208	217	1
cc10367.txt	Results There was no difference between succinylcholine and rocuronium regarding oxygen desaturations (succinylcholine 73/196; rocuronium 66/195; P = 0.67); severe oxygen desaturations (succinylcholine 20/196; rocuronium 20/195; P = 1.0); and extent of oxygen desaturations (succinylcholine -14 ± 12%; rocuronium -16 ± 13%; P = 0.77).	oxygen desaturations	81	101	P = 0.67	146	154	1
1471-2407-11-75.txt	Global quality of life was better in the 3-weekly arm (p = 0.03); patients treated with weekly schedules presented a significantly worsening in role functioning and financial scores (p = 0.02 and p < 0.001).	financial scores	165	181	p < 0.001	196	205	1
1749-799X-6-45.txt	The NIN pre-treatment score at Final was used for the primary ANCOVA comparison, demonstrating a significantly greater cumulative treatment effect of a mean 2.2 (SE 0.49) points pain reduction (p = 0.002).	pain	178	182	p = 0.002	194	203	1
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	triglycerides	206	219	P = 0.019	240	249	1
1471-2261-3-2.txt	Acetaminophen had no significant effect on body temperature during the subsequent four days compared to placebo, and ibuprofen had no statistically significant effect on body temperature during the entire study period.	body temperature	43	59	no significant	18	32	1
1824-7288-38-36.txt	Conclusion The present study did not show a statistically significant reduction in duration of severe pneumonia, or reduction in hospital stay for children given daily zinc supplementation along with standard antimicrobial therapy.	duration of severe pneumonia	83	111	not show a statistically significant	33	59	1
1472-6920-12-85.txt	In the evaluation, the students certified the arthroscopic tutorial a greater advantage concerning anatomical skills with higher spatial imagination in comparison to the ultrasound tutorial (p = 0.002; p < 0.001).	advantage concerning anatomical skills	78	116	p = 0.002	191	200	1
1471-2393-10-15.txt	There were significant differences in knowledge scores between the decision aid group and the pamphlet group (mean difference 8.6, 95% CI 3.70, 13.40).	knowledge scores	38	54	significant	11	22	1
1465-9921-12-143.txt	Results Significant efficacy of pirfenidone in reducing the decline in VC could be seen in a subpopulation having %VC ≥ 70% and SpO 2 < 90% at baseline.	efficacy	20	28	Significant	8	19	1
1471-2393-11-85.txt	Results No statistically significant difference was found between MLU and CLU in the seven key outcomes: caesarean birth (163 [14.8%] vs 84 [15.2%]; relative risk (RR) 0.97 [95% CI 0.76 to 1.24]), induction (248 [22.5%] vs 138 [25.0%]; RR 0.90 [0.75 to 1.08]), episiotomy (126 [11.4%] vs 68 [12.3%]; RR 0.93 [0.70 to 1.23]), instrumental birth (139 [12.6%] vs 79 [14.3%]; RR 0.88 [0.68 to 1.14]), Apgar scores < 8 (10 [0.9%] vs 9 [1.6%]; RR 0.56 [0.23 to 1.36]), postpartum haemorrhage (144 [13.1%] vs 75 [13.6%]; RR 0.96 [0.74 to 1.25]); breastfeeding initiation (616 [55.9%] vs 317 [57.4%]; RR 0.97 [0.89 to 1.06]).	breastfeeding initiation	539	563	No statistically significant	8	36	1
cc11676.txt	Concentration of troponin T as the most sensitive marker for myocardial injury at POD1 was significantly lower in the sevoflurane group compared with the propofol group (unadjusted difference, -0.4; 95% CI, -0.7 to -0.1; P < 0.01; adjusted difference, -0.2; 95% CI, -0.4 to -0.02; P = 0.03, respectively).	Concentration of troponin T as the most sensitive marker for myocardial injury at POD1	0	86	significantly	91	104	1
1475-2875-10-358.txt	Adjusted for age groups, sex, Plasmodium falciparum carriage and prevalence of malnutrition, IPTc + HMM showed a significant protective effect against anaemia (aOR = 0.59; 95% CI 0.42-0.82; p = 0.02).	protective effect against anaemia	125	158	p = 0.02	190	198	1
1471-2431-8-13.txt	Results PIPP scores at 90 seconds post lance were significantly lower in the KMC condition (8.871 (95% CI 7.852–9.889) versus 10.677 (95% CI 9.563–11.792) p < .001) and non-significant mean differences ranging from 1.2 to1.8.	PIPP scores	8	19	significantly	50	63	1
1475-2875-7-199.txt	Antimalarial prescriptions were significantly reduced in Arm-I (61.3%) compared to Arms-II (95.3%) and III (99.5%) (both P < 0.001), whereas antibiotic prescriptions did not vary significantly between the arms (49.9%, 54.8% and 34.2%, respectively).	antibiotic prescriptions	141	165	not vary significantly	170	192	1
ar3703.txt	For the period between baseline and month 6, WOMAC Pain, Physical Function and Total dimensions significantly improved in the OAK group compared to the control group, as did the SF-36 Physical Function, Role Physical, Body Pain, Vitality and Social Functioning domains, as well as hamstring strength in both legs.	Total dimensions	79	95	significantly	96	109	1
1471-2407-9-21.txt	In children over 6-year of age (n = 72), the rate of success was significantly higher in the pillow group (58.5% vs 41.5%, p = 0.031), with a tendency to feel less pain (median VAS 25 vs 15 mm, p = 0.39) and being more satisfied (84.4% vs 75.0%, p = 0.34).	the rate of success	41	60	p = 0.031	123	132	1
cc7695.txt	Results In the intention to treat analysis there were no statistically significant differences between the 53 patients selected for each group regarding gender (p = 0.541), age (p = 0.585) and type of surgery (p = 0.172).	gender	153	159	p = 0.541	161	170	1
1471-2334-5-2.txt	No significant changes in glucose, insulin, insulin resistance, C-peptide, or waist-to-hip ratios were observed in either treatment arm, nor were differences in these parameters noted between treatments.	insulin	35	42	No significant	0	14	1
1471-2466-12-14.txt	The number of patients who achieved asthma control at the follow-up visit and required no treatment adjustment was 33 (73.3%) in the SINA group and 27 (60%) in the GINA group ( p = 0.0125).	achieved asthma control at the follow-up visit and required no treatment adjustment	27	110	p = 0.0125	177	187	1
1475-2891-6-8.txt	Only stool consistency was significantly different between the two formulas (17% had soft stools on NF and hard stools on SF; no infants had soft stools on SF and hard stools on NF, McNemar test p = 0.046).	stool consistency	5	22	p = 0.046	195	204	1
1471-2369-10-7.txt	Results Patients receiving the citrate dialysate had significantly lower systolic blood pressure (BP) (-4.3 mmHg, p < 0.01) and peripheral resistances (PR) (-51 dyne.sec.cm -5 , p < 0.001) while stroke volume was not increased.	peripheral resistances (PR)	128	155	p < 0.001	178	187	1
1471-2466-7-4.txt	Results No significant differences in lung function (active-placebo) were found (Forced Expiratory Volume in 1 second: mean difference [95% CI] = 0.01 [-0.12 to 0.14] L, p = 0.9.	Forced Expiratory Volume in 1 second	81	117	p = 0.9	170	177	1
1471-2458-10-81.txt	Most effects of the intervention on individual-level variables of girls and parents were not significantly different from the control condition, including the primary outcome of child BMI z-score (F 1, 5 = 0.42, p = .544), parent BMI (F 1, 5 = 1.58, p = .264), and related behavioral variables.	child BMI z-score	178	195	p = .544	212	220	1
1472-6963-5-28.txt	Results Before EWRs the mean safety climate scores for nurses were similar in the control units and EWR units (78.97 and 76.78, P = 0.458) as were percent positive scores (64.6% positive and 61.1% positive).	the mean safety climate scores for nurses	20	61	P = 0.458	128	137	1
1477-7525-9-110.txt	There were no significant differences in the change of any item between the two groups after the six-month intervention period.	the change of any item	41	63	no significant	11	25	1
cc11249.txt	Considering only the subgroup of patients that used NIV, the reintubation rates related to NIV failure were significantly lower in the study group when compared with controls; two patients (6%) versus 13 (33%); P < 0.05, respectively.	the reintubation rates related to NIV failure	57	102	significantly	108	121	1
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the time to relapse	204	223	not statistically significant	229	258	1
1471-2458-12-602.txt	Conclusions These analyses indicate the efficacy of the Australian TLC Diabetes program with clinically significant post-intervention improvements in both glycaemic control and mental HRQL.	mental HRQL	177	188	significant	104	115	1
cc11249.txt	Study group patients had a significant lower reintubation rate than did controls; six patients (17%) versus 19 patients (48%), P < 0.05; respectively, and a significantly lower time under MV; 17.8 ± 6.4 versus 11.7 ± 3.5 days; P < 0.05; respectively.	time under MV	177	190	significantly	157	170	1
1471-2474-11-218.txt	Low education and poor self-reported health status predicted a work status of "not working": Odds Ratio, OR = 4.3(95% CI (1.3 to 14.9)), p = 0.02 for education, and OR = 1.06 (95% CI (1.0 to 1.1)), p = 0.001 for self-reported health status, respectively.	education	150	159	p = 0.02	137	145	1
1471-2474-12-132.txt	Responders were more likely to be older, Caucasian, have higher levels of education and income, reservist military status, non smoker, lower BMI, and have received individualized attention via the physical/USI examination (p < .05).	Caucasian	41	50	p < .05	223	230	1
1471-2466-10-11.txt	Trough FEV 1 (LSM ± SEM) at Week 12 was 1.48 ± 0.018 L for indacaterol and 1.35 ± 0.019 L for placebo, a clinically relevant difference of 130 ± 24 mL (p < 0.001).	Trough FEV 1 (LSM ± SEM)	0	24	p < 0.001	152	161	1
1757-7241-20-16.txt	Although median values for proportion of delivered compressions within target depth were higher in the feedback group (0-30 s: 54.0%; 30-60 s: 88.0%; 60-90 s: 72.6%; 90-120 s: 87.0%), no significant difference was found when compared to without feedback (0-30 s: 19.6%; 30-60 s: 33.1%; 60-90 s: 44.5%; 90-120 s: 32.7%) and no significant deteriorations over time were found within the groups.	median values for proportion of delivered compressions within target depth	9	83	no significant	323	337	1
1475-2875-5-113.txt	There was no significant difference between groups in fever and parasite clearance time, improvement of anaemia and gametocyte carriage at day 28.	fever	54	59	no significant	10	24	1
cc10289.txt	Multivariable modeling showed nicardipine patients were more likely in TR than labetalol patients at 30 minutes (OR 2.73, P = 0.028; C stat for model = 0.72) Conclusions Patients treated with nicardipine are more likely to reach the physician-specified SBP target range within 30 minutes than those treated with labetalol.	likely in TR	61	73	P = 0.028	122	131	1
1465-9921-10-69.txt	Improvement of lung function, dyspnea and quality of life as multiple criteria were statistically significant relative to placebo.	dyspnea	30	37	significant	98	109	1
1465-9921-10-69.txt	During the treatment period of 6 months the multiple criteria frequency, severity and duration of exacerbations were significantly lower in the group treated with cineole in comparison to placebo.	severity	73	81	significantly	117	130	1
1471-2431-9-21.txt	Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).	eye contact	166	177	significantly	25	38	1
1475-2891-10-120.txt	HIV-infected children between six months and three years of age had a significantly higher gain in height if they received multivitamins (n = 48; 2 cm, compared to 1 cm in the placebo group; 95% CI = 0.20, 1.70; p = 0.01; p for interaction by age group = 0.01).	gain in height	91	105	significantly	70	83	1
1471-2474-8-23.txt	Similarly there were no significant differences between groups in terms of changes to HAQ, EQ-5D utility score, EQ VAS and pain VAS.	EQ-5D utility score	91	110	no significant	21	35	1
1471-2466-11-61.txt	However, non-study COPD medication costs were higher for the LABA or LAMA therapy group ($911 SE = 91) compared to the LABA and LAMA therapy group ($668 SE = 58; p = 0.0238) and non-study respiratory medications were approximately $100 greater for the LABA or LAMA therapy group relative to both LABA and LAMA (p = .0018) and LABA, LAMA, and ICS (p = .0071) therapy groups.	non-study respiratory medications	178	211	p = .0018	311	320	1
1472-6904-8-10.txt	Reduction in LDLP was greater with simvastatin (32%, p < .001) compared to fenofibrate (17%; p = .036 vs pre; p = .027 vs simvastatin end).	LDLP	13	17	p < .001	53	61	1
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	24 hours	86	94	p < 0.05	112	120	1
1745-6215-12-13.txt	In the 2 treatment groups combined, systolic (-1.36 mm Hg) and diastolic (-0.97 mm Hg) office BPs decreased from week 5 to 10 ( P for period effect ≤0.028), but carry-over effects were not significant ( P ≥ 0.11).	carry-over effects	161	179	P ≥ 0.11	203	211	1
cc7695.txt	Results In the intention to treat analysis there were no statistically significant differences between the 53 patients selected for each group regarding gender (p = 0.541), age (p = 0.585) and type of surgery (p = 0.172).	gender	153	159	no statistically significant	54	82	1
cc2896.txt	Patients receiving the remifentanil-based regimen were extubated significantly faster than those treated with morphine (1.0 hour versus 1.93 hour, P = 0.001) but there was no difference between remifentanil and fentanyl.	were extubated	50	64	significantly	65	78	1
1465-9921-12-93.txt	In the comparison of the PFS times, statistically significant difference was also observed between pirfenidone and placebo groups.	the PFS times	21	34	significant	50	61	1
1471-2377-10-92.txt	PGIC analysis in this subgroup demonstrated that significantly more NGX-4010 recipients considered themselves much or very much improved compared with control at week 12 (40% versus 20%; p = 0.0403;).	considered themselves much or very much improved	88	136	significantly	49	62	1
bcr2320.txt	HDL levels decreased significantly across time for the exemestane arm, whereas no significant change was detected across time for the observation arm.	HDL levels	0	10	significantly	21	34	1
cc11249.txt	Study group patients had a significant lower reintubation rate than did controls; six patients (17%) versus 19 patients (48%), P < 0.05; respectively, and a significantly lower time under MV; 17.8 ± 6.4 versus 11.7 ± 3.5 days; P < 0.05; respectively.	reintubation rate	45	62	significant	27	38	1
1472-6904-8-10.txt	Reduction in LDLP was greater with simvastatin (32%, p < .001) compared to fenofibrate (17%; p = .036 vs pre; p = .027 vs simvastatin end).	LDLP	13	17	p = .027	110	118	1
1479-5868-8-41.txt	There was significant weight loss in all 3 intervention groups (GWL, 1.86 kg, P = 0.05; SWA-alone, 3.55 kg, P = 0.0002; GWL+SWA, 6.59 kg, P < 0.0001) but not in the Standard Care group (0.89 kg, P = 0.39) at month 9.	weight loss	22	33	P = 0.39	195	203	1
1747-597X-4-1.txt	At the 1, 3 and 6 month follow-up points, there were no significant differences for urine samples negative for opiates between the two groups.	urine samples negative for opiates	84	118	no significant	53	67	1
cc11180.txt	Avoidance of anticoagulation during MARS results in significant loss of treatment efficacy, due to treatment downtime.	treatment efficacy	72	90	significant	52	63	1
1749-8090-4-60.txt	The mean time to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034).	The mean time to haemostasis	0	28	p = 0.026	127	136	1
1471-2474-12-153.txt	Compared to placebo, this dosage of canakinumab was also associated with significantly more favorable responses at week 12 with respect to secondary endpoints including the Disease Activity Score 28, scores on the Health Assessment Questionnaire and Functional Assessment of Chronic Illness Therapy-Fatigue, swollen 28-joint count, and patient's and physician's global assessments of disease activity.	scores on the Health Assessment Questionnaire	200	245	significantly	73	86	1
1471-2474-12-153.txt	Compared to placebo, this dosage of canakinumab was also associated with significantly more favorable responses at week 12 with respect to secondary endpoints including the Disease Activity Score 28, scores on the Health Assessment Questionnaire and Functional Assessment of Chronic Illness Therapy-Fatigue, swollen 28-joint count, and patient's and physician's global assessments of disease activity.	the Disease Activity Score 28	169	198	significantly	73	86	1
1471-2474-8-23.txt	Similarly there were no significant differences between groups in terms of changes to HAQ, EQ-5D utility score, EQ VAS and pain VAS.	HAQ	86	89	no significant	21	35	1
1471-2431-9-21.txt	On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.	irritability	90	102	significant	12	23	1
1471-5945-4-18.txt	Results Complete healing of ulcers, regardless of location and stage, was better in the HD group than the PC [23/31(74.19%) vs 12/30(40%); difference: 34.19%, 95% CI = 10.85–57.52, (P < 0.01)] or the SD [23/31(74.19%) vs 8/30(26.66%); difference: 47.53%, 95% CI = 25.45–69.61, (P < 0.005)] groups.	Complete healing of ulcers, regardless of location and stage,	8	69	P < 0.01	182	190	1
1742-4690-3-63.txt	No significant changes in pain, bladder function, disability score, gait, proviral load or markers of T-cell activation or proliferation were seen between the two arms.	gait	68	72	No significant	0	14	1
1477-7827-4-38.txt	Conclusion Considering the significantly lower number of vials/patient and the slight (although non-significant) increase in the delivery rate with r-FSH, the cost-minimization analysis showed a 9.4% reduction in the overall therapy cost per born baby in favor of r-FSH.	the delivery rate	125	142	non-significant	96	111	1
1475-2875-5-113.txt	The 28-day PCR-corrected cure rate was 90.1% [95% CI 80.7–95.9] for AS+SP, 98.5% [95% CI 92.0–100] for AS+AQ and 100% [95.8–100] for AL, thereby revealing a weaker response to AS+SP than to AL (p = 0.003) and to AS+AQ (p = 0.06).	response	164	172	p = 0.06	219	227	1
1475-2891-3-20.txt	There was also a significant between-group difference between the fish oil group and the no-treatment controls in the rate of stress reduction ( p < 0.05).	the rate of stress reduction	114	142	p < 0.05	145	153	1
1471-230X-9-22.txt	The proportion of patients who remained relapse-free at Week 26 did not differ significantly between the placebo group (5/16, 31%) and the IFN beta-1a 44 mcg biw (6/17, 35%; p = 0.497), 44 mcg tiw (7/16, 44%; p = 0.280) or 66 mcg tiw (2/18, 11%; p = 0.333) groups.	The proportion of patients who remained relapse-free at Week 26	0	63	not differ significantly	68	92	1
1471-230X-10-16.txt	Results Thirteen participants (81%; 95% CI 57% to 93%; P = 0.012) preferred placebo to L. plantarum MF1298 treatment.	preferred placebo to L. plantarum MF1298 treatment	66	116	P = 0.012	55	64	1
1475-2840-10-78.txt	Results Cinnamon did not change gastric emptying parameters, postprandial triacylglycerol or glucose concentrations, oxidative stress, arterial function or appetite (p < 0.05).	gastric emptying parameters	32	59	p < 0.05	166	174	1
1741-7015-2-6.txt	Slightly more adverse events occurred in the fascial interposition group, but the difference was not significant.	adverse events	14	28	not significant	97	112	1
cc10289.txt	Median initial SBP was 212.5 (IQR 197, 230) and 212 mmHg (IQR 200,225) for nicardipine and labetalol patients ( P = 0.68), respectively.	Median initial SBP	0	18	P = 0.68	112	120	1
1472-6882-12-19.txt	A secondary analysis showed a significant interaction between treatment and initial weight loss (p < .036), with exploratory post hoc tests showing that greater initial weight loss was associated with more weight regain for SS but less weight regain for TAT.	interaction between treatment and initial weight loss	42	95	p < .036	97	105	1
cc10289.txt	Labetalol patients had slower heart rates at all time points ( P < 0.01).	heart rates at all time points	30	60	P < 0.01	63	71	1
1471-2431-9-21.txt	On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.	stereotypy	104	114	significant	12	23	1
1471-2415-5-6.txt	Results Systolic and diastolic blood flow velocities in the SPCA showed no significant alteration after the treatment with latanoprost or bimatoprost.	Systolic and diastolic blood flow velocities in the SPCA	8	64	no significant	72	86	1
1746-6148-8-157.txt	When comparing variables within the fish oil group as change from baseline to trial end, there were significant positive changes in PVF, HCPI, NSAID use, Quality of life VAS, as well as in all three scores in the comparative questionnaire (locomotion, every-day situations, and skin & coat).	Quality of life VAS	154	173	significant	100	111	1
1824-7288-38-36.txt	Conclusion The present study did not show a statistically significant reduction in duration of severe pneumonia, or reduction in hospital stay for children given daily zinc supplementation along with standard antimicrobial therapy.	hospital stay	129	142	not show a statistically significant	33	59	1
1471-2474-9-118.txt	At Week 6 there was a significantly lower msSBP and msDBP in the lumiracoxib group compared to the rofecoxib group ( p < 0.05).	msSBP	42	47	p < 0.05	117	125	1
1472-6882-12-19.txt	A secondary analysis showed a significant interaction between treatment and initial weight loss (p < .036), with exploratory post hoc tests showing that greater initial weight loss was associated with more weight regain for SS but less weight regain for TAT.	interaction between treatment and initial weight loss	42	95	significant	30	41	1
1472-6882-11-93.txt	There was an expected decrease in frequency of stooling in both groups, reaching 2.1 (p = 0,001) in the acupuncture group and 3.1 (p < 0,001) in the control group.	frequency of stooling	34	55	p = 0,001	86	95	1
1465-9921-7-13.txt	There were no statistically significant between-group differences for treatment success, treatment failure or patient assessment of medication effectiveness.	patient assessment of medication effectiveness	110	156	no statistically significant	11	39	1
1471-2407-9-21.txt	The LP pillow tended to increase the success rate of LPs (67% vs 57%, p = 0.23), and decreased the post-LP syndromes (15% vs 24%, p = 0.17) but the differences were not statistically significant.	the success rate of LPs	33	56	not statistically significant	165	194	1
1471-2407-11-75.txt	Global quality of life was better in the 3-weekly arm (p = 0.03); patients treated with weekly schedules presented a significantly worsening in role functioning and financial scores (p = 0.02 and p < 0.001).	role functioning	144	160	significantly	117	130	1
cc7725.txt	The duration of use of paralysing or sedative agents, mechanical ventilation, stay in the intensive care unit and mortality at 28 days did not differ significantly between the decremental PEEP titration and control groups.	mechanical ventilation	54	76	not differ significantly	139	163	1
1475-2891-7-7.txt	The supplemented group also had 22% fewer fever episodes than the placebo group (p = 0.030).	fever episodes	42	56	p = 0.030	81	90	1
1471-2431-7-27.txt	Subgroup analysis revealed a mean crying time difference of 76.52 seconds (p < 0.0171) (0–1 month) and 123.9 seconds (p < 0.0029) (1–3 month).	crying time	34	45	p < 0.0171	75	85	1
cc11215.txt	Nonsignificant differences were found in absolute FEV1, FEV1/FVC, FVC, forced expiratory flow from 25% to 75% of FVC, functional residual capacity, and CO diffusion.	FVC	66	69	Nonsignificant	0	14	1
cc10120.txt	Parathyroid hormone levels decreased by 19 and 28 pg/ml (PBO and VITD, ns) over the seven days, while 1,25(OH)D showed a transient significant increase in the VITD group only.	1,25(OH)D	102	111	significant	131	142	1
1472-6882-7-8.txt	The discomfort caused by the beads was minor, and there were no significant side effects.	side effects	76	88	no significant	61	75	1
cc1476.txt	PTEF increased significantly both after albuterol and saline treatments but the difference between the two treatments was not significant ( P = 0.6).	PTEF	0	4	not significant	122	137	1
1465-9921-8-52.txt	FEV 1 was also significantly superior at week 2 in the SFC group (mean difference 0.16L, 95% CI; 0.03 – 0.28, p = 0.015), but not at week 4 (mean difference 0.17L, 95% CI -0.01 – 0.34, p = 0.060).	FEV 1	0	5	p = 0.015	110	119	1
1471-2431-11-82.txt	[Na] increased significantly in the 0.9% group (+0.20 mmol/L/h [IQR +0.03, +0.4]; P = 0.02) and increased, but not significantly, in the 0.45% group (+0.08 mmol/L/h [IQR -0.15, +0.16]; P = 0.07).	[Na]	0	4	not significantly	111	128	1
cc11215.txt	Nonsignificant differences were found in absolute FEV1, FEV1/FVC, FVC, forced expiratory flow from 25% to 75% of FVC, functional residual capacity, and CO diffusion.	CO diffusion	152	164	Nonsignificant	0	14	1
1471-2474-3-7.txt	Results Plasma low density lipoprotein-cholesterol concentration fell 7%, 39% (p < 0.01 vs baseline) and 47% (p < 0.01 vs baseline) after 12 weeks of treatment with placebo, simvastatin 20 mg and 40 mg, respectively.	Plasma low density lipoprotein-cholesterol concentration	8	64	p < 0.01	79	87	1
1532-429X-14-61.txt	CMR performed better than SPECT in MVD (p = 0.003 vs all SPECT, p = 0.04 vs gated-SPECT), in men (p = 0.004, n = 313) and in women (p = 0.03, n = 112) as well as in the non-infarct patients (p = 0.005, n = 186 in 1–3 vessel disease and p = 0.015, n = 140 in MVD).	MVD	35	38	p = 0.004	98	107	1
1471-2458-12-206.txt	No other significant effects in health related outcomes were found.	health related outcomes	32	55	No other significant	0	20	1
1741-7015-10-54.txt	No significant effect on HOMA index was seen.	HOMA index	25	35	No significant	0	14	1
1745-6215-13-11.txt	All groups showed significant improvement in time to complete the MT (p < 0.001) and degree of help needed to perform the task: minimal assistance to supervision (CG) and independent performance (EG1+2).	degree of help needed to perform the task	85	126	significant	18	29	1
1471-2334-8-17.txt	A more rapid complete response was obtained in the IFN group (5 months before), with a significantly earlier improvement in respiratory symptoms and pulmonary lesions reduction.	pulmonary lesions	149	166	significantly	87	100	1
1471-2458-12-602.txt	Over the six-month period from baseline, participants receiving the Australian TLC (Telephone-Linked Care) Diabetes program showed a 0.8% decrease in geometric mean HbA 1c from 8.7% to 7.9%, compared with a 0.2% HbA 1c reduction (8.9% to 8.7%) in the usual care arm (p = 0.002).	HbA 1c	212	218	p = 0.002	267	276	1
1471-230X-9-85.txt	Results Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061).	GSRS abdominal pain subscore	107	135	p = 0.046	137	146	1
1471-244X-12-44.txt	At follow-up significant treatment effects were found for both violent attitudes and locus of control.	violent attitudes	63	80	significant	13	24	1
1465-9921-11-112.txt	Results After three month training period, in the Nordic Walking group time spent walking and standing as well as intensity of walking increased (Δ walking time: +14.9 ± 1.9 min/day; Δ standing time: +129 ± 26 min/day; Δ movement intensity: +0.40 ± 0.14 m/s 2 ) while time spent sitting decreased (Δ sitting time: -128 ± 15 min/day) compared to baseline (all: p < 0.01) as well as compared to controls (all: p < 0.01).	walking time	148	160	p < 0.01	408	416	1
1472-6882-7-34.txt	Compared to baseline both treatments showed significant benefits in WOMAC and VAS outcomes within one week (P < 0.05), with a similar, progressive improvement over the course of the 8 week treatment protocol (45–62% reduction in WOMAC or VAS scores).	WOMAC	68	73	significant	44	55	1
cc1476.txt	Results There were no significant changes in V PTEF / V E and t PTEF / t E after albuterol or saline treatment.	t PTEF / t E	62	74	no significant	19	33	1
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	moderate-to-vigorous physical activity	222	260	p < .001	275	283	1
1475-2875-5-113.txt	There was no significant difference between groups in fever and parasite clearance time, improvement of anaemia and gametocyte carriage at day 28.	parasite clearance time	64	87	no significant	10	24	1
1465-9921-7-141.txt	At 1 minute after inhalation, statistically significant decreases in Borg score were observed for budesonide/formoterol and salbutamol (p = 0.0233 and p < 0.0001, respectively, versus placebo), with similar rapid increases in FEV 1 (both active treatments p < 0.0001 versus placebo).	Borg score	69	79	significant	44	55	1
1471-2474-12-132.txt	Age, race/ethnicity, education, military status, smoking history, BMI, and whether a Soldier received the physical/USI examination remained statistically significant (p < .05) when considered in a full multivariate model.	smoking history	49	64	significant	154	165	1
1471-2458-11-711.txt	Results We found a lower percentage of obesity (greater than or equal to the 95 th percentile for BMI) at the end of the study among the group participating in public commitment activities compared to the control group (21.5% vs 26.6%, p = 0.02).	percentage of obesity	25	46	p = 0.02	236	244	1
1745-6215-12-13.txt	In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg ( P = 0.03) for systolic office BP; 0.70 mm Hg ( P = 0.08) for diastolic office BP; 0.36 mm Hg ( P = 0.49) for 24-h systolic BP; and 0.05 mm Hg ( P = 0.88) for 24-h diastolic BP.	24-h systolic BP	184	200	P = 0.49	170	178	1
1471-244X-12-44.txt	At follow-up significant treatment effects were found for both violent attitudes and locus of control.	locus of control	85	101	significant	13	24	1
1475-2891-7-7.txt	Results At the end of the study we observed a significant decrease in the prevalence malaria in the supplemented group (34%) compared to the placebo group (3.5%) (p < 0.001).	the prevalence malaria	70	92	significant	46	57	1
1471-2458-12-206.txt	Significant effects were found for several variables of self-reported physical activity, mood and quality of life and are discussed.	mood	89	93	Significant	0	11	1
1471-2377-8-33.txt	Conclusion Pregabalin 600 mg/d (300 mg BID) effectively reduced pain, was well tolerated, and had no statistically significant or clinically meaningful effect on NC in patients with painful DPN.	NC	162	164	no statistically significant	98	126	1
1471-2474-12-132.txt	Age, race/ethnicity, education, military status, smoking history, BMI, and whether a Soldier received the physical/USI examination remained statistically significant (p < .05) when considered in a full multivariate model.	BMI	66	69	p < .05	167	174	1
1475-2875-9-378.txt	The PCR corrected cure rates for day 28 was 97.9% in the AS + AQ arm and 95.6% in the AS + SMP arm (p = 0.15).	The PCR corrected cure rates	0	28	p = 0.15	100	108	1
bcr3051.txt	Results Progesterone receptor-negativity (HR = 0.66; 95% CI 0.47 to 0.92, P = 0.013), and Ki67-positivity (HR = 1.53; 95% CI 1.12 to 2.08, P = 0.007) were independent adverse prognostic factors.	Progesterone receptor-negativity	8	40	P = 0.013	74	83	1
1746-6148-8-157.txt	Results When comparing the two test groups at the end of the trial (16 weeks) there was no significant difference in any of the main outcome variables but owners of dogs that had taken fish oil were significantly happier with the treatment at the end visit and did significantly better at guessing what group their dogs had been in, compared to the placebo group.	happier	213	220	significantly	199	212	1
ar3496.txt	Results CBT significantly decreased global PC at the six-month follow-up examination with effect sizes of Cohen's d = 0.73 and 1.01 compared with RPT and TAU, respectively.	global PC	36	45	significantly	12	25	1
1475-2891-10-134.txt	Early invitation to food supplementation (in comparison with usual invitation) reduced the proportion of stunting from early infancy up to 54 months for boys (p = 0.01), but not for girls (p = 0.31).	the proportion of stunting	87	113	p = 0.31	189	197	1
1532-429X-13-65.txt	Interestingly, LV mass-I significantly decreased in the placebo group (48.9 ± 5.3 g/m 2 vs 44.3 ± 5.6 g/m 2 , p < 0.001) indicating reverse remodeling, whereas LV mass-I remained unchanged in the rosiglitazone group (54.7 ± 9.9 g/m 2 vs 53.7 ± 9.2 g/m 2 , p = 0.3).	LV mass-I	15	24	significantly	25	38	1
1471-230X-9-85.txt	Results Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061).	the GSRS total score	152	172	p = 0.048	174	183	1
ar4034.txt	The comparison between daily 15 mg prednisone and placebo at Day 15 yielded a statistically significant treatment effect (effect size = 1.17, P = 0.013) in change from baseline in the primary endpoint, but borderline for prednisone 7.5 mg daily versus placebo (effect size = 0.61, P = 0.071).	the primary endpoint	180	200	P = 0.013	142	151	1
1471-2458-12-1073.txt	However, there were few statistically significant differences observed for quality of life and clinical outcomes at long-term measurements at 12-months end of intervention and at 6- months post intervention (18-month follow-up).	quality of life	75	90	significant	38	49	1
1745-6215-12-13.txt	Results Among 410 analyzable patients (40.5% women; mean age, 48.4 years), the differences in the primary endpoint (rostafuroxin minus placebo) ranged from -0.18 mm Hg ( P = 0.90) on 0.15 mg/d rostafuroxin to 2.72 mm Hg ( P = 0.04) on 0.05 mg/d.	the primary endpoint	94	114	P = 0.04	222	230	1
1471-2466-10-11.txt	Indacaterol significantly reduced the percentage of days of poor control versus placebo by 22.5% (p < 0.001) and was also associated with significantly reduced use of rescue medication (p < 0.001).	the percentage of days of poor control	34	72	p < 0.001	98	107	1
1756-9966-28-131.txt	Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01).	nausea	169	175	significant	58	69	1
1472-6963-12-250.txt	Results There was no evidence that an incentive (52% versus 43%, Risk Difference (RD) -8.8 (95%CI −22.5, 4.8); or abridged questionnaire (46% versus 43%, RD −2.9 (95%CI −16.5, 10.7); statistically significantly improved dentist response rates compared to a full length questionnaire in RCT A.	dentist response rates	220	242	no evidence that an incentive (52% versus 43%, Risk Difference (RD) -8.8 (95%CI −22.5, 4.8); or abridged questionnaire (46% versus 43%, RD −2.9 (95%CI −16.5, 10.7); statistically significantly	18	210	1
1475-2891-10-72.txt	No other significant treatment effects were discerned in glucose, insulin, lipids, and weight.	insulin	66	73	No other significant	0	20	1
1475-2875-7-199.txt	On day 7 follow-up, more children reported symptoms in Arm-I compared to Arm-III, but fewer children had malaria parasitaemia (p = 0.049).	malaria parasitaemia	105	125	p = 0.049	127	136	1
1471-2369-13-49.txt	Conclusions In this crossover trial with alphacalcidol and sevelamer carbonate in patients with CKD stage 3b, the levels of iFGF23 were not significantly different after the two treatments.	the levels of iFGF23	110	130	not significantly	136	153	1
cc10143.txt	In the TA group, bleeding duration was shorter and progression to severe PPH and PRBC transfusion was less frequent than in controls ( P < 0.03).	PRBC transfusion	81	97	P < 0.03	135	143	1
1479-5868-8-41.txt	There was significant weight loss in all 3 intervention groups (GWL, 1.86 kg, P = 0.05; SWA-alone, 3.55 kg, P = 0.0002; GWL+SWA, 6.59 kg, P < 0.0001) but not in the Standard Care group (0.89 kg, P = 0.39) at month 9.	weight loss	22	33	P < 0.0001	138	148	1
1471-230X-10-16.txt	With a clinically significant difference in the IBS sum score of 2 in disfavour of active treatment, the number needed to harm was 3.7, 95% CI 2.3 to 10.9.	the IBS sum score	44	61	significant	18	29	1
1472-6963-9-14.txt	thrombolysis, 15/175 (8.6%) in the intervention arm and 2/115 (1.7%) in the control arm received thrombolysis (p = 0.02) in the ITT analysis, and respectively 15/99 (15.1%) and 2/107 (1.9%)(p = 0.001) in the PP analysis.	thrombolysis	97	109	p = 0.02	111	119	1
1465-9921-7-13.txt	No statistically significant difference between the treatment groups was apparent for the primary outcome variable, or for any of the other efficacy endpoints.	the primary outcome variable	86	114	No statistically significant	0	28	1
1471-2458-9-200.txt	Results After 12 months of follow-up there was no difference in claim duration between PT and usual care (Hazard Ratio 0.7; 95%CI, 0.4–1.1; p = 0.12) or PTCBWE and usual care (Hazard Ratio 0.9; 95%CI, 0.6–1.4; p = 0.72).	claim duration	64	78	p = 0.72	210	218	1
1475-2891-11-57.txt	Dietary energy, %fat and %saturated fat decreased while protein intake increased significantly (p < 0.001).	protein intake	56	70	p < 0.001	96	105	1
1471-2458-6-134.txt	The intervention group showed significant improvements in scores for Knowledge (+12.5%); Attitudes toward seriousness (+13.5%), complications (+8.1%), Practice (+20.0%).	scores for Knowledge	58	78	significant	30	41	1
cc11445.txt	Hemodynamic stability did not differ between SLED-BD and CVVH, whereas patients in the SLED-BD group had significantly fewer days of mechanical ventilation (17.7 ± 19.4 vs 20.9 ± 19.8, P = 0.047) and fewer days in the ICU (19.6 ± 20.1 vs 23.7 ± 21.9, P = 0.04).	days of mechanical ventilation	125	155	significantly	105	118	1
1471-2431-9-21.txt	Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).	eye contact	166	177	p = 0.0322	179	189	1
cc7695.txt	Results In the intention to treat analysis there were no statistically significant differences between the 53 patients selected for each group regarding gender (p = 0.541), age (p = 0.585) and type of surgery (p = 0.172).	type of surgery	193	208	p = 0.172	210	219	1
1472-6963-12-147.txt	No significant differences emerged between the arms in the other primary end-points.	the other primary end-points	55	83	No significant	0	14	1
1471-244X-3-16.txt	However, no significant difference was seen in the rates of opioid-positive urine tests.	the rates of opioid-positive urine tests	47	87	no significant	9	23	1
1745-6215-12-13.txt	In the 2 treatment groups combined, systolic (-1.36 mm Hg) and diastolic (-0.97 mm Hg) office BPs decreased from week 5 to 10 ( P for period effect ≤0.028), but carry-over effects were not significant ( P ≥ 0.11).	systolic (-1.36 mm Hg) and diastolic (-0.97 mm Hg) office BPs	36	97	P for period effect ≤0.028	128	154	1
1532-429X-11-24.txt	Patients were managed to have equivalent glycemic control over the study period, but in fact the rosiglitazone group lowered their HbA1c by 0.88% relative to placebo (P < 0.001).	their HbA1c	125	136	P < 0.001	167	176	1
1477-7525-1-10.txt	Results Comparing the pretest and intervention periods, the meditation group exhibited a mean decrease of 6.4 absentee periods compared to an increase of 4.8 in the control group (p < .05).	absentee periods	110	126	p < .05	180	187	1
cc11159.txt	Individual renal parameters showed that endogenous creatinine clearance (baseline to Day 28) was significantly higher in the treated group relative to placebo (from 50 ± 27 to 108 ± 73 mL/minute (mean ± SEM) for the AP group; and from 40 ± 37 to 65 ± 30 mL/minute for placebo; P = 0.01).	endogenous creatinine clearance (baseline to Day 28)	40	92	significantly	97	110	1
1471-230X-12-37.txt	The VAS score for the occurrence of nausea due to abdominal distension after ESD indicated a significant difference ( P  = 0.031).	The VAS score for the occurrence of nausea due to abdominal distension	0	70	P  = 0.031	118	128	1
1475-2840-10-78.txt	Results Cinnamon did not change gastric emptying parameters, postprandial triacylglycerol or glucose concentrations, oxidative stress, arterial function or appetite (p < 0.05).	oxidative stress	117	133	p < 0.05	166	174	1
1741-7015-2-6.txt	Fascial interposition decreased time to azoospermia (hazard ratio [HR], 1.35; P < 0.0001) and time to severe oligozoospermia (HR, 1.32; P < 0.0001) and reduced failures based on semen analysis by about half, from 12.7% (95% confidence interval [CI], 9.7 to 16.3) to 5.9% (95% CI, 3.8 to 8.6) (P < 0.0001).	time to severe oligozoospermia	94	124	P < 0.0001	136	146	1
1471-2474-11-64.txt	There was no significant difference for weeks missed due to hamstring injury (4 v14, χ2:1.12, p = 0.29) and lower-limb muscle strains (4 v 21, χ2:2.66, p = 0.10).	lower-limb muscle strains	108	133	p = 0.10	152	160	1
1471-2431-9-21.txt	Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).	receptive language	129	147	significantly	25	38	1
1471-2474-12-132.txt	Age, race/ethnicity, education, military status, smoking history, BMI, and whether a Soldier received the physical/USI examination remained statistically significant (p < .05) when considered in a full multivariate model.	race/ethnicity	5	19	p < .05	167	174	1
1475-2891-11-57.txt	There were no significant differences among the three groups in any variable related to body composition, dietary composition, or MetS components.	MetS components	130	145	no significant	11	25	1
1471-2474-12-132.txt	Responders were more likely to be older, Caucasian, have higher levels of education and income, reservist military status, non smoker, lower BMI, and have received individualized attention via the physical/USI examination (p < .05).	lower BMI	135	144	p < .05	223	230	1
1475-2891-7-7.txt	Results At the end of the study we observed a significant decrease in the prevalence malaria in the supplemented group (34%) compared to the placebo group (3.5%) (p < 0.001).	the prevalence malaria	70	92	p < 0.001	163	172	1
1471-2474-11-64.txt	The difference for primary lower-limb muscle strains was significant (OR:0.097, 95%CI:0.011-0.839, p = 0.025).	primary lower-limb muscle strains	19	52	significant	57	68	1
1471-2474-12-132.txt	Age, race/ethnicity, education, military status, smoking history, BMI, and whether a Soldier received the physical/USI examination remained statistically significant (p < .05) when considered in a full multivariate model.	education	21	30	significant	154	165	1
1471-2474-9-118.txt	However, lumiracoxib was associated with a significantly better BP profile as compared to rofecoxib.	BP profile	64	74	significantly	43	56	1
1475-2891-3-20.txt	Results There was a significant reduction in perceived stress in both the fish oil and the placebo group from baseline.	perceived stress	45	61	significant	20	31	1
cc6887.txt	After 3 months and 6 months of treatment, the dichotomized Glasgow Outcome Scale score analysis exhibited more favorable outcomes among the patients who were given progesterone compared with the control individuals ( P = 0.034 and P = 0.048, respectively).	the dichotomized Glasgow Outcome Scale score	42	86	P = 0.048	231	240	1
cc11180.txt	Between group comparison demonstrated citrate anticoagulation to significantly increase the likelihood of completed MARS treatment (Fisher's exact test, P 0.04).	the likelihood of completed MARS treatment	88	130	P 0.04	153	159	1
1471-2369-12-9.txt	Results At 12 weeks, serum phosphorus concentration was significantly lower in the calcium acetate group compared to the placebo group (4.4 ± 1.2 mg/dL vs 5.1 ± 1.4 mg/dL; p = 0.04).	serum phosphorus concentration	21	51	significantly	56	69	1
1475-2875-6-138.txt	Results Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups.	total coma duration	118	137	p = 0.07	139	147	1
1741-7015-2-7.txt	There was also no statistically significant difference in the rate of acute gastrointestinal complications (2/21 prednisone group vs 3/19 placebo group, P = 0.7).	the rate of acute gastrointestinal complications	58	106	no statistically significant	15	43	1
cc7725.txt	The duration of use of paralysing or sedative agents, mechanical ventilation, stay in the intensive care unit and mortality at 28 days did not differ significantly between the decremental PEEP titration and control groups.	The duration of use of paralysing or sedative agents	0	52	not differ significantly	139	163	1
cc6173.txt	In the TA group, we observed a significant reduction in the incidence of VS ( P = 0.003), the use of norepinephrine ( P = 0.029), and time on mechanical ventilation ( P = 0.018).	the incidence of VS	56	75	P = 0.003	78	87	1
1472-6882-12-7.txt	Results For BMD, no intent-to-treat analyses were statistically significant; however, per protocol analyses (ie, only including TC participants who completed ≥ 75% training requirements) of femoral neck BMD changes were significantly different between TC and UC (+0.04 vs -0.98%; P = 0.05).	femoral neck BMD changes	190	214	P = 0.05	280	288	1
1465-9921-11-74.txt	Improvements in ACQ score after 12 months were -0.14 (p = 0.23), -0.52 (p < 0.001) and -0.82 (p < 0.001) in the Internet group compared to usual care for patients with well, partly and uncontrolled asthma at baseline, respectively.	ACQ score	16	25	p = 0.23	54	62	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	significant	63	74	1
1475-2875-9-378.txt	The fever clearance time was similar in the two treatment groups: 1 - 2 days for both AS + SMP and AS + AQ (p = 0.271).	The fever clearance time	0	24	p = 0.271	108	117	1
1471-2466-10-11.txt	Serum potassium and blood glucose levels did not differ significantly between the two groups, and no patient had QTc >500 ms.	Serum potassium	0	15	not differ significantly	45	69	1
1741-7015-7-22.txt	Results The mean duration of diarrhea from enrolment and the mean stool weight during hospital stay were 63.7 hours and 940 grams, respectively, and there were no significant differences in the adjusted means across treatment groups.	The mean duration of diarrhea from enrolment	8	52	no significant	160	174	1
1475-2891-10-72.txt	No other significant treatment effects were discerned in glucose, insulin, lipids, and weight.	lipids	75	81	No other significant	0	20	1
1471-2458-10-81.txt	In troop meetings, intervention troop leaders promoted PA (x 2 = 23.46, p < .001) and healthful eating (x 2 = 18.14, p < .001) more frequently, and discouraged healthful eating and PA less frequently (x 2 = 9.63, p = .002) compared to control troop leaders.	healthful eating	86	102	p < .001	117	125	1
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	MLD	199	202	p = 0.204	215	224	1
1471-2377-4-13.txt	Results Patients reported significant pain relief in favor of gabapentin in the first period.	pain relief	38	49	significant	26	37	1
1471-2431-9-21.txt	On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.	irritability	90	102	p < 0.03	143	151	1
1471-2474-12-132.txt	Age, race/ethnicity, education, military status, smoking history, BMI, and whether a Soldier received the physical/USI examination remained statistically significant (p < .05) when considered in a full multivariate model.	Age	0	3	p < .05	167	174	1
bcr2320.txt	HDL levels decreased significantly across time for the exemestane arm, whereas no significant change was detected across time for the observation arm.	HDL levels	0	10	no significant	79	93	1
1471-230X-11-110.txt	The ICBT group demonstrated significantly ( p < .001) larger improvements on the IBS-related outcome scales than the waiting list group.	the IBS-related outcome scales	77	107	p < .001	44	52	1
ar4072.txt	ANCOVA analysis demonstrated superiority of adalimumab over placebo for the physician global assessment of disease activity, parents' global assessment of subject's overall well-being, active joint count (all P <0.05) and erythrocyte sedimentation rate (ESR) ( P <0.01).	active joint count	185	203	P <0.05	209	216	1
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	triglycerides	206	219	significantly	40	53	1
1479-5868-8-29.txt	However, the intervention did significantly reduce systolic blood pressure (B = -1.79 mm/Hg) and resting heart rate (B = -2.08 beats) and significantly increased body mass index (B = .18 units) compared to control.	body mass index	162	177	significantly	138	151	1
1471-2458-12-944.txt	Prevalence of high blood pressure, high cholesterol and smoking were reduced significantly (p <0.01) in both groups.	Prevalence of high blood pressure	0	33	significantly	77	90	1
1471-2474-12-132.txt	Responders were more likely to be older, Caucasian, have higher levels of education and income, reservist military status, non smoker, lower BMI, and have received individualized attention via the physical/USI examination (p < .05).	non smoker	123	133	p < .05	223	230	1
1472-6882-12-7.txt	Results For BMD, no intent-to-treat analyses were statistically significant; however, per protocol analyses (ie, only including TC participants who completed ≥ 75% training requirements) of femoral neck BMD changes were significantly different between TC and UC (+0.04 vs -0.98%; P = 0.05).	femoral neck BMD changes	190	214	significantly	220	233	1
1465-9921-11-112.txt	Results After three month training period, in the Nordic Walking group time spent walking and standing as well as intensity of walking increased (Δ walking time: +14.9 ± 1.9 min/day; Δ standing time: +129 ± 26 min/day; Δ movement intensity: +0.40 ± 0.14 m/s 2 ) while time spent sitting decreased (Δ sitting time: -128 ± 15 min/day) compared to baseline (all: p < 0.01) as well as compared to controls (all: p < 0.01).	movement intensity	221	239	p < 0.01	360	368	1
1471-2458-6-134.txt	The intervention group showed significant improvements in scores for Knowledge (+12.5%); Attitudes toward seriousness (+13.5%), complications (+8.1%), Practice (+20.0%).	Practice	151	159	significant	30	41	1
1471-2474-7-5.txt	After treatment, significant reductions were observed in functional limitations, patient's main complaints and pain intensity for all three active treatments compared to the WL.	functional limitations	57	79	significant	17	28	1
1471-2431-8-13.txt	Facial actions were highly significantly lower across all points in time reaching a two-fold difference by 120 seconds post-lance and heart rate was significantly lower across the first 90 seconds in the KMC condition.	Facial actions	0	14	significantly	27	40	1
cc11249.txt	Mean ICU length of stay after extubation was significantly lower in the study group when compared with controls (3.1 ± 2.5 versus 9.8 ± 6.7 days; P < 0.05).	Mean ICU length of stay after extubation	0	40	P < 0.05	146	154	1
1746-6148-8-162.txt	Changes in the PVF BW (P adj  = 0.0004), the CSOM (P adj  = 0.006) and the MA intensity (P adj  = 0.02) from D0 to D90 suggested an effect of diet(s).	the MA intensity	71	87	P adj  = 0.02	89	102	1
1471-2458-12-344.txt	There was also no significant difference in the QQ index (−0.5 [−4.4 to 3.3]) or SA days (0.0 [−1.2 to 0.9]).	SA days	81	88	no significant	15	29	1
1471-2474-12-132.txt	Age, race/ethnicity, education, military status, smoking history, BMI, and whether a Soldier received the physical/USI examination remained statistically significant (p < .05) when considered in a full multivariate model.	smoking history	49	64	p < .05	167	174	1
1746-6148-8-162.txt	Only the PVF BW clearly increased after the GLM-diet (P adj  = 0.003).	the PVF BW	5	15	P adj  = 0.003	54	68	1
1471-2458-10-81.txt	Most effects of the intervention on individual-level variables of girls and parents were not significantly different from the control condition, including the primary outcome of child BMI z-score (F 1, 5 = 0.42, p = .544), parent BMI (F 1, 5 = 1.58, p = .264), and related behavioral variables.	Most effects of the intervention on individual-level variables of girls and parents	0	83	not significantly	89	106	1
1475-2840-10-78.txt	Results Cinnamon did not change gastric emptying parameters, postprandial triacylglycerol or glucose concentrations, oxidative stress, arterial function or appetite (p < 0.05).	postprandial triacylglycerol	61	89	p < 0.05	166	174	1
1471-2407-9-21.txt	The LP pillow tended to increase the success rate of LPs (67% vs 57%, p = 0.23), and decreased the post-LP syndromes (15% vs 24%, p = 0.17) but the differences were not statistically significant.	the post-LP syndromes	95	116	not statistically significant	165	194	1
1532-429X-13-65.txt	Interestingly, LV mass-I significantly decreased in the placebo group (48.9 ± 5.3 g/m 2 vs 44.3 ± 5.6 g/m 2 , p < 0.001) indicating reverse remodeling, whereas LV mass-I remained unchanged in the rosiglitazone group (54.7 ± 9.9 g/m 2 vs 53.7 ± 9.2 g/m 2 , p = 0.3).	LV mass-I	15	24	p < 0.001	110	119	1
1475-2875-6-138.txt	Results Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups.	time to start oral intake	77	102	p = 0.13	104	112	1
1475-2891-10-120.txt	Supplementation resulted in significant improvement in hemoglobin levels at the end of follow-up in children of all age groups; the median increase in children receiving multivitamins was 1.0 g/dL, compared to 0.4 g/dL in children receiving placebo (p < 0.01).	hemoglobin levels	55	72	p < 0.01	250	258	1
1479-5868-8-29.txt	However, the intervention did significantly reduce systolic blood pressure (B = -1.79 mm/Hg) and resting heart rate (B = -2.08 beats) and significantly increased body mass index (B = .18 units) compared to control.	systolic blood pressure	51	74	significantly	30	43	1
1471-2415-8-11.txt	The mean age of bimatoprost was 43.0 ± 3.4 days and the mean age of latanoprost was 43.9 ± 2.8 days (P = .072).	The mean age of bimatoprost	0	27	P = .072	101	109	1
1471-2474-13-229.txt	Results Only minor adverse events were detected in some patients, such as mild pain and effusion after the injections, in particular in the PRP group, where a significantly higher post-injective pain reaction was observed (p=0.039).	post-injective pain reaction	180	208	significantly	159	172	1
1471-2474-12-132.txt	Age, race/ethnicity, education, military status, smoking history, BMI, and whether a Soldier received the physical/USI examination remained statistically significant (p < .05) when considered in a full multivariate model.	military status	32	47	significant	154	165	1
1471-2458-10-81.txt	Results The intervention was delivered with good fidelity, and intervention troops provided greater opportunities for healthful eating and PA (x 2 = 210.8, p < .001), relative to control troops.	opportunities for healthful eating and PA	100	141	p < .001	156	164	1
1475-2891-7-7.txt	Malaria episodes were lower in the supplemented group (p = 0.029), with a 30.2% reduction of malaria cases (p = 0.025).	Malaria episodes	0	16	p = 0.029	55	64	1
1471-2474-8-23.txt	Similarly there were no significant differences between groups in terms of changes to HAQ, EQ-5D utility score, EQ VAS and pain VAS.	pain VAS	123	131	no significant	21	35	1
ar3703.txt	For the period between baseline and month 6, WOMAC Pain, Physical Function and Total dimensions significantly improved in the OAK group compared to the control group, as did the SF-36 Physical Function, Role Physical, Body Pain, Vitality and Social Functioning domains, as well as hamstring strength in both legs.	Physical Function	57	74	significantly	96	109	1
1471-230X-9-85.txt	A strong placebo effect was evident which could explain the lack of statistical significant differences between the groups for many of the efficacy variables.	many of the efficacy variables	127	157	lack of statistical significant	60	91	1
cc2896.txt	Overall, mean neurological assessment times were significantly shorter when using remifentanil (remifentanil 0.41 hour versus fentanyl 0.71 hour [ P = 0.001] versus morphine 0.82 hour [ P < 0.001]).	mean neurological assessment times	9	43	P = 0.001	147	156	1
1472-6882-12-7.txt	Changes in sway parameters were significantly improved by TC vs UC (average sway velocity, P = 0.027; anterior-posterior sway range, P = 0.014).	anterior-posterior sway range	102	131	P = 0.014	133	142	1
1475-2891-6-8.txt	A significant increase in defecation frequency (NF: 3.5 pre versus 5.6/week post treatment; SF 3.6 pre versus 4.9/week post treatment) was found in both groups, but was not significantly different between the two formulas (p = 0.36).	defecation frequency	26	46	not significantly	169	186	1
1471-2369-10-7.txt	Results Patients receiving the citrate dialysate had significantly lower systolic blood pressure (BP) (-4.3 mmHg, p < 0.01) and peripheral resistances (PR) (-51 dyne.sec.cm -5 , p < 0.001) while stroke volume was not increased.	peripheral resistances (PR)	128	155	significantly	53	66	1
1477-7819-10-94.txt	The overall rate of surgical-site infection was lower in the experimental group (11.1% center 1, 17.5% center 2; overall 15.5%) than in controls (14.3% center 1, 24.2% center 2, overall 20.4%), but the observed difference was not statistically significant ( P  = 0.451), even with respect to surgical-site infection grade 1 (superficial) versus grades 2 and 3, or grade 1 and 2 versus grade 3.	The overall rate of surgical-site infection	0	43	P  = 0.451	258	268	1
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	moderate	181	189	p = .004	202	210	1
ar4072.txt	At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% ( P <0.001), the back pain score decreased by 50% ( P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% ( P <0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% ( P <0.005).	the Bath AS Functional Index (BASFI) score	166	208	P <0.02	228	235	1
cc11180.txt	Between group comparison demonstrated citrate anticoagulation to significantly increase the likelihood of completed MARS treatment (Fisher's exact test, P 0.04).	the likelihood of completed MARS treatment	88	130	significantly	65	78	1
1471-2458-11-267.txt	Results Glycated hemoglobin A1c and systolic blood pressure (SBP) levels decreased significantly in the PRECEDE group (multivariate analysis of covariance, with baseline glycated hemoglobin A1c, SBP, and variables showing statistically significant differences between groups at baseline visits).	variables	204	213	significant	236	247	1
1471-2431-9-21.txt	Conclusion Children with autism who received hyperbaric treatment at 1.3 atm and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.	social interaction	188	206	significant	119	130	1
1475-2891-10-85.txt	The disability and impact on daily life of migraines were not significantly different between the true and sham diet groups.	The disability	0	14	not significantly	58	75	1
1746-6148-8-157.txt	When comparing variables within the fish oil group as change from baseline to trial end, there were significant positive changes in PVF, HCPI, NSAID use, Quality of life VAS, as well as in all three scores in the comparative questionnaire (locomotion, every-day situations, and skin & coat).	NSAID use	143	152	significant	100	111	1
1472-6963-12-348.txt	Among the other outcomes, the PCOMS group had better motivation for treatment (estimated mean difference ITT: 0.29, 95% CI 0.00 to 0.57, p = 0.05, PP: 0.28, 95% CI 0.04, 0.52, p = 0.024).	motivation for treatment	53	77	p = 0.05	137	145	1
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	VI-910	227	233	p = 0.389	243	252	1
1748-5908-7-80.txt	No significant effect of the interventions was observed for either fluid or food fasting times.	fluid or food fasting times	67	94	No significant	0	14	1
ar3703.txt	For the period between baseline and month 6, WOMAC Pain, Physical Function and Total dimensions significantly improved in the OAK group compared to the control group, as did the SF-36 Physical Function, Role Physical, Body Pain, Vitality and Social Functioning domains, as well as hamstring strength in both legs.	Social Functioning domains	242	268	significantly	96	109	1
1471-2474-11-64.txt	Results After 24 matches there was no statistical significant difference between the groups for the incidence of hamstring injury (OR:0.116, 95% CI:0.013-1.019, p = 0.051) and primary non-contact knee injury (OR:0.116, 95% CI:0.013-1.019, p = 0.051).	the incidence of hamstring injury	96	129	p = 0.051	161	170	1
cc11215.txt	Results At 6 months post-treatment, results indicated significantly better absolute values for iNO versus placebo for mean ± SD total lung capacity (TLC, 5.54 ± 1.42 vs 4.81 ± 1.00; P = 0.026).	mean ± SD total lung capacity	118	147	significantly	54	67	1
cc6173.txt	In the TA group, we observed a significant reduction in the incidence of VS ( P = 0.003), the use of norepinephrine ( P = 0.029), and time on mechanical ventilation ( P = 0.018).	time on mechanical ventilation	134	164	P = 0.018	167	176	1
1477-7827-4-38.txt	Results The overall FSH dose needed to achieve ovulation was significantly lower with r-FSH, whereas all the other studied variables did not significantly differ with either treatments.	The overall FSH dose needed to achieve ovulation	8	56	significantly	61	74	1
1465-9921-7-13.txt	There were no statistically significant between-group differences for treatment success, treatment failure or patient assessment of medication effectiveness.	treatment failure	89	106	no statistically significant	11	39	1
cc11445.txt	Results 115 patients were treated with SLED-BD (total number of treatments n = 817) and 117 patients with CVVH (total number of treatments n = 877).The primary outcome measure, 90-day mortality, was similar between groups (SLED: 49.6% vs CVVH: 55.6%, P = 0.43).	The primary outcome measure, 90-day mortality,	148	194	P = 0.43	251	259	1
1471-2377-7-20.txt	Parkinson motor scores did not change significantly (active group 0.1, CI -3.4 to 3.7) versus controls (4.5, CI 1.6 to 7.1), p = 0.06.	Parkinson motor scores	0	22	p = 0.06	125	133	1
1465-9921-11-112.txt	Results After three month training period, in the Nordic Walking group time spent walking and standing as well as intensity of walking increased (Δ walking time: +14.9 ± 1.9 min/day; Δ standing time: +129 ± 26 min/day; Δ movement intensity: +0.40 ± 0.14 m/s 2 ) while time spent sitting decreased (Δ sitting time: -128 ± 15 min/day) compared to baseline (all: p < 0.01) as well as compared to controls (all: p < 0.01).	time spent sitting	268	286	p < 0.01	408	416	1
1471-2393-8-19.txt	Average total costs in the intervention group were much lower than in usual care, primarily due to differences in utilization of sick leave but not statistically significant.	Average total costs	0	19	not statistically significant	144	173	1
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	257	269	p < 0.05	305	313	1
1475-2891-11-57.txt	Dietary energy, %fat and %saturated fat decreased while protein intake increased significantly (p < 0.001).	protein intake	56	70	significantly	81	94	1
1471-244X-9-54.txt	Compared with their counterparts who remained on their initial therapies, individuals who switched antipsychotics experienced a significantly higher risk of acute-care services, including hospitalization (p = .013) and crisis services (p = .011).	crisis services	219	234	p = .011	236	244	1
1471-2474-3-7.txt	Results Plasma low density lipoprotein-cholesterol concentration fell 7%, 39% (p < 0.01 vs baseline) and 47% (p < 0.01 vs baseline) after 12 weeks of treatment with placebo, simvastatin 20 mg and 40 mg, respectively.	Plasma low density lipoprotein-cholesterol concentration	8	64	p < 0.01	110	118	1
1465-9921-7-141.txt	At 1 minute after inhalation, statistically significant decreases in Borg score were observed for budesonide/formoterol and salbutamol (p = 0.0233 and p < 0.0001, respectively, versus placebo), with similar rapid increases in FEV 1 (both active treatments p < 0.0001 versus placebo).	Borg score	69	79	p = 0.0233	136	146	1
1471-230X-10-16.txt	IBS sum score was 6.44 (1.81) in the period with L. plantarum MF1298 treatment compared with 5.35 (1.77) in the period with placebo ( P = 0.010).	IBS sum score	0	13	P = 0.010	134	143	1
1471-244X-3-16.txt	Non-significant, but generally favorable responses were seen in the baclofen group with other outcome measures including intensity of opioid craving and self-reported opioid and alcohol use.	intensity of opioid craving	121	148	Non-significant	0	15	1
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	743	804	p < 0.05	909	917	1
1471-2474-11-64.txt	Conclusions This study demonstrated a trend towards lower limb injury prevention with a significant reduction in primary lower limb muscle strains and weeks missed due to non-contact knee injuries through the addition of a sports chiropractic intervention to the current best practice management.	weeks missed due to non-contact knee injuries	151	196	significant	88	99	1
1471-2377-10-92.txt	PGIC analysis demonstrated that more NGX-4010 recipients considered themselves improved (much, or very much) compared with control at weeks 8 and 12, but the differences did not reach statistical significance.	considered themselves improved (much, or very much)	57	108	not reach statistical significance	174	208	1
1471-230X-10-72.txt	In multivariate analysis, HIV infection (OR 4.1; 95%CI 2.2-7.8; P < 0.001) was associated with hypochlorhydria, but taking anti-retroviral treatment (OR 0.16; 0.04-0.67; P = 0.01) and allocation to micronutrient supplementation (OR 0.53; 0.28-0.99; P < 0.05) were protective.	taking anti-retroviral treatment	116	148	P = 0.01	170	178	1
1471-2407-9-21.txt	The LP pillow tended to increase the success rate of LPs (67% vs 57%, p = 0.23), and decreased the post-LP syndromes (15% vs 24%, p = 0.17) but the differences were not statistically significant.	the post-LP syndromes	95	116	p = 0.17	130	138	1
1471-2466-10-11.txt	Standardised AUC measurements for FEV 1 (between 5 min and 4 h, 5 min and 1 h, and 1 and 4 h post-dose) at Week 12 were all significantly greater with indacaterol than placebo (p < 0.001), with LSM (± SEM) differences of 170 ± 24, 180 ± 24, and 170 ± 24 mL, respectively.	Standardised AUC measurements for FEV 1	0	39	p < 0.001	177	186	1
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	daytime arterial blood gases	516	544	p = 0.01	577	585	1
1471-2474-11-244.txt	Results We found differences between the intervention group and the control group, comparing the results at baseline and after 6 months in EuroQol-5D (p < 0.001) and in standing one leg eyes closed (p = 0.02) in favour of the intervention group.	standing one leg eyes closed	169	197	p = 0.02	199	207	1
1746-6148-8-157.txt	When comparing variables within the fish oil group as change from baseline to trial end, there were significant positive changes in PVF, HCPI, NSAID use, Quality of life VAS, as well as in all three scores in the comparative questionnaire (locomotion, every-day situations, and skin & coat).	all three scores in the comparative questionnaire (locomotion, every-day situations, and skin & coat)	189	290	significant	100	111	1
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	6-minute walking distance	627	652	p < 0.001	677	686	1
cc11159.txt	The results in renal parameters were supported by significantly more pronounced reductions in the systemic markers C-reactive protein, Interleukin-6, LPS-binding protein and in the urinary excretion of Kidney Injury Molecule-1 and Interleukin-18 in AP-treated patients relative to placebo.	the urinary excretion of Kidney Injury Molecule-1 and Interleukin-18	177	245	significantly	50	63	1
1477-7827-1-63.txt	The overall incidence of adverse events was similar in both groups, but compared to Follistim(R), injections of Bravelle(R) were reported by patients to be significantly less painful (P < 0.001).	painful	175	182	P < 0.001	184	193	1
1471-230X-10-72.txt	In multivariate analysis, HIV infection (OR 4.1; 95%CI 2.2-7.8; P < 0.001) was associated with hypochlorhydria, but taking anti-retroviral treatment (OR 0.16; 0.04-0.67; P = 0.01) and allocation to micronutrient supplementation (OR 0.53; 0.28-0.99; P < 0.05) were protective.	HIV infection	26	39	P < 0.001	64	73	1
1471-2431-6-29.txt	Children who learned guided imagery with progressive muscle relaxation had significantly greater decrease in the number of days with pain than those learning breathing exercises alone after one (67% vs 21%, P = 0.05), and two (82% vs 45%, P < 0.01) months and significantly greater decrease in days with missed activities at one (85% vs 15%, P = 0.02) and two (95% vs 77%.	days with missed activities	294	321	significantly	260	273	1
1471-2474-11-99.txt	There were no significant differences in changes in the prevalence of arm, shoulder and neck symptoms or sick leave between the intervention and usual care group.	sick leave	105	115	no significant	11	25	1
1745-6215-12-146.txt	However, the PPI scores showed significant differences between the two groups (-1.2 [-1.6 to -0.8] for the wet-cupping group and -0.2 [-0.8 to 0.4] for the waiting-list group, p < 0.01).	the PPI scores	9	23	p < 0.01	176	184	1
1471-2474-9-118.txt	At Week 6 there was a significantly lower msSBP and msDBP in the lumiracoxib group compared to the rofecoxib group ( p < 0.05).	msDBP	52	57	significantly	22	35	1
cc1476.txt	Results There were no significant changes in V PTEF / V E and t PTEF / t E after albuterol or saline treatment.	V PTEF / V E	45	57	no significant	19	33	1
cc6887.txt	After 3 months and 6 months of treatment, the dichotomized Glasgow Outcome Scale score analysis exhibited more favorable outcomes among the patients who were given progesterone compared with the control individuals ( P = 0.034 and P = 0.048, respectively).	the dichotomized Glasgow Outcome Scale score	42	86	P = 0.034	217	226	1
1471-2431-9-21.txt	On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.	total score	77	88	p < 0.03	143	151	1
1824-7288-38-36.txt	The respiratory rate, chest indrawing, cyanosis, stridor, nasal flaring, wheeze and fever in both groups recorded at enrollment and parameters did not differ significantly between the two groups.	wheeze	73	79	not differ significantly	147	171	1
cc2896.txt	Patients receiving the remifentanil-based regimen were extubated significantly faster than those treated with morphine (1.0 hour versus 1.93 hour, P = 0.001) but there was no difference between remifentanil and fentanyl.	were extubated	50	64	P = 0.001	147	156	1
1477-7827-1-63.txt	The overall incidence of adverse events was similar in both groups, but compared to Follistim(R), injections of Bravelle(R) were reported by patients to be significantly less painful (P < 0.001).	painful	175	182	significantly	156	169	1
1471-2369-10-7.txt	Results Patients receiving the citrate dialysate had significantly lower systolic blood pressure (BP) (-4.3 mmHg, p < 0.01) and peripheral resistances (PR) (-51 dyne.sec.cm -5 , p < 0.001) while stroke volume was not increased.	systolic blood pressure (BP)	73	101	p < 0.01	114	122	1
1475-2875-10-358.txt	At the end of the transmission season, malaria parasitaemia prevalence was lower in communities with IPTc + HMM (2.05% versus 4.6% p = 0.03).	malaria parasitaemia prevalence	39	70	p = 0.03	131	139	1
1532-429X-14-61.txt	Results The diagnostic performance (= area under ROC = AUC) of CMR was superior to SPECT (p = 0.0004, n = 425) and to gated-SPECT (p = 0.018, n = 253).	The diagnostic performance (= area under ROC = AUC)	8	59	p = 0.0004	90	100	1
1471-2318-12-22.txt	On the other hand, there were no significant differences between the two groups in skin barrier function.	skin barrier function	83	104	no significant	30	44	1
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	body weight	41	52	significantly	19	32	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.008	299	308	1
cc1476.txt	Both TEF10 and the ratio of the tidal expiratory flow at 25% of the remaining tidal volume to PTEF (25/PT) decreased significantly ( P < 0.05) after administration of albuterol.	the ratio of the tidal expiratory flow at 25% of the remaining tidal volume to PTEF (25/PT)	15	106	P < 0.05	133	141	1
1471-5945-4-18.txt	Complete healing of stage I ulcers in the HD group [11/13(85%)] was better than in the SD [5/11(45%); difference: 40%, 95% CI = 4.7–75.22, (P < 0.05)] or PC [2/9 (22%); difference: 63%, 95% CI = 29.69–96.3, (P < 0.005)] groups.	Complete healing of stage I ulcers	0	34	P < 0.05	140	148	1
1471-2377-11-96.txt	Results Significant intervention effects were observed in the intervention group for learning mean score (SE), [93.89 (4.00) vs 106.38 (4.32), P = 0.04] but for working memory the intervention group performed poorly [27.42 (0.66) vs 25.34 (0.73), P = 0.04].	working memory	161	175	P = 0.04	247	255	1
1471-2415-6-23.txt	The changes in normal (100%), low (4%), and very low (0.1%) illumination log CS were not statistically significant (p-values: 0.34, 0.23, and 0.32, respectively).	normal (100%)	15	28	p-values: 0.34	116	130	1
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	forced expiratory volume in 1 second (FEV 1	90	133	P = 0.042	168	177	1
1471-2474-11-64.txt	A significant difference in weeks missed due to non-contact knee injury was noted (1 v 24, χ2:6.70, p = 0.01).	weeks missed due to non-contact knee injury	28	71	significant	2	13	1
1471-2334-5-88.txt	Nausea (31.0% tigecycline, 24.8% IMI/CIS [ P = 0.052]), vomiting (25.7% tigecycline, 19.4% IMI/CIS [ P = 0.037]), and diarrhea (21.3% tigecycline, 18.9% IMI/CIS [ P = 0.435]) were the most frequently reported adverse events.	vomiting	56	64	P = 0.037	101	110	1
1471-2369-12-9.txt	The albumin-adjusted serum calcium concentration was significantly higher (9.5 ± 0.8 vs 8.8 ± 0.8; p < 0.001) and iPTH was significantly lower in the calcium acetate group compared to placebo (150 ± 157 vs 351 ± 292 pg/mL respectively; p < 0.001).	The albumin-adjusted serum calcium concentration	0	48	p < 0.001	99	108	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.000	244	253	1
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	TLC	321	324	significantly	16	29	1
1471-2474-11-26.txt	There were also significant differences in improvement in bodily pain and social function (subscales of SF-36 health status) favoring the Index Group.	social function	74	89	significant	16	27	1
1475-2840-10-78.txt	Results Cinnamon did not change gastric emptying parameters, postprandial triacylglycerol or glucose concentrations, oxidative stress, arterial function or appetite (p < 0.05).	arterial function	135	152	p < 0.05	166	174	1
1471-2377-10-91.txt	The only significant treatment-related side effects were minor diarrhea (n = 3) and seroconversion to a positive ANA (n = 2).	treatment-related side effects	21	51	significant	9	20	1
1471-2458-12-344.txt	There was also no significant difference in the QQ index (−0.5 [−4.4 to 3.3]) or SA days (0.0 [−1.2 to 0.9]).	the QQ index	44	56	no significant	15	29	1
1471-230X-12-37.txt	Results Intestinal CO 2 gas volume before and after ESD was lower in the duodenal balloon group than in the regular group ( P  = 0.00027).	Intestinal CO 2 gas volume before and after ESD	8	55	P  = 0.00027	124	136	1
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	steps/day	122	131	significant	97	108	1
1471-2458-12-944.txt	Prevalence of central obesity was reduced significantly (p <0.01) in the group receiving additional lifestyle support but not in the NHS Health Check only group.	Prevalence of central obesity	0	29	significantly	42	55	1
1479-5868-8-41.txt	Significant waist circumference reductions were achieved in all 4 groups at month 9 (Standard Care, 3.49 cm, P = 0.0004; GWL, 2.42 cm, P = 0.008; SWA-alone, 3.59 cm, P < 0.0001; GWL+SWA, 6.77 cm, P < 0.0001), but no intervention group had significantly reduced waist circumference compared to the Standard Care group.	waist circumference reductions	12	42	P < 0.0001	196	206	1
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	receptive language	157	175	significantly	53	66	1
ar4072.txt	At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% ( P <0.001), the back pain score decreased by 50% ( P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% ( P <0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% ( P <0.005).	the Bath Ankylosing Spondylitis Disease activity spinal inflammation score	11	85	P <0.001	105	113	1
1475-2875-6-138.txt	Results Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups.	sit unsupported	49	64	p = 0.81	66	74	1
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	social interaction	190	208	significantly	53	66	1
1472-6920-7-40.txt	Conclusion We conclude that significant improvement in knowledge persists six months after a standard introductory ultrasound course, and incorporating proctored ultrasound training into an emergency ultrasound curriculum may yield even higher knowledge retention.	knowledge	55	64	significant	28	39	1
1471-2377-7-20.txt	The intervention effect (difference in timing adherence pre- to post-intervention between the 2 groups) was 13.4% (CI 5.1 to 21.7), p = 0.002.	The intervention effect (difference in timing adherence pre- to post-intervention between the 2 groups)	0	103	p = 0.002	132	141	1
1745-6215-12-13.txt	Results Among 410 analyzable patients (40.5% women; mean age, 48.4 years), the differences in the primary endpoint (rostafuroxin minus placebo) ranged from -0.18 mm Hg ( P = 0.90) on 0.15 mg/d rostafuroxin to 2.72 mm Hg ( P = 0.04) on 0.05 mg/d.	the primary endpoint	94	114	P = 0.90	170	178	1
1471-230X-12-18.txt	The mean number of heartburn-free days by D7 was significantly greater in the omeprazole group: 3.7 ± 2.3 days vs 3.1 ± 2.1 ( p = 0.02).	The mean number of heartburn-free days by D7	0	44	p = 0.02	126	134	1
1471-2458-11-267.txt	Results Glycated hemoglobin A1c and systolic blood pressure (SBP) levels decreased significantly in the PRECEDE group (multivariate analysis of covariance, with baseline glycated hemoglobin A1c, SBP, and variables showing statistically significant differences between groups at baseline visits).	SBP	195	198	significant	236	247	1
1471-2318-6-18.txt	At six months there was a trend for the PRT intervention group to have lower GDS scores than the comparison group, but this finding did not reach significance (p = 0.08).	GDS scores	77	87	p = 0.08	160	168	1
1465-9921-11-112.txt	Furthermore, 6MWD significantly increased compared to baseline (Δ 6MWD: +79 ± 28 meters) as well as compared to controls (both: p < 0.01).	6MWD	13	17	significantly	18	31	1
1471-2415-6-23.txt	Lutein had a statistically significant effect on visual field (p-value: 0.038) and this effect increased in the model assuming a 6-week delay in effect of lutein.	visual field	49	61	p-value: 0.038	63	77	1
1471-2474-13-118.txt	Adherence was 91% and 83% in the NMES and RT groups respectively (p = 0.324).	Adherence	0	9	p = 0.324	66	75	1
1472-6882-11-93.txt	There was an expected decrease in frequency of stooling in both groups, reaching 2.1 (p = 0,001) in the acupuncture group and 3.1 (p < 0,001) in the control group.	frequency of stooling	34	55	p < 0,001	131	140	1
1471-2296-8-34.txt	After three months of treatment we found a statistically significant difference between the two treatment groups in GHbA 1c (mean difference = 0.59%-units, p = 0.018) and in SF-36 score (mean difference = 11.0 points, p = 0.039).	GHbA 1c	116	123	p = 0.018	156	165	1
1471-2369-13-49.txt	In group-1 the iFGF23 level was higher after treatment with alphacalcidol compared with sevelamer carbonate (mean 105.8 ± 41.6 vs 79.1 ± 36.5 pg/ml, p = 0.047 (CI: 0.4-52.9), and the iPTH level was lower (median: 26.5, range: 14.6-55.2 vs median 36.1, range 13.4-106.9 pg/ml, p = 0.011).	the iPTH level	179	193	p = 0.011	276	285	1
1472-6882-11-49.txt	Compared to usual care control, the intervention was associated with a 2.38-point decline in fatigue as measured by the BFI (90% Confidence Interval from 0.586 to 5.014; p <0.10).	fatigue as measured by the BFI	93	123	p <0.10	170	177	1
1472-6963-9-33.txt	There was a small fall in HbA1c in the yoga group which was not statistically significant and which was not sustained six months later, and no significant change in other outcome measures.	HbA1c	26	31	not statistically significant	60	89	1
cc11215.txt	Nonsignificant differences were found in absolute FEV1, FEV1/FVC, FVC, forced expiratory flow from 25% to 75% of FVC, functional residual capacity, and CO diffusion.	functional residual capacity	118	146	Nonsignificant	0	14	1
1477-7525-9-110.txt	Hyperglycaemic and hypoglycaemic distress decreased significantly after individual counselling than after group-based rehabilitation (difference -0.3 points, p = 0.04).	Hyperglycaemic and hypoglycaemic distress	0	41	significantly	52	65	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.007	283	292	1
1475-2891-11-47.txt	Plasma superoxide dismutase (SOD) activity after the 8-week KRG supplementation was significantly higher in the low-and high-dose groups compared to baseline.	Plasma superoxide dismutase (SOD) activity after the 8-week KRG supplementation	0	79	significantly	84	97	1
1471-244X-12-66.txt	Immediate and 4-month follow-up results revealed a significant time effect on all measured dimensions (social anxiety scales, general anxiety and depression levels, quality of life).	quality of life	165	180	significant	51	62	1
1471-2474-8-119.txt	Similar improvements were observed in FIQ score (p < 0.05) and EQ-VAS scale (p < 0.001).	FIQ score	38	47	p < 0.05	49	57	1
1471-2458-11-475.txt	Results Decisional conflict decreased for both arms to a level where an 'effective' MMR decision could be made one-week (effect estimate = -0.54, p < 0.001) and three-months (effect estimate = -0.60, p < 0.001) post-intervention.	Decisional conflict	8	27	p < 0.001	146	155	1
1471-2458-12-706.txt	However, treated children had significantly less pain experience (P = 0.006) (OR 0.09, [0.01-0.51]) and higher satisfaction with teeth (P = 0.001) (OR 9.91, [2.68-36.51]) compared to controls.	satisfaction with teeth	111	134	P = 0.001	136	145	1
1745-6215-13-59.txt	At randomization, the R and E groups were similar ( P  ≥ 0.11) with respect to mean age (50.7 years), body mass index (28.2 kg/m 2 ), blood pressure (153.9/91.5 mmHg) and the proportions of women (53.6%) and treatment naïve patients (72.7%).	body mass index	102	117	P  ≥ 0.11	52	61	1
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the distant metastasis rate	145	172	p = 0.2	184	191	1
1471-5945-5-13.txt	Improvements from baseline on the SF-36, PSA, PGPA, and itching VAS at Week 12 were also significantly greater in efalizumab-treated patients than for placebo.	the SF-36	30	39	significantly	89	102	1
1824-7288-38-36.txt	The respiratory rate, chest indrawing, cyanosis, stridor, nasal flaring, wheeze and fever in both groups recorded at enrollment and parameters did not differ significantly between the two groups.	fever	84	89	not differ significantly	147	171	1
1471-230X-11-100.txt	However, no significant differences were found in the mean number of polyps (MD -0.1; 95%CI -0.25 to 0.05), and the mean number of adenomas (MD 0.04 95%CI -0.09 to 0.17).	the mean number of adenomas	112	139	no significant	9	23	1
1471-230X-10-16.txt	The mean (SD) number of weeks with satisfactory relief of symptoms in the periods with L. plantarum MF1298 and placebo were 0.50 (0.89) and 1.44 (1.26), respectively ( P = 0.006).	The mean (SD) number of weeks with satisfactory relief of symptoms	0	66	P = 0.006	168	177	1
1479-5868-8-41.txt	There was significant weight loss in all 3 intervention groups (GWL, 1.86 kg, P = 0.05; SWA-alone, 3.55 kg, P = 0.0002; GWL+SWA, 6.59 kg, P < 0.0001) but not in the Standard Care group (0.89 kg, P = 0.39) at month 9.	weight loss	22	33	P = 0.0002	108	118	1
1471-2458-12-944.txt	Prevalence of high blood pressure, high cholesterol and smoking were reduced significantly (p <0.01) in both groups.	smoking	56	63	significantly	77	90	1
1471-230X-12-58.txt	Overall failure rate was 7% in the SC group vs 12% in the WC group (p = 0.71).	Overall failure rate	0	20	p = 0.71	68	76	1
1475-2840-10-78.txt	Results Cinnamon did not change gastric emptying parameters, postprandial triacylglycerol or glucose concentrations, oxidative stress, arterial function or appetite (p < 0.05).	glucose concentrations	93	115	p < 0.05	166	174	1
1479-5868-8-41.txt	Significant waist circumference reductions were achieved in all 4 groups at month 9 (Standard Care, 3.49 cm, P = 0.0004; GWL, 2.42 cm, P = 0.008; SWA-alone, 3.59 cm, P < 0.0001; GWL+SWA, 6.77 cm, P < 0.0001), but no intervention group had significantly reduced waist circumference compared to the Standard Care group.	waist circumference reductions	12	42	P = 0.008	135	144	1
1477-7827-4-38.txt	Conclusion Considering the significantly lower number of vials/patient and the slight (although non-significant) increase in the delivery rate with r-FSH, the cost-minimization analysis showed a 9.4% reduction in the overall therapy cost per born baby in favor of r-FSH.	number of vials/patient	47	70	significantly	27	40	1
1472-6920-6-38.txt	Changes in all outcomes were similar in the "Training + Feedback" group compared to the "Feedback Only" group (PRPCC: 3.7 vs1.8; trust: -0.7 vs -0.2 ; satisfaction: 1.9 vs 2.5; weight: -2.5 lbs vs -0.7 lbs; systolic blood pressure: 1.7 mm Hg vs 0.1 mm Hg; glycosylated hemoglobin 0.02% vs 0.07%; p = NS for all).	glycosylated hemoglobin	256	279	p = NS	296	302	1
1479-5868-8-59.txt	From baseline to 3-months, systolic BP [126.0 (SD = 19.1) to 120.3 (SD = 17.9) mmHg; p < 0.001] and diastolic BP [83.	systolic BP	27	38	p < 0.001	85	94	1
1471-2415-9-7.txt	Patient reported mean intra-operative pain scores by visual analog scale were 0.70 ± 0.31 in TV group and 1.8 ± 0.4 in LG group ( P < 0.001).	Patient reported mean intra-operative pain scores by visual analog scale	0	72	P < 0.001	130	139	1
1477-5751-8-3.txt	Subjective reports of TQ subscales and general quality of life areas (SF-36), objective audiometric examinations as well as investigated biomarkers for oxidative stress did not reveal any significant treatment effects.	Subjective reports of TQ subscales	0	34	not reveal any significant	173	199	1
cc7890.txt	Of patients who required ongoing propofol sedation, the proportion of time propofol was required was halved in those who received dexmedetomidine (79.5% (95% CI 61.8 to 97.2%) vs 41.2% (95% CI 0 to 88.1%) of the time intubated; P = 0.05).	the proportion of time propofol was required	52	96	P = 0.05	228	236	1
1471-2466-7-4.txt	Results No significant differences in lung function (active-placebo) were found (Forced Expiratory Volume in 1 second: mean difference [95% CI] = 0.01 [-0.12 to 0.14] L, p = 0.9.	lung function	38	51	No significant	8	22	1
1756-0500-5-273.txt	All revisions occurred within five years of surgery (three Non-resurfaced subjects; one Resurfaced subject) (p = 0.31).	All revisions	0	13	p = 0.31	109	117	1
1475-2875-9-378.txt	The parasite clearance time was also similar in the two treatment groups with 1 - 7 days for AS + SMP and 1 - 4 days for AS + AQ (p = 0.941).	The parasite clearance time	0	27	p = 0.941	130	139	1
1471-230X-9-22.txt	The proportion of patients who remained relapse-free at Week 26 did not differ significantly between the placebo group (5/16, 31%) and the IFN beta-1a 44 mcg biw (6/17, 35%; p = 0.497), 44 mcg tiw (7/16, 44%; p = 0.280) or 66 mcg tiw (2/18, 11%; p = 0.333) groups.	The proportion of patients who remained relapse-free at Week 26	0	63	p = 0.333	246	255	1
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.000	179	188	1
1471-2474-12-153.txt	Results Among 274 patients with evaluable efficacy data, the percentage of responders according to American College of Rheumatology 50 criteria (the primary endpoint, based on a 28-joint count) was significantly higher with canakinumab 150 mg SC q4wk than with placebo (26.5% vs 11.4%, respectively; p = 0.028).	the percentage of responders according to American College of Rheumatology 50 criteria (the primary endpoint, based on a 28-joint count)	57	193	significantly	198	211	1
1471-2431-9-21.txt	On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.	speech	135	141	p < 0.03	143	151	1
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	forced expiratory volume in 1 second (FEV 1	90	133	significantly	16	29	1
1471-2474-12-132.txt	One year response rate was significantly associated with demographic characteristics, health status, and individualized attention via additional testing.	associated with demographic characteristics, health status, and individualized attention via additional testing	41	152	significantly	27	40	1
1745-6215-10-103.txt	Conclusion Although our trial failed to find significant differences in VAS, QALYs and ICERs based on VAS and QALYs at one-year follow-up, CEACs suggest that postural exercise therapy according to Mensendieck/Cesar has a higher probability of being cost-effective compared to regular physiotherapy; however further research is required.	VAS	72	75	failed to find significant	30	56	1
1471-244X-12-5.txt	For example, treatment with and without support gave shorter sleep onset latency (improvement minutes [95% Confidence Interval], 35.4 [24.2 to 46.6], and 20.6 [10.6 to 30.6] respectively), and support gave a higher remission rate (defined as ISI score below 8; 61.4%), than bibliotherapy alone (24.4%, p's < .001).	remission rate	215	229	p's < .001	302	312	1
1472-6904-8-10.txt	Fenofibrate resulted in 17% rise in large LDLP (p = .06 vs pre) and 32% drop in small LDLP (p = .007 vs pre).	large LDLP	36	46	p = .06	48	55	1
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	all densitometric indices	172	197	p = 0.049	331	340	0
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	all densitometric indices	172	197	p = 0.204	215	224	0
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	all densitometric indices	172	197	p = 0.389	243	252	0
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	all densitometric indices	172	197	p = 0.452	271	280	0
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	all densitometric indices	172	197	significant	296	307	0
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	MLD	199	202	p = 0.049	331	340	0
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	MLD	199	202	p = 0.389	243	252	0
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	MLD	199	202	p = 0.452	271	280	0
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	MLD	199	202	significant	296	307	0
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	VI-910	227	233	p = 0.049	331	340	0
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	VI-910	227	233	p = 0.204	215	224	0
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	VI-910	227	233	p = 0.452	271	280	0
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	VI-910	227	233	significant	296	307	0
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	VI-950	255	261	p = 0.049	331	340	0
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	VI-950	255	261	p = 0.204	215	224	0
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	VI-950	255	261	p = 0.389	243	252	0
1465-9921-10-75.txt	Results Whole lung analysis of the total change (baseline to last CT scan) compared with placebo indicated a concordant trend that was suggestive of a treatment effect for all densitometric indices (MLD [1.402 g/L, p = 0.204]; VI-910 [-0.611, p = 0.389]; VI-950 [-0.432, p = 0.452]) and that was significant using PD15 (1.472 g/L, p = 0.049).	VI-950	255	261	significant	296	307	0
1465-9921-11-112.txt	Furthermore, 6MWD significantly increased compared to baseline (Δ 6MWD: +79 ± 28 meters) as well as compared to controls (both: p < 0.01).	6MWD	66	70	p < 0.01	128	136	0
1465-9921-11-112.txt	Furthermore, 6MWD significantly increased compared to baseline (Δ 6MWD: +79 ± 28 meters) as well as compared to controls (both: p < 0.01).	6MWD	66	70	significantly	18	31	0
1465-9921-11-66.txt	In addition all three active treatments significantly increased FEV 1 within 3 minutes of administration, at a time when inhaled AMP had induced the 30% fall in FEV 1 .	FEV 1	161	166	significantly	40	53	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	6-minute walking distance	627	652	not significantly	43	60	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	6-minute walking distance	627	652	p = 0.005	342	351	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	6-minute walking distance	627	652	p = 0.01	577	585	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	6-minute walking distance	627	652	p = 0.019	832	841	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	6-minute walking distance	627	652	p = 0.03	615	623	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	6-minute walking distance	627	652	p = 0.03	759	767	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	6-minute walking distance	627	652	p = 0.05	431	439	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	6-minute walking distance	627	652	p = 0.05	504	512	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	daytime arterial blood gases	516	544	not significantly	43	60	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	daytime arterial blood gases	516	544	p < 0.001	677	686	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	daytime arterial blood gases	516	544	p = 0.005	342	351	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	daytime arterial blood gases	516	544	p = 0.019	832	841	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	daytime arterial blood gases	516	544	p = 0.03	759	767	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	daytime arterial blood gases	516	544	p = 0.05	431	439	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	daytime arterial blood gases	516	544	p = 0.05	504	512	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	dyspnea	443	450	not significantly	43	60	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	dyspnea	443	450	p < 0.001	677	686	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	dyspnea	443	450	p = 0.005	342	351	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	dyspnea	443	450	p = 0.01	577	585	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	dyspnea	443	450	p = 0.019	832	841	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	dyspnea	443	450	p = 0.03	615	623	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	dyspnea	443	450	p = 0.03	759	767	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	dyspnea	443	450	p = 0.05	431	439	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	forced expiratory volume in 1 second	775	811	not significantly	43	60	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	forced expiratory volume in 1 second	775	811	p < 0.001	677	686	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	forced expiratory volume in 1 second	775	811	p = 0.005	342	351	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	forced expiratory volume in 1 second	775	811	p = 0.01	577	585	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	forced expiratory volume in 1 second	775	811	p = 0.03	615	623	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	forced expiratory volume in 1 second	775	811	p = 0.03	759	767	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	forced expiratory volume in 1 second	775	811	p = 0.05	431	439	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	forced expiratory volume in 1 second	775	811	p = 0.05	504	512	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	Groningen Activity and Restriction scale	690	730	not significantly	43	60	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	Groningen Activity and Restriction scale	690	730	p < 0.001	677	686	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	Groningen Activity and Restriction scale	690	730	p = 0.005	342	351	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	Groningen Activity and Restriction scale	690	730	p = 0.01	577	585	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	Groningen Activity and Restriction scale	690	730	p = 0.019	832	841	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	Groningen Activity and Restriction scale	690	730	p = 0.03	615	623	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	Groningen Activity and Restriction scale	690	730	p = 0.05	431	439	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	Groningen Activity and Restriction scale	690	730	p = 0.05	504	512	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	HRQoL assessed with the Maugeri Respiratory Failure questionnaire	252	317	not significantly	43	60	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	HRQoL assessed with the Maugeri Respiratory Failure questionnaire	252	317	p < 0.001	677	686	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	HRQoL assessed with the Maugeri Respiratory Failure questionnaire	252	317	p = 0.01	577	585	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	HRQoL assessed with the Maugeri Respiratory Failure questionnaire	252	317	p = 0.019	832	841	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	HRQoL assessed with the Maugeri Respiratory Failure questionnaire	252	317	p = 0.03	615	623	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	HRQoL assessed with the Maugeri Respiratory Failure questionnaire	252	317	p = 0.03	759	767	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	HRQoL assessed with the Maugeri Respiratory Failure questionnaire	252	317	p = 0.05	431	439	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	HRQoL assessed with the Maugeri Respiratory Failure questionnaire	252	317	p = 0.05	504	512	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	mood state	355	365	not significantly	43	60	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	mood state	355	365	p < 0.001	677	686	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	mood state	355	365	p = 0.005	342	351	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	mood state	355	365	p = 0.01	577	585	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	mood state	355	365	p = 0.019	832	841	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	mood state	355	365	p = 0.03	615	623	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	mood state	355	365	p = 0.03	759	767	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	mood state	355	365	p = 0.05	504	512	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	the Chronic Respiratory Questionnaire	69	106	p < 0.001	677	686	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	the Chronic Respiratory Questionnaire	69	106	p = 0.005	342	351	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	the Chronic Respiratory Questionnaire	69	106	p = 0.01	577	585	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	the Chronic Respiratory Questionnaire	69	106	p = 0.019	832	841	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	the Chronic Respiratory Questionnaire	69	106	p = 0.03	615	623	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	the Chronic Respiratory Questionnaire	69	106	p = 0.03	759	767	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	the Chronic Respiratory Questionnaire	69	106	p = 0.05	431	439	0
1465-9921-12-112.txt	Results Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO 2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO 2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)).	the Chronic Respiratory Questionnaire	69	106	p = 0.05	504	512	0
1465-9921-12-143.txt	Results Significant efficacy of pirfenidone in reducing the decline in VC could be seen in a subpopulation having %VC ≥ 70% and SpO 2 < 90% at baseline.	%VC	114	117	Significant	8	19	0
1465-9921-12-143.txt	Results Significant efficacy of pirfenidone in reducing the decline in VC could be seen in a subpopulation having %VC ≥ 70% and SpO 2 < 90% at baseline.	SpO 2	128	133	Significant	8	19	0
1465-9921-12-143.txt	Results Significant efficacy of pirfenidone in reducing the decline in VC could be seen in a subpopulation having %VC ≥ 70% and SpO 2 < 90% at baseline.	VC	71	73	Significant	8	19	0
1465-9921-12-93.txt	Further, the baseline characteristics of patients worsened at month 3 had generally severe impairment, and their clinical outcomes including mortality were also significantly worsened after 1 year.	generally severe impairment	74	101	significantly	161	174	0
1465-9921-6-55.txt	Results The bronchodilatory effect of deep inspiration correlated inversely with the % destroyed attachments (r = -0.51, p = 0.05) and directly with the airway smooth muscle area (r = 0.59, p = 0.03), but not with the total wall area (r = 0.39, p = 0.15).	the % destroyed attachments	81	108	p = 0.03	190	198	0
1465-9921-6-55.txt	Results The bronchodilatory effect of deep inspiration correlated inversely with the % destroyed attachments (r = -0.51, p = 0.05) and directly with the airway smooth muscle area (r = 0.59, p = 0.03), but not with the total wall area (r = 0.39, p = 0.15).	the % destroyed attachments	81	108	p = 0.05	121	129	0
1465-9921-6-55.txt	Results The bronchodilatory effect of deep inspiration correlated inversely with the % destroyed attachments (r = -0.51, p = 0.05) and directly with the airway smooth muscle area (r = 0.59, p = 0.03), but not with the total wall area (r = 0.39, p = 0.15).	the % destroyed attachments	81	108	p = 0.15	245	253	0
1465-9921-6-55.txt	Results The bronchodilatory effect of deep inspiration correlated inversely with the % destroyed attachments (r = -0.51, p = 0.05) and directly with the airway smooth muscle area (r = 0.59, p = 0.03), but not with the total wall area (r = 0.39, p = 0.15).	the airway smooth muscle area	149	178	p = 0.03	190	198	0
1465-9921-6-55.txt	Results The bronchodilatory effect of deep inspiration correlated inversely with the % destroyed attachments (r = -0.51, p = 0.05) and directly with the airway smooth muscle area (r = 0.59, p = 0.03), but not with the total wall area (r = 0.39, p = 0.15).	the airway smooth muscle area	149	178	p = 0.05	121	129	0
1465-9921-6-55.txt	Results The bronchodilatory effect of deep inspiration correlated inversely with the % destroyed attachments (r = -0.51, p = 0.05) and directly with the airway smooth muscle area (r = 0.59, p = 0.03), but not with the total wall area (r = 0.39, p = 0.15).	the airway smooth muscle area	149	178	p = 0.15	245	253	0
1465-9921-6-55.txt	Results The bronchodilatory effect of deep inspiration correlated inversely with the % destroyed attachments (r = -0.51, p = 0.05) and directly with the airway smooth muscle area (r = 0.59, p = 0.03), but not with the total wall area (r = 0.39, p = 0.15).	The bronchodilatory effect of deep inspiration	8	54	p = 0.03	190	198	0
1465-9921-6-55.txt	Results The bronchodilatory effect of deep inspiration correlated inversely with the % destroyed attachments (r = -0.51, p = 0.05) and directly with the airway smooth muscle area (r = 0.59, p = 0.03), but not with the total wall area (r = 0.39, p = 0.15).	The bronchodilatory effect of deep inspiration	8	54	p = 0.05	121	129	0
1465-9921-6-55.txt	Results The bronchodilatory effect of deep inspiration correlated inversely with the % destroyed attachments (r = -0.51, p = 0.05) and directly with the airway smooth muscle area (r = 0.59, p = 0.03), but not with the total wall area (r = 0.39, p = 0.15).	The bronchodilatory effect of deep inspiration	8	54	p = 0.15	245	253	0
1465-9921-6-55.txt	Results The bronchodilatory effect of deep inspiration correlated inversely with the % destroyed attachments (r = -0.51, p = 0.05) and directly with the airway smooth muscle area (r = 0.59, p = 0.03), but not with the total wall area (r = 0.39, p = 0.15).	the total wall area	214	233	p = 0.03	190	198	0
1465-9921-6-55.txt	Results The bronchodilatory effect of deep inspiration correlated inversely with the % destroyed attachments (r = -0.51, p = 0.05) and directly with the airway smooth muscle area (r = 0.59, p = 0.03), but not with the total wall area (r = 0.39, p = 0.15).	the total wall area	214	233	p = 0.05	121	129	0
1465-9921-6-55.txt	Results The bronchodilatory effect of deep inspiration correlated inversely with the % destroyed attachments (r = -0.51, p = 0.05) and directly with the airway smooth muscle area (r = 0.59, p = 0.03), but not with the total wall area (r = 0.39, p = 0.15).	the total wall area	214	233	p = 0.15	245	253	0
1465-9921-7-110.txt	Results In study A, a single inhalation of SFC and FBC produced a sustained bronchodilation at 16 hours with an adjusted mean increase in FEV 1 from pre-dose of 0.22 L (95% CI 0.19, 0.35 L) for SFC and 0.25 L (95% CI 0.21, 0.37 L) for FBC, which was significantly greater than placebo for both treatments (-0.05 L; p < 0.001).	a sustained bronchodilation	64	91	p < 0.001	315	324	0
1465-9921-7-110.txt	Results In study A, a single inhalation of SFC and FBC produced a sustained bronchodilation at 16 hours with an adjusted mean increase in FEV 1 from pre-dose of 0.22 L (95% CI 0.19, 0.35 L) for SFC and 0.25 L (95% CI 0.21, 0.37 L) for FBC, which was significantly greater than placebo for both treatments (-0.05 L; p < 0.001).	a sustained bronchodilation	64	91	significantly	250	263	0
1465-9921-7-141.txt	At 1 minute after inhalation, statistically significant decreases in Borg score were observed for budesonide/formoterol and salbutamol (p = 0.0233 and p < 0.0001, respectively, versus placebo), with similar rapid increases in FEV 1 (both active treatments p < 0.0001 versus placebo).	Borg score	69	79	p < 0.0001	256	266	0
1465-9921-8-67.txt	Results Both treatments had no significant effect on induced sputum inflammatory cells, although there was a trend for a reduction in sputum eosinophils.	sputum eosinophils	134	152	no significant	28	42	0
1465-9921-8-67.txt	Both treatments significantly improved airway responsiveness, whereas SFC generally led to greater improvements in symptom control and lung function than FP/M.	lung function	135	148	significantly	16	29	0
1465-9921-8-67.txt	Both treatments significantly improved airway responsiveness, whereas SFC generally led to greater improvements in symptom control and lung function than FP/M.	symptom control	115	130	significantly	16	29	0
1471-2261-3-2.txt	Acetaminophen had no significant effect on body temperature during the subsequent four days compared to placebo, and ibuprofen had no statistically significant effect on body temperature during the entire study period.	body temperature	43	59	no statistically significant	131	159	0
1471-2261-3-2.txt	Acetaminophen had no significant effect on body temperature during the subsequent four days compared to placebo, and ibuprofen had no statistically significant effect on body temperature during the entire study period.	body temperature	170	186	no significant	18	32	0
1471-227X-9-3.txt	Results Compared to preformed teams, ad-hoc forming teams had less hands-on time during the first 180 seconds of the arrest (93 ± 37 vs 124 ± 33 sec, P < 0.0001), delayed their first defibrillation (67 ± 42 vs 107 ± 46 sec, P < 0.0001), and made less leadership statements (15 ± 5 vs 21 ± 6, P < 0.0001).	delayed their first defibrillation	163	197	P < 0.0001	150	160	0
1471-227X-9-3.txt	Results Compared to preformed teams, ad-hoc forming teams had less hands-on time during the first 180 seconds of the arrest (93 ± 37 vs 124 ± 33 sec, P < 0.0001), delayed their first defibrillation (67 ± 42 vs 107 ± 46 sec, P < 0.0001), and made less leadership statements (15 ± 5 vs 21 ± 6, P < 0.0001).	delayed their first defibrillation	163	197	P < 0.0001	292	302	0
1471-227X-9-3.txt	Results Compared to preformed teams, ad-hoc forming teams had less hands-on time during the first 180 seconds of the arrest (93 ± 37 vs 124 ± 33 sec, P < 0.0001), delayed their first defibrillation (67 ± 42 vs 107 ± 46 sec, P < 0.0001), and made less leadership statements (15 ± 5 vs 21 ± 6, P < 0.0001).	hands-on time during the first 180 seconds of the arrest	67	123	P < 0.0001	224	234	0
1471-227X-9-3.txt	Results Compared to preformed teams, ad-hoc forming teams had less hands-on time during the first 180 seconds of the arrest (93 ± 37 vs 124 ± 33 sec, P < 0.0001), delayed their first defibrillation (67 ± 42 vs 107 ± 46 sec, P < 0.0001), and made less leadership statements (15 ± 5 vs 21 ± 6, P < 0.0001).	hands-on time during the first 180 seconds of the arrest	67	123	P < 0.0001	292	302	0
1471-227X-9-3.txt	Results Compared to preformed teams, ad-hoc forming teams had less hands-on time during the first 180 seconds of the arrest (93 ± 37 vs 124 ± 33 sec, P < 0.0001), delayed their first defibrillation (67 ± 42 vs 107 ± 46 sec, P < 0.0001), and made less leadership statements (15 ± 5 vs 21 ± 6, P < 0.0001).	leadership statements	251	272	P < 0.0001	150	160	0
1471-227X-9-3.txt	Results Compared to preformed teams, ad-hoc forming teams had less hands-on time during the first 180 seconds of the arrest (93 ± 37 vs 124 ± 33 sec, P < 0.0001), delayed their first defibrillation (67 ± 42 vs 107 ± 46 sec, P < 0.0001), and made less leadership statements (15 ± 5 vs 21 ± 6, P < 0.0001).	leadership statements	251	272	P < 0.0001	224	234	0
1471-2288-12-147.txt	At the dedicated clinics, response rates were 38% (257/668) not fasting and 38% fasting (257/668) (participation rate ratio (RR) = 1.00, 95%CI 0.91-1.08, p = 0.98).	participation rate ratio	99	123	p = 0.98	154	162	0
1471-2288-12-147.txt	In total, the response rate was 38% (514/1336) at the dedicated clinics and 25% (248/1004) at the pathology centres (RR = 0.67, 0.56-0.78, p < 0.01); measures of height, weight and systolic and diastolic blood pressure did not vary materially between these groups, nor did the median number of aliquots of plasma, buffy coat and red cells collected.	buffy coat	314	324	p < 0.01	139	147	0
1471-2288-12-147.txt	In total, the response rate was 38% (514/1336) at the dedicated clinics and 25% (248/1004) at the pathology centres (RR = 0.67, 0.56-0.78, p < 0.01); measures of height, weight and systolic and diastolic blood pressure did not vary materially between these groups, nor did the median number of aliquots of plasma, buffy coat and red cells collected.	measures of height	150	168	p < 0.01	139	147	0
1471-2288-12-147.txt	In total, the response rate was 38% (514/1336) at the dedicated clinics and 25% (248/1004) at the pathology centres (RR = 0.67, 0.56-0.78, p < 0.01); measures of height, weight and systolic and diastolic blood pressure did not vary materially between these groups, nor did the median number of aliquots of plasma, buffy coat and red cells collected.	red cells collected	329	348	p < 0.01	139	147	0
1471-2288-12-147.txt	In total, the response rate was 38% (514/1336) at the dedicated clinics and 25% (248/1004) at the pathology centres (RR = 0.67, 0.56-0.78, p < 0.01); measures of height, weight and systolic and diastolic blood pressure did not vary materially between these groups, nor did the median number of aliquots of plasma, buffy coat and red cells collected.	systolic and diastolic blood pressure	181	218	p < 0.01	139	147	0
1471-2288-12-147.txt	In total, the response rate was 38% (514/1336) at the dedicated clinics and 25% (248/1004) at the pathology centres (RR = 0.67, 0.56-0.78, p < 0.01); measures of height, weight and systolic and diastolic blood pressure did not vary materially between these groups, nor did the median number of aliquots of plasma, buffy coat and red cells collected.	the median number of aliquots of plasma	273	312	p < 0.01	139	147	0
1471-2288-12-147.txt	In total, the response rate was 38% (514/1336) at the dedicated clinics and 25% (248/1004) at the pathology centres (RR = 0.67, 0.56-0.78, p < 0.01); measures of height, weight and systolic and diastolic blood pressure did not vary materially between these groups, nor did the median number of aliquots of plasma, buffy coat and red cells collected.	weight	170	176	p < 0.01	139	147	0
1471-2288-7-30.txt	In the ANCOVA model with baseline score as a co-variate, follow-up group had a significant effect on outcome at six months on the ADAS-Cog score (n = 140; mean difference = -2.018; 95%CI -3.914, -0.121; p = 0.037 favouring the intensive follow-up group), and on participant-rated quality of life score (n = 142; mean difference = -1.382; 95%CI -2.642, -0.122; p = 0.032 favouring minimal follow-up group).	participant-rated quality of life score	262	301	p = 0.037	203	212	0
1471-2288-7-30.txt	In the ANCOVA model with baseline score as a co-variate, follow-up group had a significant effect on outcome at six months on the ADAS-Cog score (n = 140; mean difference = -2.018; 95%CI -3.914, -0.121; p = 0.037 favouring the intensive follow-up group), and on participant-rated quality of life score (n = 142; mean difference = -1.382; 95%CI -2.642, -0.122; p = 0.032 favouring minimal follow-up group).	the ADAS-Cog score	126	144	p = 0.032	360	369	0
1471-2296-12-2.txt	A significant change was observed for the B12 serum level, but not for the homocysteine level, hematocrit, or mean corpuscular volume.	hematocrit	95	105	significant	2	13	0
1471-2296-12-2.txt	A significant change was observed for the B12 serum level, but not for the homocysteine level, hematocrit, or mean corpuscular volume.	mean corpuscular volume	110	133	significant	2	13	0
1471-2296-12-2.txt	A significant change was observed for the B12 serum level, but not for the homocysteine level, hematocrit, or mean corpuscular volume.	the homocysteine level	71	93	significant	2	13	0
1471-2296-4-7.txt	A superior increase in sex-hormone-binding-globuline (SHBG) levels was evidenced in the paroxetine group (p = 0.01) as a sign of improved insulin sensitivity.	insulin sensitivity	138	157	p = 0.01	106	114	0
1471-2296-8-23.txt	Conclusion We demonstrated no significant benefit at the a priori 6-month assessment point, though improvement in the objective assessment of attacks was shown after 12 months.	the objective assessment of attacks	114	149	no significant	27	41	0
1471-2296-8-34.txt	After three months of treatment we found a statistically significant difference between the two treatment groups in GHbA 1c (mean difference = 0.59%-units, p = 0.018) and in SF-36 score (mean difference = 11.0 points, p = 0.039).	GHbA 1c	116	123	p = 0.039	218	227	0
1471-2296-8-34.txt	After three months of treatment we found a statistically significant difference between the two treatment groups in GHbA 1c (mean difference = 0.59%-units, p = 0.018) and in SF-36 score (mean difference = 11.0 points, p = 0.039).	SF-36 score	174	185	p = 0.018	156	165	0
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	able to assess the severity of asthma attack	125	169	p = 0.06	314	322	0
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	able to assess the severity of asthma attack	125	169	p = 0.06	410	418	0
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	able to assess the severity of asthma attack	125	169	p = 0.2	442	449	0
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	able to identify patients at high risk of severe attack	239	294	p = 0.01	221	229	0
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	able to identify patients at high risk of severe attack	239	294	p = 0.05	189	197	0
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	able to identify patients at high risk of severe attack	239	294	p = 0.06	410	418	0
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	able to identify patients at high risk of severe attack	239	294	p = 0.2	442	449	0
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	likely to provide a written asthma action plan	61	107	p = 0.01	221	229	0
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	likely to provide a written asthma action plan	61	107	p = 0.05	189	197	0
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	likely to provide a written asthma action plan	61	107	p = 0.06	314	322	0
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	likely to provide a written asthma action plan	61	107	p = 0.06	410	418	0
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	likely to provide a written asthma action plan	61	107	p = 0.2	442	449	0
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	score higher on the asthma knowledge questionnaire	339	389	p = 0.01	221	229	0
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	score higher on the asthma knowledge questionnaire	339	389	p = 0.05	189	197	0
1471-2296-9-22.txt	Results Post intervention, intervention arm GPs were no more likely to provide a written asthma action plan, but were better able to assess the severity of asthma attack (Group 1vs Group 2 p = 0.05 and Group 1 vs Group 3 p = 0.01), better able to identify patients at high risk of severe attack (Group 1vs Group 3 p = 0.06), and tended to score higher on the asthma knowledge questionnaire (Group 1 vs Group 2 p = 0.06 and Group 1 vs Group 3 p = 0.2).	score higher on the asthma knowledge questionnaire	339	389	p = 0.06	314	322	0
1471-230X-10-16.txt	With a clinically significant difference in the IBS sum score of 2 in disfavour of active treatment, the number needed to harm was 3.7, 95% CI 2.3 to 10.9.	the number needed to harm	101	126	significant	18	29	0
1471-230X-10-72.txt	In multivariate analysis, HIV infection (OR 4.1; 95%CI 2.2-7.8; P < 0.001) was associated with hypochlorhydria, but taking anti-retroviral treatment (OR 0.16; 0.04-0.67; P = 0.01) and allocation to micronutrient supplementation (OR 0.53; 0.28-0.99; P < 0.05) were protective.	allocation to micronutrient supplementation	184	227	P < 0.001	64	73	0
1471-230X-10-72.txt	In multivariate analysis, HIV infection (OR 4.1; 95%CI 2.2-7.8; P < 0.001) was associated with hypochlorhydria, but taking anti-retroviral treatment (OR 0.16; 0.04-0.67; P = 0.01) and allocation to micronutrient supplementation (OR 0.53; 0.28-0.99; P < 0.05) were protective.	allocation to micronutrient supplementation	184	227	P = 0.01	170	178	0
1471-230X-10-72.txt	In multivariate analysis, HIV infection (OR 4.1; 95%CI 2.2-7.8; P < 0.001) was associated with hypochlorhydria, but taking anti-retroviral treatment (OR 0.16; 0.04-0.67; P = 0.01) and allocation to micronutrient supplementation (OR 0.53; 0.28-0.99; P < 0.05) were protective.	HIV infection	26	39	P < 0.05	249	257	0
1471-230X-10-72.txt	In multivariate analysis, HIV infection (OR 4.1; 95%CI 2.2-7.8; P < 0.001) was associated with hypochlorhydria, but taking anti-retroviral treatment (OR 0.16; 0.04-0.67; P = 0.01) and allocation to micronutrient supplementation (OR 0.53; 0.28-0.99; P < 0.05) were protective.	HIV infection	26	39	P = 0.01	170	178	0
1471-230X-10-72.txt	In multivariate analysis, HIV infection (OR 4.1; 95%CI 2.2-7.8; P < 0.001) was associated with hypochlorhydria, but taking anti-retroviral treatment (OR 0.16; 0.04-0.67; P = 0.01) and allocation to micronutrient supplementation (OR 0.53; 0.28-0.99; P < 0.05) were protective.	hypochlorhydria	95	110	P < 0.001	64	73	0
1471-230X-10-72.txt	In multivariate analysis, HIV infection (OR 4.1; 95%CI 2.2-7.8; P < 0.001) was associated with hypochlorhydria, but taking anti-retroviral treatment (OR 0.16; 0.04-0.67; P = 0.01) and allocation to micronutrient supplementation (OR 0.53; 0.28-0.99; P < 0.05) were protective.	hypochlorhydria	95	110	P < 0.05	249	257	0
1471-230X-10-72.txt	In multivariate analysis, HIV infection (OR 4.1; 95%CI 2.2-7.8; P < 0.001) was associated with hypochlorhydria, but taking anti-retroviral treatment (OR 0.16; 0.04-0.67; P = 0.01) and allocation to micronutrient supplementation (OR 0.53; 0.28-0.99; P < 0.05) were protective.	hypochlorhydria	95	110	P = 0.01	170	178	0
1471-230X-10-72.txt	In multivariate analysis, HIV infection (OR 4.1; 95%CI 2.2-7.8; P < 0.001) was associated with hypochlorhydria, but taking anti-retroviral treatment (OR 0.16; 0.04-0.67; P = 0.01) and allocation to micronutrient supplementation (OR 0.53; 0.28-0.99; P < 0.05) were protective.	taking anti-retroviral treatment	116	148	P < 0.001	64	73	0
1471-230X-10-72.txt	In multivariate analysis, HIV infection (OR 4.1; 95%CI 2.2-7.8; P < 0.001) was associated with hypochlorhydria, but taking anti-retroviral treatment (OR 0.16; 0.04-0.67; P = 0.01) and allocation to micronutrient supplementation (OR 0.53; 0.28-0.99; P < 0.05) were protective.	taking anti-retroviral treatment	116	148	P < 0.05	249	257	0
1471-230X-12-58.txt	Overall discomfort score was less in WC than in SC patients (26 ± 4 mm vs 39 ± 4 mm VAS, respectively, p = 0.012) but there were no significant group differences in throat, chest, or overall discomfort during placement.	Overall discomfort score	0	24	no significant	129	143	0
1471-230X-12-58.txt	Overall discomfort score was less in WC than in SC patients (26 ± 4 mm vs 39 ± 4 mm VAS, respectively, p = 0.012) but there were no significant group differences in throat, chest, or overall discomfort during placement.	throat, chest, or overall discomfort during placement	165	218	p = 0.012	103	112	0
1471-230X-9-85.txt	Results Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061).	GSRS abdominal pain subscore	107	135	p = 0.048	174	183	0
1471-230X-9-85.txt	Results Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061).	GSRS abdominal pain subscore	107	135	p = 0.061	265	274	0
1471-230X-9-85.txt	Results Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061).	the GSRS abdominal distension subscore	225	263	p = 0.046	137	146	0
1471-230X-9-85.txt	Results Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061).	the GSRS abdominal distension subscore	225	263	p = 0.048	174	183	0
1471-230X-9-85.txt	Results Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061).	the GSRS abdominal distension subscore	225	263	significant	79	90	0
1471-230X-9-85.txt	Results Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061).	the GSRS total score	152	172	p = 0.046	137	146	0
1471-230X-9-85.txt	Results Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061).	the GSRS total score	152	172	p = 0.061	265	274	0
1471-2318-11-27.txt	Results Intervention attendance rates were higher in the CT and PACT groups: CT: 96%, PA: 76%, PACT: 90% (p=0.004), the interventions produced marked changes in cognitive and physical performance measures (p≤0.05), and retention rates exceeded 90%.	cognitive and physical performance measures	161	204	p=0.004	106	113	0
1471-2318-11-27.txt	Results Intervention attendance rates were higher in the CT and PACT groups: CT: 96%, PA: 76%, PACT: 90% (p=0.004), the interventions produced marked changes in cognitive and physical performance measures (p≤0.05), and retention rates exceeded 90%.	Intervention attendance rates	8	37	p≤0.05	206	212	0
1471-2318-11-27.txt	Results Intervention attendance rates were higher in the CT and PACT groups: CT: 96%, PA: 76%, PACT: 90% (p=0.004), the interventions produced marked changes in cognitive and physical performance measures (p≤0.05), and retention rates exceeded 90%.	retention rates	219	234	p=0.004	106	113	0
1471-2318-11-27.txt	Results Intervention attendance rates were higher in the CT and PACT groups: CT: 96%, PA: 76%, PACT: 90% (p=0.004), the interventions produced marked changes in cognitive and physical performance measures (p≤0.05), and retention rates exceeded 90%.	retention rates	219	234	p≤0.05	206	212	0
1471-2318-3-3.txt	For the resistance exercise group, participation was 71% (p = 0.004) and adherence was 63% (p = 0.020).	adherence	73	82	p = 0.004	58	67	0
1471-2318-3-3.txt	For the resistance exercise group, participation was 71% (p = 0.004) and adherence was 63% (p = 0.020).	participation	35	48	p = 0.020	92	101	0
1471-2318-6-18.txt	It was not possible to discern which specific components of the program influenced its impact, but in post hoc analyses, improvement in depressive status appeared to be associated with the number of exercise sessions completed (r = -0.8, p < 0.01).	depressive status	136	153	p < 0.01	238	246	0
1471-2318-6-18.txt	It was not possible to discern which specific components of the program influenced its impact, but in post hoc analyses, improvement in depressive status appeared to be associated with the number of exercise sessions completed (r = -0.8, p < 0.01).	the number of exercise sessions completed	185	226	p < 0.01	238	246	0
1471-2334-3-10.txt	In the APV600/RTV arm, significantly more patients achieved HIV-1 RNA <50 copies/mL (48% [57/118] vs 29% [11/38] with APV1200, P = 0.04), and greater mean reduction from baseline in HIV-1 RNA was observed (-2.21 vs -1.59 log 10 copies/mL, P = 0.028).	HIV-1 RNA	60	69	P = 0.028	239	248	0
1471-2334-3-10.txt	In the APV600/RTV arm, significantly more patients achieved HIV-1 RNA <50 copies/mL (48% [57/118] vs 29% [11/38] with APV1200, P = 0.04), and greater mean reduction from baseline in HIV-1 RNA was observed (-2.21 vs -1.59 log 10 copies/mL, P = 0.028).	HIV-1 RNA	182	191	P = 0.04	127	135	0
1471-2334-3-10.txt	In the APV600/RTV arm, significantly more patients achieved HIV-1 RNA <50 copies/mL (48% [57/118] vs 29% [11/38] with APV1200, P = 0.04), and greater mean reduction from baseline in HIV-1 RNA was observed (-2.21 vs -1.59 log 10 copies/mL, P = 0.028).	HIV-1 RNA	182	191	significantly	23	36	0
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	HDL-cholesterol	304	319	P < 0.001	144	153	0
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	HDL-cholesterol	304	319	P = 0.016	190	199	0
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	HDL-cholesterol	304	319	P = 0.019	240	249	0
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	HDL-cholesterol	304	319	significantly	40	53	0
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	LDL-cholesterol	156	171	P < 0.001	144	153	0
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	LDL-cholesterol	156	171	P = 0.019	240	249	0
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	LDL-cholesterol	156	171	P = 0.583	341	350	0
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	total cholesterol	107	124	P = 0.016	190	199	0
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	total cholesterol	107	124	P = 0.019	240	249	0
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	total cholesterol	107	124	P = 0.583	341	350	0
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	triglycerides	206	219	P < 0.001	144	153	0
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	triglycerides	206	219	P = 0.016	190	199	0
1471-2334-5-2.txt	At week 28, the abacavir-switch arm had significantly greater least square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583).	triglycerides	206	219	P = 0.583	341	350	0
1471-2334-5-88.txt	Nausea (31.0% tigecycline, 24.8% IMI/CIS [ P = 0.052]), vomiting (25.7% tigecycline, 19.4% IMI/CIS [ P = 0.037]), and diarrhea (21.3% tigecycline, 18.9% IMI/CIS [ P = 0.435]) were the most frequently reported adverse events.	diarrhea	118	126	P = 0.037	101	110	0
1471-2334-5-88.txt	Nausea (31.0% tigecycline, 24.8% IMI/CIS [ P = 0.052]), vomiting (25.7% tigecycline, 19.4% IMI/CIS [ P = 0.037]), and diarrhea (21.3% tigecycline, 18.9% IMI/CIS [ P = 0.435]) were the most frequently reported adverse events.	diarrhea	118	126	P = 0.052	43	52	0
1471-2334-5-88.txt	Nausea (31.0% tigecycline, 24.8% IMI/CIS [ P = 0.052]), vomiting (25.7% tigecycline, 19.4% IMI/CIS [ P = 0.037]), and diarrhea (21.3% tigecycline, 18.9% IMI/CIS [ P = 0.435]) were the most frequently reported adverse events.	frequently reported adverse events	189	223	P = 0.037	101	110	0
1471-2334-5-88.txt	Nausea (31.0% tigecycline, 24.8% IMI/CIS [ P = 0.052]), vomiting (25.7% tigecycline, 19.4% IMI/CIS [ P = 0.037]), and diarrhea (21.3% tigecycline, 18.9% IMI/CIS [ P = 0.435]) were the most frequently reported adverse events.	frequently reported adverse events	189	223	P = 0.052	43	52	0
1471-2334-5-88.txt	Nausea (31.0% tigecycline, 24.8% IMI/CIS [ P = 0.052]), vomiting (25.7% tigecycline, 19.4% IMI/CIS [ P = 0.037]), and diarrhea (21.3% tigecycline, 18.9% IMI/CIS [ P = 0.435]) were the most frequently reported adverse events.	frequently reported adverse events	189	223	P = 0.435	163	172	0
1471-2334-5-88.txt	Nausea (31.0% tigecycline, 24.8% IMI/CIS [ P = 0.052]), vomiting (25.7% tigecycline, 19.4% IMI/CIS [ P = 0.037]), and diarrhea (21.3% tigecycline, 18.9% IMI/CIS [ P = 0.435]) were the most frequently reported adverse events.	Nausea	0	6	P = 0.037	101	110	0
1471-2334-5-88.txt	Nausea (31.0% tigecycline, 24.8% IMI/CIS [ P = 0.052]), vomiting (25.7% tigecycline, 19.4% IMI/CIS [ P = 0.037]), and diarrhea (21.3% tigecycline, 18.9% IMI/CIS [ P = 0.435]) were the most frequently reported adverse events.	Nausea	0	6	P = 0.435	163	172	0
1471-2334-5-88.txt	Nausea (31.0% tigecycline, 24.8% IMI/CIS [ P = 0.052]), vomiting (25.7% tigecycline, 19.4% IMI/CIS [ P = 0.037]), and diarrhea (21.3% tigecycline, 18.9% IMI/CIS [ P = 0.435]) were the most frequently reported adverse events.	vomiting	56	64	P = 0.052	43	52	0
1471-2334-5-88.txt	Nausea (31.0% tigecycline, 24.8% IMI/CIS [ P = 0.052]), vomiting (25.7% tigecycline, 19.4% IMI/CIS [ P = 0.037]), and diarrhea (21.3% tigecycline, 18.9% IMI/CIS [ P = 0.435]) were the most frequently reported adverse events.	vomiting	56	64	P = 0.435	163	172	0
1471-2334-8-17.txt	A more rapid complete response was obtained in the IFN group (5 months before), with a significantly earlier improvement in respiratory symptoms and pulmonary lesions reduction.	rapid complete response	7	30	significantly	87	100	0
1471-2334-8-17.txt	Although differences in bacteriology were not significant during the treatment period, some patients in the placebo group converted again to positive during follow-up.	converted again to positive	122	149	not significant	42	57	0
1471-2369-10-7.txt	Results Patients receiving the citrate dialysate had significantly lower systolic blood pressure (BP) (-4.3 mmHg, p < 0.01) and peripheral resistances (PR) (-51 dyne.sec.cm -5 , p < 0.001) while stroke volume was not increased.	peripheral resistances (PR)	128	155	p < 0.01	114	122	0
1471-2369-10-7.txt	Results Patients receiving the citrate dialysate had significantly lower systolic blood pressure (BP) (-4.3 mmHg, p < 0.01) and peripheral resistances (PR) (-51 dyne.sec.cm -5 , p < 0.001) while stroke volume was not increased.	stroke volume	195	208	p < 0.001	178	187	0
1471-2369-10-7.txt	Results Patients receiving the citrate dialysate had significantly lower systolic blood pressure (BP) (-4.3 mmHg, p < 0.01) and peripheral resistances (PR) (-51 dyne.sec.cm -5 , p < 0.001) while stroke volume was not increased.	stroke volume	195	208	p < 0.01	114	122	0
1471-2369-10-7.txt	Results Patients receiving the citrate dialysate had significantly lower systolic blood pressure (BP) (-4.3 mmHg, p < 0.01) and peripheral resistances (PR) (-51 dyne.sec.cm -5 , p < 0.001) while stroke volume was not increased.	stroke volume	195	208	significantly	53	66	0
1471-2369-10-7.txt	Results Patients receiving the citrate dialysate had significantly lower systolic blood pressure (BP) (-4.3 mmHg, p < 0.01) and peripheral resistances (PR) (-51 dyne.sec.cm -5 , p < 0.001) while stroke volume was not increased.	systolic blood pressure (BP)	73	101	p < 0.001	178	187	0
1471-2369-10-7.txt	With the C+ dialysate the BP gap was less pronounced but the reduction in PR was even greater (-226 dyne.sec.cm -5 , p < 0.001).	the BP gap	22	32	p < 0.001	117	126	0
1471-2369-10-7.txt	Conclusion The positive impact on dialysis efficiency, acid-base status and haemodynamics, as well as the subjective tolerance, together indicate that citrate dialysate can significantly contribute to improving haemodialysis in selected patients.	acid-base status	55	71	significantly	173	186	0
1471-2369-10-7.txt	Conclusion The positive impact on dialysis efficiency, acid-base status and haemodynamics, as well as the subjective tolerance, together indicate that citrate dialysate can significantly contribute to improving haemodialysis in selected patients.	dialysis efficiency	34	53	significantly	173	186	0
1471-2369-10-7.txt	Conclusion The positive impact on dialysis efficiency, acid-base status and haemodynamics, as well as the subjective tolerance, together indicate that citrate dialysate can significantly contribute to improving haemodialysis in selected patients.	haemodialysis	211	224	significantly	173	186	0
1471-2369-10-7.txt	Conclusion The positive impact on dialysis efficiency, acid-base status and haemodynamics, as well as the subjective tolerance, together indicate that citrate dialysate can significantly contribute to improving haemodialysis in selected patients.	haemodynamics	76	89	significantly	173	186	0
1471-2369-10-7.txt	Conclusion The positive impact on dialysis efficiency, acid-base status and haemodynamics, as well as the subjective tolerance, together indicate that citrate dialysate can significantly contribute to improving haemodialysis in selected patients.	the subjective tolerance	102	126	significantly	173	186	0
1471-2369-12-9.txt	The albumin-adjusted serum calcium concentration was significantly higher (9.5 ± 0.8 vs 8.8 ± 0.8; p < 0.001) and iPTH was significantly lower in the calcium acetate group compared to placebo (150 ± 157 vs 351 ± 292 pg/mL respectively; p < 0.001).	iPTH	114	118	p < 0.001	99	108	0
1471-2369-12-9.txt	The albumin-adjusted serum calcium concentration was significantly higher (9.5 ± 0.8 vs 8.8 ± 0.8; p < 0.001) and iPTH was significantly lower in the calcium acetate group compared to placebo (150 ± 157 vs 351 ± 292 pg/mL respectively; p < 0.001).	iPTH	114	118	significantly	53	66	0
1471-2369-12-9.txt	The albumin-adjusted serum calcium concentration was significantly higher (9.5 ± 0.8 vs 8.8 ± 0.8; p < 0.001) and iPTH was significantly lower in the calcium acetate group compared to placebo (150 ± 157 vs 351 ± 292 pg/mL respectively; p < 0.001).	The albumin-adjusted serum calcium concentration	0	48	p < 0.001	236	245	0
1471-2369-12-9.txt	The albumin-adjusted serum calcium concentration was significantly higher (9.5 ± 0.8 vs 8.8 ± 0.8; p < 0.001) and iPTH was significantly lower in the calcium acetate group compared to placebo (150 ± 157 vs 351 ± 292 pg/mL respectively; p < 0.001).	The albumin-adjusted serum calcium concentration	0	48	significantly	123	136	0
1471-2369-13-15.txt	U-AQP2 CR increased significantly more after saline in patients than controls, whereas u-ENaC β-CR increased similarly.	u-ENaC β-CR	87	98	significantly	20	33	0
1471-2369-13-49.txt	In group-1 the iFGF23 level was higher after treatment with alphacalcidol compared with sevelamer carbonate (mean 105.8 ± 41.6 vs 79.1 ± 36.5 pg/ml, p = 0.047 (CI: 0.4-52.9), and the iPTH level was lower (median: 26.5, range: 14.6-55.2 vs median 36.1, range 13.4-106.9 pg/ml, p = 0.011).	the iFGF23 level	11	27	p = 0.011	276	285	0
1471-2369-13-49.txt	In group-1 the iFGF23 level was higher after treatment with alphacalcidol compared with sevelamer carbonate (mean 105.8 ± 41.6 vs 79.1 ± 36.5 pg/ml, p = 0.047 (CI: 0.4-52.9), and the iPTH level was lower (median: 26.5, range: 14.6-55.2 vs median 36.1, range 13.4-106.9 pg/ml, p = 0.011).	the iPTH level	179	193	p = 0.047	149	158	0
1471-2369-13-99.txt	However, patients that experienced a cystatin C increase of ≥10% showed significantly higher MBL levels than patients with a rise of <10% (median 2885 (IQR 1193–4471) vs 1997 (IQR 439–3504)ng/mL, p = 0.01).	cystatin C	37	47	p = 0.01	196	204	0
1471-2369-13-99.txt	However, patients that experienced a cystatin C increase of ≥10% showed significantly higher MBL levels than patients with a rise of <10% (median 2885 (IQR 1193–4471) vs 1997 (IQR 439–3504)ng/mL, p = 0.01).	cystatin C	37	47	significantly	72	85	0
1471-2369-13-99.txt	In logistic regression analysis MBL deficiency (MBL levels≤500 ng/ml) was identified as an inverse predictor of a cystatin C increase ≥10% (OR 0.34, 95% CI 0.15-0.8, p = 0.01).	cystatin C	114	124	p = 0.01	166	174	0
1471-2377-10-91.txt	Results The ABC-C Irritability Subscale scores showed significant improvement (p < 0.001), as did the VAS (p = 0.003) and the CGI (p < 0.001).	The ABC-C Irritability Subscale scores	8	46	p < 0.001	131	140	0
1471-2377-10-91.txt	Results The ABC-C Irritability Subscale scores showed significant improvement (p < 0.001), as did the VAS (p = 0.003) and the CGI (p < 0.001).	The ABC-C Irritability Subscale scores	8	46	p = 0.003	107	116	0
1471-2377-10-91.txt	Results The ABC-C Irritability Subscale scores showed significant improvement (p < 0.001), as did the VAS (p = 0.003) and the CGI (p < 0.001).	the CGI	122	129	p < 0.001	79	88	0
1471-2377-10-91.txt	Results The ABC-C Irritability Subscale scores showed significant improvement (p < 0.001), as did the VAS (p = 0.003) and the CGI (p < 0.001).	the CGI	122	129	p = 0.003	107	116	0
1471-2377-10-91.txt	Results The ABC-C Irritability Subscale scores showed significant improvement (p < 0.001), as did the VAS (p = 0.003) and the CGI (p < 0.001).	the CGI	122	129	significant	54	65	0
1471-2377-10-91.txt	Results The ABC-C Irritability Subscale scores showed significant improvement (p < 0.001), as did the VAS (p = 0.003) and the CGI (p < 0.001).	the VAS	98	105	p < 0.001	79	88	0
1471-2377-10-91.txt	Results The ABC-C Irritability Subscale scores showed significant improvement (p < 0.001), as did the VAS (p = 0.003) and the CGI (p < 0.001).	the VAS	98	105	p < 0.001	131	140	0
1471-2377-10-91.txt	Results The ABC-C Irritability Subscale scores showed significant improvement (p < 0.001), as did the VAS (p = 0.003) and the CGI (p < 0.001).	the VAS	98	105	significant	54	65	0
1471-2377-10-91.txt	Conclusions Results from this study demonstrate that minocycline provides significant functional benefits to FXS patients and that it is well-tolerated.	well-tolerated	137	151	significant	74	85	0
1471-2377-11-96.txt	Results Significant intervention effects were observed in the intervention group for learning mean score (SE), [93.89 (4.00) vs 106.38 (4.32), P = 0.04] but for working memory the intervention group performed poorly [27.42 (0.66) vs 25.34 (0.73), P = 0.04].	learning mean score	85	104	P = 0.04	247	255	0
1471-2377-11-96.txt	Results Significant intervention effects were observed in the intervention group for learning mean score (SE), [93.89 (4.00) vs 106.38 (4.32), P = 0.04] but for working memory the intervention group performed poorly [27.42 (0.66) vs 25.34 (0.73), P = 0.04].	working memory	161	175	P = 0.04	143	151	0
1471-2377-11-96.txt	Results Significant intervention effects were observed in the intervention group for learning mean score (SE), [93.89 (4.00) vs 106.38 (4.32), P = 0.04] but for working memory the intervention group performed poorly [27.42 (0.66) vs 25.34 (0.73), P = 0.04].	working memory	161	175	Significant	8	19	0
1471-2377-4-13.txt	Therapy effect in the second period was less; finally resulting in no significant effect combining results of both periods.	Therapy effect in the second period	0	35	no significant	67	81	0
1471-2377-8-33.txt	Conclusion Pregabalin 600 mg/d (300 mg BID) effectively reduced pain, was well tolerated, and had no statistically significant or clinically meaningful effect on NC in patients with painful DPN.	pain	64	68	no statistically significant	98	126	0
1471-2377-8-33.txt	Conclusion Pregabalin 600 mg/d (300 mg BID) effectively reduced pain, was well tolerated, and had no statistically significant or clinically meaningful effect on NC in patients with painful DPN.	well tolerated	74	88	no statistically significant	98	126	0
1471-2393-10-15.txt	Significantly, the decision aid group were more informed of labour analgesia options, and considered the opinion of their care providers more often when making their analgesia decisions, thus improving informed decision making.	considered the opinion of their care providers	90	136	Significantly	0	13	0
1471-2393-10-15.txt	Significantly, the decision aid group were more informed of labour analgesia options, and considered the opinion of their care providers more often when making their analgesia decisions, thus improving informed decision making.	informed decision making	202	226	Significantly	0	13	0
1471-2393-10-15.txt	Significantly, the decision aid group were more informed of labour analgesia options, and considered the opinion of their care providers more often when making their analgesia decisions, thus improving informed decision making.	informed of labour analgesia options	48	84	Significantly	0	13	0
1471-2393-8-19.txt	Results Intention-to-treat outcomes showed a statistical significant better estimated regression coefficient RDQ -1.6 [-2.9;-0.5] associated with treatment, as well as better IPA subscale autonomy in self-care -1.0 [-1.9;-0.03] and TSK -2.4 [-3.8;-1.1] but were not clinical relevant over time.	IPA subscale autonomy	175	196	significant	57	68	0
1471-2393-8-19.txt	Results Intention-to-treat outcomes showed a statistical significant better estimated regression coefficient RDQ -1.6 [-2.9;-0.5] associated with treatment, as well as better IPA subscale autonomy in self-care -1.0 [-1.9;-0.03] and TSK -2.4 [-3.8;-1.1] but were not clinical relevant over time.	self-care	200	209	significant	57	68	0
1471-2393-8-19.txt	Results Intention-to-treat outcomes showed a statistical significant better estimated regression coefficient RDQ -1.6 [-2.9;-0.5] associated with treatment, as well as better IPA subscale autonomy in self-care -1.0 [-1.9;-0.03] and TSK -2.4 [-3.8;-1.1] but were not clinical relevant over time.	TSK	232	235	significant	57	68	0
1471-2407-11-131.txt	Overall higher RTDI was correlated with a shorter TTDP (log-rank p = 0.0525 for 85% RTDI cut-off).	a shorter TTDP	40	54	p = 0.0525	65	75	0
1471-2407-11-131.txt	Overall higher RTDI was correlated with a shorter TTDP (log-rank p = 0.0525 for 85% RTDI cut-off).	Overall higher RTDI	0	19	p = 0.0525	65	75	0
1471-2407-11-75.txt	Global quality of life was better in the 3-weekly arm (p = 0.03); patients treated with weekly schedules presented a significantly worsening in role functioning and financial scores (p = 0.02 and p < 0.001).	financial scores	165	181	p = 0.02	183	191	0
1471-2407-11-75.txt	Global quality of life was better in the 3-weekly arm (p = 0.03); patients treated with weekly schedules presented a significantly worsening in role functioning and financial scores (p = 0.02 and p < 0.001).	financial scores	165	181	p = 0.03	55	63	0
1471-2407-11-75.txt	Global quality of life was better in the 3-weekly arm (p = 0.03); patients treated with weekly schedules presented a significantly worsening in role functioning and financial scores (p = 0.02 and p < 0.001).	Global quality of life	0	22	p < 0.001	196	205	0
1471-2407-11-75.txt	Global quality of life was better in the 3-weekly arm (p = 0.03); patients treated with weekly schedules presented a significantly worsening in role functioning and financial scores (p = 0.02 and p < 0.001).	Global quality of life	0	22	p = 0.02	183	191	0
1471-2407-11-75.txt	Global quality of life was better in the 3-weekly arm (p = 0.03); patients treated with weekly schedules presented a significantly worsening in role functioning and financial scores (p = 0.02 and p < 0.001).	Global quality of life	0	22	significantly	117	130	0
1471-2407-11-75.txt	Global quality of life was better in the 3-weekly arm (p = 0.03); patients treated with weekly schedules presented a significantly worsening in role functioning and financial scores (p = 0.02 and p < 0.001).	role functioning	144	160	p < 0.001	196	205	0
1471-2407-11-75.txt	Global quality of life was better in the 3-weekly arm (p = 0.03); patients treated with weekly schedules presented a significantly worsening in role functioning and financial scores (p = 0.02 and p < 0.001).	role functioning	144	160	p = 0.03	55	63	0
1471-2407-12-423.txt	Although the median PFS time for maintenance phase for both arms was 3.2 months, the one-sided p-value for the PFS HR comparison was less than the prespecified limit of 0.2 (HR = 0.76, two-sided 95% confidence interval [CI]: 0.42 to 1.37; one-sided p-value = 0.1815), indicating that PFS was sufficiently long in the pemetrexed/BSC arm to warrant further investigation.	PFS	284	287	p-value = 0.1815	249	265	0
1471-2407-12-423.txt	Although the median PFS time for maintenance phase for both arms was 3.2 months, the one-sided p-value for the PFS HR comparison was less than the prespecified limit of 0.2 (HR = 0.76, two-sided 95% confidence interval [CI]: 0.42 to 1.37; one-sided p-value = 0.1815), indicating that PFS was sufficiently long in the pemetrexed/BSC arm to warrant further investigation.	the median PFS time for maintenance phase	9	50	p-value = 0.1815	249	265	0
1471-2407-12-495.txt	At 3 months post-radiotherapy, TT patients had a clinically significant increase in role- and social-functioning scores and a clinically significant decrease in fatigue.	fatigue	161	168	significant	60	71	0
1471-2407-12-495.txt	At 3 months post-radiotherapy, TT patients had a clinically significant increase in role- and social-functioning scores and a clinically significant decrease in fatigue.	role- and social-functioning scores	84	119	significant	137	148	0
1471-2407-7-166.txt	After three and six months the treatment group showed a significant improvement in shoulder mobility and had significantly less pain than the control group.	pain	128	132	significant	56	67	0
1471-2407-7-166.txt	After three and six months the treatment group showed a significant improvement in shoulder mobility and had significantly less pain than the control group.	shoulder mobility	83	100	significantly	109	122	0
1471-2407-9-21.txt	The LP pillow tended to increase the success rate of LPs (67% vs 57%, p = 0.23), and decreased the post-LP syndromes (15% vs 24%, p = 0.17) but the differences were not statistically significant.	the post-LP syndromes	95	116	p = 0.23	70	78	0
1471-2407-9-21.txt	The LP pillow tended to increase the success rate of LPs (67% vs 57%, p = 0.23), and decreased the post-LP syndromes (15% vs 24%, p = 0.17) but the differences were not statistically significant.	the success rate of LPs	33	56	p = 0.17	130	138	0
1471-2407-9-21.txt	In children over 6-year of age (n = 72), the rate of success was significantly higher in the pillow group (58.5% vs 41.5%, p = 0.031), with a tendency to feel less pain (median VAS 25 vs 15 mm, p = 0.39) and being more satisfied (84.4% vs 75.0%, p = 0.34).	pain	164	168	p = 0.031	123	132	0
1471-2407-9-21.txt	In children over 6-year of age (n = 72), the rate of success was significantly higher in the pillow group (58.5% vs 41.5%, p = 0.031), with a tendency to feel less pain (median VAS 25 vs 15 mm, p = 0.39) and being more satisfied (84.4% vs 75.0%, p = 0.34).	pain	164	168	p = 0.34	246	254	0
1471-2407-9-21.txt	In children over 6-year of age (n = 72), the rate of success was significantly higher in the pillow group (58.5% vs 41.5%, p = 0.031), with a tendency to feel less pain (median VAS 25 vs 15 mm, p = 0.39) and being more satisfied (84.4% vs 75.0%, p = 0.34).	pain	164	168	p = 0.39	194	202	0
1471-2407-9-21.txt	In children over 6-year of age (n = 72), the rate of success was significantly higher in the pillow group (58.5% vs 41.5%, p = 0.031), with a tendency to feel less pain (median VAS 25 vs 15 mm, p = 0.39) and being more satisfied (84.4% vs 75.0%, p = 0.34).	pain	164	168	significantly	65	78	0
1471-2407-9-21.txt	In children over 6-year of age (n = 72), the rate of success was significantly higher in the pillow group (58.5% vs 41.5%, p = 0.031), with a tendency to feel less pain (median VAS 25 vs 15 mm, p = 0.39) and being more satisfied (84.4% vs 75.0%, p = 0.34).	satisfied	219	228	p = 0.031	123	132	0
1471-2407-9-21.txt	In children over 6-year of age (n = 72), the rate of success was significantly higher in the pillow group (58.5% vs 41.5%, p = 0.031), with a tendency to feel less pain (median VAS 25 vs 15 mm, p = 0.39) and being more satisfied (84.4% vs 75.0%, p = 0.34).	satisfied	219	228	p = 0.39	194	202	0
1471-2407-9-21.txt	In children over 6-year of age (n = 72), the rate of success was significantly higher in the pillow group (58.5% vs 41.5%, p = 0.031), with a tendency to feel less pain (median VAS 25 vs 15 mm, p = 0.39) and being more satisfied (84.4% vs 75.0%, p = 0.34).	satisfied	219	228	significantly	65	78	0
1471-2407-9-21.txt	In children over 6-year of age (n = 72), the rate of success was significantly higher in the pillow group (58.5% vs 41.5%, p = 0.031), with a tendency to feel less pain (median VAS 25 vs 15 mm, p = 0.39) and being more satisfied (84.4% vs 75.0%, p = 0.34).	the rate of success	41	60	p = 0.34	246	254	0
1471-2407-9-21.txt	In children over 6-year of age (n = 72), the rate of success was significantly higher in the pillow group (58.5% vs 41.5%, p = 0.031), with a tendency to feel less pain (median VAS 25 vs 15 mm, p = 0.39) and being more satisfied (84.4% vs 75.0%, p = 0.34).	the rate of success	41	60	p = 0.39	194	202	0
1471-2407-9-21.txt	In children over 6-year of age (n = 72), the rate of success was significantly higher in the pillow group (58.5% vs 41.5%, p = 0.031), with a tendency to feel less pain (median VAS 25 vs 15 mm, p = 0.39) and being more satisfied (84.4% vs 75.0%, p = 0.34).	VAS	177	180	p = 0.031	123	132	0
1471-2407-9-21.txt	In children over 6-year of age (n = 72), the rate of success was significantly higher in the pillow group (58.5% vs 41.5%, p = 0.031), with a tendency to feel less pain (median VAS 25 vs 15 mm, p = 0.39) and being more satisfied (84.4% vs 75.0%, p = 0.34).	VAS	177	180	p = 0.34	246	254	0
1471-2407-9-21.txt	In children over 6-year of age (n = 72), the rate of success was significantly higher in the pillow group (58.5% vs 41.5%, p = 0.031), with a tendency to feel less pain (median VAS 25 vs 15 mm, p = 0.39) and being more satisfied (84.4% vs 75.0%, p = 0.34).	VAS	177	180	significantly	65	78	0
1471-2415-12-9.txt	Conclusions IOP reductions were observed in all treatment groups postbaseline, with no clinically relevant or statistically significant differences detected favoring any of the higher concentrations of latanoprost compared with latanoprost 50 μg/mL.	IOP	12	15	significant	124	135	0
1471-2415-6-23.txt	Results For visual acuity (VA) at normal illumination level, treatment with lutein reduced logMAR, ie improved VA, but this effect was not statistically significant.	logMAR	91	97	not statistically significant	135	164	0
1471-2415-6-23.txt	Results For visual acuity (VA) at normal illumination level, treatment with lutein reduced logMAR, ie improved VA, but this effect was not statistically significant.	visual acuity (VA) at normal illumination level	12	59	not statistically significant	135	164	0
1471-2431-6-29.txt	Children who learned guided imagery with progressive muscle relaxation had significantly greater decrease in the number of days with pain than those learning breathing exercises alone after one (67% vs 21%, P = 0.05), and two (82% vs 45%, P < 0.01) months and significantly greater decrease in days with missed activities at one (85% vs 15%, P = 0.02) and two (95% vs 77%.	days with missed activities	294	321	P < 0.01	239	247	0
1471-2431-6-29.txt	Children who learned guided imagery with progressive muscle relaxation had significantly greater decrease in the number of days with pain than those learning breathing exercises alone after one (67% vs 21%, P = 0.05), and two (82% vs 45%, P < 0.01) months and significantly greater decrease in days with missed activities at one (85% vs 15%, P = 0.02) and two (95% vs 77%.	days with missed activities	294	321	P = 0.05	207	215	0
1471-2431-6-29.txt	Children who learned guided imagery with progressive muscle relaxation had significantly greater decrease in the number of days with pain than those learning breathing exercises alone after one (67% vs 21%, P = 0.05), and two (82% vs 45%, P < 0.01) months and significantly greater decrease in days with missed activities at one (85% vs 15%, P = 0.02) and two (95% vs 77%.	days with missed activities	294	321	significantly	75	88	0
1471-2431-6-29.txt	Children who learned guided imagery with progressive muscle relaxation had significantly greater decrease in the number of days with pain than those learning breathing exercises alone after one (67% vs 21%, P = 0.05), and two (82% vs 45%, P < 0.01) months and significantly greater decrease in days with missed activities at one (85% vs 15%, P = 0.02) and two (95% vs 77%.	the number of days with pain	109	137	P = 0.02	342	350	0
1471-2431-6-29.txt	Children who learned guided imagery with progressive muscle relaxation had significantly greater decrease in the number of days with pain than those learning breathing exercises alone after one (67% vs 21%, P = 0.05), and two (82% vs 45%, P < 0.01) months and significantly greater decrease in days with missed activities at one (85% vs 15%, P = 0.02) and two (95% vs 77%.	the number of days with pain	109	137	significantly	260	273	0
1471-2431-7-27.txt	Pacifier use reduced FLACC score (not statistically significant), crying times (statistically significant) but not heart rate.	crying times	66	78	not statistically significant	34	63	0
1471-2431-7-27.txt	Pacifier use reduced FLACC score (not statistically significant), crying times (statistically significant) but not heart rate.	FLACC score	21	32	significant	94	105	0
1471-2431-7-27.txt	Pacifier use reduced FLACC score (not statistically significant), crying times (statistically significant) but not heart rate.	heart rate	115	125	not statistically significant	34	63	0
1471-2431-7-27.txt	Pacifier use reduced FLACC score (not statistically significant), crying times (statistically significant) but not heart rate.	heart rate	115	125	significant	94	105	0
1471-2431-8-13.txt	Results PIPP scores at 90 seconds post lance were significantly lower in the KMC condition (8.871 (95% CI 7.852–9.889) versus 10.677 (95% CI 9.563–11.792) p < .001) and non-significant mean differences ranging from 1.2 to1.8.	PIPP scores	8	19	non-significant	169	184	0
1471-2431-8-13.txt	Facial actions were highly significantly lower across all points in time reaching a two-fold difference by 120 seconds post-lance and heart rate was significantly lower across the first 90 seconds in the KMC condition.	Facial actions	0	14	significantly	149	162	0
1471-2431-8-13.txt	Facial actions were highly significantly lower across all points in time reaching a two-fold difference by 120 seconds post-lance and heart rate was significantly lower across the first 90 seconds in the KMC condition.	heart rate	134	144	significantly	27	40	0
1471-2431-8-23.txt	Amoxicillin significantly reduced the proportion of children with i) perforation at the end of therapy (27% to 12% RD = -16% [-31,-1]), ii) recurrent perforation during therapy (18% to 4% RD = -14% [-25,-2]), and iii) reduced the proportion of examinations with a diagnosis of perforation during therapy (20% to 8% adjusted risk ratio 0.36 [0.15,0.83] p = 0.017).	the proportion of children with i) perforation at the end of therapy (27% to 12% RD = -16% [-31,-1]), ii) recurrent perforation during therapy (18% to 4% RD = -14% [-25,-2])	34	207	p = 0.017	352	361	0
1471-2431-8-23.txt	Amoxicillin significantly reduced the proportion of children with i) perforation at the end of therapy (27% to 12% RD = -16% [-31,-1]), ii) recurrent perforation during therapy (18% to 4% RD = -14% [-25,-2]), and iii) reduced the proportion of examinations with a diagnosis of perforation during therapy (20% to 8% adjusted risk ratio 0.36 [0.15,0.83] p = 0.017).	the proportion of examinations with a diagnosis of perforation during therapy	226	303	significantly	12	25	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	eye contact	227	238	p < 0.0001	177	187	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	eye contact	227	238	p = 0.0008	144	154	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	eye contact	227	238	p = 0.0024	479	489	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	eye contact	227	238	p = 0.0471	385	395	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	eye contact	227	238	p = 0.0473	210	220	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	mean physician CGI scores	27	52	p < 0.0001	177	187	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	mean physician CGI scores	27	52	p = 0.0008	144	154	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	mean physician CGI scores	27	52	p = 0.0024	479	489	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	mean physician CGI scores	27	52	p = 0.0102	240	250	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	mean physician CGI scores	27	52	p = 0.0471	385	395	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	mean physician CGI scores	27	52	p = 0.0473	210	220	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	overall functioning	123	142	p < 0.0001	177	187	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	overall functioning	123	142	p = 0.0024	479	489	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	overall functioning	123	142	p = 0.0102	240	250	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	overall functioning	123	142	p = 0.0471	385	395	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	overall functioning	123	142	p = 0.0473	210	220	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	receptive language	157	175	p = 0.0008	144	154	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	receptive language	157	175	p = 0.0024	479	489	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	receptive language	157	175	p = 0.0102	240	250	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	receptive language	157	175	p = 0.0471	385	395	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	receptive language	157	175	p = 0.0473	210	220	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	social interaction	190	208	p < 0.0001	177	187	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	social interaction	190	208	p = 0.0008	144	154	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	social interaction	190	208	p = 0.0024	479	489	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	social interaction	190	208	p = 0.0102	240	250	0
1471-2431-9-21.txt	Results After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).	social interaction	190	208	p = 0.0471	385	395	0
1471-2431-9-21.txt	Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).	eye contact	166	177	p = 0.0168	149	159	0
1471-2431-9-21.txt	Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).	eye contact	166	177	p = 0.0336	116	126	0
1471-2431-9-21.txt	Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).	Mean parental CGI scores	0	24	p = 0.0168	149	159	0
1471-2431-9-21.txt	Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).	Mean parental CGI scores	0	24	p = 0.0322	179	189	0
1471-2431-9-21.txt	Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).	Mean parental CGI scores	0	24	p = 0.0336	116	126	0
1471-2431-9-21.txt	Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).	overall functioning	95	114	p = 0.0168	149	159	0
1471-2431-9-21.txt	Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).	overall functioning	95	114	p = 0.0322	179	189	0
1471-2431-9-21.txt	Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).	receptive language	129	147	p = 0.0322	179	189	0
1471-2431-9-21.txt	Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).	receptive language	129	147	p = 0.0336	116	126	0
1471-2431-9-21.txt	On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.	the ABC	3	10	p < 0.03	143	151	0
1471-2431-9-21.txt	On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.	the ABC	3	10	significant	12	23	0
1471-2431-9-21.txt	In the treatment group compared to the control group, mean changes on the ABC total score and subscales were similar except a greater number of children improved in irritability (p = 0.0311).	the ABC total score and subscales	70	103	p = 0.0311	179	189	0
1471-2431-9-21.txt	On the ATEC, sensory/cognitive awareness significantly improved (p = 0.0367) in the treatment group compared to the control group.	the ATEC	3	11	p = 0.0367	65	75	0
1471-2431-9-21.txt	On the ATEC, sensory/cognitive awareness significantly improved (p = 0.0367) in the treatment group compared to the control group.	the ATEC	3	11	significantly	41	54	0
1471-244X-5-5.txt	Results There was significant improvement from baseline to endpoint on the Yale-Brown Obsessive-Compulsive Scale in both the quetiapine and placebo groups (quetiapine, n = 20, p < 0.0001; placebo, n = 21, p = 0.001) with 40% (n = 8) of quetiapine and 47.6% (n = 10) of placebo treated subjects being classified as responders.	being classified as responders	294	324	p < 0.0001	176	186	0
1471-244X-5-5.txt	Results There was significant improvement from baseline to endpoint on the Yale-Brown Obsessive-Compulsive Scale in both the quetiapine and placebo groups (quetiapine, n = 20, p < 0.0001; placebo, n = 21, p = 0.001) with 40% (n = 8) of quetiapine and 47.6% (n = 10) of placebo treated subjects being classified as responders.	being classified as responders	294	324	p = 0.001	205	214	0
1471-244X-5-5.txt	Results There was significant improvement from baseline to endpoint on the Yale-Brown Obsessive-Compulsive Scale in both the quetiapine and placebo groups (quetiapine, n = 20, p < 0.0001; placebo, n = 21, p = 0.001) with 40% (n = 8) of quetiapine and 47.6% (n = 10) of placebo treated subjects being classified as responders.	being classified as responders	294	324	significant	18	29	0
1471-244X-7-13.txt	Significant improvement of the online working alliance in the course of treatment and a substantial correlation between the quality of the online relationship at the end of treatment and treatment outcome emerged.	the quality of the online relationship at the end of treatment	120	182	Significant	0	11	0
1471-244X-9-54.txt	Compared with their counterparts who remained on their initial therapies, individuals who switched antipsychotics experienced a significantly higher risk of acute-care services, including hospitalization (p = .013) and crisis services (p = .011).	crisis services	219	234	p = .013	205	213	0
1471-244X-9-54.txt	Compared with their counterparts who remained on their initial therapies, individuals who switched antipsychotics experienced a significantly higher risk of acute-care services, including hospitalization (p = .013) and crisis services (p = .011).	crisis services	219	234	significantly	128	141	0
1471-244X-9-54.txt	Compared with their counterparts who remained on their initial therapies, individuals who switched antipsychotics experienced a significantly higher risk of acute-care services, including hospitalization (p = .013) and crisis services (p = .011).	hospitalization	188	203	p = .011	236	244	0
1471-244X-9-54.txt	Compared with their counterparts who remained on their initial therapies, individuals who switched antipsychotics experienced a significantly higher risk of acute-care services, including hospitalization (p = .013) and crisis services (p = .011).	hospitalization	188	203	significantly	128	141	0
1471-244X-9-54.txt	Compared with their counterparts who remained on their initial therapies, individuals who switched antipsychotics experienced a significantly higher risk of acute-care services, including hospitalization (p = .013) and crisis services (p = .011).	risk of acute-care services	149	176	p = .011	236	244	0
1471-244X-9-54.txt	Compared with their counterparts who remained on their initial therapies, individuals who switched antipsychotics experienced a significantly higher risk of acute-care services, including hospitalization (p = .013) and crisis services (p = .011).	risk of acute-care services	149	176	p = .013	205	213	0
1471-244X-9-54.txt	Patients undergoing medication switches also used acute-care services significantly sooner (p = .004) and accrued an additional $3,000 (a 25% increase) in annual total health care costs per patient, most of which was due to acute-care expenditures.	annual total health care costs per patient	155	197	p = .004	92	100	0
1471-244X-9-54.txt	Patients undergoing medication switches also used acute-care services significantly sooner (p = .004) and accrued an additional $3,000 (a 25% increase) in annual total health care costs per patient, most of which was due to acute-care expenditures.	annual total health care costs per patient	155	197	significantly	70	83	0
1471-2458-10-81.txt	Results The intervention was delivered with good fidelity, and intervention troops provided greater opportunities for healthful eating and PA (x 2 = 210.8, p < .001), relative to control troops.	fidelity	49	57	p < .001	156	164	0
1471-2458-10-81.txt	In troop meetings, intervention troop leaders promoted PA (x 2 = 23.46, p < .001) and healthful eating (x 2 = 18.14, p < .001) more frequently, and discouraged healthful eating and PA less frequently (x 2 = 9.63, p = .002) compared to control troop leaders.	discouraged healthful eating and PA	148	183	p < .001	72	80	0
1471-2458-10-81.txt	In troop meetings, intervention troop leaders promoted PA (x 2 = 23.46, p < .001) and healthful eating (x 2 = 18.14, p < .001) more frequently, and discouraged healthful eating and PA less frequently (x 2 = 9.63, p = .002) compared to control troop leaders.	discouraged healthful eating and PA	148	183	p < .001	117	125	0
1471-2458-10-81.txt	In troop meetings, intervention troop leaders promoted PA (x 2 = 23.46, p < .001) and healthful eating (x 2 = 18.14, p < .001) more frequently, and discouraged healthful eating and PA less frequently (x 2 = 9.63, p = .002) compared to control troop leaders.	healthful eating	86	102	p < .001	72	80	0
1471-2458-10-81.txt	In troop meetings, intervention troop leaders promoted PA (x 2 = 23.46, p < .001) and healthful eating (x 2 = 18.14, p < .001) more frequently, and discouraged healthful eating and PA less frequently (x 2 = 9.63, p = .002) compared to control troop leaders.	healthful eating	86	102	p = .002	213	221	0
1471-2458-10-81.txt	In troop meetings, intervention troop leaders promoted PA (x 2 = 23.46, p < .001) and healthful eating (x 2 = 18.14, p < .001) more frequently, and discouraged healthful eating and PA less frequently (x 2 = 9.63, p = .002) compared to control troop leaders.	promoted PA	46	57	p < .001	117	125	0
1471-2458-10-81.txt	In troop meetings, intervention troop leaders promoted PA (x 2 = 23.46, p < .001) and healthful eating (x 2 = 18.14, p < .001) more frequently, and discouraged healthful eating and PA less frequently (x 2 = 9.63, p = .002) compared to control troop leaders.	promoted PA	46	57	p = .002	213	221	0
1471-2458-10-81.txt	Most effects of the intervention on individual-level variables of girls and parents were not significantly different from the control condition, including the primary outcome of child BMI z-score (F 1, 5 = 0.42, p = .544), parent BMI (F 1, 5 = 1.58, p = .264), and related behavioral variables.	child BMI z-score	178	195	p = .264	250	258	0
1471-2458-10-81.txt	Most effects of the intervention on individual-level variables of girls and parents were not significantly different from the control condition, including the primary outcome of child BMI z-score (F 1, 5 = 0.42, p = .544), parent BMI (F 1, 5 = 1.58, p = .264), and related behavioral variables.	Most effects of the intervention on individual-level variables of girls and parents	0	83	p = .264	250	258	0
1471-2458-10-81.txt	Most effects of the intervention on individual-level variables of girls and parents were not significantly different from the control condition, including the primary outcome of child BMI z-score (F 1, 5 = 0.42, p = .544), parent BMI (F 1, 5 = 1.58, p = .264), and related behavioral variables.	Most effects of the intervention on individual-level variables of girls and parents	0	83	p = .544	212	220	0
1471-2458-10-81.txt	Most effects of the intervention on individual-level variables of girls and parents were not significantly different from the control condition, including the primary outcome of child BMI z-score (F 1, 5 = 0.42, p = .544), parent BMI (F 1, 5 = 1.58, p = .264), and related behavioral variables.	parent BMI	223	233	p = .544	212	220	0
1471-2458-10-81.txt	Most effects of the intervention on individual-level variables of girls and parents were not significantly different from the control condition, including the primary outcome of child BMI z-score (F 1, 5 = 0.42, p = .544), parent BMI (F 1, 5 = 1.58, p = .264), and related behavioral variables.	related behavioral variables	265	293	p = .264	250	258	0
1471-2458-10-81.txt	Most effects of the intervention on individual-level variables of girls and parents were not significantly different from the control condition, including the primary outcome of child BMI z-score (F 1, 5 = 0.42, p = .544), parent BMI (F 1, 5 = 1.58, p = .264), and related behavioral variables.	related behavioral variables	265	293	p = .544	212	220	0
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	moderate	181	189	p < .001	275	283	0
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	moderate	181	189	p = .011	151	159	0
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	moderate	181	189	significantly	110	123	0
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	moderate-to-vigorous physical activity	222	260	p = .004	202	210	0
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	moderate-to-vigorous physical activity	222	260	p = .011	151	159	0
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	moderate-to-vigorous physical activity	222	260	significantly	110	123	0
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	moderate-to-vigorous physical activity	222	260	significantly	162	175	0
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	objectively assessed troop PA	30	59	p < .001	275	283	0
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	objectively assessed troop PA	30	59	p = .004	202	210	0
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	objectively assessed troop PA	30	59	p = .011	151	159	0
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	objectively assessed troop PA	30	59	significantly	110	123	0
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	objectively assessed troop PA	30	59	significantly	162	175	0
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	sedentary	129	138	p < .001	275	283	0
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	sedentary	129	138	p = .004	202	210	0
1471-2458-10-81.txt	The notable exception was for objectively assessed troop PA, wherein girls in intervention troops accumulated significantly less sedentary (x 2 = 6.3, p = .011), significantly more moderate (x 2 = 8.2, p = .004), and more moderate-to-vigorous physical activity, (x 2 = 18.4, p < .001), than girls in control troops.	sedentary	129	138	significantly	162	175	0
1471-2458-11-267.txt	Results Glycated hemoglobin A1c and systolic blood pressure (SBP) levels decreased significantly in the PRECEDE group (multivariate analysis of covariance, with baseline glycated hemoglobin A1c, SBP, and variables showing statistically significant differences between groups at baseline visits).	baseline glycated hemoglobin A1c	161	193	significantly	83	96	0
1471-2458-11-267.txt	Results Glycated hemoglobin A1c and systolic blood pressure (SBP) levels decreased significantly in the PRECEDE group (multivariate analysis of covariance, with baseline glycated hemoglobin A1c, SBP, and variables showing statistically significant differences between groups at baseline visits).	Glycated hemoglobin A1c	8	31	significant	236	247	0
1471-2458-11-267.txt	Results Glycated hemoglobin A1c and systolic blood pressure (SBP) levels decreased significantly in the PRECEDE group (multivariate analysis of covariance, with baseline glycated hemoglobin A1c, SBP, and variables showing statistically significant differences between groups at baseline visits).	SBP	195	198	significantly	83	96	0
1471-2458-11-267.txt	Results Glycated hemoglobin A1c and systolic blood pressure (SBP) levels decreased significantly in the PRECEDE group (multivariate analysis of covariance, with baseline glycated hemoglobin A1c, SBP, and variables showing statistically significant differences between groups at baseline visits).	systolic blood pressure (SBP) levels	36	72	significant	236	247	0
1471-2458-11-267.txt	Results Glycated hemoglobin A1c and systolic blood pressure (SBP) levels decreased significantly in the PRECEDE group (multivariate analysis of covariance, with baseline glycated hemoglobin A1c, SBP, and variables showing statistically significant differences between groups at baseline visits).	variables	204	213	significantly	83	96	0
1471-2458-11-573.txt	Conclusion This study shows that high coverage of the IPTi can be obtained when the strategy is implemented using routine health services and implementation results in a significant increase in coverage of EPI vaccines in the district of Kolokani, Mali.	coverage of the IPTi	38	58	significant	170	181	0
1471-2458-11-711.txt	Results We found a lower percentage of obesity (greater than or equal to the 95 th percentile for BMI) at the end of the study among the group participating in public commitment activities compared to the control group (21.5% vs 26.6%, p = 0.02).	BMI	98	101	p = 0.02	236	244	0
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	main effect of time	22	41	p < 0.001	235	244	0
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	main effect of time	22	41	p < 0.001	327	336	0
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	main effect of time	22	41	p < 0.001	423	432	0
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	main effect of time	22	41	significant	97	108	0
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	step-counts	69	80	p < 0.001	44	53	0
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	step-counts	69	80	p < 0.001	235	244	0
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	step-counts	69	80	p < 0.001	327	336	0
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	step-counts	69	80	p < 0.001	423	432	0
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	step-counts	69	80	significant	10	21	0
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	step-counts	69	80	significant	97	108	0
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	steps/day	122	131	p < 0.001	44	53	0
1471-2458-12-206.txt	Results A significant main effect of time ( p < 0.001) was found for step-counts attributable to significant increases in steps/day between: pre-intervention ( M = 6941, SD = 3047) and 12 weeks ( M = 9327, SD = 4136), t (78) = - 6.52, p < 0.001, d = 0.66; pre-intervention and 24 weeks ( M = 8804, SD = 4145), t (78) = - 4.82, p < 0.001, d = 0.52; and pre-intervention and 48 weeks ( M = 8450, SD = 3855), t (78) = - 4.15, p < 0.001, d = 0.44.	steps/day	122	131	significant	10	21	0
1471-2458-12-706.txt	However, treated children had significantly less pain experience (P = 0.006) (OR 0.09, [0.01-0.51]) and higher satisfaction with teeth (P = 0.001) (OR 9.91, [2.68-36.51]) compared to controls.	pain experience	49	64	P = 0.001	136	145	0
1471-2458-12-706.txt	However, treated children had significantly less pain experience (P = 0.006) (OR 0.09, [0.01-0.51]) and higher satisfaction with teeth (P = 0.001) (OR 9.91, [2.68-36.51]) compared to controls.	satisfaction with teeth	111	134	P = 0.006	66	75	0
1471-2458-12-706.txt	However, treated children had significantly less pain experience (P = 0.006) (OR 0.09, [0.01-0.51]) and higher satisfaction with teeth (P = 0.001) (OR 9.91, [2.68-36.51]) compared to controls.	satisfaction with teeth	111	134	significantly	30	43	0
1471-2458-9-200.txt	Both types of physical training and usual care improved in pain and functional status over time, but there was only a statistically significant difference in favor of PT on pain improvement at 6 months.	functional status	68	85	significant	132	143	0
1471-2458-9-200.txt	Both types of physical training and usual care improved in pain and functional status over time, but there was only a statistically significant difference in favor of PT on pain improvement at 6 months.	pain	59	63	significant	132	143	0
1471-2466-10-11.txt	Standardised AUC measurements for FEV 1 (between 5 min and 4 h, 5 min and 1 h, and 1 and 4 h post-dose) at Week 12 were all significantly greater with indacaterol than placebo (p < 0.001), with LSM (± SEM) differences of 170 ± 24, 180 ± 24, and 170 ± 24 mL, respectively.	LSM (± SEM)	194	205	p < 0.001	177	186	0
1471-2466-10-11.txt	Standardised AUC measurements for FEV 1 (between 5 min and 4 h, 5 min and 1 h, and 1 and 4 h post-dose) at Week 12 were all significantly greater with indacaterol than placebo (p < 0.001), with LSM (± SEM) differences of 170 ± 24, 180 ± 24, and 170 ± 24 mL, respectively.	LSM (± SEM)	194	205	significantly	124	137	0
1471-2466-10-11.txt	Indacaterol significantly reduced the percentage of days of poor control versus placebo by 22.5% (p < 0.001) and was also associated with significantly reduced use of rescue medication (p < 0.001).	the percentage of days of poor control	34	72	p < 0.001	186	195	0
1471-2466-10-11.txt	Indacaterol significantly reduced the percentage of days of poor control versus placebo by 22.5% (p < 0.001) and was also associated with significantly reduced use of rescue medication (p < 0.001).	the percentage of days of poor control	34	72	significantly	138	151	0
1471-2466-10-11.txt	Indacaterol significantly reduced the percentage of days of poor control versus placebo by 22.5% (p < 0.001) and was also associated with significantly reduced use of rescue medication (p < 0.001).	use of rescue medication	160	184	p < 0.001	98	107	0
1471-2466-10-11.txt	Indacaterol significantly reduced the percentage of days of poor control versus placebo by 22.5% (p < 0.001) and was also associated with significantly reduced use of rescue medication (p < 0.001).	use of rescue medication	160	184	significantly	12	25	0
1471-2466-10-11.txt	Serum potassium and blood glucose levels did not differ significantly between the two groups, and no patient had QTc >500 ms.	QTc	113	116	not differ significantly	45	69	0
1471-2466-10-11.txt	provided clinically significant and sustained bronchodilation, reduced rescue medication use, and had a safety and tolerability profile similar to placebo.	a safety and tolerability profile	102	135	significant	20	31	0
1471-2466-10-11.txt	provided clinically significant and sustained bronchodilation, reduced rescue medication use, and had a safety and tolerability profile similar to placebo.	rescue medication use	71	92	significant	20	31	0
1471-2466-11-16.txt	Results At 4 weeks, there was no improvement in the atorvastatin group compared to the placebo group in morning peak expiratory flow [-10.67 L/min, 95% CI -38.70 to 17.37, p = 0.449], but there was an improvement with atorvastatin in asthma quality of life score [0.52, 95% CI 0.17 to 0.87 p = 0.005].	asthma quality of life score	234	262	p = 0.449	172	181	0
1471-2466-11-16.txt	Results At 4 weeks, there was no improvement in the atorvastatin group compared to the placebo group in morning peak expiratory flow [-10.67 L/min, 95% CI -38.70 to 17.37, p = 0.449], but there was an improvement with atorvastatin in asthma quality of life score [0.52, 95% CI 0.17 to 0.87 p = 0.005].	morning peak expiratory flow	104	132	p = 0.005	290	299	0
1471-2466-11-61.txt	However, non-study COPD medication costs were higher for the LABA or LAMA therapy group ($911 SE = 91) compared to the LABA and LAMA therapy group ($668 SE = 58; p = 0.0238) and non-study respiratory medications were approximately $100 greater for the LABA or LAMA therapy group relative to both LABA and LAMA (p = .0018) and LABA, LAMA, and ICS (p = .0071) therapy groups.	non-study COPD medication costs	9	40	p = .0018	311	320	0
1471-2466-11-61.txt	However, non-study COPD medication costs were higher for the LABA or LAMA therapy group ($911 SE = 91) compared to the LABA and LAMA therapy group ($668 SE = 58; p = 0.0238) and non-study respiratory medications were approximately $100 greater for the LABA or LAMA therapy group relative to both LABA and LAMA (p = .0018) and LABA, LAMA, and ICS (p = .0071) therapy groups.	non-study COPD medication costs	9	40	p = .0071	347	356	0
1471-2466-11-61.txt	However, non-study COPD medication costs were higher for the LABA or LAMA therapy group ($911 SE = 91) compared to the LABA and LAMA therapy group ($668 SE = 58; p = 0.0238) and non-study respiratory medications were approximately $100 greater for the LABA or LAMA therapy group relative to both LABA and LAMA (p = .0018) and LABA, LAMA, and ICS (p = .0071) therapy groups.	non-study respiratory medications	178	211	p = 0.0238	162	172	0
1471-2466-11-61.txt	While there was no observed difference in outpatient costs, there was a slightly higher number of outpatient visits per patient in the LABA and LAMA (25.5 SE = 0.9, p = 0.0070) relative to the LABA or LAMA therapy group (22.3 SE = 0.8) and higher utilization (89.7% of patients) with COPD visits in the LABA and LAMA therapy group relative to both the LABA or LAMA (73.8%; p < .0001) and LABA, LAMA and ICS therapy groups (85.3; p = 0.0305).	number of outpatient visits per patient	88	127	p < .0001	373	382	0
1471-2466-11-61.txt	While there was no observed difference in outpatient costs, there was a slightly higher number of outpatient visits per patient in the LABA and LAMA (25.5 SE = 0.9, p = 0.0070) relative to the LABA or LAMA therapy group (22.3 SE = 0.8) and higher utilization (89.7% of patients) with COPD visits in the LABA and LAMA therapy group relative to both the LABA or LAMA (73.8%; p < .0001) and LABA, LAMA and ICS therapy groups (85.3; p = 0.0305).	number of outpatient visits per patient	88	127	p = 0.0305	429	439	0
1471-2466-11-61.txt	While there was no observed difference in outpatient costs, there was a slightly higher number of outpatient visits per patient in the LABA and LAMA (25.5 SE = 0.9, p = 0.0070) relative to the LABA or LAMA therapy group (22.3 SE = 0.8) and higher utilization (89.7% of patients) with COPD visits in the LABA and LAMA therapy group relative to both the LABA or LAMA (73.8%; p < .0001) and LABA, LAMA and ICS therapy groups (85.3; p = 0.0305).	outpatient costs	42	58	p < .0001	373	382	0
1471-2466-11-61.txt	While there was no observed difference in outpatient costs, there was a slightly higher number of outpatient visits per patient in the LABA and LAMA (25.5 SE = 0.9, p = 0.0070) relative to the LABA or LAMA therapy group (22.3 SE = 0.8) and higher utilization (89.7% of patients) with COPD visits in the LABA and LAMA therapy group relative to both the LABA or LAMA (73.8%; p < .0001) and LABA, LAMA and ICS therapy groups (85.3; p = 0.0305).	outpatient costs	42	58	p = 0.0070	165	175	0
1471-2466-11-61.txt	While there was no observed difference in outpatient costs, there was a slightly higher number of outpatient visits per patient in the LABA and LAMA (25.5 SE = 0.9, p = 0.0070) relative to the LABA or LAMA therapy group (22.3 SE = 0.8) and higher utilization (89.7% of patients) with COPD visits in the LABA and LAMA therapy group relative to both the LABA or LAMA (73.8%; p < .0001) and LABA, LAMA and ICS therapy groups (85.3; p = 0.0305).	outpatient costs	42	58	p = 0.0305	429	439	0
1471-2466-11-61.txt	While there was no observed difference in outpatient costs, there was a slightly higher number of outpatient visits per patient in the LABA and LAMA (25.5 SE = 0.9, p = 0.0070) relative to the LABA or LAMA therapy group (22.3 SE = 0.8) and higher utilization (89.7% of patients) with COPD visits in the LABA and LAMA therapy group relative to both the LABA or LAMA (73.8%; p < .0001) and LABA, LAMA and ICS therapy groups (85.3; p = 0.0305).	utilization (89.7% of patients) with COPD visits	247	295	p = 0.0070	165	175	0
1471-2466-12-14.txt	The number of patients who achieved asthma control at the follow-up visit and required no treatment adjustment was 33 (73.3%) in the SINA group and 27 (60%) in the GINA group ( p = 0.0125).	asthma control	36	50	p = 0.0125	177	187	0
1471-2466-12-14.txt	The number of patients who achieved asthma control at the follow-up visit and required no treatment adjustment was 33 (73.3%) in the SINA group and 27 (60%) in the GINA group ( p = 0.0125).	treatment adjustment	90	110	p = 0.0125	177	187	0
1471-2466-7-4.txt	Results No significant differences in lung function (active-placebo) were found (Forced Expiratory Volume in 1 second: mean difference [95% CI] = 0.01 [-0.12 to 0.14] L, p = 0.9.	Forced Expiratory Volume in 1 second	81	117	No significant	8	22	0
1471-2466-7-4.txt	Results No significant differences in lung function (active-placebo) were found (Forced Expiratory Volume in 1 second: mean difference [95% CI] = 0.01 [-0.12 to 0.14] L, p = 0.9.	lung function	38	51	p = 0.9	170	177	0
1471-2466-7-4.txt	Trends to clinical improvements favouring active treatment were however consistently seen in the patient-centered outcomes: Asthma Control Questionnaire mean difference (active – placebo) [95% CI] = -0.35 [-0.78 to 0.07], p = 0.10, Asthma Quality of Life Questionnaire mean difference 0.42 [-0.08 to 0.93], p = 0.09, Leicester Cough Questionnaire mean difference 0.49, [-0.18 to 1.16], p = 0.15.	Asthma Control Questionnaire mean difference	124	168	p = 0.09	307	315	0
1471-2466-7-4.txt	Trends to clinical improvements favouring active treatment were however consistently seen in the patient-centered outcomes: Asthma Control Questionnaire mean difference (active – placebo) [95% CI] = -0.35 [-0.78 to 0.07], p = 0.10, Asthma Quality of Life Questionnaire mean difference 0.42 [-0.08 to 0.93], p = 0.09, Leicester Cough Questionnaire mean difference 0.49, [-0.18 to 1.16], p = 0.15.	Asthma Control Questionnaire mean difference	124	168	p = 0.15	386	394	0
1471-2466-7-4.txt	Trends to clinical improvements favouring active treatment were however consistently seen in the patient-centered outcomes: Asthma Control Questionnaire mean difference (active – placebo) [95% CI] = -0.35 [-0.78 to 0.07], p = 0.10, Asthma Quality of Life Questionnaire mean difference 0.42 [-0.08 to 0.93], p = 0.09, Leicester Cough Questionnaire mean difference 0.49, [-0.18 to 1.16], p = 0.15.	Asthma Quality of Life Questionnaire mean difference	232	284	p = 0.10	222	230	0
1471-2466-7-4.txt	Trends to clinical improvements favouring active treatment were however consistently seen in the patient-centered outcomes: Asthma Control Questionnaire mean difference (active – placebo) [95% CI] = -0.35 [-0.78 to 0.07], p = 0.10, Asthma Quality of Life Questionnaire mean difference 0.42 [-0.08 to 0.93], p = 0.09, Leicester Cough Questionnaire mean difference 0.49, [-0.18 to 1.16], p = 0.15.	Asthma Quality of Life Questionnaire mean difference	232	284	p = 0.15	386	394	0
1471-2466-7-4.txt	Trends to clinical improvements favouring active treatment were however consistently seen in the patient-centered outcomes: Asthma Control Questionnaire mean difference (active – placebo) [95% CI] = -0.35 [-0.78 to 0.07], p = 0.10, Asthma Quality of Life Questionnaire mean difference 0.42 [-0.08 to 0.93], p = 0.09, Leicester Cough Questionnaire mean difference 0.49, [-0.18 to 1.16], p = 0.15.	Leicester Cough Questionnaire mean difference	317	362	p = 0.09	307	315	0
1471-2466-7-4.txt	Trends to clinical improvements favouring active treatment were however consistently seen in the patient-centered outcomes: Asthma Control Questionnaire mean difference (active – placebo) [95% CI] = -0.35 [-0.78 to 0.07], p = 0.10, Asthma Quality of Life Questionnaire mean difference 0.42 [-0.08 to 0.93], p = 0.09, Leicester Cough Questionnaire mean difference 0.49, [-0.18 to 1.16], p = 0.15.	Leicester Cough Questionnaire mean difference	317	362	p = 0.10	222	230	0
1471-2474-10-118.txt	When analysing the results in a mixed model analysis on repeated measures including interaction between age-group and treatment effect the training group demonstrated significantly improved results compared to the control group in subjects younger than 40 years of age regarding OMAS (p = 0.028), muscle strength in the plantar flexors (p = 0.029) and dorsiflexors (p = 0.030).	dorsiflexors	352	364	p = 0.028	285	294	0
1471-2474-10-118.txt	When analysing the results in a mixed model analysis on repeated measures including interaction between age-group and treatment effect the training group demonstrated significantly improved results compared to the control group in subjects younger than 40 years of age regarding OMAS (p = 0.028), muscle strength in the plantar flexors (p = 0.029) and dorsiflexors (p = 0.030).	muscle strength in the plantar flexors	297	335	p = 0.028	285	294	0
1471-2474-10-118.txt	When analysing the results in a mixed model analysis on repeated measures including interaction between age-group and treatment effect the training group demonstrated significantly improved results compared to the control group in subjects younger than 40 years of age regarding OMAS (p = 0.028), muscle strength in the plantar flexors (p = 0.029) and dorsiflexors (p = 0.030).	muscle strength in the plantar flexors	297	335	p = 0.030	366	375	0
1471-2474-10-118.txt	When analysing the results in a mixed model analysis on repeated measures including interaction between age-group and treatment effect the training group demonstrated significantly improved results compared to the control group in subjects younger than 40 years of age regarding OMAS (p = 0.028), muscle strength in the plantar flexors (p = 0.029) and dorsiflexors (p = 0.030).	OMAS	279	283	p = 0.029	337	346	0
1471-2474-10-118.txt	When analysing the results in a mixed model analysis on repeated measures including interaction between age-group and treatment effect the training group demonstrated significantly improved results compared to the control group in subjects younger than 40 years of age regarding OMAS (p = 0.028), muscle strength in the plantar flexors (p = 0.029) and dorsiflexors (p = 0.030).	OMAS	279	283	p = 0.030	366	375	0
1471-2474-11-155.txt	During treatment, low back pain decreased from 6.2 (SD 2.2) to 1.6 (2.3, p < 0.001) and disc height increased from 7.5 (1.7) mm to 8.8 (1.7) mm (p < 0.001).	disc height	88	99	p < 0.001	73	82	0
1471-2474-11-155.txt	During treatment, low back pain decreased from 6.2 (SD 2.2) to 1.6 (2.3, p < 0.001) and disc height increased from 7.5 (1.7) mm to 8.8 (1.7) mm (p < 0.001).	low back pain	18	31	p < 0.001	145	154	0
1471-2474-11-155.txt	Increase in disc height and reduction in pain were significantly correlated (r = 0.36, p = 0.044).	disc height	12	23	p = 0.044	87	96	0
1471-2474-11-155.txt	Increase in disc height and reduction in pain were significantly correlated (r = 0.36, p = 0.044).	disc height	12	23	significantly	51	64	0
1471-2474-11-155.txt	Increase in disc height and reduction in pain were significantly correlated (r = 0.36, p = 0.044).	pain	41	45	p = 0.044	87	96	0
1471-2474-11-155.txt	Increase in disc height and reduction in pain were significantly correlated (r = 0.36, p = 0.044).	pain	41	45	significantly	51	64	0
1471-2474-11-218.txt	Low education and poor self-reported health status predicted a work status of "not working": Odds Ratio, OR = 4.3(95% CI (1.3 to 14.9)), p = 0.02 for education, and OR = 1.06 (95% CI (1.0 to 1.1)), p = 0.001 for self-reported health status, respectively.	a work status of "not working"	61	91	p = 0.001	198	207	0
1471-2474-11-218.txt	Low education and poor self-reported health status predicted a work status of "not working": Odds Ratio, OR = 4.3(95% CI (1.3 to 14.9)), p = 0.02 for education, and OR = 1.06 (95% CI (1.0 to 1.1)), p = 0.001 for self-reported health status, respectively.	a work status of "not working"	61	91	p = 0.02	137	145	0
1471-2474-11-244.txt	Results We found differences between the intervention group and the control group, comparing the results at baseline and after 6 months in EuroQol-5D (p < 0.001) and in standing one leg eyes closed (p = 0.02) in favour of the intervention group.	EuroQol-5D	139	149	p = 0.02	199	207	0
1471-2474-11-244.txt	Results We found differences between the intervention group and the control group, comparing the results at baseline and after 6 months in EuroQol-5D (p < 0.001) and in standing one leg eyes closed (p = 0.02) in favour of the intervention group.	standing one leg eyes closed	169	197	p < 0.001	151	160	0
1471-2474-11-64.txt	Results After 24 matches there was no statistical significant difference between the groups for the incidence of hamstring injury (OR:0.116, 95% CI:0.013-1.019, p = 0.051) and primary non-contact knee injury (OR:0.116, 95% CI:0.013-1.019, p = 0.051).	primary non-contact knee injury	176	207	p = 0.051	161	170	0
1471-2474-11-64.txt	Results After 24 matches there was no statistical significant difference between the groups for the incidence of hamstring injury (OR:0.116, 95% CI:0.013-1.019, p = 0.051) and primary non-contact knee injury (OR:0.116, 95% CI:0.013-1.019, p = 0.051).	the incidence of hamstring injury	96	129	p = 0.051	239	248	0
1471-2474-11-64.txt	There was no significant difference for weeks missed due to hamstring injury (4 v14, χ2:1.12, p = 0.29) and lower-limb muscle strains (4 v 21, χ2:2.66, p = 0.10).	lower-limb muscle strains	108	133	p = 0.29	94	102	0
1471-2474-11-64.txt	There was no significant difference for weeks missed due to hamstring injury (4 v14, χ2:1.12, p = 0.29) and lower-limb muscle strains (4 v 21, χ2:2.66, p = 0.10).	weeks missed due to hamstring injury	40	76	p = 0.10	152	160	0
1471-2474-11-64.txt	Conclusions This study demonstrated a trend towards lower limb injury prevention with a significant reduction in primary lower limb muscle strains and weeks missed due to non-contact knee injuries through the addition of a sports chiropractic intervention to the current best practice management.	limb injury prevention	58	80	significant	88	99	0
1471-2474-11-99.txt	At 12-month follow-up, the intervention group showed a significant positive change (OR = 0.48) in receiving information on healthy computer use, as well as a significant positive change regarding risk indicators for work posture and movement, compared to the usual care group.	receiving information on healthy computer use	98	143	significant	158	169	0
1471-2474-11-99.txt	At 12-month follow-up, the intervention group showed a significant positive change (OR = 0.48) in receiving information on healthy computer use, as well as a significant positive change regarding risk indicators for work posture and movement, compared to the usual care group.	risk indicators for work posture and movement	196	241	significant	55	66	0
1471-2474-12-132.txt	One year response rate was significantly associated with demographic characteristics, health status, and individualized attention via additional testing.	demographic characteristics	57	84	significantly	27	40	0
1471-2474-12-132.txt	One year response rate was significantly associated with demographic characteristics, health status, and individualized attention via additional testing.	health status	86	99	significantly	27	40	0
1471-2474-12-132.txt	One year response rate was significantly associated with demographic characteristics, health status, and individualized attention via additional testing.	individualized attention via additional testing	105	152	significantly	27	40	0
1471-2474-12-132.txt	One year response rate was significantly associated with demographic characteristics, health status, and individualized attention via additional testing.	One year response rate	0	22	significantly	27	40	0
1471-2474-12-136.txt	0.66, 95%CI - 2.79 to 4.11, p = 0.703), total extension deficit of operated digits (degrees: adjusted mean diff 5.11, 95%CI -2.33 to 12.55, p = 0.172) or patient satisfaction (0-10 numerical rating scale: adjusted mean diff -0.35, 95%CI -1.04 to 0.34, p = 0.315) at 1 year post surgery.	patient satisfaction	154	174	p = 0.172	140	149	0
1471-2474-12-136.txt	0.66, 95%CI - 2.79 to 4.11, p = 0.703), total extension deficit of operated digits (degrees: adjusted mean diff 5.11, 95%CI -2.33 to 12.55, p = 0.172) or patient satisfaction (0-10 numerical rating scale: adjusted mean diff -0.35, 95%CI -1.04 to 0.34, p = 0.315) at 1 year post surgery.	patient satisfaction	154	174	p = 0.703	28	37	0
1471-2474-12-136.txt	0.66, 95%CI - 2.79 to 4.11, p = 0.703), total extension deficit of operated digits (degrees: adjusted mean diff 5.11, 95%CI -2.33 to 12.55, p = 0.172) or patient satisfaction (0-10 numerical rating scale: adjusted mean diff -0.35, 95%CI -1.04 to 0.34, p = 0.315) at 1 year post surgery.	total extension deficit of operated digits	40	82	p = 0.315	252	261	0
1471-2474-12-136.txt	0.66, 95%CI - 2.79 to 4.11, p = 0.703), total extension deficit of operated digits (degrees: adjusted mean diff 5.11, 95%CI -2.33 to 12.55, p = 0.172) or patient satisfaction (0-10 numerical rating scale: adjusted mean diff -0.35, 95%CI -1.04 to 0.34, p = 0.315) at 1 year post surgery.	total extension deficit of operated digits	40	82	p = 0.703	28	37	0
1471-2474-13-141.txt	Evaluation of the intensity of pain with a visual analogue scale (VAS) showed a statistically significant difference (p = 0,035) at day 16.	Evaluation of the intensity of pain with a visual analogue scale (VAS)	0	70	p = 0	118	123	0
1471-2474-13-15.txt	Conclusions In African American subjects with significant comorbidities, febuxostat 80 mg is significantly more efficacious than either febuxostat 40 mg or allopurinol 200/300 mg. Febuxostat was well tolerated in this African American population.	efficacious	112	123	significant	46	57	0
1471-2474-13-229.txt	Results Only minor adverse events were detected in some patients, such as mild pain and effusion after the injections, in particular in the PRP group, where a significantly higher post-injective pain reaction was observed (p=0.039).	effusion	88	96	p=0.039	223	230	0
1471-2474-13-229.txt	Results Only minor adverse events were detected in some patients, such as mild pain and effusion after the injections, in particular in the PRP group, where a significantly higher post-injective pain reaction was observed (p=0.039).	effusion	88	96	significantly	159	172	0
1471-2474-13-229.txt	Results Only minor adverse events were detected in some patients, such as mild pain and effusion after the injections, in particular in the PRP group, where a significantly higher post-injective pain reaction was observed (p=0.039).	minor adverse events	13	33	p=0.039	223	230	0
1471-2474-13-229.txt	Results Only minor adverse events were detected in some patients, such as mild pain and effusion after the injections, in particular in the PRP group, where a significantly higher post-injective pain reaction was observed (p=0.039).	minor adverse events	13	33	significantly	159	172	0
1471-2474-13-229.txt	Results Only minor adverse events were detected in some patients, such as mild pain and effusion after the injections, in particular in the PRP group, where a significantly higher post-injective pain reaction was observed (p=0.039).	pain	79	83	p=0.039	223	230	0
1471-2474-13-229.txt	Results Only minor adverse events were detected in some patients, such as mild pain and effusion after the injections, in particular in the PRP group, where a significantly higher post-injective pain reaction was observed (p=0.039).	pain	79	83	significantly	159	172	0
1471-2474-13-229.txt	At the follow-up evaluations, both groups presented a clinical improvement but the comparison between the two groups showed a not statistically significant difference in all scores evaluated.	a clinical improvement	52	74	not statistically significant	126	155	0
1471-2474-3-7.txt	At 6 and 12 weeks, bone marker concentrations were not different from baseline, and no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.	bone marker concentrations	19	45	no significant	84	98	0
1471-2474-8-119.txt	Similar improvements were observed in FIQ score (p < 0.05) and EQ-VAS scale (p < 0.001).	EQ-VAS scale	63	75	p < 0.05	49	57	0
1471-2474-8-119.txt	Similar improvements were observed in FIQ score (p < 0.05) and EQ-VAS scale (p < 0.001).	FIQ score	38	47	p < 0.001	77	86	0
1471-2474-8-23.txt	Sensitivity analyses confirmed an advantage for hydrotherapy if we assumed non-completers would all not have responded (response rates 70% versus 38%; p < 0.001) or if we assumed that non-completers would have had the same response as completers (response rates 82% versus 55% p = 0.002).	response rates	120	134	p = 0.002	277	286	0
1471-2474-8-23.txt	Sensitivity analyses confirmed an advantage for hydrotherapy if we assumed non-completers would all not have responded (response rates 70% versus 38%; p < 0.001) or if we assumed that non-completers would have had the same response as completers (response rates 82% versus 55% p = 0.002).	response rates	247	261	p < 0.001	151	160	0
1471-2474-9-118.txt	Results Lumiracoxib and rofecoxib displayed similar GI safety profiles with no statistically significant difference in predefined GI AEs between the two groups (43.5% vs 37.4%, respectively).	GI safety profiles	52	70	no statistically significant	76	104	0
1471-2474-9-143.txt	Results At the end of the study period, the temperature asymmetry was not significantly reduced in the tadalafil group compared with the placebo group, but there was a significant and clinically relevant reduction of pain in the tadalafil group.	pain	217	221	not significantly	70	87	0
1471-2474-9-143.txt	Results At the end of the study period, the temperature asymmetry was not significantly reduced in the tadalafil group compared with the placebo group, but there was a significant and clinically relevant reduction of pain in the tadalafil group.	the temperature asymmetry	40	65	significant	168	179	0
1471-2474-9-143.txt	Muscle force improved in both treatment groups and the AM revealed small, non-significant improvements in time spent standing, walking, and the number of short walking periods.	Muscle force	0	12	non-significant	74	89	0
1472-6831-11-35.txt	Statistically significant differences detected in the amount (millimetres) of calculus were too small to be clinically significant.	the amount (millimetres) of calculus	50	86	significant	119	130	0
1472-6831-12-13.txt	The change in mean tooth shade scores was statistically significantly greater in the gum-group than in the tablet group at 2 (p = 0.015), 6 (p = 0.011) and 12 weeks (p = 0.003) with greater lightening in the gum-group at each examination period.	lightening	190	200	p = 0.003	166	175	0
1472-6831-12-13.txt	The change in mean tooth shade scores was statistically significantly greater in the gum-group than in the tablet group at 2 (p = 0.015), 6 (p = 0.011) and 12 weeks (p = 0.003) with greater lightening in the gum-group at each examination period.	lightening	190	200	p = 0.011	141	150	0
1472-6831-12-13.txt	The change in mean tooth shade scores was statistically significantly greater in the gum-group than in the tablet group at 2 (p = 0.015), 6 (p = 0.011) and 12 weeks (p = 0.003) with greater lightening in the gum-group at each examination period.	lightening	190	200	p = 0.015	126	135	0
1472-6831-12-13.txt	The change in mean tooth shade scores was statistically significantly greater in the gum-group than in the tablet group at 2 (p = 0.015), 6 (p = 0.011) and 12 weeks (p = 0.003) with greater lightening in the gum-group at each examination period.	lightening	190	200	significantly	56	69	0
1472-6882-11-49.txt	Outcomes associated with cognitive dysfunction were not statistically significant.	cognitive dysfunction	25	46	not statistically significant	52	81	0
1472-6882-11-93.txt	Furthermore there were no significant differences between the groups regarding the frequency of stooling, neither at baseline, at which point the infants of both groups had bowel movements 4.2 times/day, nor during the intervention weeks.	bowel movements	173	188	no significant	23	37	0
1472-6882-11-93.txt	There was an expected decrease in frequency of stooling in both groups, reaching 2.1 (p = 0,001) in the acupuncture group and 3.1 (p < 0,001) in the control group.	frequency of stooling	34	55	p < 0	131	136	0
1472-6882-11-93.txt	There was an expected decrease in frequency of stooling in both groups, reaching 2.1 (p = 0,001) in the acupuncture group and 3.1 (p < 0,001) in the control group.	frequency of stooling	34	55	p = 0	86	91	0
1472-6882-11-93.txt	The groups differed regarding large bowel movements which decreased linearly in the control group (p = 0,011) but not in the acupuncture group (p = 0,787).	large bowel movements	30	51	p = 0	99	104	0
1472-6882-11-93.txt	The groups differed regarding large bowel movements which decreased linearly in the control group (p = 0,011) but not in the acupuncture group (p = 0,787).	large bowel movements	30	51	p = 0	144	149	0
1472-6882-12-19.txt	In the primary outcome model, there was no significant difference in weight regain between the two arms (1.72 kg (se 0.85) weight regain for TAT and 2.96 kg (se 0.96) weight regain for SS, p < 0.097) Tests of between- arm differences for secondary outcomes were also not significant.	secondary outcomes	238	256	no significant	40	54	0
1472-6882-12-19.txt	In the primary outcome model, there was no significant difference in weight regain between the two arms (1.72 kg (se 0.85) weight regain for TAT and 2.96 kg (se 0.96) weight regain for SS, p < 0.097) Tests of between- arm differences for secondary outcomes were also not significant.	secondary outcomes	238	256	p < 0.097	189	198	0
1472-6882-12-19.txt	In the primary outcome model, there was no significant difference in weight regain between the two arms (1.72 kg (se 0.85) weight regain for TAT and 2.96 kg (se 0.96) weight regain for SS, p < 0.097) Tests of between- arm differences for secondary outcomes were also not significant.	weight regain	69	82	not significant	267	282	0
1472-6882-12-19.txt	In the primary outcome model, there was no significant difference in weight regain between the two arms (1.72 kg (se 0.85) weight regain for TAT and 2.96 kg (se 0.96) weight regain for SS, p < 0.097) Tests of between- arm differences for secondary outcomes were also not significant.	weight regain	123	136	no significant	40	54	0
1472-6882-12-19.txt	In the primary outcome model, there was no significant difference in weight regain between the two arms (1.72 kg (se 0.85) weight regain for TAT and 2.96 kg (se 0.96) weight regain for SS, p < 0.097) Tests of between- arm differences for secondary outcomes were also not significant.	weight regain	123	136	not significant	267	282	0
1472-6882-12-19.txt	In the primary outcome model, there was no significant difference in weight regain between the two arms (1.72 kg (se 0.85) weight regain for TAT and 2.96 kg (se 0.96) weight regain for SS, p < 0.097) Tests of between- arm differences for secondary outcomes were also not significant.	weight regain	123	136	p < 0.097	189	198	0
1472-6882-12-19.txt	In the primary outcome model, there was no significant difference in weight regain between the two arms (1.72 kg (se 0.85) weight regain for TAT and 2.96 kg (se 0.96) weight regain for SS, p < 0.097) Tests of between- arm differences for secondary outcomes were also not significant.	weight regain	167	180	no significant	40	54	0
1472-6882-12-19.txt	In the primary outcome model, there was no significant difference in weight regain between the two arms (1.72 kg (se 0.85) weight regain for TAT and 2.96 kg (se 0.96) weight regain for SS, p < 0.097) Tests of between- arm differences for secondary outcomes were also not significant.	weight regain	167	180	not significant	267	282	0
1472-6882-12-19.txt	In the primary outcome model, there was no significant difference in weight regain between the two arms (1.72 kg (se 0.85) weight regain for TAT and 2.96 kg (se 0.96) weight regain for SS, p < 0.097) Tests of between- arm differences for secondary outcomes were also not significant.	weight regain	167	180	p < 0.097	189	198	0
1472-6882-12-19.txt	A secondary analysis showed a significant interaction between treatment and initial weight loss (p < .036), with exploratory post hoc tests showing that greater initial weight loss was associated with more weight regain for SS but less weight regain for TAT.	initial weight loss	161	180	p < .036	97	105	0
1472-6882-12-19.txt	A secondary analysis showed a significant interaction between treatment and initial weight loss (p < .036), with exploratory post hoc tests showing that greater initial weight loss was associated with more weight regain for SS but less weight regain for TAT.	initial weight loss	161	180	significant	30	41	0
1472-6882-12-19.txt	A secondary analysis showed a significant interaction between treatment and initial weight loss (p < .036), with exploratory post hoc tests showing that greater initial weight loss was associated with more weight regain for SS but less weight regain for TAT.	weight regain	206	219	p < .036	97	105	0
1472-6882-12-19.txt	A secondary analysis showed a significant interaction between treatment and initial weight loss (p < .036), with exploratory post hoc tests showing that greater initial weight loss was associated with more weight regain for SS but less weight regain for TAT.	weight regain	206	219	significant	30	41	0
1472-6882-12-19.txt	A secondary analysis showed a significant interaction between treatment and initial weight loss (p < .036), with exploratory post hoc tests showing that greater initial weight loss was associated with more weight regain for SS but less weight regain for TAT.	weight regain	236	249	p < .036	97	105	0
1472-6882-12-19.txt	A secondary analysis showed a significant interaction between treatment and initial weight loss (p < .036), with exploratory post hoc tests showing that greater initial weight loss was associated with more weight regain for SS but less weight regain for TAT.	weight regain	236	249	significant	30	41	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.000	179	188	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.000	195	204	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.000	244	253	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.000	467	476	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.000	483	492	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.000	586	595	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.001	260	269	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.001	326	335	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.001	342	351	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.001	570	579	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.002	413	422	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.004	429	438	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.007	283	292	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.008	299	308	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.008	522	531	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.009	642	651	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.011	538	547	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	6MWD	354	358	P = 0.015	626	635	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.000	179	188	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.000	195	204	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.000	467	476	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.000	483	492	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.000	586	595	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.001	326	335	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.001	342	351	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.001	570	579	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.002	413	422	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.004	429	438	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.007	283	292	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.008	299	308	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.008	522	531	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.009	642	651	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.011	538	547	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.015	626	635	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.042	381	390	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	duration of acute exacerbation	207	237	P = 0.045	365	374	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.000	179	188	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.000	195	204	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.000	244	253	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.000	467	476	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.000	483	492	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.000	586	595	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.001	260	269	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.001	326	335	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.001	342	351	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.001	570	579	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.007	283	292	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.008	299	308	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.008	522	531	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.009	642	651	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.011	538	547	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.015	626	635	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.042	381	390	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	dyspnea scale	393	406	P = 0.045	365	374	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.000	179	188	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.000	195	204	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.000	244	253	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.000	467	476	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.000	483	492	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.000	586	595	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.001	260	269	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.001	326	335	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.001	342	351	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.001	570	579	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.002	413	422	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.004	429	438	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.007	283	292	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.008	299	308	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.008	522	531	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.011	538	547	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.042	381	390	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	environment domain	601	619	P = 0.045	365	374	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.000	179	188	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.000	195	204	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.000	244	253	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.000	467	476	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.000	483	492	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.000	586	595	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.001	260	269	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.001	326	335	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.001	342	351	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.001	570	579	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.002	413	422	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.004	429	438	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.008	522	531	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.009	642	651	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.011	538	547	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.015	626	635	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.042	381	390	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	FEV1	272	276	P = 0.045	365	374	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.000	244	253	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.000	467	476	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.000	483	492	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.000	586	595	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.001	260	269	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.001	326	335	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.001	342	351	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.001	570	579	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.002	413	422	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.004	429	438	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.007	283	292	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.008	299	308	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.008	522	531	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.009	642	651	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.011	538	547	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.015	626	635	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.042	381	390	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	frequency of acute exacerbation	141	172	P = 0.045	365	374	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.000	179	188	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.000	195	204	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.000	244	253	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.000	586	595	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.001	260	269	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.001	326	335	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.001	342	351	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.001	570	579	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.002	413	422	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.004	429	438	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.007	283	292	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.008	299	308	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.008	522	531	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.009	642	651	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.011	538	547	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.015	626	635	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.042	381	390	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	physical domain	445	460	P = 0.045	365	374	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.000	179	188	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.000	195	204	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.000	244	253	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.000	467	476	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.000	483	492	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.000	586	595	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.001	260	269	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.001	326	335	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.001	342	351	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.001	570	579	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.002	413	422	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.004	429	438	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.007	283	292	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.008	299	308	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.009	642	651	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.015	626	635	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.042	381	390	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	psychological domain	495	515	P = 0.045	365	374	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.000	179	188	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.000	195	204	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.000	244	253	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.000	467	476	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.000	483	492	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.001	260	269	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.001	326	335	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.001	342	351	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.002	413	422	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.004	429	438	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.007	283	292	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.008	299	308	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.008	522	531	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.009	642	651	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.011	538	547	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.015	626	635	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.042	381	390	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	social domain	550	563	P = 0.045	365	374	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.000	179	188	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.000	195	204	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.000	244	253	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.000	467	476	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.000	483	492	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.000	586	595	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.001	260	269	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.001	570	579	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.002	413	422	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.004	429	438	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.007	283	292	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.008	299	308	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.008	522	531	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.009	642	651	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.011	538	547	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.015	626	635	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.042	381	390	0
1472-6882-12-197.txt	After the 6-month treatment and 12-month follow-up, there were significant differences between the trial and control group in the following: frequency of acute exacerbation (FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007; PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale (FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS: P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015; PPS: P = 0.009) of the WHOQOL-BREF questionnaire.	symptoms	311	319	P = 0.045	365	374	0
1472-6882-12-7.txt	Results For BMD, no intent-to-treat analyses were statistically significant; however, per protocol analyses (ie, only including TC participants who completed ≥ 75% training requirements) of femoral neck BMD changes were significantly different between TC and UC (+0.04 vs -0.98%; P = 0.05).	BMD	12	15	P = 0.05	280	288	0
1472-6882-12-7.txt	Results For BMD, no intent-to-treat analyses were statistically significant; however, per protocol analyses (ie, only including TC participants who completed ≥ 75% training requirements) of femoral neck BMD changes were significantly different between TC and UC (+0.04 vs -0.98%; P = 0.05).	BMD	12	15	significantly	220	233	0
1472-6882-12-7.txt	Results For BMD, no intent-to-treat analyses were statistically significant; however, per protocol analyses (ie, only including TC participants who completed ≥ 75% training requirements) of femoral neck BMD changes were significantly different between TC and UC (+0.04 vs -0.98%; P = 0.05).	femoral neck BMD changes	190	214	significant	64	75	0
1472-6882-12-7.txt	Changes in sway parameters were significantly improved by TC vs UC (average sway velocity, P = 0.027; anterior-posterior sway range, P = 0.014).	anterior-posterior sway range	102	131	P = 0.027	91	100	0
1472-6882-12-7.txt	Changes in sway parameters were significantly improved by TC vs UC (average sway velocity, P = 0.027; anterior-posterior sway range, P = 0.014).	anterior-posterior sway range	102	131	significantly	32	45	0
1472-6882-12-7.txt	Changes in sway parameters were significantly improved by TC vs UC (average sway velocity, P = 0.027; anterior-posterior sway range, P = 0.014).	sway parameters	11	26	P = 0.014	133	142	0
1472-6882-12-7.txt	Changes in sway parameters were significantly improved by TC vs UC (average sway velocity, P = 0.027; anterior-posterior sway range, P = 0.014).	sway parameters	11	26	P = 0.027	91	100	0
1472-6882-12-7.txt	Changes in sway parameters were significantly improved by TC vs UC (average sway velocity, P = 0.027; anterior-posterior sway range, P = 0.014).	sway velocity	76	89	P = 0.014	133	142	0
1472-6882-12-7.txt	Changes in sway parameters were significantly improved by TC vs UC (average sway velocity, P = 0.027; anterior-posterior sway range, P = 0.014).	sway velocity	76	89	significantly	32	45	0
1472-6882-7-34.txt	Compared to baseline both treatments showed significant benefits in WOMAC and VAS outcomes within one week (P < 0.05), with a similar, progressive improvement over the course of the 8 week treatment protocol (45–62% reduction in WOMAC or VAS scores).	VAS scores	238	248	P < 0.05	108	116	0
1472-6882-7-34.txt	Compared to baseline both treatments showed significant benefits in WOMAC and VAS outcomes within one week (P < 0.05), with a similar, progressive improvement over the course of the 8 week treatment protocol (45–62% reduction in WOMAC or VAS scores).	VAS scores	238	248	significant	44	55	0
1472-6882-7-34.txt	Compared to baseline both treatments showed significant benefits in WOMAC and VAS outcomes within one week (P < 0.05), with a similar, progressive improvement over the course of the 8 week treatment protocol (45–62% reduction in WOMAC or VAS scores).	WOMAC	229	234	P < 0.05	108	116	0
1472-6882-7-34.txt	Compared to baseline both treatments showed significant benefits in WOMAC and VAS outcomes within one week (P < 0.05), with a similar, progressive improvement over the course of the 8 week treatment protocol (45–62% reduction in WOMAC or VAS scores).	WOMAC	229	234	significant	44	55	0
1472-6882-7-34.txt	Response rates were high and the safety profile was excellent, with significantly less rescue medication use with reparagen.	Response rates	0	14	significantly	68	81	0
1472-6882-7-34.txt	Response rates were high and the safety profile was excellent, with significantly less rescue medication use with reparagen.	the safety profile	29	47	significantly	68	81	0
1472-6882-7-8.txt	Participants who dropped out reported significantly fewer previous quit attempts, but no other significant differences.	previous quit attempts	58	80	significant	95	106	0
1472-6882-7-8.txt	The discomfort caused by the beads was minor, and there were no significant side effects.	The discomfort caused by the beads	0	34	no significant	61	75	0
1472-6904-8-10.txt	Fenofibrate resulted in 17% rise in large LDLP (p = .06 vs pre) and 32% drop in small LDLP (p = .007 vs pre).	large LDLP	36	46	p = .007	92	100	0
1472-6904-8-10.txt	Fenofibrate resulted in 17% rise in large LDLP (p = .06 vs pre) and 32% drop in small LDLP (p = .007 vs pre).	small LDLP	80	90	p = .06	48	55	0
1472-6904-8-10.txt	Simvastatin led to decrease in both LDLP fractions (19% large LDLP; p = .001 vs fenofibrate end; 34% small LDLP, p = .019 vs pre).	both LDLP fractions	31	50	p = .001	68	76	0
1472-6904-8-10.txt	Simvastatin led to decrease in both LDLP fractions (19% large LDLP; p = .001 vs fenofibrate end; 34% small LDLP, p = .019 vs pre).	both LDLP fractions	31	50	p = .019	113	121	0
1472-6904-8-10.txt	Simvastatin led to decrease in both LDLP fractions (19% large LDLP; p = .001 vs fenofibrate end; 34% small LDLP, p = .019 vs pre).	large LDLP	56	66	p = .019	113	121	0
1472-6904-8-10.txt	Simvastatin led to decrease in both LDLP fractions (19% large LDLP; p = .001 vs fenofibrate end; 34% small LDLP, p = .019 vs pre).	small LDLP	101	111	p = .001	68	76	0
1472-6920-12-85.txt	The final examination (OSCE) showed no significant differences between any of the groups with good overall performances.	overall performances	99	119	no significant	36	50	0
1472-6920-12-85.txt	In the evaluation, the students certified the arthroscopic tutorial a greater advantage concerning anatomical skills with higher spatial imagination in comparison to the ultrasound tutorial (p = 0.002; p < 0.001).	advantage concerning anatomical skills	78	116	p < 0.001	202	211	0
1472-6920-12-85.txt	In the evaluation, the students certified the arthroscopic tutorial a greater advantage concerning anatomical skills with higher spatial imagination in comparison to the ultrasound tutorial (p = 0.002; p < 0.001).	spatial imagination	129	148	p = 0.002	191	200	0
1472-6920-4-17.txt	Physicians with higher baseline screening rates were significantly more likely to log on to the course.	baseline screening rates	23	47	significantly	53	66	0
1472-6920-7-40.txt	Conclusion We conclude that significant improvement in knowledge persists six months after a standard introductory ultrasound course, and incorporating proctored ultrasound training into an emergency ultrasound curriculum may yield even higher knowledge retention.	knowledge retention	244	263	significant	28	39	0
1472-6963-11-58.txt	Results Overall at long-term follow-up (average 6 years) significantly more individuals in the CNP group (72%) had improved (i.e had fewer symptoms) compared to those in the SC group (67%) (difference of 5% 95% (CI = 0.6 to 9;p = 0.02)).	symptoms	139	147	p = 0.02	226	234	0
1472-6963-11-58.txt	Results Overall at long-term follow-up (average 6 years) significantly more individuals in the CNP group (72%) had improved (i.e had fewer symptoms) compared to those in the SC group (67%) (difference of 5% 95% (CI = 0.6 to 9;p = 0.02)).	symptoms	139	147	significantly	57	70	0
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	alliance	89	97	no statistically significant	231	259	0
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	alliance	89	97	p = 0.137	390	399	0
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	alliance	89	97	p = 0.248	462	471	0
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	alliance	89	97	p = 0.819	215	224	0
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	alliance	336	344	p = 0.248	462	471	0
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	alliance	336	344	p = 0.760	143	152	0
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	alliance	336	344	p = 0.819	215	224	0
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	satisfaction	157	169	no statistically significant	231	259	0
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	satisfaction	157	169	p = 0.137	390	399	0
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	satisfaction	157	169	p = 0.248	462	471	0
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	satisfaction	157	169	p = 0.760	143	152	0
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	satisfaction	404	416	p = 0.137	390	399	0
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	satisfaction	404	416	p = 0.760	143	152	0
1472-6963-12-348.txt	There were no differences between the groups in the intention to treat (ITT) analyses on alliance (mean difference = 0.08, 95% CI −0.44, 0.59, p = 0.760) or satisfaction (mean difference = 0.24, 95% CI −1.85, 2.32, p = 0.819), and no statistically significant differences between the groups in the per protocol (PP, n = 58) analyses on alliance (mean difference = 0.32, 95% CI −0.84, 3.16, p = 0.137) or satisfaction (mean difference = 1.16, 95% CI −0.84, 3.16, p = 0.248) six weeks after the treatment started.	satisfaction	404	416	p = 0.819	215	224	0
1472-6963-9-33.txt	There was a small fall in HbA1c in the yoga group which was not statistically significant and which was not sustained six months later, and no significant change in other outcome measures.	HbA1c	26	31	no significant	140	154	0
1472-6963-9-33.txt	There was a small fall in HbA1c in the yoga group which was not statistically significant and which was not sustained six months later, and no significant change in other outcome measures.	other outcome measures	165	187	not statistically significant	60	89	0
1475-2840-10-78.txt	Strong relationships were evident (p < 0.05) between GE T half and 1-day palmitoleic acid (r = -0.78), eiconsenoic acid (r = -0.84) and total omega-3 intake (r = -0.72).	eiconsenoic acid	103	119	p < 0.05	35	43	0
1475-2840-10-78.txt	Strong relationships were evident (p < 0.05) between GE T half and 1-day palmitoleic acid (r = -0.78), eiconsenoic acid (r = -0.84) and total omega-3 intake (r = -0.72).	GE T half and 1-day palmitoleic acid	53	89	p < 0.05	35	43	0
1475-2840-10-78.txt	Strong relationships were evident (p < 0.05) between GE T half and 1-day palmitoleic acid (r = -0.78), eiconsenoic acid (r = -0.84) and total omega-3 intake (r = -0.72).	total omega-3 intake	136	156	p < 0.05	35	43	0
1475-2875-10-2.txt	The incidence rate of malaria in children who received IPTc was 0.44 clinical attacks per 1,000 child months at risk while that for control children was 1.32 per 1,000 child months at risk, a protective efficacy of 66% (95% CI -23% to 96%; p = 0.35).	The incidence rate of malaria	0	29	p = 0.35	240	248	0
1475-2875-11-217.txt	The median parasite clearance time was significantly slower in the ARPQ group compared with the ASAQ group (48 h vs 36 h, P <0.001) and fever clearance times were shorter in the ASAQ group (12 h vs 24 h, P  = 0.07).	fever clearance times	136	157	P <0.001	122	130	0
1475-2875-11-217.txt	The median parasite clearance time was significantly slower in the ARPQ group compared with the ASAQ group (48 h vs 36 h, P <0.001) and fever clearance times were shorter in the ASAQ group (12 h vs 24 h, P  = 0.07).	fever clearance times	136	157	significantly	39	52	0
1475-2875-11-217.txt	The median parasite clearance time was significantly slower in the ARPQ group compared with the ASAQ group (48 h vs 36 h, P <0.001) and fever clearance times were shorter in the ASAQ group (12 h vs 24 h, P  = 0.07).	The median parasite clearance time	0	34	P  = 0.07	204	213	0
1475-2875-5-113.txt	The 28-day PCR-corrected cure rate was 90.1% [95% CI 80.7–95.9] for AS+SP, 98.5% [95% CI 92.0–100] for AS+AQ and 100% [95.8–100] for AL, thereby revealing a weaker response to AS+SP than to AL (p = 0.003) and to AS+AQ (p = 0.06).	The 28-day PCR-corrected cure rate	0	34	p = 0.003	194	203	0
1475-2875-5-113.txt	The 28-day PCR-corrected cure rate was 90.1% [95% CI 80.7–95.9] for AS+SP, 98.5% [95% CI 92.0–100] for AS+AQ and 100% [95.8–100] for AL, thereby revealing a weaker response to AS+SP than to AL (p = 0.003) and to AS+AQ (p = 0.06).	The 28-day PCR-corrected cure rate	0	34	p = 0.06	219	227	0
1475-2875-6-138.txt	Results Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups.	sit unsupported	49	64	p = 0.07	139	147	0
1475-2875-6-138.txt	Results Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups.	sit unsupported	49	64	p = 0.11	38	46	0
1475-2875-6-138.txt	Results Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups.	sit unsupported	49	64	p = 0.13	104	112	0
1475-2875-6-138.txt	Results Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups.	Time to regain consciousness	8	36	p = 0.07	139	147	0
1475-2875-6-138.txt	Results Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups.	Time to regain consciousness	8	36	p = 0.13	104	112	0
1475-2875-6-138.txt	Results Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups.	Time to regain consciousness	8	36	p = 0.81	66	74	0
1475-2875-6-138.txt	Results Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups.	time to start oral intake	77	102	p = 0.07	139	147	0
1475-2875-6-138.txt	Results Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups.	time to start oral intake	77	102	p = 0.11	38	46	0
1475-2875-6-138.txt	Results Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups.	time to start oral intake	77	102	p = 0.81	66	74	0
1475-2875-6-138.txt	Results Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups.	total coma duration	118	137	p = 0.11	38	46	0
1475-2875-6-138.txt	Results Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups.	total coma duration	118	137	p = 0.13	104	112	0
1475-2875-6-138.txt	Results Time to regain consciousness (p = 0.11), sit unsupported (p = 0.81), time to start oral intake (p = 0.13) and total coma duration (p = 0.07) were similar in both groups.	total coma duration	118	137	p = 0.81	66	74	0
1475-2875-7-199.txt	Antimalarial prescriptions were significantly reduced in Arm-I (61.3%) compared to Arms-II (95.3%) and III (99.5%) (both P < 0.001), whereas antibiotic prescriptions did not vary significantly between the arms (49.9%, 54.8% and 34.2%, respectively).	antibiotic prescriptions	141	165	P < 0.001	121	130	0
1475-2875-7-199.txt	Antimalarial prescriptions were significantly reduced in Arm-I (61.3%) compared to Arms-II (95.3%) and III (99.5%) (both P < 0.001), whereas antibiotic prescriptions did not vary significantly between the arms (49.9%, 54.8% and 34.2%, respectively).	antibiotic prescriptions	141	165	significantly	32	45	0
1475-2875-7-199.txt	On day 7 follow-up, more children reported symptoms in Arm-I compared to Arm-III, but fewer children had malaria parasitaemia (p = 0.049).	reported symptoms	34	51	p = 0.049	127	136	0
1475-2875-9-378.txt	Serious Adverse Events were not reported in any of the patients and in all children, laboratory values (packed cell volume, liver enzymes, bilirubin) remained within normal levels during the follow-up period but the packed cell volume was significantly lower in the AS + SMP group.	bilirubin	139	148	significantly	239	252	0
1475-2875-9-378.txt	Serious Adverse Events were not reported in any of the patients and in all children, laboratory values (packed cell volume, liver enzymes, bilirubin) remained within normal levels during the follow-up period but the packed cell volume was significantly lower in the AS + SMP group.	laboratory values	85	102	significantly	239	252	0
1475-2875-9-378.txt	Serious Adverse Events were not reported in any of the patients and in all children, laboratory values (packed cell volume, liver enzymes, bilirubin) remained within normal levels during the follow-up period but the packed cell volume was significantly lower in the AS + SMP group.	liver enzymes	124	137	significantly	239	252	0
1475-2875-9-378.txt	Serious Adverse Events were not reported in any of the patients and in all children, laboratory values (packed cell volume, liver enzymes, bilirubin) remained within normal levels during the follow-up period but the packed cell volume was significantly lower in the AS + SMP group.	packed cell volume	104	122	significantly	239	252	0
1475-2891-10-85.txt	Conclusions Use of the ELISA test with subsequent diet elimination advice did not reduce the disability or impact on daily life of migraine like headaches or the number of migraine like headaches at 12 weeks but it did significantly reduce the number of migraine like headaches at 4 weeks.	impact on daily life of migraine like headaches	107	154	significantly	219	232	0
1475-2891-10-85.txt	Conclusions Use of the ELISA test with subsequent diet elimination advice did not reduce the disability or impact on daily life of migraine like headaches or the number of migraine like headaches at 12 weeks but it did significantly reduce the number of migraine like headaches at 4 weeks.	the disability	89	103	significantly	219	232	0
1475-2891-10-85.txt	Conclusions Use of the ELISA test with subsequent diet elimination advice did not reduce the disability or impact on daily life of migraine like headaches or the number of migraine like headaches at 12 weeks but it did significantly reduce the number of migraine like headaches at 4 weeks.	the number of migraine like headaches at 12 weeks	158	207	significantly	219	232	0
1475-2891-11-47.txt	Furthermore, the DNA tail length and tail moment were significantly reduced after the supplementation (low-dose and high-dose), and plasma oxidized low-density lipoprotein (LDL) levels were reduced in low-dose and high-dose groups, but increased in the placebo group.	plasma oxidized low-density lipoprotein (LDL) levels	132	184	significantly	54	67	0
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	body composition	92	108	p < 0.001	205	214	0
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	body composition	92	108	p < 0.027	160	169	0
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	body composition	92	108	significantly	19	32	0
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	body weight	41	52	p < 0.001	110	119	0
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	body weight	41	52	p < 0.001	205	214	0
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	body weight	41	52	p < 0.027	160	169	0
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	body weight	41	52	significant	64	75	0
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	components of metabolic syndrome	126	158	p < 0.001	110	119	0
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	components of metabolic syndrome	126	158	p < 0.001	205	214	0
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	components of metabolic syndrome	126	158	significantly	19	32	0
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	HDL	190	193	p < 0.001	110	119	0
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	HDL	190	193	p < 0.027	160	169	0
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	HDL	190	193	significant	64	75	0
1475-2891-11-57.txt	Results All groups significantly reduced body weight and showed significant improvements in body composition (p < 0.001), and components of metabolic syndrome (p < 0.027 to 0.002), although HDL decreased (p < 0.001).	HDL	190	193	significantly	19	32	0
1475-2891-11-57.txt	Dietary energy, %fat and %saturated fat decreased while protein intake increased significantly (p < 0.001).	%fat	16	20	p < 0.001	96	105	0
1475-2891-11-57.txt	Dietary energy, %fat and %saturated fat decreased while protein intake increased significantly (p < 0.001).	%fat	16	20	significantly	81	94	0
1475-2891-11-57.txt	Dietary energy, %fat and %saturated fat decreased while protein intake increased significantly (p < 0.001).	%saturated fat	25	39	p < 0.001	96	105	0
1475-2891-11-57.txt	Dietary energy, %fat and %saturated fat decreased while protein intake increased significantly (p < 0.001).	%saturated fat	25	39	significantly	81	94	0
1475-2891-11-57.txt	Dietary energy, %fat and %saturated fat decreased while protein intake increased significantly (p < 0.001).	Dietary energy	0	14	p < 0.001	96	105	0
1475-2891-11-57.txt	Dietary energy, %fat and %saturated fat decreased while protein intake increased significantly (p < 0.001).	Dietary energy	0	14	significantly	81	94	0
1475-2891-6-8.txt	Only stool consistency was significantly different between the two formulas (17% had soft stools on NF and hard stools on SF; no infants had soft stools on SF and hard stools on NF, McNemar test p = 0.046).	hard stools	107	118	p = 0.046	195	204	0
1475-2891-6-8.txt	Only stool consistency was significantly different between the two formulas (17% had soft stools on NF and hard stools on SF; no infants had soft stools on SF and hard stools on NF, McNemar test p = 0.046).	hard stools	107	118	significantly	27	40	0
1475-2891-6-8.txt	Only stool consistency was significantly different between the two formulas (17% had soft stools on NF and hard stools on SF; no infants had soft stools on SF and hard stools on NF, McNemar test p = 0.046).	hard stools	163	174	p = 0.046	195	204	0
1475-2891-6-8.txt	Only stool consistency was significantly different between the two formulas (17% had soft stools on NF and hard stools on SF; no infants had soft stools on SF and hard stools on NF, McNemar test p = 0.046).	hard stools	163	174	significantly	27	40	0
1475-2891-6-8.txt	Only stool consistency was significantly different between the two formulas (17% had soft stools on NF and hard stools on SF; no infants had soft stools on SF and hard stools on NF, McNemar test p = 0.046).	soft stools	85	96	p = 0.046	195	204	0
1475-2891-6-8.txt	Only stool consistency was significantly different between the two formulas (17% had soft stools on NF and hard stools on SF; no infants had soft stools on SF and hard stools on NF, McNemar test p = 0.046).	soft stools	85	96	significantly	27	40	0
1475-2891-6-8.txt	Only stool consistency was significantly different between the two formulas (17% had soft stools on NF and hard stools on SF; no infants had soft stools on SF and hard stools on NF, McNemar test p = 0.046).	soft stools	141	152	p = 0.046	195	204	0
1475-2891-6-8.txt	Only stool consistency was significantly different between the two formulas (17% had soft stools on NF and hard stools on SF; no infants had soft stools on SF and hard stools on NF, McNemar test p = 0.046).	soft stools	141	152	significantly	27	40	0
1475-2891-7-7.txt	Malaria episodes were lower in the supplemented group (p = 0.029), with a 30.2% reduction of malaria cases (p = 0.025).	malaria cases	93	106	p = 0.029	55	64	0
1475-2891-7-7.txt	Malaria episodes were lower in the supplemented group (p = 0.029), with a 30.2% reduction of malaria cases (p = 0.025).	Malaria episodes	0	16	p = 0.025	108	117	0
1477-7525-5-57.txt	Results and discussion Significant Questionnaire effects and a Questionnaire × Ceiling interaction (p < 0.001) in both trial datasets showed that the DTSQc detected more improvement in Treatment Satisfaction than the DTSQs, especially when patients had DTSQs scores at/near ceiling at baseline.	DTSQs scores at/near ceiling	253	281	p < 0.001	100	109	0
1477-7525-5-57.txt	Results and discussion Significant Questionnaire effects and a Questionnaire × Ceiling interaction (p < 0.001) in both trial datasets showed that the DTSQc detected more improvement in Treatment Satisfaction than the DTSQs, especially when patients had DTSQs scores at/near ceiling at baseline.	DTSQs scores at/near ceiling	253	281	Significant	23	34	0
1477-7525-5-57.txt	Results and discussion Significant Questionnaire effects and a Questionnaire × Ceiling interaction (p < 0.001) in both trial datasets showed that the DTSQc detected more improvement in Treatment Satisfaction than the DTSQs, especially when patients had DTSQs scores at/near ceiling at baseline.	Treatment Satisfaction	185	207	p < 0.001	100	109	0
1477-7525-5-57.txt	Results and discussion Significant Questionnaire effects and a Questionnaire × Ceiling interaction (p < 0.001) in both trial datasets showed that the DTSQc detected more improvement in Treatment Satisfaction than the DTSQs, especially when patients had DTSQs scores at/near ceiling at baseline.	Treatment Satisfaction	185	207	Significant	23	34	0
1477-7525-5-57.txt	Additionally, significant Treatment effects favouring insulin glargine (p < 0.001) and a Treatment × Questionnaire interaction (p < 0.019), with the DTSQc showing more benefits, were found in the type 1 trial.	a Treatment × Questionnaire interaction	87	126	p < 0.001	72	81	0
1477-7525-5-57.txt	Additionally, significant Treatment effects favouring insulin glargine (p < 0.001) and a Treatment × Questionnaire interaction (p < 0.019), with the DTSQc showing more benefits, were found in the type 1 trial.	a Treatment × Questionnaire interaction	87	126	significant	14	25	0
1477-7525-5-57.txt	Additionally, significant Treatment effects favouring insulin glargine (p < 0.001) and a Treatment × Questionnaire interaction (p < 0.019), with the DTSQc showing more benefits, were found in the type 1 trial.	Treatment effects	26	43	p < 0.019	128	137	0
1477-7819-10-94.txt	The overall rate of surgical-site infection was lower in the experimental group (11.1% center 1, 17.5% center 2; overall 15.5%) than in controls (14.3% center 1, 24.2% center 2, overall 20.4%), but the observed difference was not statistically significant ( P  = 0.451), even with respect to surgical-site infection grade 1 (superficial) versus grades 2 and 3, or grade 1 and 2 versus grade 3.	surgical-site infection	292	315	not statistically significant	226	255	0
1477-7819-10-94.txt	The overall rate of surgical-site infection was lower in the experimental group (11.1% center 1, 17.5% center 2; overall 15.5%) than in controls (14.3% center 1, 24.2% center 2, overall 20.4%), but the observed difference was not statistically significant ( P  = 0.451), even with respect to surgical-site infection grade 1 (superficial) versus grades 2 and 3, or grade 1 and 2 versus grade 3.	surgical-site infection	292	315	P  = 0.451	258	268	0
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the cancer-related death rate	49	78	p = .16	135	142	0
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the cancer-related death rate	49	78	p = 0.2	184	191	0
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the cancer-related death rate	49	78	p = 0.36	38	46	0
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the distant metastasis rate	145	172	p = .16	135	142	0
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the distant metastasis rate	145	172	p = .2	90	96	0
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the distant metastasis rate	145	172	p = 0.36	38	46	0
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the local recurrence rate	99	124	p = .2	90	96	0
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the local recurrence rate	99	124	p = 0.2	184	191	0
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the local recurrence rate	99	124	p = 0.36	38	46	0
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	The overall mortality rate	0	26	p = .16	135	142	0
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	The overall mortality rate	0	26	p = .2	90	96	0
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	The overall mortality rate	0	26	p = 0.2	184	191	0
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the time to relapse	204	223	p = .16	135	142	0
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the time to relapse	204	223	p = .2	90	96	0
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the time to relapse	204	223	p = 0.2	184	191	0
1477-7819-7-32.txt	The overall mortality rate (28 vs 25, p = 0.36), the cancer-related death rate (17 vs 19, p = .2), the local recurrence rate (7 vs 12, p = .16), the distant metastasis rate (13 vs 18, p = 0.2) as well as the time to relapse were not statistically significant different.	the time to relapse	204	223	p = 0.36	38	46	0
1477-7827-1-63.txt	The overall incidence of adverse events was similar in both groups, but compared to Follistim(R), injections of Bravelle(R) were reported by patients to be significantly less painful (P < 0.001).	The overall incidence of adverse events	0	39	P < 0.001	184	193	0
1477-7827-1-63.txt	The overall incidence of adverse events was similar in both groups, but compared to Follistim(R), injections of Bravelle(R) were reported by patients to be significantly less painful (P < 0.001).	The overall incidence of adverse events	0	39	significantly	156	169	0
1477-7827-1-63.txt	There were no differences in the nature or number of adverse events between the treatment groups although Bravelle(R) injections were reported to be significantly less painful.	the nature or number of adverse events	29	67	significantly	149	162	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	24 hours	86	94	p < 0.01	72	80	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	24 hours	86	94	p < 0.05	202	210	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	24 hours	86	94	p < 0.05	276	284	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	24 hours	86	94	p < 0.05	341	349	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	additional doses were required	296	326	p < 0.01	72	80	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	additional doses were required	296	326	p < 0.05	112	120	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	additional doses were required	296	326	p < 0.05	202	210	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	additional doses were required	296	326	p < 0.05	276	284	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	delivered within 12 hours	29	54	p < 0.05	112	120	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	delivered within 12 hours	29	54	p < 0.05	202	210	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	delivered within 12 hours	29	54	p < 0.05	276	284	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	delivered within 12 hours	29	54	p < 0.05	341	349	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	need for oxytocin augmentation	228	258	p < 0.01	72	80	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	need for oxytocin augmentation	228	258	p < 0.05	112	120	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	need for oxytocin augmentation	228	258	p < 0.05	202	210	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	need for oxytocin augmentation	228	258	p < 0.05	341	349	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	spontaneous rupture of the membranes occurred	123	168	p < 0.01	72	80	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	spontaneous rupture of the membranes occurred	123	168	p < 0.05	112	120	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	spontaneous rupture of the membranes occurred	123	168	p < 0.05	276	284	0
1477-7827-2-70.txt	With misoprostol, more women delivered within 12 hours (57.5% vs 32.5%, p < 0.01) and 24 hours (98.7% vs 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs 22%, p < 0.05).	spontaneous rupture of the membranes occurred	123	168	p < 0.05	341	349	0
1477-7827-2-70.txt	Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs 12%, p > 0.05).	abnormal fetal heart rate (FHR) tracings	168	208	not statistically significant	9	38	0
1477-7827-2-70.txt	Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs 12%, p > 0.05).	abnormal fetal heart rate (FHR) tracings	168	208	p > 0.05	122	130	0
1477-7827-2-70.txt	Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs 12%, p > 0.05).	Caesarean section (CS) rate	48	75	p > 0.05	224	232	0
1477-7827-4-38.txt	Results The overall FSH dose needed to achieve ovulation was significantly lower with r-FSH, whereas all the other studied variables did not significantly differ with either treatments.	the other studied variables	105	132	not significantly	137	154	0
1477-7827-4-38.txt	Results The overall FSH dose needed to achieve ovulation was significantly lower with r-FSH, whereas all the other studied variables did not significantly differ with either treatments.	the other studied variables	105	132	significantly	61	74	0
1477-7827-4-38.txt	Results The overall FSH dose needed to achieve ovulation was significantly lower with r-FSH, whereas all the other studied variables did not significantly differ with either treatments.	The overall FSH dose needed to achieve ovulation	8	56	not significantly	137	154	0
1477-7827-4-38.txt	Conclusion Considering the significantly lower number of vials/patient and the slight (although non-significant) increase in the delivery rate with r-FSH, the cost-minimization analysis showed a 9.4% reduction in the overall therapy cost per born baby in favor of r-FSH.	number of vials/patient	47	70	non-significant	96	111	0
1477-7827-4-38.txt	Conclusion Considering the significantly lower number of vials/patient and the slight (although non-significant) increase in the delivery rate with r-FSH, the cost-minimization analysis showed a 9.4% reduction in the overall therapy cost per born baby in favor of r-FSH.	the delivery rate	125	142	significantly	27	40	0
1477-7827-4-38.txt	Conclusion Considering the significantly lower number of vials/patient and the slight (although non-significant) increase in the delivery rate with r-FSH, the cost-minimization analysis showed a 9.4% reduction in the overall therapy cost per born baby in favor of r-FSH.	the overall therapy cost per born baby	213	251	non-significant	96	111	0
1477-7827-4-38.txt	Conclusion Considering the significantly lower number of vials/patient and the slight (although non-significant) increase in the delivery rate with r-FSH, the cost-minimization analysis showed a 9.4% reduction in the overall therapy cost per born baby in favor of r-FSH.	the overall therapy cost per born baby	213	251	significantly	27	40	0
1479-5868-8-29.txt	However, the intervention did significantly reduce systolic blood pressure (B = -1.79 mm/Hg) and resting heart rate (B = -2.08 beats) and significantly increased body mass index (B = .18 units) compared to control.	body mass index	162	177	significantly	30	43	0
1479-5868-8-29.txt	However, the intervention did significantly reduce systolic blood pressure (B = -1.79 mm/Hg) and resting heart rate (B = -2.08 beats) and significantly increased body mass index (B = .18 units) compared to control.	resting heart rate	97	115	significantly	138	151	0
1479-5868-8-29.txt	However, the intervention did significantly reduce systolic blood pressure (B = -1.79 mm/Hg) and resting heart rate (B = -2.08 beats) and significantly increased body mass index (B = .18 units) compared to control.	systolic blood pressure	51	74	significantly	138	151	0
1479-5868-8-41.txt	Significant waist circumference reductions were achieved in all 4 groups at month 9 (Standard Care, 3.49 cm, P = 0.0004; GWL, 2.42 cm, P = 0.008; SWA-alone, 3.59 cm, P < 0.0001; GWL+SWA, 6.77 cm, P < 0.0001), but no intervention group had significantly reduced waist circumference compared to the Standard Care group.	waist circumference	261	280	P < 0.0001	166	176	0
1479-5868-8-41.txt	Significant waist circumference reductions were achieved in all 4 groups at month 9 (Standard Care, 3.49 cm, P = 0.0004; GWL, 2.42 cm, P = 0.008; SWA-alone, 3.59 cm, P < 0.0001; GWL+SWA, 6.77 cm, P < 0.0001), but no intervention group had significantly reduced waist circumference compared to the Standard Care group.	waist circumference	261	280	P < 0.0001	196	206	0
1479-5868-8-41.txt	Significant waist circumference reductions were achieved in all 4 groups at month 9 (Standard Care, 3.49 cm, P = 0.0004; GWL, 2.42 cm, P = 0.008; SWA-alone, 3.59 cm, P < 0.0001; GWL+SWA, 6.77 cm, P < 0.0001), but no intervention group had significantly reduced waist circumference compared to the Standard Care group.	waist circumference	261	280	P = 0.0004	109	119	0
1479-5868-8-41.txt	Significant waist circumference reductions were achieved in all 4 groups at month 9 (Standard Care, 3.49 cm, P = 0.0004; GWL, 2.42 cm, P = 0.008; SWA-alone, 3.59 cm, P < 0.0001; GWL+SWA, 6.77 cm, P < 0.0001), but no intervention group had significantly reduced waist circumference compared to the Standard Care group.	waist circumference	261	280	P = 0.008	135	144	0
1479-5868-8-41.txt	Significant waist circumference reductions were achieved in all 4 groups at month 9 (Standard Care, 3.49 cm, P = 0.0004; GWL, 2.42 cm, P = 0.008; SWA-alone, 3.59 cm, P < 0.0001; GWL+SWA, 6.77 cm, P < 0.0001), but no intervention group had significantly reduced waist circumference compared to the Standard Care group.	waist circumference	261	280	Significant	0	11	0
1479-5868-8-41.txt	Significant waist circumference reductions were achieved in all 4 groups at month 9 (Standard Care, 3.49 cm, P = 0.0004; GWL, 2.42 cm, P = 0.008; SWA-alone, 3.59 cm, P < 0.0001; GWL+SWA, 6.77 cm, P < 0.0001), but no intervention group had significantly reduced waist circumference compared to the Standard Care group.	waist circumference	261	280	significantly	239	252	0
1479-5868-8-41.txt	Significant waist circumference reductions were achieved in all 4 groups at month 9 (Standard Care, 3.49 cm, P = 0.0004; GWL, 2.42 cm, P = 0.008; SWA-alone, 3.59 cm, P < 0.0001; GWL+SWA, 6.77 cm, P < 0.0001), but no intervention group had significantly reduced waist circumference compared to the Standard Care group.	waist circumference reductions	12	42	significantly	239	252	0
1479-5868-8-59.txt	From baseline to 3-months, systolic BP [126.0 (SD = 19.1) to 120.3 (SD = 17.9) mmHg; p < 0.001] and diastolic BP [83.	diastolic BP	100	112	p < 0.001	85	94	0
1479-5868-9-54.txt	Results Only aerobic fitness at 24 weeks met the conditions for mediation, and was a significant mediator of BMI.	BMI	109	112	significant	85	96	0
1532-429X-11-24.txt	Patients were managed to have equivalent glycemic control over the study period, but in fact the rosiglitazone group lowered their HbA1c by 0.88% relative to placebo (P < 0.001).	glycemic control	41	57	P < 0.001	167	176	0
1532-429X-13-65.txt	Interestingly, LV mass-I significantly decreased in the placebo group (48.9 ± 5.3 g/m 2 vs 44.3 ± 5.6 g/m 2 , p < 0.001) indicating reverse remodeling, whereas LV mass-I remained unchanged in the rosiglitazone group (54.7 ± 9.9 g/m 2 vs 53.7 ± 9.2 g/m 2 , p = 0.3).	LV mass-I	15	24	p = 0.3	256	263	0
1532-429X-13-65.txt	Interestingly, LV mass-I significantly decreased in the placebo group (48.9 ± 5.3 g/m 2 vs 44.3 ± 5.6 g/m 2 , p < 0.001) indicating reverse remodeling, whereas LV mass-I remained unchanged in the rosiglitazone group (54.7 ± 9.9 g/m 2 vs 53.7 ± 9.2 g/m 2 , p = 0.3).	LV mass-I	160	169	p < 0.001	110	119	0
1532-429X-13-65.txt	Interestingly, LV mass-I significantly decreased in the placebo group (48.9 ± 5.3 g/m 2 vs 44.3 ± 5.6 g/m 2 , p < 0.001) indicating reverse remodeling, whereas LV mass-I remained unchanged in the rosiglitazone group (54.7 ± 9.9 g/m 2 vs 53.7 ± 9.2 g/m 2 , p = 0.3).	LV mass-I	160	169	significantly	25	38	0
1532-429X-13-65.txt	After correction for systolic and diastolic blood pressure and triglyceride, the kind of therapy (rosiglitazone vs placebo) remained the only significant predictor of LV mass-I reduction.	LV mass-I	167	176	significant	142	153	0
1741-7015-10-71.txt	Results Compared with the patients in the UC arm, the patients in the CP arm had a significantly lower risk of mortality at 7 days (OR = 0.10; 95% CI 0.01 to 0.95) and significantly lower rates of adverse functional outcomes, expressed as the odds of not returning to pre-stroke functioning in their daily life (OR = 0.42; 95 CI 0.18 to 0.98).	rates of adverse functional outcomes, expressed as the odds of not returning to pre-stroke functioning in their daily life	188	310	significantly	83	96	0
1741-7015-10-71.txt	Results Compared with the patients in the UC arm, the patients in the CP arm had a significantly lower risk of mortality at 7 days (OR = 0.10; 95% CI 0.01 to 0.95) and significantly lower rates of adverse functional outcomes, expressed as the odds of not returning to pre-stroke functioning in their daily life (OR = 0.42; 95 CI 0.18 to 0.98).	risk of mortality	103	120	significantly	168	181	0
1741-7015-10-71.txt	Conclusions CPs can significantly improve the outcomes of patients with ischemic patients with stroke, indicating better application of evidence-based key interventions and of diagnostic and therapeutic procedures.	application of evidence-based key interventions and of diagnostic and therapeutic procedures	121	213	significantly	20	33	0
1741-7015-2-6.txt	Fascial interposition decreased time to azoospermia (hazard ratio [HR], 1.35; P < 0.0001) and time to severe oligozoospermia (HR, 1.32; P < 0.0001) and reduced failures based on semen analysis by about half, from 12.7% (95% confidence interval [CI], 9.7 to 16.3) to 5.9% (95% CI, 3.8 to 8.6) (P < 0.0001).	failures based on semen analysis	160	192	P < 0.0001	78	88	0
1741-7015-2-6.txt	Fascial interposition decreased time to azoospermia (hazard ratio [HR], 1.35; P < 0.0001) and time to severe oligozoospermia (HR, 1.32; P < 0.0001) and reduced failures based on semen analysis by about half, from 12.7% (95% confidence interval [CI], 9.7 to 16.3) to 5.9% (95% CI, 3.8 to 8.6) (P < 0.0001).	failures based on semen analysis	160	192	P < 0.0001	136	146	0
1741-7015-2-6.txt	Fascial interposition decreased time to azoospermia (hazard ratio [HR], 1.35; P < 0.0001) and time to severe oligozoospermia (HR, 1.32; P < 0.0001) and reduced failures based on semen analysis by about half, from 12.7% (95% confidence interval [CI], 9.7 to 16.3) to 5.9% (95% CI, 3.8 to 8.6) (P < 0.0001).	time to azoospermia	32	51	P < 0.0001	136	146	0
1741-7015-2-6.txt	Fascial interposition decreased time to azoospermia (hazard ratio [HR], 1.35; P < 0.0001) and time to severe oligozoospermia (HR, 1.32; P < 0.0001) and reduced failures based on semen analysis by about half, from 12.7% (95% confidence interval [CI], 9.7 to 16.3) to 5.9% (95% CI, 3.8 to 8.6) (P < 0.0001).	time to azoospermia	32	51	P < 0.0001	293	303	0
1741-7015-2-6.txt	Fascial interposition decreased time to azoospermia (hazard ratio [HR], 1.35; P < 0.0001) and time to severe oligozoospermia (HR, 1.32; P < 0.0001) and reduced failures based on semen analysis by about half, from 12.7% (95% confidence interval [CI], 9.7 to 16.3) to 5.9% (95% CI, 3.8 to 8.6) (P < 0.0001).	time to severe oligozoospermia	94	124	P < 0.0001	78	88	0
1741-7015-2-6.txt	Fascial interposition decreased time to azoospermia (hazard ratio [HR], 1.35; P < 0.0001) and time to severe oligozoospermia (HR, 1.32; P < 0.0001) and reduced failures based on semen analysis by about half, from 12.7% (95% confidence interval [CI], 9.7 to 16.3) to 5.9% (95% CI, 3.8 to 8.6) (P < 0.0001).	time to severe oligozoospermia	94	124	P < 0.0001	293	303	0
1741-7015-7-54.txt	Mud plastering did not reduce sand fly density (Bangladesh study); lime plastering in India and one Nepali site, resulted in a significant reduction of sand fly density but not in the second Nepali site.	sand fly density	30	46	significant	127	138	0
1741-7015-9-10.txt	Results The probability of overall survival (OS) at three years was 0.88 for patients in Arm A and 0.86 for those in Arm B, while the five-year OS probability was 0.78 and 0.76 for patients in Arm A and Arm B, respectively (P = 0.436).	The probability of overall survival (OS) at three years	8	63	P = 0.436	224	233	0
1741-7015-9-10.txt	With the exception of leucopenia and neutropenia, which were higher in patients in Arm A, there were no significant differences in Grades 3 and 4 toxicities between the two regimens.	leucopenia	22	32	no significant	101	115	0
1741-7015-9-10.txt	With the exception of leucopenia and neutropenia, which were higher in patients in Arm A, there were no significant differences in Grades 3 and 4 toxicities between the two regimens.	neutropenia	37	48	no significant	101	115	0
1743-0003-8-50.txt	Conclusion Our findings indicated that robotic arm therapy alone, without additional physical therapy interventions tailored to the paretic arm, was as effective as standard physiotherapy treatment for all responses and more effective than conventional treatment for the CMSA Arm (p = 0.04) and Hand (p = 0.04).	all responses	202	215	p = 0.04	281	289	0
1743-0003-8-50.txt	Conclusion Our findings indicated that robotic arm therapy alone, without additional physical therapy interventions tailored to the paretic arm, was as effective as standard physiotherapy treatment for all responses and more effective than conventional treatment for the CMSA Arm (p = 0.04) and Hand (p = 0.04).	all responses	202	215	p = 0.04	301	309	0
1743-0003-8-50.txt	Conclusion Our findings indicated that robotic arm therapy alone, without additional physical therapy interventions tailored to the paretic arm, was as effective as standard physiotherapy treatment for all responses and more effective than conventional treatment for the CMSA Arm (p = 0.04) and Hand (p = 0.04).	effective	152	161	p = 0.04	281	289	0
1743-0003-8-50.txt	Conclusion Our findings indicated that robotic arm therapy alone, without additional physical therapy interventions tailored to the paretic arm, was as effective as standard physiotherapy treatment for all responses and more effective than conventional treatment for the CMSA Arm (p = 0.04) and Hand (p = 0.04).	effective	152	161	p = 0.04	301	309	0
1743-0003-8-50.txt	Conclusion Our findings indicated that robotic arm therapy alone, without additional physical therapy interventions tailored to the paretic arm, was as effective as standard physiotherapy treatment for all responses and more effective than conventional treatment for the CMSA Arm (p = 0.04) and Hand (p = 0.04).	effective	225	234	p = 0.04	281	289	0
1743-0003-8-50.txt	Conclusion Our findings indicated that robotic arm therapy alone, without additional physical therapy interventions tailored to the paretic arm, was as effective as standard physiotherapy treatment for all responses and more effective than conventional treatment for the CMSA Arm (p = 0.04) and Hand (p = 0.04).	effective	225	234	p = 0.04	301	309	0
1745-6215-10-103.txt	Conclusion Although our trial failed to find significant differences in VAS, QALYs and ICERs based on VAS and QALYs at one-year follow-up, CEACs suggest that postural exercise therapy according to Mensendieck/Cesar has a higher probability of being cost-effective compared to regular physiotherapy; however further research is required.	probability of being cost-effective	228	263	failed to find significant	30	56	0
1745-6215-12-13.txt	In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg ( P = 0.03) for systolic office BP; 0.70 mm Hg ( P = 0.08) for diastolic office BP; 0.36 mm Hg ( P = 0.49) for 24-h systolic BP; and 0.05 mm Hg ( P = 0.88) for 24-h diastolic BP.	24-h diastolic BP	233	250	P = 0.03	75	83	0
1745-6215-12-13.txt	In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg ( P = 0.03) for systolic office BP; 0.70 mm Hg ( P = 0.08) for diastolic office BP; 0.36 mm Hg ( P = 0.49) for 24-h systolic BP; and 0.05 mm Hg ( P = 0.88) for 24-h diastolic BP.	24-h diastolic BP	233	250	P = 0.08	122	130	0
1745-6215-12-13.txt	In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg ( P = 0.03) for systolic office BP; 0.70 mm Hg ( P = 0.08) for diastolic office BP; 0.36 mm Hg ( P = 0.49) for 24-h systolic BP; and 0.05 mm Hg ( P = 0.88) for 24-h diastolic BP.	24-h diastolic BP	233	250	P = 0.49	170	178	0
1745-6215-12-13.txt	In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg ( P = 0.03) for systolic office BP; 0.70 mm Hg ( P = 0.08) for diastolic office BP; 0.36 mm Hg ( P = 0.49) for 24-h systolic BP; and 0.05 mm Hg ( P = 0.88) for 24-h diastolic BP.	24-h systolic BP	184	200	P = 0.03	75	83	0
1745-6215-12-13.txt	In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg ( P = 0.03) for systolic office BP; 0.70 mm Hg ( P = 0.08) for diastolic office BP; 0.36 mm Hg ( P = 0.49) for 24-h systolic BP; and 0.05 mm Hg ( P = 0.88) for 24-h diastolic BP.	24-h systolic BP	184	200	P = 0.08	122	130	0
1745-6215-12-13.txt	In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg ( P = 0.03) for systolic office BP; 0.70 mm Hg ( P = 0.08) for diastolic office BP; 0.36 mm Hg ( P = 0.49) for 24-h systolic BP; and 0.05 mm Hg ( P = 0.88) for 24-h diastolic BP.	24-h systolic BP	184	200	P = 0.88	219	227	0
1745-6215-12-13.txt	In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg ( P = 0.03) for systolic office BP; 0.70 mm Hg ( P = 0.08) for diastolic office BP; 0.36 mm Hg ( P = 0.49) for 24-h systolic BP; and 0.05 mm Hg ( P = 0.88) for 24-h diastolic BP.	diastolic office BP	136	155	P = 0.03	75	83	0
1745-6215-12-13.txt	In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg ( P = 0.03) for systolic office BP; 0.70 mm Hg ( P = 0.08) for diastolic office BP; 0.36 mm Hg ( P = 0.49) for 24-h systolic BP; and 0.05 mm Hg ( P = 0.88) for 24-h diastolic BP.	diastolic office BP	136	155	P = 0.49	170	178	0
1745-6215-12-13.txt	In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg ( P = 0.03) for systolic office BP; 0.70 mm Hg ( P = 0.08) for diastolic office BP; 0.36 mm Hg ( P = 0.49) for 24-h systolic BP; and 0.05 mm Hg ( P = 0.88) for 24-h diastolic BP.	diastolic office BP	136	155	P = 0.88	219	227	0
1745-6215-12-13.txt	In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg ( P = 0.03) for systolic office BP; 0.70 mm Hg ( P = 0.08) for diastolic office BP; 0.36 mm Hg ( P = 0.49) for 24-h systolic BP; and 0.05 mm Hg ( P = 0.88) for 24-h diastolic BP.	systolic office BP	89	107	P = 0.08	122	130	0
1745-6215-12-13.txt	In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg ( P = 0.03) for systolic office BP; 0.70 mm Hg ( P = 0.08) for diastolic office BP; 0.36 mm Hg ( P = 0.49) for 24-h systolic BP; and 0.05 mm Hg ( P = 0.88) for 24-h diastolic BP.	systolic office BP	89	107	P = 0.49	170	178	0
1745-6215-12-13.txt	In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg ( P = 0.03) for systolic office BP; 0.70 mm Hg ( P = 0.08) for diastolic office BP; 0.36 mm Hg ( P = 0.49) for 24-h systolic BP; and 0.05 mm Hg ( P = 0.88) for 24-h diastolic BP.	systolic office BP	89	107	P = 0.88	219	227	0
1745-6215-12-13.txt	In the 2 treatment groups combined, systolic (-1.36 mm Hg) and diastolic (-0.97 mm Hg) office BPs decreased from week 5 to 10 ( P for period effect ≤0.028), but carry-over effects were not significant ( P ≥ 0.11).	systolic (-1.36 mm Hg) and diastolic (-0.97 mm Hg) office BPs	36	97	non significant	185	200	0
1745-6215-12-239.txt	For the non-HPD stratum, the intent-to-treat relative risks of spontaneous premature birth at < 34 and < 37 weeks' gestation were 0.33 (0.03, 3.16) and 0.49 (0.17, 1.44), respectively, and they were non-significant (ns) with p = 0.31 and 0.14.	0.14	238	242	non-significant	199	214	0
1745-6215-12-239.txt	For the non-HPD stratum, the intent-to-treat relative risks of spontaneous premature birth at < 34 and < 37 weeks' gestation were 0.33 (0.03, 3.16) and 0.49 (0.17, 1.44), respectively, and they were non-significant (ns) with p = 0.31 and 0.14.	0.14	238	242	p = 0.31	225	233	0
1745-6215-12-239.txt	For the non-HPD stratum, the intent-to-treat relative risks of spontaneous premature birth at < 34 and < 37 weeks' gestation were 0.33 (0.03, 3.16) and 0.49 (0.17, 1.44), respectively, and they were non-significant (ns) with p = 0.31 and 0.14.	spontaneous premature birth at < 34	63	98	non-significant	199	214	0
1745-6215-12-239.txt	For the non-HPD stratum, the intent-to-treat relative risks of spontaneous premature birth at < 34 and < 37 weeks' gestation were 0.33 (0.03, 3.16) and 0.49 (0.17, 1.44), respectively, and they were non-significant (ns) with p = 0.31 and 0.14.	spontaneous premature birth at < 34 and < 37 weeks' gestation	63	124	p = 0.31	225	233	0
1745-6215-12-239.txt	The corresponding actual treatment figures were zero and 0.32 (0.09, 1.19), which were ns with p = 0.12 and 0.06.	ns	87	89	p = 0.12	95	103	0
1745-6215-12-239.txt	The corresponding actual treatment figures were zero and 0.32 (0.09, 1.19), which were ns with p = 0.12 and 0.06.	ns	87	89	p = 0.12 and 0.06	95	112	0
1745-6215-12-239.txt	The corresponding actual treatment figures were zero and 0.32 (0.09, 1.19), which were ns with p = 0.12 and 0.06.	The corresponding actual treatment figures	0	42	p = 0.12	95	103	0
1745-6215-12-239.txt	The intent-to-treat relative risk of spontaneous premature birth at < 37 weeks of gestation for the trial as a whole, including HPD and non-HPD participants, was 0.69 (0.26, 1.78), p = 0.30 (ns).	ns	191	193	p = 0.30	181	189	0
1745-6215-12-239.txt	Conclusions The efficacy of the tested probiotics to prevent preterm delivery among women without a history of preterm delivery was not determined because the study sample was insufficient to estimate statistically significant intent-to-treat effects; additional studies are needed to evaluate this intervention among these women.	The efficacy of the tested probiotics to prevent preterm delivery among women without a history of preterm delivery	12	127	significant	215	226	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	inhibitory effect of plaque regrowth	64	100	p < 0.05	227	235	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	inhibitory effect of plaque regrowth	64	100	p < 0.05	305	313	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	inhibitory effect of plaque regrowth	64	100	p < 0.05	383	391	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	inhibitory effect of plaque regrowth	64	100	p < 0.05	460	468	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	inhibitory effect of plaque regrowth	64	100	p < 0.05	536	544	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	179	191	p < 0.05	305	313	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	179	191	p < 0.05	383	391	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	179	191	p < 0.05	460	468	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	179	191	p < 0.05	536	544	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	257	269	p < 0.05	227	235	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	257	269	p < 0.05	383	391	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	257	269	p < 0.05	460	468	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	257	269	p < 0.05	536	544	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	335	347	p < 0.05	227	235	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	335	347	p < 0.05	305	313	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	335	347	p < 0.05	460	468	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	335	347	p < 0.05	536	544	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	412	424	p < 0.05	227	235	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	412	424	p < 0.05	305	313	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	412	424	p < 0.05	383	391	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	412	424	p < 0.05	536	544	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	488	500	p < 0.05	227	235	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	488	500	p < 0.05	305	313	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	488	500	p < 0.05	383	391	0
1745-6215-12-262.txt	Results The essential oil mouthwash with ethanol shows a better inhibitory effect of plaque regrowth in 3-days than the mouthwash test with only essential oil in the whole mouth (plaque index = 2.18 against 2.46, respectively, p < 0.05); for the lower jaw (plaque index = 2.28 against 2.57, respectively, p < 0.05); for the upper jaw (plaque index = 2.08 against 2.35, respectively, p < 0.05); for the incisors (plaque index = 1.93 against 2.27, respectively, p < 0.05); and the canines (plaque index = 1.99 against 2.47, respectively, p < 0.05).	plaque index	488	500	p < 0.05	460	468	0
1745-6215-13-11.txt	All groups showed significant improvement in time to complete the MT (p < 0.001) and degree of help needed to perform the task: minimal assistance to supervision (CG) and independent performance (EG1+2).	degree of help needed to perform the task	85	126	p < 0.001	70	79	0
1745-6215-13-11.txt	All groups showed significant improvement in time to complete the MT (p < 0.001) and degree of help needed to perform the task: minimal assistance to supervision (CG) and independent performance (EG1+2).	independent performance (EG1+2)	171	202	p < 0.001	70	79	0
1745-6215-13-11.txt	All groups showed significant improvement in time to complete the MT (p < 0.001) and degree of help needed to perform the task: minimal assistance to supervision (CG) and independent performance (EG1+2).	minimal assistance to supervision (CG)	128	166	p < 0.001	70	79	0
1746-6148-8-157.txt	Results When comparing the two test groups at the end of the trial (16 weeks) there was no significant difference in any of the main outcome variables but owners of dogs that had taken fish oil were significantly happier with the treatment at the end visit and did significantly better at guessing what group their dogs had been in, compared to the placebo group.	guessing what group their dogs had been in	289	331	no significant	88	102	0
1746-6148-8-157.txt	Results When comparing the two test groups at the end of the trial (16 weeks) there was no significant difference in any of the main outcome variables but owners of dogs that had taken fish oil were significantly happier with the treatment at the end visit and did significantly better at guessing what group their dogs had been in, compared to the placebo group.	guessing what group their dogs had been in	289	331	significantly	199	212	0
1746-6148-8-157.txt	Results When comparing the two test groups at the end of the trial (16 weeks) there was no significant difference in any of the main outcome variables but owners of dogs that had taken fish oil were significantly happier with the treatment at the end visit and did significantly better at guessing what group their dogs had been in, compared to the placebo group.	happier	213	220	no significant	88	102	0
1746-6148-8-157.txt	Results When comparing the two test groups at the end of the trial (16 weeks) there was no significant difference in any of the main outcome variables but owners of dogs that had taken fish oil were significantly happier with the treatment at the end visit and did significantly better at guessing what group their dogs had been in, compared to the placebo group.	happier	213	220	significantly	265	278	0
1746-6148-8-157.txt	Within the placebo group there were significant positive changes only in the HCPI and a significant deterioration according to veterinary assessment.	the HCPI	73	81	significant	88	99	0
1746-6148-8-157.txt	Within the placebo group there were significant positive changes only in the HCPI and a significant deterioration according to veterinary assessment.	veterinary assessment	127	148	significant	36	47	0
1746-6148-8-157.txt	Within the placebo group there were significant positive changes only in the HCPI and a significant deterioration according to veterinary assessment.	veterinary assessment	127	148	significant	88	99	0
1746-6148-8-162.txt	The CSOM exhibited a negative relationship with the PVF BW (P = 0.02) and MA duration (P = 0.02).	MA duration	74	85	P = 0.02	60	68	0
1746-6148-8-162.txt	The CSOM exhibited a negative relationship with the PVF BW (P = 0.02) and MA duration (P = 0.02).	MA duration	74	85	P = 0.02	87	95	0
1746-6148-8-162.txt	The CSOM exhibited a negative relationship with the PVF BW (P = 0.02) and MA duration (P = 0.02).	the PVF BW	48	58	P = 0.02	60	68	0
1746-6148-8-162.txt	The CSOM exhibited a negative relationship with the PVF BW (P = 0.02) and MA duration (P = 0.02).	the PVF BW	48	58	P = 0.02	87	95	0
1748-5908-6-129.txt	The BP message produced a statistically significant reduction in diastolic BP (-0.62 mmHg; 95% confidence interval -0.82 to -0.42 mmHg) but not systolic BP (-0.06 mmHg, -0.42 to 0.30 mmHg) and increased the odds of achieving target BP control (odds ratio 1.05; 1.00, 1.10).	systolic BP	144	155	significant	40	51	0
1748-5908-6-129.txt	The BP message produced a statistically significant reduction in diastolic BP (-0.62 mmHg; 95% confidence interval -0.82 to -0.42 mmHg) but not systolic BP (-0.06 mmHg, -0.42 to 0.30 mmHg) and increased the odds of achieving target BP control (odds ratio 1.05; 1.00, 1.10).	target BP control	225	242	significant	40	51	0
1749-799X-6-45.txt	The NIN pre-treatment score at Final was used for the primary ANCOVA comparison, demonstrating a significantly greater cumulative treatment effect of a mean 2.2 (SE 0.49) points pain reduction (p = 0.002).	cumulative treatment effect	119	146	p = 0.002	194	203	0
1749-799X-6-45.txt	The NIN pre-treatment score at Final was used for the primary ANCOVA comparison, demonstrating a significantly greater cumulative treatment effect of a mean 2.2 (SE 0.49) points pain reduction (p = 0.002).	pain	178	182	significantly	97	110	0
1749-8090-4-60.txt	The mean time to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034).	mean blood loss after cross-clamp removal	292	333	p < 0.001	280	289	0
1749-8090-4-60.txt	The mean time to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034).	mean blood loss after cross-clamp removal	292	333	p = 0.026	127	136	0
1749-8090-4-60.txt	The mean time to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034).	mean blood loss after cross-clamp removal	292	333	p = 0.034	558	567	0
1749-8090-4-60.txt	The mean time to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034).	mean blood loss during the operation	139	175	p < 0.001	422	431	0
1749-8090-4-60.txt	The mean time to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034).	mean blood loss during the operation	139	175	p = 0.026	127	136	0
1749-8090-4-60.txt	The mean time to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034).	mean blood loss during the operation	139	175	p = 0.034	558	567	0
1749-8090-4-60.txt	The mean time to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034).	mean drain volume	437	454	p < 0.001	280	289	0
1749-8090-4-60.txt	The mean time to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034).	mean drain volume	437	454	p < 0.001	422	431	0
1749-8090-4-60.txt	The mean time to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034).	mean drain volume	437	454	p = 0.026	127	136	0
1749-8090-4-60.txt	The mean time to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034).	The mean time to haemostasis	0	28	p < 0.001	280	289	0
1749-8090-4-60.txt	The mean time to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034).	The mean time to haemostasis	0	28	p < 0.001	422	431	0
1749-8090-4-60.txt	The mean time to haemostasis was 264 ± 127.1 s (range: 180-600 s) in Group I and 408 ± 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 ± 20.7 cc (range: 474-545 cc) in Group I and 615.7 ± 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 ± 4 g (range: 22-34 g) in Group I and 45.4 ± 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 ± 41.4 cc (range: 79-230 cc) in Group I and 134.5 ± 42.8 cc (range: 101-250 cc) in Group II (p = 0.034).	The mean time to haemostasis	0	28	p = 0.034	558	567	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for acute nausea and vomiting	29	76	p < 0.05	271	279	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for acute nausea and vomiting	29	76	p < 0.05	312	320	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for acute nausea and vomiting	29	76	p < 0.05	477	485	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for acute nausea and vomiting	29	76	p < 0.05	518	526	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for acute nausea and vomiting	29	76	p < 0.05	691	699	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for acute nausea and vomiting	29	76	p < 0.05	732	740	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for acute nausea and vomiting	29	76	p < 0.05	909	917	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for acute nausea and vomiting	29	76	p < 0.05	950	958	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	121	170	p < 0.05	477	485	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	121	170	p < 0.05	518	526	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	121	170	p < 0.05	691	699	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	121	170	p < 0.05	732	740	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	121	170	p < 0.05	909	917	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	121	170	p < 0.05	950	958	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	121	170	p > 0.05	110	118	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	323	372	p < 0.05	271	279	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	323	372	p < 0.05	312	320	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	323	372	p < 0.05	691	699	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	323	372	p < 0.05	732	740	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	323	372	p < 0.05	909	917	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	323	372	p < 0.05	950	958	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for delayed nausea and vomiting	323	372	p > 0.05	110	118	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	529	590	p < 0.05	271	279	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	529	590	p < 0.05	312	320	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	529	590	p < 0.05	477	485	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	529	590	p < 0.05	518	526	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	529	590	p < 0.05	909	917	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	529	590	p < 0.05	950	958	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	529	590	p > 0.05	110	118	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	743	804	p < 0.05	271	279	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	743	804	p < 0.05	312	320	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	743	804	p < 0.05	477	485	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	743	804	p < 0.05	518	526	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	743	804	p < 0.05	691	699	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	743	804	p < 0.05	732	740	0
1756-9966-28-131.txt	Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05).	complete response for the whole period of nausea and vomiting	743	804	p > 0.05	110	118	0
1757-7241-20-16.txt	Significant differences were not found in secondary outcome and in other performance variables between the groups and over time Conclusions Quality of CPR was maintained during 2 minutes of continuous compressions regardless of feedback in a group of trained rescuers.	Quality of CPR	140	154	Significant	0	11	0
1757-7241-20-16.txt	Significant differences were not found in secondary outcome and in other performance variables between the groups and over time Conclusions Quality of CPR was maintained during 2 minutes of continuous compressions regardless of feedback in a group of trained rescuers.	Quality of CPR	140	154	Significant differences were not found	0	38	0
1824-7288-37-48.txt	Paracetamol was significantly more effective than placebo in the SPID of children and parents ( P < 0.05) but not in the SPID reported by investigators, 1 hour after drug administration.	the SPID reported by investigators	117	151	P < 0.05	96	104	0
1824-7288-37-48.txt	Paracetamol was significantly more effective than placebo in the SPID of children and parents ( P < 0.05) but not in the SPID reported by investigators, 1 hour after drug administration.	the SPID reported by investigators	117	151	significantly	16	29	0
ar2702.txt	Results Subjects with lower HAQ-DI or SF-36 scores generally had statistically greater RA-associated losses in productivity within and outside the home compared with subjects with higher scores (25 of 32 evaluations were statistically significant).	HAQ-DI	28	34	significant	235	246	0
ar2702.txt	Results Subjects with lower HAQ-DI or SF-36 scores generally had statistically greater RA-associated losses in productivity within and outside the home compared with subjects with higher scores (25 of 32 evaluations were statistically significant).	SF-36 scores	38	50	significant	235	246	0
ar2702.txt	Results Subjects with lower HAQ-DI or SF-36 scores generally had statistically greater RA-associated losses in productivity within and outside the home compared with subjects with higher scores (25 of 32 evaluations were statistically significant).	statistically greater	65	86	significant	235	246	0
ar2702.txt	At week 24, ACR20 and HAQ-DI responders reported large improvements in productivity within and outside the home; non-responders reported mainly a worsening in productivity ( P ≤ 0.05).	productivity within and outside the home	71	111	P ≤ 0.05	174	182	0
ar4072.txt	At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% ( P <0.001), the back pain score decreased by 50% ( P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% ( P <0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% ( P <0.005).	the back pain score	116	135	P <0.001	105	113	0
ar4072.txt	At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% ( P <0.001), the back pain score decreased by 50% ( P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% ( P <0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% ( P <0.005).	the back pain score	116	135	P <0.005	341	349	0
ar4072.txt	At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% ( P <0.001), the back pain score decreased by 50% ( P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% ( P <0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% ( P <0.005).	the back pain score	116	135	P <0.02	228	235	0
ar4072.txt	At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% ( P <0.001), the back pain score decreased by 50% ( P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% ( P <0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% ( P <0.005).	the Bath Ankylosing Spondylitis Disease activity spinal inflammation score	11	85	P <0.005	155	163	0
ar4072.txt	At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% ( P <0.001), the back pain score decreased by 50% ( P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% ( P <0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% ( P <0.005).	the Bath Ankylosing Spondylitis Disease activity spinal inflammation score	11	85	P <0.005	341	349	0
ar4072.txt	At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% ( P <0.001), the back pain score decreased by 50% ( P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% ( P <0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% ( P <0.005).	the Bath Ankylosing Spondylitis Disease activity spinal inflammation score	11	85	P <0.02	228	235	0
ar4072.txt	At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% ( P <0.001), the back pain score decreased by 50% ( P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% ( P <0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% ( P <0.005).	the Bath AS Functional Index (BASFI) score	166	208	P <0.001	105	113	0
ar4072.txt	At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% ( P <0.001), the back pain score decreased by 50% ( P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% ( P <0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% ( P <0.005).	the Bath AS Functional Index (BASFI) score	166	208	P <0.005	155	163	0
ar4072.txt	At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% ( P <0.001), the back pain score decreased by 50% ( P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% ( P <0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% ( P <0.005).	the Bath AS Functional Index (BASFI) score	166	208	P <0.005	341	349	0
ar4072.txt	At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% ( P <0.001), the back pain score decreased by 50% ( P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% ( P <0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% ( P <0.005).	the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score	244	322	P <0.001	105	113	0
ar4072.txt	At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% ( P <0.001), the back pain score decreased by 50% ( P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% ( P <0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% ( P <0.005).	the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score	244	322	P <0.005	155	163	0
ar4072.txt	At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% ( P <0.001), the back pain score decreased by 50% ( P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% ( P <0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% ( P <0.005).	the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score	244	322	P <0.02	228	235	0
ar4072.txt	ANCOVA analysis demonstrated superiority of adalimumab over placebo for the physician global assessment of disease activity, parents' global assessment of subject's overall well-being, active joint count (all P <0.05) and erythrocyte sedimentation rate (ESR) ( P <0.01).	active joint count	185	203	P <0.01	261	268	0
ar4072.txt	ANCOVA analysis demonstrated superiority of adalimumab over placebo for the physician global assessment of disease activity, parents' global assessment of subject's overall well-being, active joint count (all P <0.05) and erythrocyte sedimentation rate (ESR) ( P <0.01).	erythrocyte sedimentation rate (ESR)	222	258	P <0.05	209	216	0
ar4072.txt	ANCOVA analysis demonstrated superiority of adalimumab over placebo for the physician global assessment of disease activity, parents' global assessment of subject's overall well-being, active joint count (all P <0.05) and erythrocyte sedimentation rate (ESR) ( P <0.01).	parents' global assessment of subject's overall well-being	125	183	P <0.01	261	268	0
ar4072.txt	ANCOVA analysis demonstrated superiority of adalimumab over placebo for the physician global assessment of disease activity, parents' global assessment of subject's overall well-being, active joint count (all P <0.05) and erythrocyte sedimentation rate (ESR) ( P <0.01).	the physician global assessment of disease activity	72	123	P <0.01	261	268	0
bcr2320.txt	Results TC and LDL levels increased significantly across time for both arms; TC increase was more pronounced for the observation arm, and that was sustained up to 24 months.	TC	77	79	significantly	36	49	0
bcr2320.txt	Conclusions Exemestane lacks the beneficial effect of tamoxifen on lipids; however, sequential adjuvant treatment with exemestane in postmenopausal breast cancer patients after cessation of 5 to 7 years of tamoxifen does not appear to alter the lipid profile significantly compared with that of an observational arm.	lipids	67	73	does not appear to alter the lipid profile significantly	216	272	0
bcr3051.txt	Results Progesterone receptor-negativity (HR = 0.66; 95% CI 0.47 to 0.92, P = 0.013), and Ki67-positivity (HR = 1.53; 95% CI 1.12 to 2.08, P = 0.007) were independent adverse prognostic factors.	Ki67-positivity	90	105	P = 0.013	74	83	0
bcr3051.txt	Results Progesterone receptor-negativity (HR = 0.66; 95% CI 0.47 to 0.92, P = 0.013), and Ki67-positivity (HR = 1.53; 95% CI 1.12 to 2.08, P = 0.007) were independent adverse prognostic factors.	Progesterone receptor-negativity	8	40	P = 0.007	139	148	0
bcr3051.txt	Out of the 34 proteins, only Ki67-positivity was associated with DFS improvement with docetaxel addition (adjusted HR = 0.51, 95% CI 0.33 to 0.79 for Ki67-positive versus HR = 1.10, 95% CI 0.75 to 1.61 for Ki67-negative tumors, P for interaction = 0.012).	DFS improvement	65	80	P for interaction = 0.012	228	253	0
bcr3051.txt	Out of the 34 proteins, only Ki67-positivity was associated with DFS improvement with docetaxel addition (adjusted HR = 0.51, 95% CI 0.33 to 0.79 for Ki67-positive versus HR = 1.10, 95% CI 0.75 to 1.61 for Ki67-negative tumors, P for interaction = 0.012).	Ki67-positivity	29	44	P for interaction = 0.012	228	253	0
cc10084.txt	VPW correlated with PAOP (r = 0.41; P < 0.001) and less well with CVP (r = 0.21; P = 0.001).	CVP	66	69	P < 0.001	36	45	0
cc10084.txt	VPW correlated with PAOP (r = 0.41; P < 0.001) and less well with CVP (r = 0.21; P = 0.001).	CVP	66	69	P = 0.001	81	90	0
cc10084.txt	VPW correlated with PAOP (r = 0.41; P < 0.001) and less well with CVP (r = 0.21; P = 0.001).	PAOP	20	24	P < 0.001	36	45	0
cc10084.txt	VPW correlated with PAOP (r = 0.41; P < 0.001) and less well with CVP (r = 0.21; P = 0.001).	PAOP	20	24	P = 0.001	81	90	0
cc10084.txt	VPW correlated with PAOP (r = 0.41; P < 0.001) and less well with CVP (r = 0.21; P = 0.001).	VPW	0	3	P < 0.001	36	45	0
cc10084.txt	VPW correlated with PAOP (r = 0.41; P < 0.001) and less well with CVP (r = 0.21; P = 0.001).	VPW	0	3	P = 0.001	81	90	0
cc10084.txt	VPW discriminated achievement of PAOP <8 mm Hg (AUC = 0.73; P = 0.04) with VPW ≤67 mm demonstrating 71% sensitivity (95% CI 30 to 95%) and 68% specificity (95% CI 59 to 75%).	PAOP	33	37	P = 0.04	60	68	0
cc10120.txt	From day 0 to day 7, total serum calcium levels increased by 0.10 (PBO) and 0.15 mmol/L (VITD; P < 0.05 for both), while ionized calcium levels increased by 0.11 (PBO) and 0.05 mmol/L (VITD; P < 0.05 for both).	ionized calcium levels	121	143	P < 0.05	95	103	0
cc10120.txt	From day 0 to day 7, total serum calcium levels increased by 0.10 (PBO) and 0.15 mmol/L (VITD; P < 0.05 for both), while ionized calcium levels increased by 0.11 (PBO) and 0.05 mmol/L (VITD; P < 0.05 for both).	total serum calcium levels	21	47	P < 0.05	191	199	0
cc10120.txt	Parathyroid hormone levels decreased by 19 and 28 pg/ml (PBO and VITD, ns) over the seven days, while 1,25(OH)D showed a transient significant increase in the VITD group only.	Parathyroid hormone levels	0	26	significant	131	142	0
cc10289.txt	Multivariable modeling showed nicardipine patients were more likely in TR than labetalol patients at 30 minutes (OR 2.73, P = 0.028; C stat for model = 0.72) Conclusions Patients treated with nicardipine are more likely to reach the physician-specified SBP target range within 30 minutes than those treated with labetalol.	likely to reach the physician-specified SBP target range within 30 minutes	213	287	P = 0.028	122	131	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	E-selectin	252	262	P = -0.03	277	286	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	E-selectin	252	262	P = 0.004	177	186	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	E-selectin	252	262	P = 0.008	145	154	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	E-selectin	252	262	P = 0.009	375	384	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	E-selectin	252	262	P = 0.014	310	319	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	E-selectin	252	262	P = 0.015	208	217	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	E-selectin	252	262	P = 0.025	240	249	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	E-selectin	252	262	P = 0.029	341	350	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	E-selectin	252	262	significant	26	37	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-10	220	225	P = -0.03	277	286	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-10	220	225	P = 0.004	177	186	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-10	220	225	P = 0.008	145	154	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-10	220	225	P = 0.009	375	384	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-10	220	225	P = 0.014	310	319	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-10	220	225	P = 0.015	208	217	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-10	220	225	P = 0.025	240	249	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-10	220	225	P = 0.029	341	350	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-10	220	225	significant	26	37	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-1ra	289	295	P = -0.03	277	286	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-1ra	289	295	P = 0.004	177	186	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-1ra	289	295	P = 0.008	145	154	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-1ra	289	295	P = 0.009	375	384	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-1ra	289	295	P = 0.014	310	319	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-1ra	289	295	P = 0.015	208	217	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-1ra	289	295	P = 0.025	240	249	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-1ra	289	295	P = 0.029	341	350	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-1ra	289	295	significant	26	37	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-2	356	360	P = -0.03	277	286	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-2	356	360	P = 0.004	177	186	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-2	356	360	P = 0.008	145	154	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-2	356	360	P = 0.009	375	384	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-2	356	360	P = 0.014	310	319	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-2	356	360	P = 0.015	208	217	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-2	356	360	P = 0.025	240	249	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-2	356	360	P = 0.029	341	350	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-2	356	360	significant	26	37	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-6	322	326	P = -0.03	277	286	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-6	322	326	P = 0.004	177	186	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-6	322	326	P = 0.008	145	154	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-6	322	326	P = 0.009	375	384	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-6	322	326	P = 0.014	310	319	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-6	322	326	P = 0.015	208	217	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-6	322	326	P = 0.025	240	249	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-6	322	326	P = 0.029	341	350	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-6	322	326	significant	26	37	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-8	189	193	P = -0.03	277	286	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-8	189	193	P = 0.004	177	186	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-8	189	193	P = 0.008	145	154	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-8	189	193	P = 0.009	375	384	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-8	189	193	P = 0.014	310	319	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-8	189	193	P = 0.015	208	217	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-8	189	193	P = 0.025	240	249	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-8	189	193	P = 0.029	341	350	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	IL-8	189	193	significant	26	37	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	levels of vascular cell adhesion molecule (VCAM)	83	131	P = -0.03	277	286	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	levels of vascular cell adhesion molecule (VCAM)	83	131	P = 0.004	177	186	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	levels of vascular cell adhesion molecule (VCAM)	83	131	P = 0.008	145	154	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	levels of vascular cell adhesion molecule (VCAM)	83	131	P = 0.009	375	384	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	levels of vascular cell adhesion molecule (VCAM)	83	131	P = 0.014	310	319	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	levels of vascular cell adhesion molecule (VCAM)	83	131	P = 0.015	208	217	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	levels of vascular cell adhesion molecule (VCAM)	83	131	P = 0.025	240	249	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	levels of vascular cell adhesion molecule (VCAM)	83	131	P = 0.029	341	350	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	levels of vascular cell adhesion molecule (VCAM)	83	131	significant	26	37	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	plasma CoQ10 levels	59	78	P = -0.03	277	286	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	plasma CoQ10 levels	59	78	P = 0.004	177	186	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	plasma CoQ10 levels	59	78	P = 0.008	145	154	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	plasma CoQ10 levels	59	78	P = 0.009	375	384	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	plasma CoQ10 levels	59	78	P = 0.014	310	319	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	plasma CoQ10 levels	59	78	P = 0.015	208	217	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	plasma CoQ10 levels	59	78	P = 0.025	240	249	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	plasma CoQ10 levels	59	78	P = 0.029	341	350	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	plasma CoQ10 levels	59	78	significant	26	37	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	TNF-α	157	162	P = -0.03	277	286	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	TNF-α	157	162	P = 0.004	177	186	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	TNF-α	157	162	P = 0.008	145	154	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	TNF-α	157	162	P = 0.009	375	384	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	TNF-α	157	162	P = 0.014	310	319	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	TNF-α	157	162	P = 0.015	208	217	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	TNF-α	157	162	P = 0.025	240	249	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	TNF-α	157	162	P = 0.029	341	350	0
cc10343.txt	There was a statistically significant relationship between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) ( r 2 = 0.2; P = 0.008), TNF-α ( r 2 = 0.28; P = 0.004), IL-8 ( r 2 = 0.21; P = 0.015), IL-10 ( r 2 = 0.18; P = 0.025), E-selectin ( r 2 = 0.17; P = -0.03), IL-1ra ( r 2 = 0.21; P = 0.014), IL-6 ( r 2 = 0.17; P = 0.029) and IL-2 ( r 2 = 0.23; P = 0.009).	TNF-α	157	162	significant	26	37	0
cc10343.txt	After adjusting for LDL levels, there was a statistically significant inverse relationship between plasma CoQ10 levels and levels of VCAM ( r 2 = 0.24; P = 0.01) (Figure 3) and IL-10 ( r 2 = 0.24; P = 0.02).	IL-10	177	182	P = 0.01	152	160	0
cc10343.txt	After adjusting for LDL levels, there was a statistically significant inverse relationship between plasma CoQ10 levels and levels of VCAM ( r 2 = 0.24; P = 0.01) (Figure 3) and IL-10 ( r 2 = 0.24; P = 0.02).	IL-10	177	182	P = 0.02	197	205	0
cc10343.txt	After adjusting for LDL levels, there was a statistically significant inverse relationship between plasma CoQ10 levels and levels of VCAM ( r 2 = 0.24; P = 0.01) (Figure 3) and IL-10 ( r 2 = 0.24; P = 0.02).	IL-10	177	182	significant	58	69	0
cc10343.txt	After adjusting for LDL levels, there was a statistically significant inverse relationship between plasma CoQ10 levels and levels of VCAM ( r 2 = 0.24; P = 0.01) (Figure 3) and IL-10 ( r 2 = 0.24; P = 0.02).	levels of VCAM	123	137	P = 0.01	152	160	0
cc10343.txt	After adjusting for LDL levels, there was a statistically significant inverse relationship between plasma CoQ10 levels and levels of VCAM ( r 2 = 0.24; P = 0.01) (Figure 3) and IL-10 ( r 2 = 0.24; P = 0.02).	levels of VCAM	123	137	P = 0.02	197	205	0
cc10343.txt	After adjusting for LDL levels, there was a statistically significant inverse relationship between plasma CoQ10 levels and levels of VCAM ( r 2 = 0.24; P = 0.01) (Figure 3) and IL-10 ( r 2 = 0.24; P = 0.02).	levels of VCAM	123	137	significant	58	69	0
cc10343.txt	After adjusting for LDL levels, there was a statistically significant inverse relationship between plasma CoQ10 levels and levels of VCAM ( r 2 = 0.24; P = 0.01) (Figure 3) and IL-10 ( r 2 = 0.24; P = 0.02).	plasma CoQ10 levels	99	118	P = 0.01	152	160	0
cc10343.txt	After adjusting for LDL levels, there was a statistically significant inverse relationship between plasma CoQ10 levels and levels of VCAM ( r 2 = 0.24; P = 0.01) (Figure 3) and IL-10 ( r 2 = 0.24; P = 0.02).	plasma CoQ10 levels	99	118	P = 0.02	197	205	0
cc10343.txt	After adjusting for LDL levels, there was a statistically significant inverse relationship between plasma CoQ10 levels and levels of VCAM ( r 2 = 0.24; P = 0.01) (Figure 3) and IL-10 ( r 2 = 0.24; P = 0.02).	plasma CoQ10 levels	99	118	significant	58	69	0
cc10367.txt	Results There was no difference between succinylcholine and rocuronium regarding oxygen desaturations (succinylcholine 73/196; rocuronium 66/195; P = 0.67); severe oxygen desaturations (succinylcholine 20/196; rocuronium 20/195; P = 1.0); and extent of oxygen desaturations (succinylcholine -14 ± 12%; rocuronium -16 ± 13%; P = 0.77).	extent of oxygen desaturations	243	273	P = 0.67	146	154	0
cc10367.txt	Results There was no difference between succinylcholine and rocuronium regarding oxygen desaturations (succinylcholine 73/196; rocuronium 66/195; P = 0.67); severe oxygen desaturations (succinylcholine 20/196; rocuronium 20/195; P = 1.0); and extent of oxygen desaturations (succinylcholine -14 ± 12%; rocuronium -16 ± 13%; P = 0.77).	extent of oxygen desaturations	243	273	P = 1.0	229	236	0
cc10367.txt	Results There was no difference between succinylcholine and rocuronium regarding oxygen desaturations (succinylcholine 73/196; rocuronium 66/195; P = 0.67); severe oxygen desaturations (succinylcholine 20/196; rocuronium 20/195; P = 1.0); and extent of oxygen desaturations (succinylcholine -14 ± 12%; rocuronium -16 ± 13%; P = 0.77).	oxygen desaturations	81	101	P = 0.77	324	332	0
cc10367.txt	Results There was no difference between succinylcholine and rocuronium regarding oxygen desaturations (succinylcholine 73/196; rocuronium 66/195; P = 0.67); severe oxygen desaturations (succinylcholine 20/196; rocuronium 20/195; P = 1.0); and extent of oxygen desaturations (succinylcholine -14 ± 12%; rocuronium -16 ± 13%; P = 0.77).	oxygen desaturations	81	101	P = 1.0	229	236	0
cc10367.txt	Results There was no difference between succinylcholine and rocuronium regarding oxygen desaturations (succinylcholine 73/196; rocuronium 66/195; P = 0.67); severe oxygen desaturations (succinylcholine 20/196; rocuronium 20/195; P = 1.0); and extent of oxygen desaturations (succinylcholine -14 ± 12%; rocuronium -16 ± 13%; P = 0.77).	severe oxygen desaturations	157	184	P = 0.67	146	154	0
cc10367.txt	Results There was no difference between succinylcholine and rocuronium regarding oxygen desaturations (succinylcholine 73/196; rocuronium 66/195; P = 0.67); severe oxygen desaturations (succinylcholine 20/196; rocuronium 20/195; P = 1.0); and extent of oxygen desaturations (succinylcholine -14 ± 12%; rocuronium -16 ± 13%; P = 0.77).	severe oxygen desaturations	157	184	P = 0.77	324	332	0
cc10367.txt	Intubation conditions (succinylcholine 8.3 ± 0.8; rocuronium 8.2 ± 0.9; P = 0.7) and failed first intubation attempts (succinylcholine 32/200; rocuronium 36/201; P = 1.0) did not differ between the groups.	failed first intubation attempts	85	117	P = 0.7	72	79	0
cc10367.txt	Intubation conditions (succinylcholine 8.3 ± 0.8; rocuronium 8.2 ± 0.9; P = 0.7) and failed first intubation attempts (succinylcholine 32/200; rocuronium 36/201; P = 1.0) did not differ between the groups.	Intubation conditions	0	21	P = 1.0	162	169	0
cc10453.txt	The specific data were as follows (median (IQR)): 9.7% (2.6 to 19.8) for TP, 8.9% (0.0 to 17.8) for AVP, and 6.9% (3.5 to 10.1) for placebo ( P < 0.05 vs baseline for each comparison), as well as perfused vessel density 18.6% (8.6 to 36.9) for TP, 20.2% (-3.0 to 37.2) for AVP, and 11.4% (-3.0 to 19.4) for placebo ( P < 0.05 vs baseline for each comparison).	perfused vessel density	196	219	P < 0.05	142	150	0
cc10592.txt	The median pre-operative fluid loading volume was 1,875 ml (IQR 1,375 to 2,025) in the fluid group compared to 0 (IQR 0 to 0) in controls with days in hospital after surgery 12.2 (SD 11.5) days compared to 17.4 (SD 20.0) and an adjusted mean difference of 5.5 days (median 2.2 days; 95% CI -0.44 to 11.44; P = 0.07).	The median pre-operative fluid loading volume	0	45	P = 0.07	306	314	0
cc10592.txt	There was a reduction in adverse events in the fluid intervention group ( P = 0.048) and no increase in fluid based complications.	fluid based complications	104	129	P = 0.048	74	83	0
cc10592.txt	Conclusions Pre-operative intravenous fluid loading leads to a non-significant reduction in hospital length of stay after high-risk major surgery and is likely to be cost-effective.	likely to be cost-effective	153	180	non-significant	63	78	0
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	FEV 1 /FVC	258	268	P < 0.001	358	367	0
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	FEV 1 /FVC	258	268	P = 0.019	243	252	0
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	FEV 1 /FVC	258	268	P = 0.042	168	177	0
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	forced expiratory volume in 1 second (FEV 1	90	133	P < 0.001	358	367	0
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	forced expiratory volume in 1 second (FEV 1	90	133	P = 0.019	243	252	0
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	forced expiratory volume in 1 second (FEV 1	90	133	P = 0.033	302	311	0
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	forced vital capacity (FVC	183	209	P < 0.001	358	367	0
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	forced vital capacity (FVC	183	209	P = 0.033	302	311	0
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	forced vital capacity (FVC	183	209	P = 0.042	168	177	0
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	TLC	321	324	P = 0.019	243	252	0
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	TLC	321	324	P = 0.033	302	311	0
cc11215.txt	There were also significantly better values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV 1 , 80.23 ± 21.21 vs 69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs 69.84 ± 27.40; P = 0.019), c) FEV 1 /FVC (96.14 ± 13.79 vs 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs 76.10 ± 21.84; P < 0.001).	TLC	321	324	P = 0.042	168	177	0
cc11249.txt	Study group patients had a significant lower reintubation rate than did controls; six patients (17%) versus 19 patients (48%), P < 0.05; respectively, and a significantly lower time under MV; 17.8 ± 6.4 versus 11.7 ± 3.5 days; P < 0.05; respectively.	reintubation rate	45	62	P < 0.05	227	235	0
cc11249.txt	Study group patients had a significant lower reintubation rate than did controls; six patients (17%) versus 19 patients (48%), P < 0.05; respectively, and a significantly lower time under MV; 17.8 ± 6.4 versus 11.7 ± 3.5 days; P < 0.05; respectively.	reintubation rate	45	62	significantly	157	170	0
cc11249.txt	Study group patients had a significant lower reintubation rate than did controls; six patients (17%) versus 19 patients (48%), P < 0.05; respectively, and a significantly lower time under MV; 17.8 ± 6.4 versus 11.7 ± 3.5 days; P < 0.05; respectively.	time under MV	177	190	P < 0.05	127	135	0
cc11249.txt	Study group patients had a significant lower reintubation rate than did controls; six patients (17%) versus 19 patients (48%), P < 0.05; respectively, and a significantly lower time under MV; 17.8 ± 6.4 versus 11.7 ± 3.5 days; P < 0.05; respectively.	time under MV	177	190	significant	27	38	0
cc11445.txt	Hemodynamic stability did not differ between SLED-BD and CVVH, whereas patients in the SLED-BD group had significantly fewer days of mechanical ventilation (17.7 ± 19.4 vs 20.9 ± 19.8, P = 0.047) and fewer days in the ICU (19.6 ± 20.1 vs 23.7 ± 21.9, P = 0.04).	days in the ICU	206	221	P = 0.047	185	194	0
cc11445.txt	Hemodynamic stability did not differ between SLED-BD and CVVH, whereas patients in the SLED-BD group had significantly fewer days of mechanical ventilation (17.7 ± 19.4 vs 20.9 ± 19.8, P = 0.047) and fewer days in the ICU (19.6 ± 20.1 vs 23.7 ± 21.9, P = 0.04).	days in the ICU	206	221	significantly	105	118	0
cc11445.txt	Hemodynamic stability did not differ between SLED-BD and CVVH, whereas patients in the SLED-BD group had significantly fewer days of mechanical ventilation (17.7 ± 19.4 vs 20.9 ± 19.8, P = 0.047) and fewer days in the ICU (19.6 ± 20.1 vs 23.7 ± 21.9, P = 0.04).	days of mechanical ventilation	125	155	P = 0.04	251	259	0
cc11445.txt	Hemodynamic stability did not differ between SLED-BD and CVVH, whereas patients in the SLED-BD group had significantly fewer days of mechanical ventilation (17.7 ± 19.4 vs 20.9 ± 19.8, P = 0.047) and fewer days in the ICU (19.6 ± 20.1 vs 23.7 ± 21.9, P = 0.04).	Hemodynamic stability	0	21	P = 0.04	251	259	0
cc11445.txt	Hemodynamic stability did not differ between SLED-BD and CVVH, whereas patients in the SLED-BD group had significantly fewer days of mechanical ventilation (17.7 ± 19.4 vs 20.9 ± 19.8, P = 0.047) and fewer days in the ICU (19.6 ± 20.1 vs 23.7 ± 21.9, P = 0.04).	Hemodynamic stability	0	21	P = 0.047	185	194	0
cc11445.txt	Hemodynamic stability did not differ between SLED-BD and CVVH, whereas patients in the SLED-BD group had significantly fewer days of mechanical ventilation (17.7 ± 19.4 vs 20.9 ± 19.8, P = 0.047) and fewer days in the ICU (19.6 ± 20.1 vs 23.7 ± 21.9, P = 0.04).	Hemodynamic stability	0	21	significantly	105	118	0
cc11445.txt	Patients treated with SLED needed fewer blood transfusions (1,375 ± 2,573 ml vs 1,976 ± 3,316 ml, P = 0.02) and had a substantial reduction in nursing time spent for renal replacement therapy ( P < 0.001) resulting in lower costs.	blood transfusions	40	58	P < 0.001	194	203	0
cc11445.txt	Patients treated with SLED needed fewer blood transfusions (1,375 ± 2,573 ml vs 1,976 ± 3,316 ml, P = 0.02) and had a substantial reduction in nursing time spent for renal replacement therapy ( P < 0.001) resulting in lower costs.	costs	224	229	P < 0.001	194	203	0
cc11445.txt	Patients treated with SLED needed fewer blood transfusions (1,375 ± 2,573 ml vs 1,976 ± 3,316 ml, P = 0.02) and had a substantial reduction in nursing time spent for renal replacement therapy ( P < 0.001) resulting in lower costs.	costs	224	229	P = 0.02	98	106	0
cc11445.txt	Patients treated with SLED needed fewer blood transfusions (1,375 ± 2,573 ml vs 1,976 ± 3,316 ml, P = 0.02) and had a substantial reduction in nursing time spent for renal replacement therapy ( P < 0.001) resulting in lower costs.	nursing time spent for renal replacement therapy	143	191	P = 0.02	98	106	0
cc11657.txt	Diabetes mellitus was significantly associated with a loss of complexity (diabetic (n = 33) versus non-diabetic patients (n = 141) (DFA: 1.58 (1.48 to 1.65) versus 1.53 (1.44 to 1.59); P = 0.01).	a loss of complexity	52	72	P = 0.01	185	193	0
cc11657.txt	Diabetes mellitus was significantly associated with a loss of complexity (diabetic (n = 33) versus non-diabetic patients (n = 141) (DFA: 1.58 (1.48 to 1.65) versus 1.53 (1.44 to 1.59); P = 0.01).	a loss of complexity	52	72	significantly	22	35	0
cc11657.txt	Diabetes mellitus was significantly associated with a loss of complexity (diabetic (n = 33) versus non-diabetic patients (n = 141) (DFA: 1.58 (1.48 to 1.65) versus 1.53 (1.44 to 1.59); P = 0.01).	Diabetes mellitus	0	17	P = 0.01	185	193	0
cc11657.txt	Diabetes mellitus was significantly associated with a loss of complexity (diabetic (n = 33) versus non-diabetic patients (n = 141) (DFA: 1.58 (1.48 to 1.65) versus 1.53 (1.44 to 1.59); P = 0.01).	Diabetes mellitus	0	17	significantly	22	35	0
cc6104.txt	After the target temperature was reached, the intravascular cooling device was 11.2 ± 18.7% of the time out of range, which was significantly less compared to all other methods.	the target temperature	6	28	significantly	128	141	0
cc6173.txt	In the TA group, we observed a significant reduction in the incidence of VS ( P = 0.003), the use of norepinephrine ( P = 0.029), and time on mechanical ventilation ( P = 0.018).	the incidence of VS	56	75	P = 0.018	167	176	0
cc6173.txt	In the TA group, we observed a significant reduction in the incidence of VS ( P = 0.003), the use of norepinephrine ( P = 0.029), and time on mechanical ventilation ( P = 0.018).	the incidence of VS	56	75	P = 0.029	118	127	0
cc6173.txt	In the TA group, we observed a significant reduction in the incidence of VS ( P = 0.003), the use of norepinephrine ( P = 0.029), and time on mechanical ventilation ( P = 0.018).	the use of norepinephrine	90	115	P = 0.003	78	87	0
cc6173.txt	In the TA group, we observed a significant reduction in the incidence of VS ( P = 0.003), the use of norepinephrine ( P = 0.029), and time on mechanical ventilation ( P = 0.018).	the use of norepinephrine	90	115	P = 0.018	167	176	0
cc6173.txt	In the TA group, we observed a significant reduction in the incidence of VS ( P = 0.003), the use of norepinephrine ( P = 0.029), and time on mechanical ventilation ( P = 0.018).	time on mechanical ventilation	134	164	P = 0.003	78	87	0
cc6173.txt	In the TA group, we observed a significant reduction in the incidence of VS ( P = 0.003), the use of norepinephrine ( P = 0.029), and time on mechanical ventilation ( P = 0.018).	time on mechanical ventilation	134	164	P = 0.029	118	127	0
cc6173.txt	These patients showed significantly lower D-dimer, plasminogen activator inhibitor 1, and creatine-kinase levels and a trend toward lower levels of soluble tumor necrosis factor receptor and interleukin-6 within the first 24 hours after CPB.	interleukin-6	191	204	significantly	22	35	0
cc6173.txt	These patients showed significantly lower D-dimer, plasminogen activator inhibitor 1, and creatine-kinase levels and a trend toward lower levels of soluble tumor necrosis factor receptor and interleukin-6 within the first 24 hours after CPB.	levels of soluble tumor necrosis factor receptor	138	186	significantly	22	35	0
cc6999.txt	Under logistic regression analysis – undertaken in an effort to adjust for the cranial tomography characteristics, which were unfavourable for pentobarbital – thiopental was more effective than pentobarbital in terms of controlling intracranial pressure (odds ratio = 5.1, 95% confidence interval 1.2 to 21.9; P = 0.027).	effective	179	188	P = 0.027	310	319	0
cc7112.txt	There were no unexpected deaths and no significant differences in secondary measures.	unexpected deaths	14	31	no significant	36	50	0
cc7695.txt	Results In the intention to treat analysis there were no statistically significant differences between the 53 patients selected for each group regarding gender (p = 0.541), age (p = 0.585) and type of surgery (p = 0.172).	age	173	176	p = 0.172	210	219	0
cc7695.txt	Results In the intention to treat analysis there were no statistically significant differences between the 53 patients selected for each group regarding gender (p = 0.541), age (p = 0.585) and type of surgery (p = 0.172).	age	173	176	p = 0.541	161	170	0
cc7695.txt	Results In the intention to treat analysis there were no statistically significant differences between the 53 patients selected for each group regarding gender (p = 0.541), age (p = 0.585) and type of surgery (p = 0.172).	gender	153	159	p = 0.172	210	219	0
cc7695.txt	Results In the intention to treat analysis there were no statistically significant differences between the 53 patients selected for each group regarding gender (p = 0.541), age (p = 0.585) and type of surgery (p = 0.172).	gender	153	159	p = 0.585	178	187	0
cc7695.txt	Results In the intention to treat analysis there were no statistically significant differences between the 53 patients selected for each group regarding gender (p = 0.541), age (p = 0.585) and type of surgery (p = 0.172).	type of surgery	193	208	p = 0.541	161	170	0
cc7695.txt	Results In the intention to treat analysis there were no statistically significant differences between the 53 patients selected for each group regarding gender (p = 0.541), age (p = 0.585) and type of surgery (p = 0.172).	type of surgery	193	208	p = 0.585	178	187	0
